doc_id,cell_id,assay_cell_type,tid,assay_tax_id,assay_category,src_assay_id,bao_format,assay_type,tissue_id,chembl_id,variant_id,assay_subcellular_fraction,curated_by,assay_tissue,src_id,confidence_score,assay_strain,assay_organism,relationship_type,assay_test_type,assay_id,description
11087,,,12052,,,,BAO_0000019,B,,CHEMBL615117,,,Autocuration,,1,8,,,H,,1,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM
684,,,22226,,,,BAO_0000219,F,,CHEMBL615118,,,Autocuration,,1,0,,,U,,2,Compound was evaluated for its ability to mobilize calcium in 1321NI cells
15453,,,22226,,,,BAO_0000019,B,,CHEMBL615119,,,Autocuration,,1,0,,,U,,3,
17841,,,104729,9913.0,,,BAO_0000249,B,,CHEMBL615120,,,Autocuration,,1,4,,Bos taurus,H,,4,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680
17430,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615121,,,Intermediate,,1,1,,Homo sapiens,N,,5,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
17430,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615122,,,Intermediate,,1,1,,Homo sapiens,N,,6,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line)
13799,163.0,143B,80001,10090.0,,,BAO_0000219,F,,CHEMBL615123,,,Intermediate,,1,1,,Mus musculus,N,,7,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells
17774,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615124,,,Expert,,1,1,,Homo sapiens,N,,8,In vitro cell cytotoxicity was determined against 143B cell line
3801,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615125,,,Intermediate,,1,1,,Homo sapiens,N,,9,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound
17430,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615126,,,Intermediate,,1,1,,Homo sapiens,N,,10,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
17430,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615127,,,Intermediate,,1,1,,Homo sapiens,N,,11,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK
17774,163.0,143B,80001,9606.0,,,BAO_0000219,F,,CHEMBL615128,,,Expert,,1,1,,Homo sapiens,N,,12,In vitro cell cytotoxicity was determined against 143B-LTK cell line
11324,,,50185,1280.0,,,BAO_0000218,F,,CHEMBL857900,,,Intermediate,,1,1,,Staphylococcus aureus,N,,13,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
11324,,,50185,1280.0,,,BAO_0000218,F,,CHEMBL615129,,,Intermediate,,1,1,,Staphylococcus aureus,N,,14,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
11324,,,50185,1280.0,,,BAO_0000218,F,,CHEMBL615130,,,Intermediate,,1,1,,Staphylococcus aureus,N,,15,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
11324,,,50185,1280.0,,,BAO_0000218,F,,CHEMBL615131,,,Intermediate,,1,1,,Staphylococcus aureus,N,,16,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus"
11347,,,100122,10116.0,,,BAO_0000357,A,,CHEMBL884521,,,Expert,,1,9,,Rattus norvegicus,D,,17,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase
16474,,,12054,,,,BAO_0000357,B,,CHEMBL615132,,,Autocuration,,1,8,,,H,,18,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO)
10091,,,12054,,,,BAO_0000019,B,,CHEMBL615133,,,Autocuration,,1,8,,,H,,19,Inhibition of partially purified 15-lipoxygenase from human leukocytes
16474,,,12054,,,,BAO_0000357,B,,CHEMBL615134,,,Autocuration,,1,8,,,H,,20,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
16474,,,12054,,,,BAO_0000357,B,,CHEMBL615135,,,Autocuration,,1,8,,,H,,21,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO)
16474,,,12054,,,,BAO_0000357,B,,CHEMBL615136,,,Autocuration,,1,8,,,H,,22,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO)
16474,,,12054,,,,BAO_0000357,B,,CHEMBL615137,,,Autocuration,,1,8,,,H,,23,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
16474,,,12054,,,,BAO_0000357,B,,CHEMBL615138,,,Autocuration,,1,8,,,H,,24,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition
14352,,,22226,,,,BAO_0000219,B,,CHEMBL836324,,,Autocuration,,1,0,,,U,,25,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M."
5646,,,12054,9986.0,,,BAO_0000357,B,,CHEMBL615139,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,26,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase
5646,,,12054,9986.0,,,BAO_0000357,B,,CHEMBL615140,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,27,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM)
10997,,,12426,,,,BAO_0000219,B,,CHEMBL615141,,,Autocuration,,1,8,,,H,,28,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes
6309,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL615142,,,Autocuration,,1,8,,soya bean,H,,29,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean
167,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL615143,,,Autocuration,,1,8,,Glycine max,H,,30,Inhibitory activity against soybean 15-lipoxygenase was evaluated
167,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL615144,,,Autocuration,,1,8,,Glycine max,H,,31,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM
11087,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL872867,,,Autocuration,,1,8,,Glycine max,H,,32,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM
11087,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL615145,,,Autocuration,,1,8,,Glycine max,H,,33,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM
13622,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL615146,,,Autocuration,,1,8,,Glycine max,H,,34,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean
13622,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL615147,,,Autocuration,,1,8,,Glycine max,H,,35,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean
11347,,,22226,10116.0,,,BAO_0000019,A,,CHEMBL615148,,,Autocuration,,1,0,,Rattus norvegicus,U,,36,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase
5926,,,22226,562.0,,,BAO_0000019,B,,CHEMBL615149,,,Autocuration,,1,0,,Escherichia coli,U,,37,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay
4567,,,22226,,,,BAO_0000019,B,,CHEMBL615150,,,Autocuration,,1,0,,,U,,38,Dissociation constant with dimeric 16S rRNA RNA construct B
3782,,,22222,,,,BAO_0000225,B,,CHEMBL615151,,,Intermediate,,1,3,,,M,,39,Dissociation constant towards 16S rRNA construct A
3782,,,22222,,,,BAO_0000225,B,,CHEMBL615152,,,Intermediate,,1,3,,,M,,40,Dissociation constant towards 16S rRNA construct B
4466,,,100263,562.0,,,BAO_0000225,B,,CHEMBL615153,,,Expert,,1,3,,Escherichia coli,M,,41,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli
6592,,,100263,562.0,,,BAO_0000225,B,,CHEMBL615154,,,Expert,,1,3,,Escherichia coli,M,,42,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli
898,,,13053,,,,BAO_0000019,B,,CHEMBL615155,,,Autocuration,,1,8,,,H,,43,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
898,,,13053,,,,BAO_0000019,B,,CHEMBL615156,,,Autocuration,,1,8,,,H,,44,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
13163,,,20001,9606.0,,,BAO_0000019,B,,CHEMBL615157,,,Autocuration,,1,8,,Homo sapiens,H,,45,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
13163,,,20001,9606.0,,,BAO_0000019,B,,CHEMBL615158,,,Autocuration,,1,8,,Homo sapiens,H,,46,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes
10691,,,12971,10116.0,,,BAO_0000019,B,,CHEMBL615159,,,Expert,,1,9,,Rattus norvegicus,D,,47,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
10691,,,12971,10116.0,,,BAO_0000019,B,,CHEMBL615172,,,Expert,,1,9,,Rattus norvegicus,D,,48,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation"
10691,,,12971,10116.0,,,BAO_0000019,B,,CHEMBL615173,,,Expert,,1,9,,Rattus norvegicus,D,,49,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
10691,,,12971,10116.0,,,BAO_0000019,B,,CHEMBL615174,,,Expert,,1,9,,Rattus norvegicus,D,,50,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM"
898,,,13053,,,,BAO_0000019,B,,CHEMBL884518,,,Autocuration,,1,8,,,H,,51,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2)
912,,,11512,,,,BAO_0000357,B,,CHEMBL615175,,,Autocuration,,1,8,,,H,,52,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1)
912,,,11512,,,,BAO_0000357,B,,CHEMBL615176,,,Autocuration,,1,8,,,H,,53,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration
912,,,11512,,,,BAO_0000357,B,,CHEMBL615177,,,Autocuration,,1,8,,,H,,54,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration
15103,,,104740,10116.0,,,BAO_0000249,B,,CHEMBL615178,,Membranes,Autocuration,,1,5,,Rattus norvegicus,D,,55,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes
5116,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615179,,,Intermediate,,1,1,,Homo sapiens,N,,56,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined
14578,,Oocytes,104835,10116.0,,,BAO_0000219,F,,CHEMBL615180,,,Autocuration,,1,7,,Rattus norvegicus,D,,57,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype
14578,,Oocytes,104821,10116.0,,,BAO_0000219,F,,CHEMBL615181,,,Autocuration,,1,7,,Rattus norvegicus,D,,58,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor
14578,,Oocytes,104848,10116.0,,,BAO_0000219,F,,CHEMBL615182,,,Autocuration,,1,7,,Rattus norvegicus,D,,59,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor
4787,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615183,,,Expert,,1,1,,Homo sapiens,N,,60,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation
4787,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615184,,,Intermediate,,1,1,,Homo sapiens,N,,61,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation
3547,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615185,,,Intermediate,,1,1,,Homo sapiens,N,,62,Cytotoxic activity against human ovarian cancer (1A9) cell line
3547,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615186,,,Intermediate,,1,1,,Homo sapiens,N,,63,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined
6726,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615187,,,Intermediate,,1,1,,Homo sapiens,N,,64,Effective dose of compound against replication of 1A9 cell line was evaluated
3455,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL885343,,,Expert,,1,1,,Homo sapiens,N,,65,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line
5726,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615188,,,Intermediate,,1,1,,Homo sapiens,N,,66,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line)
5726,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615189,,,Intermediate,,1,1,,Homo sapiens,N,,67,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active
5726,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615190,,,Intermediate,,1,1,,Homo sapiens,N,,68,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL
3395,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615191,,,Intermediate,,1,1,,Homo sapiens,N,,69,Inhibitory activity against Taxol resistant 1A9 cell lines
3415,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615192,,,Expert,,1,1,,Homo sapiens,N,,70,Cytotoxicity against human ovarian cancer (1A9) cell lines.
3415,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL827083,,,Expert,,1,1,,Homo sapiens,N,,71,Percentage inhibition of human ovarian cancer (1A9) cell lines.
17099,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615193,,,Expert,,1,1,,Homo sapiens,N,,72,Effective dose required for inhibitory activity against 1A9 human tumor cell line.
17099,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615194,,,Intermediate,,1,1,,Homo sapiens,N,,73,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL
17099,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615195,,,Intermediate,,1,1,,Homo sapiens,N,,74,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL
17099,506.0,1A9,80002,9606.0,,,BAO_0000219,F,,CHEMBL615196,,,Intermediate,,1,1,,Homo sapiens,N,,75,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL
17721,503.0,Jurkat,81072,9606.0,,,BAO_0000219,F,,CHEMBL615197,,,Intermediate,,1,1,,Homo sapiens,N,,76,Inhibitory concentration against Jurkat cells
1229,,,22226,,,,BAO_0000019,F,,CHEMBL615198,,,Intermediate,,1,0,,,U,,77,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive
11347,,,100121,10116.0,,,BAO_0000357,A,,CHEMBL615199,,,Expert,,1,9,,Rattus norvegicus,D,,78,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase
17117,,,11231,,,,BAO_0000357,B,,CHEMBL615200,,,Expert,,1,8,,,H,,79,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
17117,,,11231,,,,BAO_0000357,B,,CHEMBL615201,,,Expert,,1,8,,,H,,80,"In vitro inhibition of human 2,3-oxidosqualene cyclase."
17117,,,11231,,,,BAO_0000357,B,,CHEMBL615202,,,Expert,,1,8,,,H,,81,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM."
11375,,,11231,5476.0,,,BAO_0000251,B,,CHEMBL615203,,Microsomes,Autocuration,,1,8,,Candida albicans,H,,82,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes"
11375,,,11231,5476.0,,,BAO_0000251,B,,CHEMBL615204,,Microsomes,Autocuration,,1,8,,Candida albicans,H,,83,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes"
11375,,,11231,4932.0,,,BAO_0000251,B,,CHEMBL615205,,Microsomes,Autocuration,,1,8,,Saccharomyces cerevisiae,H,,84,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes"
11375,,,11231,4932.0,,,BAO_0000251,B,,CHEMBL615206,,Microsomes,Autocuration,,1,8,,Saccharomyces cerevisiae,H,,85,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes"
11375,,,12083,9823.0,,,BAO_0000251,B,2107.0,CHEMBL615207,,Microsomes,Autocuration,Liver,1,8,,Sus scrofa,H,,86,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes"
791,,,11231,10116.0,,,BAO_0000019,B,,CHEMBL827084,,,Autocuration,,1,8,,Rattus norvegicus,H,,87,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase"
791,,,11231,10116.0,,,BAO_0000019,B,,CHEMBL615208,,,Autocuration,,1,8,,Rattus norvegicus,H,,88,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)"
791,,,11231,10116.0,,,BAO_0000019,B,,CHEMBL615209,,,Autocuration,,1,8,,Rattus norvegicus,H,,89,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki"
11375,,,12083,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615210,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,90,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes"
11375,,,12083,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615211,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,91,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
153,,,12083,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615212,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,92,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes"
8269,,,11377,,,,BAO_0000357,B,,CHEMBL615213,,,Expert,,1,8,,,H,,93,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease)
8269,,,11377,,,,BAO_0000357,B,,CHEMBL615273,,,Expert,,1,8,,,H,,94,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex
17653,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615274,,,Expert,,1,1,,Homo sapiens,N,,95,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
14277,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615275,,,Intermediate,,1,1,,Homo sapiens,N,,96,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.
1717,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615276,,,Intermediate,,1,1,,Homo sapiens,N,,97,Antiviral activity against Hepatitis B virus in 2.2.15 cell line
14091,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615277,,,Intermediate,,1,1,,Homo sapiens,N,,98,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells
14091,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615326,,,Intermediate,,1,1,,Homo sapiens,N,,99,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined
17653,,,50606,10407.0,,,BAO_0000218,F,,CHEMBL883130,,,Expert,,1,1,,Hepatitis B virus,N,,100,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line
13105,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL884519,,,Intermediate,,1,1,,Homo sapiens,N,,101,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.
1717,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615327,,,Intermediate,,1,1,,Homo sapiens,N,,102,Concentration required to inhibit 50% of 2.2.15 cell line
13105,726.0,HepG2,81020,9606.0,,,BAO_0000219,A,,CHEMBL615328,,,Intermediate,,1,1,,Homo sapiens,N,,103,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).
13600,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615329,,,Intermediate,,1,1,,Homo sapiens,N,,104,Cytotoxic activity of compound against uninfected 2.2.15 cells.
13467,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615330,,,Intermediate,,1,1,,Homo sapiens,N,,105,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.
17477,,2.2.15,50606,10407.0,,,BAO_0000218,F,,CHEMBL615331,,,Expert,,1,1,,Hepatitis B virus,N,,106,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay"
1593,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615332,,,Intermediate,,1,1,,Homo sapiens,N,,107,In vitro anti-HBV activity in 2.2.15 cells
1593,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615333,,,Intermediate,,1,1,,Homo sapiens,N,,108,In vitro anti-HBV activity in 2.2.15 cells; Not determined
15089,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615334,,,Intermediate,,1,1,,Homo sapiens,N,,109,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells
15089,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615335,,,Intermediate,,1,1,,Homo sapiens,N,,110,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells
1593,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615336,,,Intermediate,,1,1,,Homo sapiens,N,,111,Cytotoxicity in 2.2.15 cells
1593,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615337,,,Intermediate,,1,1,,Homo sapiens,N,,112,Cytotoxicity in 2.2.15 cells; Not determined
13600,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615338,,,Intermediate,,1,1,,Homo sapiens,N,,113,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells
13467,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615339,,,Intermediate,,1,1,,Homo sapiens,N,,114,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.
13467,,2.2.15,50587,9606.0,,,BAO_0000218,F,,CHEMBL615340,,,Intermediate,,1,1,,Homo sapiens,N,,115,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.
14764,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615341,,,Intermediate,,1,1,,Homo sapiens,N,,116,Antiviral activity against HBV was determined in 2.215 cell line
6531,,,22226,9606.0,,,BAO_0000251,B,,CHEMBL615342,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,,117,Inhibition of 20-HETE synthesis in human renal microsomes
17322,,,22226,,,,BAO_0000019,B,,CHEMBL615343,,,Autocuration,,1,0,,,U,,118,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.
17072,388.0,2008,80612,9606.0,,,BAO_0000219,F,,CHEMBL615344,,,Intermediate,,1,1,,Homo sapiens,N,,119,Inhibitory concentration against 2008 (ovarian) cells
16936,388.0,2008,80612,9606.0,,,BAO_0000219,F,,CHEMBL615345,,,Intermediate,,1,1,,Homo sapiens,N,,120,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.
16936,388.0,2008,80612,9606.0,,,BAO_0000219,F,,CHEMBL615346,,,Intermediate,,1,1,,Homo sapiens,N,,121,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008)
17146,388.0,2008,80612,9606.0,,,BAO_0000219,F,,CHEMBL615347,,,Intermediate,,1,1,,Homo sapiens,N,,122,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells
17146,388.0,2008,80612,9606.0,,,BAO_0000219,F,,CHEMBL615348,,,Intermediate,,1,1,,Homo sapiens,N,,123,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected
10797,561.0,2008/R,80613,9606.0,,,BAO_0000219,F,,CHEMBL827085,,,Intermediate,,1,1,,Homo sapiens,N,,124,In vitro inhibition of 2008/R ovarian cancer cell line
10797,561.0,2008/R,80613,9606.0,,,BAO_0000219,F,,CHEMBL615349,,,Intermediate,,1,1,,Homo sapiens,N,,125,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable
10797,389.0,2008/S,80614,9606.0,,,BAO_0000219,F,,CHEMBL615350,,,Intermediate,,1,1,,Homo sapiens,N,,126,In vitro inhibition of 2008/S ovarian cancer cell line
10797,389.0,2008/S,80614,9606.0,,,BAO_0000219,F,,CHEMBL615351,,,Intermediate,,1,1,,Homo sapiens,N,,127,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable
4823,,,100256,9606.0,,,BAO_0000220,B,,CHEMBL615352,,,Expert,,1,2,,Homo sapiens,S,,128,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome
12912,,,100256,9606.0,,,BAO_0000220,B,,CHEMBL615353,,,Intermediate,,1,2,,Homo sapiens,S,,129,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain
2957,,,100256,,,,BAO_0000220,B,,CHEMBL615354,,,Expert,,1,2,,,S,,130,Inhibition of chymotrypsin-like activity of 20S proteasome
2957,,,100256,,,,BAO_0000220,B,,CHEMBL615355,,,Expert,,1,2,,,S,,131,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM
3260,,,100256,,,,BAO_0000220,B,,CHEMBL615356,,,Intermediate,,1,2,,,S,,132,Inhibitory activity against 20S proteosome
3451,,,22226,9606.0,,,BAO_0000019,B,,CHEMBL615357,,,Autocuration,,1,0,,Homo sapiens,U,,133,Compound was tested for inhibitory activity against tryptase
13885,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL615358,,,Intermediate,,1,1,,Homo sapiens,N,,134,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line
13885,726.0,HepG2,81020,9606.0,,,BAO_0000219,F,,CHEMBL827086,,,Intermediate,,1,1,,Homo sapiens,N,,135,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line
3676,,,22226,,,,BAO_0000019,B,,CHEMBL615359,,,Autocuration,,1,0,,,U,,136,Compound was tested for the inhibition of Alpha-glucosidase
6043,,,235,,,,BAO_0000357,B,,CHEMBL615360,,,Autocuration,,1,8,,,H,,137,Inhibitory concentration against human neutrophil elastase (HNE)
11140,,,22226,10116.0,,,BAO_0000218,F,948.0,CHEMBL615361,,,Autocuration,Heart,1,0,,Rattus norvegicus,U,,138,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat
10543,,,19640,,,,BAO_0000019,F,,CHEMBL615362,,,Autocuration,,1,8,,,H,,139,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
10543,,,19640,,,,BAO_0000019,F,,CHEMBL615363,,,Expert,,1,8,,,H,,140,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
10543,,,19640,,,,BAO_0000357,B,,CHEMBL615364,,,Autocuration,,1,8,,,H,,141,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates
10543,,,19640,,,,BAO_0000019,F,,CHEMBL615365,,,Expert,,1,8,,,H,,142,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates
11365,524.0,P338,80360,10090.0,,,BAO_0000219,F,,CHEMBL615366,,,Intermediate,,1,1,,Mus musculus,N,,143,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines
11365,524.0,P338,80360,10090.0,,,BAO_0000219,F,,CHEMBL615367,,,Intermediate,,1,1,,Mus musculus,N,,144,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines
11803,554.0,PBL,80384,9606.0,,,BAO_0000219,F,,CHEMBL615368,,,Intermediate,,1,1,,Homo sapiens,N,,145,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).
11803,,,22226,9940.0,,,BAO_0000019,F,,CHEMBL615369,,,Autocuration,,1,0,,Ovis aries,U,,146,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells
11803,,,22226,9940.0,,,BAO_0000019,F,,CHEMBL615370,,,Autocuration,,1,0,,Ovis aries,U,,147,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.
12278,,,191,,,,BAO_0000357,B,,CHEMBL615673,,,Autocuration,,1,8,,,H,,148,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C)
8249,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615674,,,Autocuration,,1,0,,Homo sapiens,U,,149,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5
8249,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615675,,,Autocuration,,1,0,,Homo sapiens,U,,150,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6
8249,635.0,CCRF-CEM,22226,9606.0,,,BAO_0000219,F,,CHEMBL615676,,,Autocuration,,1,0,,Homo sapiens,U,,151,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7
8249,635.0,CCRF-CEM,22226,9606.0,,,BAO_0000219,F,,CHEMBL615677,,,Autocuration,,1,0,,Homo sapiens,U,,152,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4
8249,635.0,CCRF-CEM,22226,9606.0,,,BAO_0000219,F,,CHEMBL615678,,,Autocuration,,1,0,,Homo sapiens,U,,153,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5
8249,635.0,CCRF-CEM,22226,9606.0,,,BAO_0000219,F,,CHEMBL615679,,,Autocuration,,1,0,,Homo sapiens,U,,154,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6
8249,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615680,,,Autocuration,,1,0,,Homo sapiens,U,,155,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.
8249,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615681,,,Autocuration,,1,0,,Homo sapiens,U,,156,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4
16992,,,104290,,,,BAO_0000249,B,,CHEMBL857972,,,Autocuration,,1,6,,,H,,157,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain
10543,,,50264,1314.0,,,BAO_0000218,F,,CHEMBL857899,,,Intermediate,,1,1,,Streptococcus pyogenes,N,,158,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse
17833,,,50527,10335.0,,,BAO_0000218,F,,CHEMBL615371,,,Intermediate,,1,1,,Human herpesvirus 3,N,,159,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV)
17290,468.0,HEL,50527,10335.0,,,BAO_0000218,F,,CHEMBL615372,,,Expert,,1,1,,vericilla zoster virus,N,,160,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.
17290,,,50527,10335.0,,,BAO_0000218,F,,CHEMBL615373,,,Intermediate,,1,1,,vericilla zoster virus,N,,161,Antiviral activity against 07/1 strain of VZV; ND: No data
17290,,,50527,10335.0,,,BAO_0000218,F,,CHEMBL615374,,,Intermediate,,1,1,,vericilla zoster virus,N,,162,Antiviral activity against 07/1 strain of VZV; ND=No data
10932,,,50145,561.0,,,BAO_0000218,F,,CHEMBL615375,,,Intermediate,,1,1,,escherichia cloac,N,,163,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)"
9707,,,22226,,,,BAO_0000019,B,,CHEMBL615376,,,Autocuration,,1,0,,,U,,164,Ratio of Ki at A2 to Ki at A1 receptors
2346,,,11143,5476.0,,,BAO_0000249,B,,CHEMBL615377,,,Expert,,1,8,,Candida albicans,H,,165,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay."
2205,,,18077,284593.0,,,BAO_0000357,B,,CHEMBL615378,,,Expert,,1,8,,Candida glabrata CBS 138,H,,166,"Inhibition of 1,3-beta-glucan synthase"
11900,832.0,1-87 tumor cell line,80609,9606.0,,,BAO_0000219,F,,CHEMBL615379,,,Intermediate,,1,1,,Homo sapiens,N,,167,Inhibition of growth of 1-87 human tumor cell line
14864,,,12166,10116.0,,,BAO_0000219,B,,CHEMBL615380,,,Expert,,1,9,,Rattus norvegicus,D,,168,Inhibition of 1-lipoxygenase (LOX)in RBL cells
16474,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615381,,,Autocuration,,1,9,,Glycine max,D,,169,Inhibitory activity against soybean 1-lipoxygenase (SLO)
16474,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615382,,,Autocuration,,1,9,,Glycine max,D,,170,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect
16474,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615383,,,Autocuration,,1,9,,Glycine max,D,,171,% inhibition against soybean 1-lipoxygenase (SLO)
16474,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615384,,,Autocuration,,1,9,,Glycine max,D,,172,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615385,,,Autocuration,,1,9,,Glycine max,D,,173,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615386,,,Autocuration,,1,9,,Glycine max,D,,174,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615387,,,Autocuration,,1,9,,Glycine max,D,,175,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615388,,,Autocuration,,1,9,,Glycine max,D,,176,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615214,,,Autocuration,,1,9,,Glycine max,D,,177,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL827087,,,Autocuration,,1,9,,Glycine max,D,,178,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615215,,,Autocuration,,1,9,,Glycine max,D,,179,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615216,,,Autocuration,,1,9,,Glycine max,D,,180,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615217,,,Autocuration,,1,9,,Glycine max,D,,181,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615218,,,Autocuration,,1,9,,Glycine max,D,,182,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3
3094,,,100171,3847.0,,,BAO_0000357,B,,CHEMBL615219,,,Autocuration,,1,9,,Glycine max,D,,183,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1
10413,,,22226,10090.0,,,BAO_0000019,B,,CHEMBL615220,,,Autocuration,,1,0,,Mus musculus,U,,184,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM
16929,294.0,C3H 10T1/2,80049,10090.0,,,BAO_0000219,F,,CHEMBL615221,,,Intermediate,,1,1,,Mus musculus,N,,185,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity)
1229,,,22226,,,,BAO_0000019,F,,CHEMBL615222,,,Intermediate,,1,0,,,U,,186,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive
16587,,,11489,,,,BAO_0000357,B,,CHEMBL615223,,,Autocuration,,1,8,,,H,,187,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
16587,,,11862,,,,BAO_0000357,B,,CHEMBL615224,,,Autocuration,,1,8,,,H,,188,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA)
16587,,,11862,,,,BAO_0000357,B,,CHEMBL615225,,,Autocuration,,1,8,,,H,,189,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).
16587,,,11489,,,,BAO_0000357,B,,CHEMBL615226,,,Autocuration,,1,8,,,H,,190,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2
16587,,,11862,,,,BAO_0000357,B,,CHEMBL615227,,,Autocuration,,1,8,,,H,,191,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition
8058,,,12347,9913.0,,,BAO_0000019,F,,CHEMBL615228,,,Expert,,1,9,,Bos taurus,D,,192,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase
9065,,,100120,10116.0,,,BAO_0000357,B,,CHEMBL615229,,,Expert,,1,9,,Rattus norvegicus,D,,193,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect
8865,,,100120,10116.0,,,BAO_0000357,B,2369.0,CHEMBL615230,,,Expert,Adrenal gland,1,9,,Rattus norvegicus,D,,194,Inhibition of 11 beta-hydroxylase from rat adrenal gland
9066,,,100120,10116.0,,,BAO_0000357,B,,CHEMBL615231,,,Expert,,1,9,,Rattus norvegicus,D,,195,Inhibition of rat adrenal 11-beta-hydroxylase
8394,,,100120,10116.0,,,BAO_0000357,B,,CHEMBL884520,,,Expert,,1,9,,Rattus norvegicus,D,,196,Inhibition of rat adrenal 11-beta-hydroxylase
8394,,,100120,10116.0,,,BAO_0000357,B,,CHEMBL615232,,,Expert,,1,9,,Rattus norvegicus,D,,197,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M
6431,,,10328,,,,BAO_0000019,B,,CHEMBL615233,,,Autocuration,,1,8,,,H,,198,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone
6431,,,11490,,,,BAO_0000357,B,,CHEMBL827088,,,Autocuration,,1,8,,,H,,199,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
6431,,,11490,,,,BAO_0000357,B,,CHEMBL615234,,,Autocuration,,1,8,,,H,,200,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol
9295,,,11134,,,,BAO_0000019,F,,CHEMBL615235,,,Autocuration,,1,8,,,H,,201,Compound was tested for the percent of inhibition against 12-LO at 10 uM
10193,,,12052,,,,BAO_0000019,B,,CHEMBL615236,,,Autocuration,,1,8,,,H,,202,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
13622,,,11134,,,,BAO_0000019,B,,CHEMBL615237,,,Autocuration,,1,8,,,H,,203,Compound was tested in vitro for inhibition of 12-LO human platelet
12079,,,11134,,,,BAO_0000019,F,,CHEMBL615238,,,Autocuration,,1,8,,,H,,204,Inhibitory concentration against human platelet 12-lipoxygenase
13622,,,11134,,,,BAO_0000019,B,,CHEMBL615239,,,Autocuration,,1,8,,,H,,205,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet
12079,,,11134,9606.0,,,BAO_0000019,F,,CHEMBL615240,,,Autocuration,,1,9,,Homo sapiens,D,,206,Inhibitory concentration against human platelet 12-lipoxygenase
13500,,,11835,,,,BAO_0000019,B,,CHEMBL615241,,,Expert,,1,8,,,H,,207,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates
13723,,,11601,,,,BAO_0000357,B,,CHEMBL615242,,,Expert,,1,8,,,H,,208,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase
16474,,,11134,,,,BAO_0000019,B,,CHEMBL615243,,,Autocuration,,1,8,,,H,,209,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO)
1630,,,11134,,,,BAO_0000019,B,,CHEMBL615244,,,Autocuration,,1,8,,,H,,210,Inhibitory activity against human platelet 12-lipoxygenase
167,,,11134,,,,BAO_0000019,B,,CHEMBL615245,,,Autocuration,,1,8,,,H,,211,Inhibitory activity against human platelet 12-lipoxygenase was evaluated
16474,,,11134,,,,BAO_0000019,B,,CHEMBL615246,,,Autocuration,,1,8,,,H,,212,% inhibition against human platelet 12-lipoxygenase (12-HLO)
167,,,11134,,,,BAO_0000019,B,,CHEMBL615247,,,Autocuration,,1,8,,,H,,213,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM
16474,,,11134,,,,BAO_0000019,B,,CHEMBL615248,,,Autocuration,,1,8,,,H,,214,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition
10091,,,11601,,,,BAO_0000357,B,,CHEMBL615249,,,Autocuration,,1,8,,,H,,215,Inhibitory activity towards porcine 12-lipoxygenase
11966,,,11601,,,,BAO_0000357,B,,CHEMBL615250,,,Autocuration,,1,8,,,H,,216,Tested for inhibition against porcine 12-LO
951,,,12052,,,,BAO_0000019,B,,CHEMBL615251,,,Autocuration,,1,8,,,H,,217,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect
10997,,,12052,,,,BAO_0000019,B,,CHEMBL615252,,,Autocuration,,1,8,,,H,,218,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma
10193,,,12052,,,,BAO_0000019,B,,CHEMBL828340,,,Expert,,1,8,,,H,,219,In vitro inhibition of rat platelet 12-lipoxygenase
10193,,,12052,,,,BAO_0000019,B,,CHEMBL615253,,,Autocuration,,1,8,,,H,,220,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
10193,,,12052,,,,BAO_0000019,B,,CHEMBL615254,,,Autocuration,,1,8,,,H,,221,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM
10193,,,12052,,,,BAO_0000019,B,,CHEMBL615255,,,Autocuration,,1,8,,,H,,222,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM
10193,,,12052,,,,BAO_0000019,B,,CHEMBL615256,,,Autocuration,,1,8,,,H,,223,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM
10193,,,12052,,,,BAO_0000019,B,,CHEMBL615257,,,Autocuration,,1,8,,,H,,224,In vitro inhibitory activity against rat platelet 12-lipoxygenase
11087,,,12052,,,,BAO_0000019,B,,CHEMBL615258,,,Autocuration,,1,8,,,H,,225,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM
15569,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL615259,,,Intermediate,,1,1,,Homo sapiens,N,,226,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure
12989,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL615260,,,Expert,,1,1,,Homo sapiens,N,,227,In vitro antitumor activity against 41M cell line.
16745,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL615261,,,Intermediate,,1,1,,Homo sapiens,N,,228,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.
15569,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL615262,,,Intermediate,,1,1,,Homo sapiens,N,,229,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure
12989,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL615263,,,Expert,,1,1,,Homo sapiens,N,,230,In vitro antitumor activity against 41McisR cell line.
12989,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL838393,,,Expert,,1,1,,Homo sapiens,N,,231,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line
16745,621.0,41M,80007,9606.0,,,BAO_0000219,F,,CHEMBL615264,,,Intermediate,,1,1,,Homo sapiens,N,,232,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay
6210,,,84,9606.0,,,BAO_0000357,B,,CHEMBL615265,,,Expert,,1,9,,Homo sapiens,D,,233,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I)
6210,,,68,9606.0,,,BAO_0000357,B,,CHEMBL615266,,,Expert,,1,9,,Homo sapiens,D,,234,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
6226,,,68,,,,BAO_0000357,B,,CHEMBL615267,,,Expert,,1,8,,,H,,235,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II)
17855,,,10201,,,,BAO_0000357,B,,CHEMBL615268,,,Expert,,1,8,,,H,,236,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase
17855,,,10201,,,,BAO_0000357,B,,CHEMBL615269,,,Expert,,1,8,,,H,,237,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined
17855,,,10201,,,,BAO_0000357,B,,CHEMBL615270,,,Expert,,1,8,,,H,,238,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase
10413,,,12220,,,,BAO_0000357,B,,CHEMBL615271,,,Autocuration,,1,8,,,H,,239,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
10413,,,11303,562.0,,,BAO_0000357,B,,CHEMBL615272,,,Autocuration,,1,8,,Escherichia coli,H,,240,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
10413,,,11303,562.0,,,BAO_0000357,B,,CHEMBL615103,,,Autocuration,,1,8,,Escherichia coli,H,,241,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested"
10413,,,11303,562.0,,,BAO_0000357,B,,CHEMBL615104,,,Autocuration,,1,8,,Escherichia coli,H,,242,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested"
10413,,,12220,,,,BAO_0000357,B,,CHEMBL615105,,,Autocuration,,1,8,,,H,,243,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM"
10413,,,12220,,,,BAO_0000357,B,,CHEMBL872866,,,Autocuration,,1,8,,,H,,244,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM"
7587,,,11303,9823.0,,,BAO_0000357,B,,CHEMBL615106,,,Autocuration,,1,8,,Sus scrofa,H,,245,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL615107,,,Autocuration,,1,8,,Sus scrofa,H,,246,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme."
7587,,,11303,9823.0,,,BAO_0000357,B,,CHEMBL615108,,,Autocuration,,1,8,,Sus scrofa,H,,247,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000357,B,,CHEMBL615109,,,Autocuration,,1,8,,Sus scrofa,H,,248,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000357,B,,CHEMBL615110,,,Autocuration,,1,8,,Sus scrofa,H,,249,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL840105,,,Autocuration,,1,8,,Sus scrofa,H,,250,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL615111,,,Autocuration,,1,8,,Sus scrofa,H,,251,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL615112,,,Autocuration,,1,8,,Sus scrofa,H,,252,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL615113,,,Autocuration,,1,8,,Sus scrofa,H,,253,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL615114,,,Autocuration,,1,8,,Sus scrofa,H,,254,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme."
7587,,,11303,9823.0,,,BAO_0000357,B,,CHEMBL615115,,,Autocuration,,1,8,,Sus scrofa,H,,255,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration"
7587,,,11303,9823.0,,,BAO_0000019,B,,CHEMBL615116,,,Autocuration,,1,8,,Sus scrofa,H,,256,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration"
7323,,,11303,,,,BAO_0000357,B,,CHEMBL615698,,,Autocuration,,1,8,,,H,,257,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate"
7587,,,22226,9823.0,,,BAO_0000019,B,,CHEMBL615699,,,Autocuration,,1,0,,Sus scrofa,U,,258,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration"
7587,,,22226,9823.0,,,BAO_0000019,B,,CHEMBL615700,,,Autocuration,,1,0,,Sus scrofa,U,,259,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme."
13750,,,100249,4932.0,,,BAO_0000357,B,,CHEMBL615701,,,Expert,,1,8,,Saccharomyces cerevisiae,H,,260,Inhibition of 5-Desaturase involved in ergosterol biosynthesis
7662,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615702,,,Autocuration,,1,0,,Rattus norvegicus,U,,261,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
7662,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615703,,,Autocuration,,1,0,,Rattus norvegicus,U,,262,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase
7662,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615704,,,Autocuration,,1,0,,Rattus norvegicus,U,,263,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor"
12211,,,104698,,,,BAO_0000019,F,,CHEMBL615705,,,Autocuration,,1,6,,,H,,264,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
12211,,,104698,,,,BAO_0000019,F,,CHEMBL615706,,,Autocuration,,1,6,,,H,,265,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat"
12211,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL615707,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,266,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig
12211,,,10623,,,,BAO_0000019,F,,CHEMBL615708,,,Expert,,1,8,,,H,,267,Stimulatory activity of intragastric pressure was tested in the rat
15453,,,121,,,,BAO_0000357,B,,CHEMBL615709,,,Autocuration,,1,8,,,H,,268,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.
11884,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615710,,,Autocuration,,1,0,,Rattus norvegicus,U,,269,Dose to reduce neuronal firing against 5-HT cells in rats (iv)
7185,,,12688,,,,BAO_0000019,F,,CHEMBL615711,,,Autocuration,,1,8,,,H,,270,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
6876,,,121,9606.0,,,BAO_0000357,B,,CHEMBL615712,,,Expert,,1,9,,Homo sapiens,D,,271,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine
6876,,,121,9606.0,,,BAO_0000357,B,,CHEMBL836325,,,Expert,,1,9,,Homo sapiens,D,,272,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data
11863,,,12198,,,,BAO_0000019,F,,CHEMBL615713,,,Autocuration,,1,8,,,H,,273,Inhibition of high affinity 5-HT uptake at concentration of 1 uM
11863,,,12198,,,,BAO_0000357,B,,CHEMBL615714,,,Autocuration,,1,8,,,H,,274,Inhibition constant of high-affinity 5-HT uptake
11863,,,12198,,,,BAO_0000019,F,,CHEMBL615715,,,Autocuration,,1,8,,,H,,275,Michaelis-Menten constant was reported for high affinity transport of 5-HT
11863,,,12198,,,,BAO_0000019,F,,CHEMBL615716,,,Autocuration,,1,8,,,H,,276,Maximum rate was determined for high affinity transport of 5-HT
4639,,,104714,,,,BAO_0000019,F,,CHEMBL615717,,,Autocuration,,1,4,,,H,,277,Compound was tested for agonistic activity against 5-HT uptake
15796,,,10577,,,,BAO_0000019,B,,CHEMBL881818,,,Expert,,1,8,,,H,,278,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay
15796,,,105,9913.0,,,BAO_0000357,B,,CHEMBL884540,,,Expert,,1,8,,Bos taurus,H,,279,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay
12801,,,104744,10116.0,,,BAO_0000224,B,,CHEMBL615718,,,Autocuration,,1,5,,Rattus norvegicus,D,,280,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
12801,,,104744,,,,BAO_0000224,B,,CHEMBL615719,,,Autocuration,,1,4,,,H,,281,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand
12120,,,104744,,,,BAO_0000249,B,,CHEMBL615720,,Membranes,Autocuration,,1,4,,,H,,282,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M
12120,,,104744,,,,BAO_0000249,B,,CHEMBL615721,,Membranes,Autocuration,,1,4,,,H,,283,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.
11963,,,104744,,,,BAO_0000019,B,,CHEMBL615722,,,Autocuration,,1,4,,,H,,284,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
11701,,,51,,,,BAO_0000019,F,,CHEMBL615723,,,Autocuration,,1,8,,,H,,285,Dose required to reduce neuronal firing of 5-HT1A cells by 50%
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615724,,,Autocuration,Hippocampus,1,8,,,H,,286,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615725,,,Autocuration,Hippocampus,1,8,,,H,,287,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615726,,,Autocuration,Hippocampus,1,8,,,H,,288,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615727,,,Autocuration,,1,8,,,H,In vivo,289,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52)
11574,,,105570,10141.0,,,BAO_0000019,F,,CHEMBL615728,,,Intermediate,,1,9,,Cavia porcellus,D,,290,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.
15779,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL857971,,,Autocuration,,1,8,,,H,,291,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
15363,,,107,,,,BAO_0000357,B,,CHEMBL615729,,,Autocuration,,1,8,,,H,,292,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor
15363,,,12687,10116.0,,,BAO_0000019,F,,CHEMBL615730,,,Expert,,1,9,,Rattus norvegicus,D,,293,Efficacy against 5-hydroxytryptamine 2A receptor
15329,,,12687,,,,BAO_0000019,F,,CHEMBL615731,,,Expert,,1,8,,,H,,294,Intrinsic activity towards 5-HT2A receptor of rat tail artery
15329,,,12687,,,,BAO_0000019,F,,CHEMBL615732,,,Expert,,1,8,,,H,,295,Relative potency towards 5-HT2A receptor of rat tail artery
15329,,,12687,,,,BAO_0000019,F,,CHEMBL615733,,,Expert,,1,8,,,H,,296,Blocking 5-HT2A receptor-mediated contractions of rat tail artery
15329,,,12687,,,,BAO_0000019,F,,CHEMBL615734,,,Expert,,1,8,,,H,,297,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery
15329,,,12687,,,,BAO_0000019,F,,CHEMBL615735,,,Autocuration,,1,8,,,H,,298,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.
15329,,,12687,,,,BAO_0000019,F,,CHEMBL615736,,,Expert,,1,8,,,H,,299,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery
273,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL615737,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,300,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
273,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL615738,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,301,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI)
273,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL615739,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,302,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.
12092,,,10623,,,,BAO_0000357,B,,CHEMBL615278,,,Autocuration,,1,8,,,H,,303,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.
1317,,,10623,10116.0,,,BAO_0000019,F,,CHEMBL615279,,,Expert,,1,9,,Rattus norvegicus,D,,304,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
12409,,,168,,,,BAO_0000357,B,,CHEMBL615280,,,Expert,,1,8,,,H,,305,Binding affinity against 5-hydroxytryptamine 4 receptor
11126,,,22226,9031.0,,,BAO_0000019,B,,CHEMBL615281,,,Autocuration,,1,0,,Gallus gallus,U,,306,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine
11126,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615282,,,Autocuration,,1,0,,Homo sapiens,U,,307,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity
11126,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615283,,,Autocuration,,1,0,,Homo sapiens,U,,308,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control
11126,649.0,HL-60,80156,9606.0,,,BAO_0000219,B,,CHEMBL615284,,,Autocuration,,1,1,,Homo sapiens,N,,309,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells
11126,,,22226,9606.0,,,BAO_0000019,B,,CHEMBL615285,,,Autocuration,,1,0,,Homo sapiens,U,,310,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity
11126,,,22226,9606.0,,,BAO_0000019,B,,CHEMBL615286,,,Autocuration,,1,0,,Homo sapiens,U,,311,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control
17807,,Oocytes,104703,9606.0,,,BAO_0000219,B,,CHEMBL615287,,,Autocuration,,1,7,,Homo sapiens,D,,312,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes
16575,,,100256,,,,BAO_0000220,F,,CHEMBL615288,,,Intermediate,,1,2,,,S,,313,Chymotryptic inhibitory activity against 26S proteasome
15407,,,100256,,,,BAO_0000220,B,,CHEMBL615289,,,Intermediate,,1,2,,,S,,314,Inhibitory activity against 26S proteasome degradation of IkB
10797,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL615290,,,Intermediate,,1,1,,Homo sapiens,N,,315,In vitro inhibition of 2780/DOX ovarian cancer cell line
10797,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL884522,,,Intermediate,,1,1,,Homo sapiens,N,,316,In vitro inhibition of 2780/S ovarian cancer cell line
3469,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615291,,,Autocuration,,1,0,,Homo sapiens,U,,317,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells
16037,,,22222,,,,BAO_0000225,B,,CHEMBL615292,,,Intermediate,,1,3,,,M,,318,Association constant for binding to AATT 28-mer AATT hairpin
16037,,,22222,,,,BAO_0000225,B,,CHEMBL615293,,,Intermediate,,1,3,,,M,,319,Kinetically Defined Association Constant for 28-mer AATT hairpin.
16037,,,22222,,,,BAO_0000225,B,,CHEMBL615294,,,Intermediate,,1,3,,,M,,320,Reaction Rate Parameter for 28-mer AATT hairpin
16037,,,22222,,,,BAO_0000225,B,,CHEMBL615295,,,Intermediate,,1,3,,,M,,321,Reaction Rate Parameter for 28-mer AATT hairpin
16524,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL825021,,,Autocuration,,1,0,,Homo sapiens,U,,322,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1)
16524,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615296,,,Autocuration,,1,0,,Homo sapiens,U,,323,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2)
16524,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615297,,,Autocuration,,1,0,,Homo sapiens,U,,324,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1
16758,,,22226,10029.0,,,BAO_0000019,F,,CHEMBL615298,,,Autocuration,,1,0,,Cricetulus griseus,U,,325,Cytotoxicity against cell line 2SC/20 determined by MTT test
16758,,,22226,10029.0,,,BAO_0000019,F,,CHEMBL615299,,,Autocuration,,1,0,,Cricetulus griseus,U,,326,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test
16758,,,22226,10029.0,,,BAO_0000019,F,,CHEMBL615300,,,Autocuration,,1,0,,Cricetulus griseus,U,,327,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test
14360,,,241,,,,BAO_0000357,B,,CHEMBL615301,,,Autocuration,,1,8,,,H,,328,Binding affinity on 3 beta-hydroxysteroid dehydrogenase
14360,,,241,9606.0,,,BAO_0000357,B,,CHEMBL615302,,,Expert,,1,9,,Homo sapiens,D,,329,Binding affinity for 3-beta-hydroxysteroid dehydrogenase
9964,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615303,,,Autocuration,,1,0,,Rattus norvegicus,U,,330,Selectivity ratio of ID50 in liver and heart
9964,,,12132,,,,BAO_0000019,B,,CHEMBL615304,,,Autocuration,,1,8,,,H,,331,"Selectivity, ratio of relative ID50 in liver and heart"
9964,,,12132,,,,BAO_0000019,B,,CHEMBL615305,,,Autocuration,,1,8,,,H,,332,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3
9964,,,12132,,,,BAO_0000218,B,,CHEMBL615306,,,Autocuration,,1,8,,,H,,333,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
9964,,,12132,,,,BAO_0000218,B,,CHEMBL615307,,,Autocuration,,1,8,,,H,,334,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
9964,,,12132,,,,BAO_0000218,B,,CHEMBL615308,,,Autocuration,,1,8,,,H,In vivo,335,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
9964,,,12132,,,,BAO_0000218,F,,CHEMBL615309,,,Autocuration,,1,8,,,H,In vivo,336,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
9964,,,22226,,,,BAO_0000019,B,,CHEMBL615310,,,Autocuration,,1,0,,,U,,337,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine"
9964,,,12132,,,,BAO_0000019,B,,CHEMBL615311,,,Autocuration,,1,8,,,H,,338,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3
9964,,,22226,9606.0,,,BAO_0000019,B,,CHEMBL615312,,,Autocuration,,1,0,,Homo sapiens,U,,339,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart"
9964,,,12132,,,,BAO_0000019,B,,CHEMBL615313,,,Autocuration,,1,8,,,H,,340,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
9964,,,12132,,,,BAO_0000019,F,,CHEMBL615314,,,Autocuration,,1,8,,,H,,341,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3
9964,,,12132,,,,BAO_0000019,B,,CHEMBL615315,,,Autocuration,,1,8,,,H,,342,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor"
9964,,,22226,10116.0,,,BAO_0000218,B,,CHEMBL615316,,,Autocuration,,1,0,,Rattus norvegicus,U,,343,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration"
9964,,,12132,,,,BAO_0000218,B,,CHEMBL615317,,,Autocuration,,1,8,,,H,In vivo,344,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3
9964,,,12132,,,,BAO_0000218,B,,CHEMBL615318,,,Autocuration,,1,8,,,H,,345,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor"
9964,,,22226,10116.0,,,BAO_0000218,B,,CHEMBL615319,,,Autocuration,,1,0,,Rattus norvegicus,U,,346,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration"
9964,,,12132,,,,BAO_0000019,B,,CHEMBL615320,,,Autocuration,,1,8,,,H,,347,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
9964,,,12132,,,,BAO_0000019,F,,CHEMBL615321,,,Autocuration,,1,8,,,H,,348,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor"
3796,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615322,,,Autocuration,,1,0,,Rattus norvegicus,U,,349,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor"
4251,,,19690,562.0,,,BAO_0000357,B,,CHEMBL615323,,,Autocuration,,1,8,,Escherichia coli,H,,350,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
4251,,,19690,562.0,,,BAO_0000357,B,,CHEMBL615407,,,Autocuration,,1,8,,Escherichia coli,H,,351,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli
4251,,,19690,562.0,,,BAO_0000357,B,,CHEMBL857267,,,Autocuration,,1,8,,Escherichia coli,H,,352,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli
4251,,,19690,562.0,,,BAO_0000357,B,,CHEMBL615408,,,Autocuration,,1,8,,Escherichia coli,H,,353,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli
166,,,19690,,,,BAO_0000357,B,,CHEMBL615409,,,Autocuration,,1,8,,,H,,354,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible
17861,,,19690,,,,BAO_0000357,B,,CHEMBL615410,,,Autocuration,,1,8,,,H,,355,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase
166,,,19690,,,,BAO_0000357,B,,CHEMBL615411,,,Autocuration,,1,8,,,H,,356,Inhibition constant against 3-dehydroquinate synthase
166,,,19690,,,,BAO_0000357,B,,CHEMBL615412,,,Autocuration,,1,8,,,H,,357,Association rate constant against 3-dehydroquinate synthase
166,,,19690,,,,BAO_0000357,B,,CHEMBL615413,,,Autocuration,,1,8,,,H,,358,Rate constant against 3-dehydroquinate synthase
3548,,,22226,,,,BAO_0000019,B,,CHEMBL615414,,,Autocuration,,1,0,,,U,,359,Inhibitory activity against fuc-TVII
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615415,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,360,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615416,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,361,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615417,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,362,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615418,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,363,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615419,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,364,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615420,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,365,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615421,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,366,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615422,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,367,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615423,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,368,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL872868,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,369,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM
9877,,,12236,10116.0,,,BAO_0000251,B,2107.0,CHEMBL615424,,Microsomes,Autocuration,Liver,1,9,,Rattus norvegicus,D,,370,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM
3003,,,104832,,,,BAO_0000224,B,,CHEMBL825022,,,Autocuration,,1,4,,,H,,371,Inhibitory activity against 3-phosphoglycerate kinase.
3003,,,104832,,,,BAO_0000224,B,,CHEMBL615425,,,Autocuration,,1,4,,,H,,372,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1
3003,,,104832,,,,BAO_0000224,B,,CHEMBL615426,,,Autocuration,,1,4,,,H,,373,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase"
17185,,,10612,9606.0,,,BAO_0000357,B,,CHEMBL615427,,,Expert,,1,9,,Homo sapiens,D,,374,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM
6072,844.0,3677 melanoma cell line,80616,9606.0,,,BAO_0000219,F,,CHEMBL615428,,,Intermediate,,1,1,,Homo sapiens,N,,375,Cytotoxicity on 3677 melanoma cells
6072,844.0,3677 melanoma cell line,80616,9606.0,,,BAO_0000219,F,,CHEMBL615429,,,Intermediate,,1,1,,Homo sapiens,N,,376,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL
5018,700.0,MC-38,80617,10090.0,,,BAO_0000219,F,,CHEMBL615430,,,Intermediate,,1,1,,Mus musculus,N,,377,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay
2852,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL615431,,,Intermediate,,1,0,,Homo sapiens,U,,378,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines
8663,798.0,B16,22226,,,,BAO_0000218,F,,CHEMBL615432,,,Autocuration,,1,0,,,U,,379,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested
8663,798.0,B16,22226,,,,BAO_0000218,F,,CHEMBL615433,,,Autocuration,,1,0,,,U,,380,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.
3245,,,12464,12131.0,,,BAO_0000019,F,,CHEMBL615434,,,Expert,,1,9,,Human rhinovirus 14,D,,381,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease
3245,,,50085,169066.0,,,BAO_0000218,F,,CHEMBL615435,,,Intermediate,,1,1,,Human rhinovirus sp.,N,,382,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM
3877,,,50679,169066.0,,,BAO_0000218,F,,CHEMBL615436,,,Intermediate,,1,1,,human rhinovirus type 14,N,,383,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI
3877,,,50679,169066.0,,,BAO_0000218,F,,CHEMBL615437,,,Intermediate,,1,1,,human rhinovirus type 14,N,,384,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact
5861,,,12464,12131.0,,,BAO_0000019,F,,CHEMBL615438,,,Expert,,1,9,,Human rhinovirus 14,D,,385,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
5861,,,12464,12131.0,,,BAO_0000019,F,,CHEMBL615439,,,Expert,,1,9,,Human rhinovirus 14,D,,386,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
5861,,,12464,12131.0,,,BAO_0000019,F,,CHEMBL615440,,,Expert,,1,9,,Human rhinovirus 14,D,,387,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay
5861,,,12464,12131.0,,,BAO_0000019,F,,CHEMBL615441,,,Expert,,1,9,,Human rhinovirus 14,D,,388,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive
13748,,,50665,12059.0,,,BAO_0000218,F,,CHEMBL615641,,,Intermediate,,1,1,,Enterovirus,N,,389,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease
13748,,,50665,12059.0,,,BAO_0000218,F,,CHEMBL872065,,,Intermediate,,1,1,,Enterovirus,N,,390,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease
13748,,,50665,12059.0,,,BAO_0000218,F,,CHEMBL825023,,,Intermediate,,1,1,,Enterovirus,N,,391,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease
13748,,,50665,12059.0,,,BAO_0000218,F,,CHEMBL615642,,,Intermediate,,1,1,,Enterovirus,N,,392,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease
13748,,,12464,147712.0,,,BAO_0000357,B,,CHEMBL615643,,,Expert,,1,8,,Human rhinovirus B,H,,393,Inhibition of human rhinovirus 3C protease
17699,,,22226,9606.0,,,BAO_0000019,B,,CHEMBL615644,,,Autocuration,,1,0,,Homo sapiens,U,,394,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited
7145,833.0,3EM 37,80619,10090.0,,,BAO_0000218,F,,CHEMBL615645,,,Intermediate,,1,1,,Mus musculus,N,,395,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5)
7145,833.0,3EM 37,80619,10090.0,,,BAO_0000218,F,,CHEMBL615646,,,Intermediate,,1,1,,Mus musculus,N,,396,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16)
7145,833.0,3EM 37,80619,10090.0,,,BAO_0000218,F,,CHEMBL615647,,,Intermediate,,1,1,,Mus musculus,N,,397,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10)
7145,833.0,3EM 37,80619,10090.0,,,BAO_0000218,F,,CHEMBL615648,,,Intermediate,,1,1,,Mus musculus,N,,398,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6)
7145,833.0,3EM 37,80619,10090.0,,,BAO_0000218,F,,CHEMBL615649,,,Intermediate,,1,1,,Mus musculus,N,,399,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg
7145,833.0,3EM 37,80619,10090.0,,,BAO_0000218,F,,CHEMBL615650,,,Intermediate,,1,1,,Mus musculus,N,,400,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg
5325,847.0,3LL cell line,80620,10090.0,,,BAO_0000218,F,,CHEMBL615651,,,Intermediate,,1,1,,Mus musculus,N,,401,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
5325,847.0,3LL cell line,80620,10090.0,,,BAO_0000218,F,,CHEMBL615652,,,Intermediate,,1,1,,Mus musculus,N,,402,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor
5325,847.0,3LL cell line,80620,10090.0,,,BAO_0000218,F,,CHEMBL615653,,,Expert,,1,1,,Mus musculus,N,,403,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615654,,,Intermediate,,1,1,,Mus musculus,N,,404,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615655,,,Intermediate,,1,1,,Mus musculus,N,,405,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL825024,,,Intermediate,,1,1,,Mus musculus,N,,406,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615656,,,Intermediate,,1,1,,Mus musculus,N,,407,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615657,,,Intermediate,,1,1,,Mus musculus,N,,408,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615658,,,Intermediate,,1,1,,Mus musculus,N,,409,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615659,,,Intermediate,,1,1,,Mus musculus,N,,410,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615660,,,Intermediate,,1,1,,Mus musculus,N,,411,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615661,,,Intermediate,,1,1,,Mus musculus,N,,412,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615662,,,Intermediate,,1,1,,Mus musculus,N,,413,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615663,,,Intermediate,,1,1,,Mus musculus,N,,414,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615664,,,Intermediate,,1,1,,Mus musculus,N,,415,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615665,,,Intermediate,,1,1,,Mus musculus,N,,416,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615666,,,Intermediate,,1,1,,Mus musculus,N,,417,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615667,,,Intermediate,,1,1,,Mus musculus,N,,418,putrescine levels in 3LL cells after the treatment of 1 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615668,,,Intermediate,,1,1,,Mus musculus,N,,419,putrescine levels in 3LL cells after the treatment of 10 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615669,,,Intermediate,,1,1,,Mus musculus,N,,420,putrescine levels in 3LL cells after the treatment of 250 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615670,,,Intermediate,,1,1,,Mus musculus,N,,421,putrescine levels in 3LL cells after the treatment of 50 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL836739,,,Intermediate,,1,1,,Mus musculus,N,,422,spermidine levels in 3LL cells after the treatment of 1 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615671,,,Intermediate,,1,1,,Mus musculus,N,,423,spermidine levels in 3LL cells after the treatment of 10 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615672,,,Intermediate,,1,1,,Mus musculus,N,,424,spermidine levels in 3LL cells after the treatment of 250 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615791,,,Intermediate,,1,1,,Mus musculus,N,,425,spermidine levels in 3LL cells after the treatment of 50 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615792,,,Intermediate,,1,1,,Mus musculus,N,,426,spermine levels in 3LL cells after the treatment of 1 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615793,,,Intermediate,,1,1,,Mus musculus,N,,427,spermine levels in 3LL cells after the treatment of 10 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615794,,,Intermediate,,1,1,,Mus musculus,N,,428,spermine levels in 3LL cells after the treatment of 250 uM of Compound
16169,847.0,3LL cell line,80620,10090.0,,,BAO_0000219,F,,CHEMBL615795,,,Intermediate,,1,1,,Mus musculus,N,,429,spermine levels in 3LL cells after the treatment of 50 uM of Compound
15547,971.0,3LLD122,80621,9606.0,,,BAO_0000219,F,,CHEMBL615590,,,Intermediate,,1,1,,Homo sapiens,N,,430,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%
8663,,,22226,,,,BAO_0000218,F,,CHEMBL615591,,,Autocuration,,1,0,,,U,,431,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity
8663,,,22226,,,,BAO_0000218,F,,CHEMBL615592,,,Autocuration,,1,0,,,U,,432,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.
8663,,,22226,,,,BAO_0000218,F,,CHEMBL615593,,,Autocuration,,1,0,,,U,,433,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested
8663,,,22226,,,,BAO_0000218,F,,CHEMBL615594,,,Autocuration,,1,0,,,U,,434,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.
4504,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615595,,,Intermediate,,1,1,,Mus musculus,N,,435,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
4504,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615596,,,Intermediate,,1,1,,Mus musculus,N,,436,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts
12695,723.0,NIH3T3,11169,,,,BAO_0000219,F,,CHEMBL615597,,,Expert,,1,8,,,H,,437,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay
12695,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615598,,,Intermediate,,1,1,,Mus musculus,N,,438,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active
12695,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615599,,,Intermediate,,1,1,,Mus musculus,N,,439,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested
17642,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615600,,,Expert,,1,1,,Mus musculus,N,,440,Effective dose against murine 3T3 fibroblasts cells
17642,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615601,,,Expert,,1,1,,Mus musculus,N,,441,Dose required against murine 3T3 fibroblasts cells; 1-10 uM
12340,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615602,,,Expert,,1,1,,Mus musculus,N,,442,Cytotoxic effect on 3T3 cells
12340,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615603,,,Expert,,1,1,,Mus musculus,N,,443,Cytotoxic effect on 3T3 cells
12716,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615604,,,Intermediate,,1,1,,Mus musculus,N,,444,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615605,,,Intermediate,,1,1,,Mus musculus,N,,445,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615606,,,Intermediate,,1,1,,Mus musculus,N,,446,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL884526,,,Expert,,1,1,,Mus musculus,N,,447,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615607,,,Expert,,1,1,,Mus musculus,N,,448,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615608,,,Intermediate,,1,1,,Mus musculus,N,,449,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615609,,,Expert,,1,1,,Mus musculus,N,,450,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615682,,,Expert,,1,1,,Mus musculus,N,,451,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615683,,,Intermediate,,1,1,,Mus musculus,N,,452,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested
17780,723.0,NIH3T3,80951,10090.0,,,BAO_0000218,F,,CHEMBL615684,,,Expert,,1,1,,Mus musculus,N,,453,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models
12751,,,104860,10090.0,,,BAO_0000219,F,,CHEMBL615685,,,Autocuration,,1,7,,Mus musculus,D,,454,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells
12380,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615686,,,Expert,,1,1,,Mus musculus,N,,455,Inhibition of Swiss 3T3 Mouse fibroblast proliferation
14892,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615687,,,Intermediate,,1,1,,Mus musculus,N,,456,Inhibitory activity against 3T3 cell line
12695,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL884523,,,Intermediate,,1,1,,Mus musculus,N,,457,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured
12695,,,11169,,,,BAO_0000019,F,,CHEMBL615688,,,Expert,,1,8,,,H,,458,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.
12695,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615689,,,Intermediate,,1,1,,Mus musculus,N,,459,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested
12695,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615690,,,Intermediate,,1,1,,Mus musculus,N,,460,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured
12695,,,11169,,,,BAO_0000019,F,,CHEMBL615691,,,Expert,,1,8,,,H,,461,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells
12695,,,11169,,,,BAO_0000019,F,,CHEMBL615692,,,Expert,,1,8,,,H,,462,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615693,,,Intermediate,,1,1,,Mus musculus,N,,463,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration
6277,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615324,,,Expert,,1,1,,Mus musculus,N,,464,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data
4959,723.0,NIH3T3,9,9606.0,,,BAO_0000219,F,,CHEMBL615325,,,Expert,,1,9,,Homo sapiens,D,,465,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells
4959,723.0,NIH3T3,9,9606.0,,,BAO_0000219,F,,CHEMBL615490,,,Expert,,1,9,,Homo sapiens,D,,466,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested)
4959,723.0,NIH3T3,188,9606.0,,,BAO_0000219,F,,CHEMBL615491,,,Expert,,1,9,,Homo sapiens,D,,467,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells
4959,723.0,NIH3T3,188,9606.0,,,BAO_0000219,F,,CHEMBL615492,,,Expert,,1,9,,Homo sapiens,D,,468,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested)
12082,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615493,,,Intermediate,,1,1,,Mus musculus,N,,469,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation
12082,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615494,,,Intermediate,,1,1,,Mus musculus,N,,470,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation
12082,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615495,,,Intermediate,,1,1,,Mus musculus,N,,471,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay
12082,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615496,,,Intermediate,,1,1,,Mus musculus,N,,472,Inhibitory concentration was calculated on 3T3 cells by using growth assay
2643,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615497,,,Intermediate,,1,1,,Mus musculus,N,,473,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells
11926,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615498,,,Expert,,1,1,,Mus musculus,N,,474,Inhibition of Swiss 3T3 mouse fibroblast proliferation
15204,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,A,,CHEMBL615499,,,Intermediate,,1,1,,Mus musculus,N,,475,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.
15992,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL835522,,,Expert,,1,1,,Mus musculus,N,,476,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts
16279,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615500,,,Intermediate,,1,1,,Mus musculus,N,,477,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested
16279,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615501,,,Intermediate,,1,1,,Mus musculus,N,,478,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
16279,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615502,,,Intermediate,,1,1,,Mus musculus,N,,479,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
16279,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615503,,,Intermediate,,1,1,,Mus musculus,N,,480,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
16279,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615504,,,Intermediate,,1,1,,Mus musculus,N,,481,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
16279,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615505,,,Intermediate,,1,1,,Mus musculus,N,,482,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014)
12831,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615506,,,Expert,,1,1,,Mus musculus,N,,483,Inhibition of swiss 3T3 mouse fibroblast proliferation
13497,723.0,NIH3T3,80951,10090.0,,,BAO_0000219,F,,CHEMBL615507,,,Intermediate,,1,1,,Mus musculus,N,,484,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615508,,,Intermediate,,1,1,,,N,,485,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
13618,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615509,,,Intermediate,,1,1,,Mus musculus,N,,486,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation
11902,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615510,,,Intermediate,,1,1,,Mus musculus,N,,487,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM
11902,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615511,,,Intermediate,,1,1,,Mus musculus,N,,488,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM
11902,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615512,,,Intermediate,,1,1,,Mus musculus,N,,489,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM
14840,620.0,3T3-L1,80006,10090.0,,,BAO_0000218,F,,CHEMBL615513,,,Intermediate,,1,1,,Mus musculus,N,,490,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr"
14840,620.0,3T3-L1,80006,10090.0,,,BAO_0000218,F,,CHEMBL615514,,,Intermediate,,1,1,,Mus musculus,N,,491,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr"
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615515,,,Intermediate,,1,1,,,N,,492,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615516,,,Intermediate,,1,1,,,N,,493,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615517,,,Intermediate,,1,1,,,N,,494,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615518,,,Intermediate,,1,1,,,N,,495,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615519,,,Intermediate,,1,1,,,N,,496,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615520,,,Intermediate,,1,1,,,N,,497,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615521,,,Intermediate,,1,1,,,N,,498,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615522,,,Intermediate,,1,1,,,N,,499,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615523,,,Intermediate,,1,1,,,N,,500,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615524,,,Expert,,1,1,,,N,,501,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615525,,,Expert,,1,1,,,N,,502,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615526,,,Intermediate,,1,1,,,N,,503,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615527,,,Intermediate,,1,1,,,N,,504,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615528,,,Intermediate,,1,1,,,N,,505,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615529,,,Expert,,1,1,,,N,,506,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615530,,,Expert,,1,1,,,N,,507,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615531,,,Expert,,1,1,,,N,,508,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615532,,,Intermediate,,1,1,,,N,,509,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615533,,,Intermediate,,1,1,,,N,,510,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000219,F,,CHEMBL615534,,,Intermediate,,1,1,,,N,,511,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615535,,,Intermediate,,1,1,,,N,,512,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615536,,,Intermediate,,1,1,,,N,,513,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615537,,,Intermediate,,1,1,,,N,,514,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL615538,,,Intermediate,,1,1,,,N,,515,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.
13715,620.0,3T3-L1,80006,,,,BAO_0000218,F,,CHEMBL836166,,,Intermediate,,1,1,,,N,,516,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.
6411,620.0,3T3-L1,11214,,,,BAO_0000219,F,,CHEMBL615539,,,Expert,,1,8,,,H,,517,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells
6411,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615540,,,Intermediate,,1,1,,Mus musculus,N,,518,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data
6411,620.0,3T3-L1,11214,,,,BAO_0000219,F,,CHEMBL615541,,,Expert,,1,8,,,H,,519,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active
3966,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615542,,,Expert,,1,1,,Mus musculus,N,,520,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone
3966,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615543,,,Intermediate,,1,1,,Mus musculus,N,,521,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone
15556,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615544,,,Expert,,1,1,,Mus musculus,N,,522,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone
5845,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615545,,,Expert,,1,1,,Mus musculus,N,,523,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
14422,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615546,,,Expert,,1,1,,Mus musculus,N,,524,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells
5845,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615547,,,Expert,,1,1,,Mus musculus,N,,525,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells
14508,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615548,,,Expert,,1,1,,Mus musculus,N,,526,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.
14508,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615549,,,Expert,,1,1,,Mus musculus,N,,527,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.
14508,620.0,3T3-L1,80006,10090.0,,,BAO_0000219,F,,CHEMBL615550,,,Expert,,1,1,,Mus musculus,N,,528,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.
6349,1118.0,3Y1 cell line,80622,10116.0,,,BAO_0000219,F,,CHEMBL615551,,,Intermediate,,1,1,,Rattus norvegicus,N,,529,Inhibitory activity against rat fibroblast (3Y1) cell line
15899,1118.0,3Y1 cell line,80622,10116.0,,,BAO_0000219,F,,CHEMBL615552,,,Expert,,1,1,,Rattus norvegicus,N,,530,Mean concentration causing inhibition of cell growth in 3Y1 cells.
15899,1118.0,3Y1 cell line,80622,10116.0,,,BAO_0000219,F,,CHEMBL615553,,,Expert,,1,1,,Rattus norvegicus,N,,531,Cytotoxicity in 3Y1 cells.
15899,1118.0,3Y1 cell line,80622,10116.0,,,BAO_0000219,F,,CHEMBL615554,,,Expert,,1,1,,Rattus norvegicus,N,,532,Cytostatic effect in 3Y1 cells.
15899,1118.0,3Y1 cell line,80622,10116.0,,,BAO_0000219,F,,CHEMBL615555,,,Intermediate,,1,1,,Rattus norvegicus,N,,533,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect"
17038,1118.0,3Y1 cell line,80622,10116.0,,,BAO_0000219,F,,CHEMBL615556,,,Expert,,1,1,,Rattus norvegicus,N,,534,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure
12421,,,22226,,,,BAO_0000019,B,,CHEMBL615557,,,Autocuration,,1,0,,,U,,535,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase
12947,,,22226,,,,BAO_0000019,B,,CHEMBL615558,,,Autocuration,,1,0,,,U,,536,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
12947,,,22226,,,,BAO_0000019,B,,CHEMBL872066,,,Autocuration,,1,0,,,U,,537,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase
4896,,,11607,9823.0,,,BAO_0000019,B,,CHEMBL615559,,,Expert,,1,9,,Sus scrofa,D,,538,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method
6148,,,11607,,,,BAO_0000019,B,,CHEMBL615560,,,Autocuration,,1,8,,,H,,539,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver
16432,,,11607,,,,BAO_0000019,B,,CHEMBL615561,,,Autocuration,,1,8,,,H,,540,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme
4978,,,11607,,,,BAO_0000019,B,,CHEMBL857062,,,Expert,,1,8,,,H,,541,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver
4978,,,11607,,,,BAO_0000019,B,,CHEMBL615562,,,Expert,,1,8,,,H,,542,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value)
3723,,,11607,,,,BAO_0000019,B,,CHEMBL615563,,,Autocuration,,1,8,,,H,,543,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method
3518,,,11607,,,,BAO_0000357,B,,CHEMBL615564,,,Autocuration,,1,8,,,H,,544,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD)
4164,,,11607,,,,BAO_0000019,B,,CHEMBL615565,,,Autocuration,,1,8,,,H,,545,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method
3518,,,11607,,,,BAO_0000019,B,,CHEMBL615566,,,Autocuration,,1,8,,,H,,546,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated
4164,,,11607,9823.0,,,BAO_0000019,B,,CHEMBL615567,,,Expert,,1,9,,Sus scrofa,D,,547,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method
3518,,,11607,,,,BAO_0000019,B,,CHEMBL615568,,,Autocuration,,1,8,,,H,,548,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.
3518,,,11607,,,,BAO_0000357,B,,CHEMBL615569,,,Autocuration,,1,8,,,H,,549,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM)
4978,,,11607,,,,BAO_0000019,B,,CHEMBL615570,,,Autocuration,,1,8,,,H,,550,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver
4978,,,11607,,,,BAO_0000019,B,,CHEMBL615571,,,Autocuration,,1,8,,,H,,551,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value)
6455,,,104733,,,,BAO_0000224,B,,CHEMBL615572,,,Autocuration,,1,4,,,H,,552,Binding affinity against melatonin (MT1) receptor (pC1)
2222,,,22226,,,,BAO_0000019,B,,CHEMBL615573,,,Autocuration,,1,0,,,U,,553,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor
13020,,,22226,,,,BAO_0000019,B,,CHEMBL615574,,,Autocuration,,1,0,,,U,,554,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M
13021,,,22226,,,,BAO_0000019,B,,CHEMBL615575,,,Autocuration,,1,0,,,U,,555,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system
14532,,,10619,,,,BAO_0000357,B,,CHEMBL615576,,,Autocuration,,1,8,,,H,,556,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration
14118,,,10619,,,,BAO_0000357,B,,CHEMBL615577,,,Autocuration,,1,8,,,H,,557,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand
11884,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615578,,,Autocuration,Hippocampus,1,8,,,H,,558,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT
13969,,,51,,,,BAO_0000357,B,,CHEMBL615579,,,Expert,,1,8,,,H,,559,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand
13392,,,51,,,,BAO_0000357,B,,CHEMBL615580,,,Expert,,1,8,,,H,,560,Binding affinity for 5-hydroxytryptamine 1A receptor
14430,,,51,,,,BAO_0000019,B,,CHEMBL615581,,,Expert,,1,8,,,H,,561,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT
12248,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615582,,,Autocuration,Hippocampus,1,8,,,H,,562,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
12249,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615583,,,Autocuration,Hippocampus,1,8,,,H,,563,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615584,,,Autocuration,Hippocampus,1,8,,,H,,564,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL833691,,,Autocuration,Hippocampus,1,8,,,H,,565,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615585,,,Autocuration,Hippocampus,1,8,,,H,,566,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615586,,,Autocuration,Hippocampus,1,8,,,H,,567,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL884524,,,Autocuration,Hippocampus,1,8,,,H,,568,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
12249,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615587,,,Autocuration,Hippocampus,1,8,,,H,,569,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
11799,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615588,,,Autocuration,Hippocampus,1,8,,,H,,570,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
14331,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL615589,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,571,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes
11884,,,51,9913.0,,,BAO_0000221,B,10000000.0,CHEMBL615442,,,Expert,Hippocampus,1,8,,Bos taurus,H,,572,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.
14331,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615443,,,Autocuration,Hippocampus,1,8,,,H,,573,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined
11701,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615444,,,Autocuration,Hippocampus,1,8,,,H,,574,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus
11701,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615445,,,Expert,Hippocampus,1,8,,,H,,575,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.
12248,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615446,,,Autocuration,Hippocampus,1,8,,,H,,576,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus
12248,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615447,,,Autocuration,,1,8,,,H,,577,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells
12248,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615448,,,Expert,Hippocampus,1,8,,,H,,578,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
12249,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615449,,,Expert,Hippocampus,1,8,,,H,,579,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus
12248,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615450,,,Autocuration,,1,8,,,H,,580,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
11799,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615451,,,Expert,Hippocampus,1,8,,,H,,581,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand"
634,,,51,,,,BAO_0000357,B,,CHEMBL615452,,,Autocuration,,1,8,,,H,,582,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615453,,,Autocuration,Hippocampus,1,8,,,H,,583,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615454,,,Autocuration,Hippocampus,1,8,,,H,,584,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615455,,,Autocuration,Hippocampus,1,8,,,H,,585,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615456,,,Autocuration,Hippocampus,1,8,,,H,,586,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus
9995,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615457,,,Autocuration,Hippocampus,1,8,,,H,,587,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus
12210,,,51,,,,BAO_0000218,B,10000000.0,CHEMBL615458,,,Expert,Hippocampus,1,8,,,H,,588,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.
13311,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL615459,,,Expert,Hippocampus,1,8,,,H,,589,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
2331,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL615460,,,Expert,,1,9,,Homo sapiens,D,,590,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells."
1375,,,51,10141.0,,,BAO_0000019,F,,CHEMBL615461,,,Autocuration,,1,8,,Cavia porcellus,H,,591,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig
1375,,,51,10141.0,,,BAO_0000019,F,,CHEMBL615462,,,Autocuration,,1,8,,Cavia porcellus,H,,592,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested
11574,,,51,10141.0,,,BAO_0000221,F,10000000.0,CHEMBL615463,,,Autocuration,Hippocampus,1,8,,Cavia porcellus,H,,593,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.
12867,,,51,10141.0,,,BAO_0000221,B,2116.0,CHEMBL615464,,,Autocuration,Ileum,1,8,,Cavia porcellus,H,,594,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
12867,,,51,10141.0,,,BAO_0000221,B,2116.0,CHEMBL615465,,,Autocuration,Ileum,1,8,,Cavia porcellus,H,,595,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
12867,,,51,10141.0,,,BAO_0000221,B,2116.0,CHEMBL615466,,,Autocuration,Ileum,1,8,,Cavia porcellus,H,,596,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.
12867,,,51,10141.0,,,BAO_0000221,B,2116.0,CHEMBL615467,,,Autocuration,Ileum,1,8,,Cavia porcellus,H,,597,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
12867,,,51,10141.0,,,BAO_0000221,B,2116.0,CHEMBL615468,,,Autocuration,Ileum,1,8,,Cavia porcellus,H,,598,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM
12867,,,51,10141.0,,,BAO_0000221,B,2116.0,CHEMBL615469,,,Autocuration,Ileum,1,8,,Cavia porcellus,H,,599,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM
11574,,,51,10141.0,,,BAO_0000357,B,,CHEMBL615470,,,Autocuration,,1,8,,Cavia porcellus,H,,600,Binding affinity against 5-hydroxytryptamine 1A receptor
13114,,,51,10141.0,,,BAO_0000357,B,,CHEMBL615471,,,Autocuration,,1,8,,Cavia porcellus,H,,601,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor
13181,,,51,10141.0,,,BAO_0000357,B,,CHEMBL615472,,,Autocuration,,1,8,,Cavia porcellus,H,,602,Binding affinity was determined against 5-hydroxytryptamine 1A receptor
10639,,,106,10141.0,,,BAO_0000221,B,10000000.0,CHEMBL883242,,,Autocuration,Hippocampus,1,8,,Cavia porcellus,H,,603,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
10639,,,106,10141.0,,,BAO_0000221,F,10000000.0,CHEMBL615473,,,Autocuration,Hippocampus,1,8,,Cavia porcellus,H,,604,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus
11883,449.0,CHO,11863,10029.0,,,BAO_0000218,B,,CHEMBL615474,,,Autocuration,,1,8,,Cricetulus griseus,H,,605,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
17785,,,51,,,,BAO_0000357,B,,CHEMBL615475,,,Autocuration,,1,8,,,H,,606,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor
1558,308.0,HeLa,51,,,,BAO_0000219,F,,CHEMBL615476,,,Autocuration,,1,8,,,H,,607,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370
1558,308.0,HeLa,51,,,,BAO_0000219,F,,CHEMBL615477,,,Autocuration,,1,8,,,H,,608,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320
15740,,,51,,,,BAO_0000019,F,,CHEMBL615478,,,Autocuration,,1,8,,,H,,609,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615160,,,Autocuration,,1,8,,,H,,610,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615161,,,Expert,,1,8,,,H,,611,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615162,,,Autocuration,,1,8,,,H,,612,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615163,,,Autocuration,,1,8,,,H,,613,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615164,,,Expert,,1,8,,,H,,614,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615165,,,Expert,,1,8,,,H,,615,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615166,,,Autocuration,,1,8,,,H,,616,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined
14256,,,51,,,,BAO_0000219,F,,CHEMBL615167,,,Autocuration,,1,8,,,H,,617,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP
3445,308.0,HeLa,51,9606.0,,,BAO_0000219,B,,CHEMBL615168,,,Expert,,1,9,,Homo sapiens,D,,618,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
3445,308.0,HeLa,51,9606.0,,,BAO_0000219,B,,CHEMBL615169,,,Expert,,1,9,,Homo sapiens,D,,619,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse
17200,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL615170,,,Expert,,1,9,,Homo sapiens,D,,620,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor
17200,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL615171,,,Expert,,1,9,,Homo sapiens,D,,621,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined
15180,,,51,,,,BAO_0000019,F,,CHEMBL615694,,,Autocuration,,1,8,,,H,,622,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
15180,,,51,,,,BAO_0000019,F,,CHEMBL615695,,,Autocuration,,1,8,,,H,,623,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor
16026,,,51,,,,BAO_0000019,F,,CHEMBL615696,,,Autocuration,,1,8,,,H,,624,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615697,,,Autocuration,,1,8,,,H,,625,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
2759,449.0,CHO,51,9606.0,,,BAO_0000219,F,,CHEMBL859410,,,Expert,,1,9,,Homo sapiens,D,,626,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615841,,,Autocuration,,1,8,,,H,,627,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
2759,449.0,CHO,51,9606.0,,,BAO_0000219,F,,CHEMBL615842,,,Expert,,1,9,,Homo sapiens,D,,628,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL835003,,,Autocuration,,1,8,,,H,,629,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615843,,,Autocuration,,1,8,,,H,,630,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1)
2759,449.0,CHO,51,9606.0,,,BAO_0000219,F,,CHEMBL615979,,,Expert,,1,9,,Homo sapiens,D,,631,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1)
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615980,,,Autocuration,,1,8,,,H,,632,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2)
2759,449.0,CHO,51,9606.0,,,BAO_0000219,F,,CHEMBL615981,,,Expert,,1,9,,Homo sapiens,D,,633,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2)
3445,,,51,9606.0,,,BAO_0000019,F,,CHEMBL615982,,,Expert,,1,9,,Homo sapiens,D,,634,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL615983,,,Expert,,1,9,,Homo sapiens,D,,635,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL615984,,,Expert,,1,9,,Homo sapiens,D,,636,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL615985,,,Expert,,1,9,,Homo sapiens,D,,637,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,"
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615986,,,Autocuration,,1,8,,,H,,638,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615987,,,Autocuration,,1,8,,,H,,639,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615988,,,Autocuration,,1,8,,,H,,640,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615989,,,Expert,,1,8,,,H,,641,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615990,,,Autocuration,,1,8,,,H,,642,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615991,,,Autocuration,,1,8,,,H,,643,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615992,,,Autocuration,,1,8,,,H,,644,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615993,,,Autocuration,,1,8,,,H,,645,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615994,,,Expert,,1,8,,,H,,646,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615995,,,Autocuration,,1,8,,,H,,647,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615996,,,Autocuration,,1,8,,,H,,648,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615997,,,Autocuration,,1,8,,,H,,649,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined
6563,,,51,,,,BAO_0000019,F,,CHEMBL615998,,,Autocuration,,1,8,,,H,,650,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
6563,,,51,,,,BAO_0000019,F,,CHEMBL615999,,,Autocuration,,1,8,,,H,,651,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
6563,,,51,,,,BAO_0000019,F,,CHEMBL616000,,,Autocuration,,1,8,,,H,,652,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
17296,722.0,HEK293,51,,,,BAO_0000219,F,,CHEMBL616001,,,Autocuration,,1,8,,,H,,653,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
6876,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616002,,,Expert,,1,9,,Homo sapiens,D,,654,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine"
6876,,,51,,,,BAO_0000019,F,,CHEMBL616003,,,Expert,,1,8,,,H,,655,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616004,,,Expert,,1,9,,Homo sapiens,D,,656,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616005,,,Expert,,1,9,,Homo sapiens,D,,657,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data
5548,,,51,,,,BAO_0000019,F,,CHEMBL616006,,,Autocuration,,1,8,,,H,,658,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
5548,,,51,,,,BAO_0000019,F,,CHEMBL616007,,,Expert,,1,8,,,H,,659,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding"
5548,,,51,,,,BAO_0000019,F,,CHEMBL616008,,,Autocuration,,1,8,,,H,,660,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
5548,,,51,,,,BAO_0000019,F,,CHEMBL616009,,,Autocuration,,1,8,,,H,,661,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined"
5929,,,51,,,,BAO_0000019,F,,CHEMBL616010,,,Expert,,1,8,,,H,,662,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding"
5929,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616011,,,Expert,,1,9,,Homo sapiens,D,,663,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined"
5929,,,51,9606.0,,,BAO_0000019,F,,CHEMBL615740,,,Expert,,1,9,,Homo sapiens,D,,664,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined"
16245,,,51,,,,BAO_0000019,F,,CHEMBL615741,,,Autocuration,,1,8,,,H,,665,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor"
5640,,,51,,,,BAO_0000019,F,,CHEMBL615742,,,Expert,,1,8,,,H,,666,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
5640,,,51,,,,BAO_0000019,F,,CHEMBL615743,,,Autocuration,,1,8,,,H,,667,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined"
14509,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615744,,,Autocuration,,1,8,,,H,,668,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay
14509,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615745,,,Expert,,1,8,,,H,,669,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.
15331,,,51,,,,BAO_0000357,B,,CHEMBL615746,,,Autocuration,,1,8,,,H,,670,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
15331,,,51,,,,BAO_0000357,B,,CHEMBL615747,,,Autocuration,,1,8,,,H,,671,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
6563,,,51,,,,BAO_0000019,F,,CHEMBL615748,,,Autocuration,,1,8,,,H,,672,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
6563,,,51,,,,BAO_0000019,F,,CHEMBL615749,,,Autocuration,,1,8,,,H,,673,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available"
6563,,,51,,,,BAO_0000019,F,,CHEMBL615750,,,Autocuration,,1,8,,,H,,674,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay
6563,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616259,,,Expert,,1,9,,Homo sapiens,D,,675,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor
6563,,,51,,,,BAO_0000019,F,,CHEMBL616260,,,Autocuration,,1,8,,,H,,676,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616261,,,Expert,,1,9,,Homo sapiens,D,,677,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616262,,,Expert,,1,9,,Homo sapiens,D,,678,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616263,,,Expert,,1,9,,Homo sapiens,D,,679,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616264,,,Expert,,1,9,,Homo sapiens,D,,680,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616265,,,Expert,,1,9,,Homo sapiens,D,,681,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616266,,,Expert,,1,9,,Homo sapiens,D,,682,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616267,,,Expert,,1,9,,Homo sapiens,D,,683,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data"
5272,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616268,,,Expert,,1,9,,Homo sapiens,D,,684,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data
16146,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616269,,,Expert,,1,9,,Homo sapiens,D,,685,Inhibition of human 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL884528,,,Autocuration,,1,8,,,H,,686,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
13706,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL616270,,,Expert,,1,9,,,D,,687,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells
15250,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL616271,,,Autocuration,,1,8,,,H,,688,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL616272,,,Autocuration,,1,8,,,H,,689,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
6861,,,51,,,,BAO_0000357,B,,CHEMBL616273,,,Expert,,1,8,,,H,,690,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay
17200,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616274,,,Expert,,1,9,,Homo sapiens,D,,691,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL616275,,,Autocuration,,1,8,,,H,,692,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL616276,,,Autocuration,,1,8,,,H,,693,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616277,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,694,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616278,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,695,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616279,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,696,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616280,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,697,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616281,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,698,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616282,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,699,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616283,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,700,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616284,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,701,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616285,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,702,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616286,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,703,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616287,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,704,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616288,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,705,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL616289,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,706,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615610,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,707,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615611,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,708,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615612,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,709,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615613,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,710,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615614,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,711,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested
12058,,,22226,10116.0,,,BAO_0000218,F,,CHEMBL615615,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,712,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration
11440,,,105093,,,,BAO_0000019,B,,CHEMBL615616,,,Autocuration,,1,4,,,H,,713,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.
6238,,,11923,,,,BAO_0000249,B,1898.0,CHEMBL615617,,,Autocuration,Hypothalamus,1,8,,,H,,714,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand
10046,,,10577,,,,BAO_0000019,B,,CHEMBL615618,,,Autocuration,,1,8,,,H,,715,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data
10046,,,10577,,,,BAO_0000019,B,,CHEMBL615619,,,Autocuration,,1,8,,,H,,716,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.
10046,,,10577,,,,BAO_0000019,B,,CHEMBL615620,,,Expert,,1,8,,,H,,717,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
167,,,55,,,,BAO_0000357,B,,CHEMBL615621,,,Autocuration,,1,8,,,H,,718,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated"
167,,,55,,,,BAO_0000357,B,,CHEMBL615622,,,Autocuration,,1,8,,,H,,719,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated"
11520,,,12166,,,,BAO_0000019,F,,CHEMBL615623,,,Autocuration,,1,8,,,H,,720,Compound was evaluated for the inhibition of 5-LO (lipoxygenase)
11520,,,12166,,,,BAO_0000019,F,,CHEMBL615624,,,Autocuration,,1,8,,,H,,721,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
11520,,,12166,,,,BAO_0000019,F,,CHEMBL615625,,,Autocuration,,1,8,,,H,,722,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
11520,,,12166,,,,BAO_0000019,F,,CHEMBL767045,,,Autocuration,,1,8,,,H,,723,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).
135,,,55,10141.0,,,BAO_0000019,F,,CHEMBL615626,,,Autocuration,,1,8,,Cavia porcellus,H,,724,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN
135,,,55,10141.0,,,BAO_0000019,F,,CHEMBL615627,,,Autocuration,,1,8,,Cavia porcellus,H,,725,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity
11311,,,55,10141.0,,,BAO_0000019,B,,CHEMBL615628,,,Autocuration,,1,8,,Cavia porcellus,H,,726,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes
10193,,,55,10141.0,,,BAO_0000357,B,,CHEMBL615629,,,Autocuration,,1,8,,Cavia porcellus,H,,727,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
12281,,,55,9606.0,,,BAO_0000357,B,,CHEMBL615630,,,Expert,,1,9,,Homo sapiens,D,,728,Inhibitory concentration against 5-lipoxygenase from human whole blood
11311,,,55,,,,BAO_0000219,B,,CHEMBL615631,,,Autocuration,,1,8,,,H,,729,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS]
12576,,,17087,,,,BAO_0000218,F,,CHEMBL615632,,,Autocuration,,1,8,,,H,,730,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
12281,,,17087,,,,BAO_0000357,B,,CHEMBL615633,,,Autocuration,,1,8,,,H,,731,Inhibitory concentration against 5-lipoxygenase from mouse macrophage
12576,,,17087,,,,BAO_0000218,F,,CHEMBL615634,,,Autocuration,,1,8,,,H,,732,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg
11089,,,55,9823.0,,,BAO_0000019,B,,CHEMBL615635,,,Expert,,1,8,,Sus scrofa,H,,733,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.
11006,,,12166,,,,BAO_0000357,B,,CHEMBL615636,,,Expert,,1,8,,,H,,734,In vitro inhibition of rat 5-Lipoxygenase
11481,,,12166,10116.0,,,BAO_0000357,B,,CHEMBL615637,,,Expert,,1,9,,Rattus norvegicus,D,,735,Inhibitory activity against 5-Lipoxygenase
10864,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL615638,,,Expert,,1,8,,,H,,736,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL615639,,,Autocuration,,1,8,,,H,,737,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
11311,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL615640,,,Autocuration,,1,8,,,H,,738,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1
11311,,,12166,,,,BAO_0000019,B,,CHEMBL615796,,,Autocuration,,1,8,,,H,,739,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood
11311,,,12166,,,,BAO_0000219,B,,CHEMBL615845,,,Autocuration,,1,8,,,H,,740,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS]
11006,,,12166,,,,BAO_0000357,B,,CHEMBL615846,,,Autocuration,,1,8,,,H,,741,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL615847,,,Autocuration,,1,8,,,H,,742,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
11311,,,12166,,,,BAO_0000357,B,,CHEMBL615848,,,Autocuration,,1,8,,,H,,743,The compound was tested for inhibition of isolated 5-Lipoxygenase
11481,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615849,,,Autocuration,,1,0,,Rattus norvegicus,U,,744,Ratio of IC50 against 5-LO and COX
11006,,,12166,,,,BAO_0000357,B,,CHEMBL615850,,,Autocuration,,1,8,,,H,,745,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM
11006,,,12166,,,,BAO_0000357,B,,CHEMBL615851,,,Autocuration,,1,8,,,H,,746,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%
11311,,,12166,,,,BAO_0000219,B,,CHEMBL615852,,,Autocuration,,1,8,,,H,,747,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration
11006,,,12166,,,,BAO_0000019,F,,CHEMBL615853,,,Autocuration,,1,8,,,H,,748,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo
4288,,,120,,,,BAO_0000357,B,2367.0,CHEMBL884527,,,Autocuration,Prostate gland,1,8,,,H,,749,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates
7587,,,22226,8932.0,,,BAO_0000019,B,,CHEMBL872871,,,Autocuration,,1,0,,Columba livia,U,,750,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration
7587,,,22226,8932.0,,,BAO_0000019,B,,CHEMBL615854,,,Autocuration,,1,0,,Columba livia,U,,751,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration
7587,,,22226,8932.0,,,BAO_0000019,B,,CHEMBL767046,,,Autocuration,,1,0,,Columba livia,U,,752,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.
11249,,,10732,,,,BAO_0000357,B,,CHEMBL615855,,,Autocuration,,1,8,,,H,,753,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM
8003,,,12198,10116.0,,,BAO_0000019,F,,CHEMBL615856,,,Expert,,1,9,,Rattus norvegicus,D,,754,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested
8003,,,12198,10116.0,,,BAO_0000019,F,,CHEMBL615857,,,Expert,,1,9,,Rattus norvegicus,D,,755,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
8003,,,12198,10116.0,,,BAO_0000019,F,,CHEMBL615858,,,Expert,,1,9,,Rattus norvegicus,D,,756,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT)
12416,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615859,,,Expert,Hippocampus,1,8,,,H,,757,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
16293,,,51,,,,BAO_0000357,B,,CHEMBL615860,,,Autocuration,,1,8,,,H,,758,Binding affinity towards human 5-hydroxytryptamine 1 receptor
13047,,,22226,9986.0,,,BAO_0000019,B,,CHEMBL615861,,,Autocuration,,1,0,,Oryctolagus cuniculus,U,,759,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
13047,,,22226,9986.0,,,BAO_0000019,B,,CHEMBL615862,,,Autocuration,,1,0,,Oryctolagus cuniculus,U,,760,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
13047,,,22226,9986.0,,,BAO_0000019,B,,CHEMBL615863,,,Autocuration,,1,0,,Oryctolagus cuniculus,U,,761,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.
13047,,,22226,9986.0,,,BAO_0000019,B,,CHEMBL615864,,,Autocuration,,1,0,,Oryctolagus cuniculus,U,,762,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
10085,,,104744,,,,BAO_0000221,B,10000000.0,CHEMBL615865,,,Autocuration,Hippocampus,1,4,,,H,,763,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
10085,,,104744,,,,BAO_0000221,B,10000000.0,CHEMBL615866,,,Autocuration,Hippocampus,1,4,,,H,,764,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
10085,,,104744,,,,BAO_0000221,B,10000000.0,CHEMBL615867,,,Autocuration,Hippocampus,1,4,,,H,,765,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT
9841,,,104744,,,,BAO_0000249,B,,CHEMBL615868,,Membranes,Autocuration,,1,4,,,H,,766,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes
8822,,,104744,10116.0,,,BAO_0000249,B,,CHEMBL615869,,,Autocuration,,1,5,,Rattus norvegicus,D,,767,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat
9806,,,104744,10116.0,,,BAO_0000019,B,,CHEMBL615870,,,Autocuration,,1,5,,Rattus norvegicus,D,,768,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand
9806,,,104744,10116.0,,,BAO_0000019,B,,CHEMBL615871,,,Autocuration,,1,5,,Rattus norvegicus,D,,769,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates
8868,,,104744,,,,BAO_0000224,B,,CHEMBL615872,,,Autocuration,,1,4,,,H,,770,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay
9036,,,104744,,,,BAO_0000221,B,10000000.0,CHEMBL833492,,,Autocuration,Hippocampus,1,4,,,H,,771,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT
11374,,,104744,,,,BAO_0000221,B,10000000.0,CHEMBL615873,,,Autocuration,Hippocampus,1,4,,,H,,772,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus
10881,,,104744,,,,BAO_0000224,B,,CHEMBL615479,,,Autocuration,,1,4,,,H,,773,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.
8822,,,104744,,,,BAO_0000019,B,,CHEMBL615480,,,Autocuration,,1,4,,,H,,774,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat
9806,,,104744,10116.0,,,BAO_0000249,B,,CHEMBL615481,,,Autocuration,,1,5,,Rattus norvegicus,D,,775,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.
15463,,,104744,,,,BAO_0000019,B,,CHEMBL872869,,,Autocuration,,1,4,,,H,,776,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
15463,,,104744,,,,BAO_0000019,B,,CHEMBL615482,,,Autocuration,,1,4,,,H,,777,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
14542,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615483,,,Autocuration,Brain,1,4,,,H,,778,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
14542,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615484,,,Autocuration,Brain,1,4,,,H,,779,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
8569,,,104744,,,,BAO_0000019,B,,CHEMBL615485,,,Autocuration,,1,4,,,H,,780,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM
10062,,,104744,10116.0,,,BAO_0000224,B,,CHEMBL615486,,,Autocuration,,1,5,,Rattus norvegicus,D,,781,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor
4771,,,104744,,,,BAO_0000224,B,,CHEMBL615487,,,Autocuration,,1,4,,,H,,782,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor
10062,,,104744,,,,BAO_0000224,B,,CHEMBL615488,,,Autocuration,,1,4,,,H,,783,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
10062,,,104744,,,,BAO_0000224,B,,CHEMBL615489,,,Autocuration,,1,4,,,H,,784,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
10062,,,104744,,,,BAO_0000224,B,,CHEMBL615389,,,Autocuration,,1,4,,,H,,785,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor
15463,,,104744,,,,BAO_0000019,B,,CHEMBL615390,,,Autocuration,,1,4,,,H,,786,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
15463,,,104744,,,,BAO_0000019,B,,CHEMBL615391,,,Autocuration,,1,4,,,H,,787,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand
9098,,,104744,,,,BAO_0000224,B,,CHEMBL615392,,,Autocuration,,1,4,,,H,,788,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined
3070,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615393,,,Autocuration,,1,0,,Rattus norvegicus,U,,789,Affinity for 5-hydroxytryptamine 1 receptor
14542,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615394,,,Autocuration,Brain,1,4,,,H,,790,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex
14542,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615395,,,Autocuration,Brain,1,4,,,H,,791,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM
6398,,,104744,,,,BAO_0000224,B,,CHEMBL615396,,,Autocuration,,1,4,,,H,,792,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding
1344,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615397,,,Autocuration,Brain,1,4,,,H,,793,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay
11963,,,104744,,,,BAO_0000019,B,,CHEMBL615398,,,Autocuration,,1,4,,,H,,794,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex
8908,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615399,,,Autocuration,,1,0,,Rattus norvegicus,U,,795,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex
9098,,,104744,,,,BAO_0000019,B,,CHEMBL615400,,,Autocuration,,1,4,,,H,,796,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.
8841,,,104744,10116.0,,,BAO_0000019,B,,CHEMBL615401,,,Autocuration,,1,5,,Rattus norvegicus,D,,797,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex
8814,,,22226,10116.0,,,BAO_0000019,B,,CHEMBL615402,,,Autocuration,,1,0,,Rattus norvegicus,U,,798,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates
11752,,,104744,,,,BAO_0000019,B,,CHEMBL615403,,,Autocuration,,1,4,,,H,,799,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex
11642,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615404,,,Autocuration,Brain,1,4,,,H,,800,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue
11642,,,104744,,,,BAO_0000019,B,,CHEMBL615781,,,Autocuration,,1,4,,,H,,801,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex
9231,,,104744,,,,BAO_0000220,B,955.0,CHEMBL615782,,,Autocuration,Brain,1,4,,,H,,802,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes
11351,,,104744,,,,BAO_0000221,B,955.0,CHEMBL615783,,,Autocuration,Brain,1,4,,,H,,803,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.
4639,,,22226,,,,BAO_0000019,B,,CHEMBL873481,,,Autocuration,,1,0,,,U,,804,Compound was tested for binding affinity against 5-HT1 receptor
1205,,,22226,,,,BAO_0000019,B,,CHEMBL615784,,,Autocuration,,1,0,,,U,,805,Inhibitory concentration against 5-hydroxytryptamine 1 receptor
10025,,,10576,,,,BAO_0000357,B,,CHEMBL615785,,,Expert,,1,8,,,H,,806,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
13241,,,10576,,,,BAO_0000249,F,,CHEMBL615786,,,Autocuration,,1,8,,,H,,807,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
16245,,,10576,,,,BAO_0000218,F,,CHEMBL615787,,,Autocuration,,1,8,,,H,In vivo,808,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
16245,,,10576,,,,BAO_0000218,F,,CHEMBL615788,,,Autocuration,,1,8,,,H,In vivo,809,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
12438,,,10576,,,,BAO_0000019,F,,CHEMBL767044,,,Autocuration,,1,8,,,H,,810,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor
16245,,,10576,,,,BAO_0000218,F,,CHEMBL615789,,,Autocuration,,1,8,,,H,In vivo,811,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration
16245,,,10576,,,,BAO_0000218,F,,CHEMBL615790,,,Autocuration,,1,8,,,H,In vivo,812,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration
15740,,,10576,,,,BAO_0000019,F,,CHEMBL615813,,,Autocuration,,1,8,,,H,,813,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats
15535,,,10576,,,,BAO_0000219,F,,CHEMBL615814,,,Autocuration,,1,8,,,H,,814,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration
15535,,,51,,,,BAO_0000219,F,,CHEMBL615815,,,Expert,,1,8,,,H,,815,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT
15535,,,10576,,,,BAO_0000219,F,,CHEMBL615816,,,Autocuration,,1,8,,,H,,816,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect
9888,,,10576,,,,BAO_0000249,B,,CHEMBL615817,,,Expert,,1,8,,,H,,817,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values
10085,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615818,,,Autocuration,Hippocampus,1,8,,,H,,818,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT
10085,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615819,,,Autocuration,Hippocampus,1,8,,,H,,819,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT
17331,,,10576,,,,BAO_0000249,B,,CHEMBL615820,,Membranes,Expert,,1,8,,,H,,820,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes
10845,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL615821,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,821,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT
10845,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL615822,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,822,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
10845,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615823,,,Expert,Hippocampus,1,8,,,H,,823,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand
10845,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL615824,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,824,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive
10845,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL615825,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,825,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT
13730,,,10576,,,,BAO_0000357,B,,CHEMBL615826,,,Expert,,1,8,,,H,,826,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand
13508,,,10576,,,,BAO_0000249,B,,CHEMBL615827,,,Expert,,1,8,,,H,,827,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand
13508,,,10576,,,,BAO_0000249,B,10000000.0,CHEMBL615828,,,Expert,Hippocampus,1,8,,,H,,828,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand
12073,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615829,,,Expert,Hippocampus,1,8,,,H,,829,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
4671,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615830,,,Autocuration,Hippocampus,1,8,,,H,,830,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand
13631,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615831,,,Expert,Hippocampus,1,8,,,H,,831,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand
12438,,,10576,,,,BAO_0000357,B,,CHEMBL615832,,,Autocuration,,1,8,,,H,,832,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor
10483,,,10576,,,,BAO_0000019,B,,CHEMBL615833,,,Autocuration,,1,8,,,H,,833,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand
10483,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615834,,,Autocuration,Hippocampus,1,8,,,H,,834,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand
12352,,,10576,,,,BAO_0000249,B,,CHEMBL615835,,,Intermediate,,1,8,,,H,,835,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes
14732,,,10576,,,,BAO_0000249,B,10000000.0,CHEMBL615836,,,Autocuration,Hippocampus,1,8,,,H,,836,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.
11049,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL615837,,,Expert,,1,9,,Rattus norvegicus,D,,837,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.
11049,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL615838,,,Expert,,1,9,,Rattus norvegicus,D,,838,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined
13657,,,10576,,,,BAO_0000249,B,,CHEMBL615839,,,Expert,,1,8,,,H,,839,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)"
11473,,,10576,,,,BAO_0000019,B,,CHEMBL884525,,,Autocuration,,1,8,,,H,,840,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand
2014,,,10576,,,,BAO_0000249,B,,CHEMBL615840,,,Autocuration,,1,8,,,H,,841,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
3086,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615405,,,Expert,Hippocampus,1,8,,,H,,842,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
15854,,,10576,,,,BAO_0000019,B,,CHEMBL615406,,,Expert,,1,8,,,H,,843,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
10922,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615900,,,Expert,Hippocampus,1,8,,,H,,844,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
13346,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615901,,,Expert,Hippocampus,1,8,,,H,,845,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.
15311,,,10576,,,,BAO_0000357,B,,CHEMBL615902,,,Expert,,1,8,,,H,,846,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.
10922,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615903,,,Autocuration,Hippocampus,1,8,,,H,,847,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue
10025,,,10576,,,,BAO_0000357,B,,CHEMBL615904,,,Autocuration,,1,8,,,H,,848,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM
10025,,,10576,,,,BAO_0000357,B,,CHEMBL615905,,,Expert,,1,8,,,H,,849,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM
9742,,,10576,,,,BAO_0000019,B,,CHEMBL615906,,,Autocuration,,1,8,,,H,,850,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
9742,,,10576,,,,BAO_0000019,F,,CHEMBL615907,,,Autocuration,,1,8,,,H,,851,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat
12304,,,10576,,,,BAO_0000019,B,,CHEMBL615908,,,Expert,,1,8,,,H,,852,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
15789,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615909,,,Autocuration,Hippocampus,1,8,,,H,,853,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus
9912,,,10576,,,,BAO_0000019,B,,CHEMBL615910,,,Autocuration,,1,8,,,H,,854,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand"
9912,,,10576,,,,BAO_0000019,B,,CHEMBL615911,,,Autocuration,,1,8,,,H,,855,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand."
9912,,,10576,,,,BAO_0000019,B,,CHEMBL615912,,,Autocuration,,1,8,,,H,,856,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand"
16693,,,10576,,,,BAO_0000019,B,,CHEMBL615913,,,Expert,,1,8,,,H,,857,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand
13276,,,10576,,,,BAO_0000357,B,,CHEMBL615914,,,Expert,,1,8,,,H,,858,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
12678,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615915,,,Autocuration,Hippocampus,1,8,,,H,,859,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
11825,,,10576,,,,BAO_0000357,B,,CHEMBL615916,,,Autocuration,,1,8,,,H,,860,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated
12443,,,10576,,,,BAO_0000357,B,,CHEMBL615917,,,Expert,,1,8,,,H,,861,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin
13830,,,10576,,,,BAO_0000357,B,,CHEMBL615918,,,Expert,,1,8,,,H,,862,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
14286,,,10576,,,,BAO_0000249,B,10000000.0,CHEMBL615919,,,Expert,Hippocampus,1,8,,,H,,863,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.
14356,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL615920,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,864,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
15306,,,10576,,,,BAO_0000357,B,,CHEMBL615921,,,Autocuration,,1,8,,,H,,865,Inhibition concentration against 5-hydroxytryptamine 1A receptor
15306,,,10576,,,,BAO_0000357,B,,CHEMBL615922,,,Expert,,1,8,,,H,,866,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration)
16616,,,10576,10116.0,,,BAO_0000249,F,,CHEMBL881290,,,Expert,,1,9,,Rattus norvegicus,D,,867,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
3651,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615923,,,Autocuration,Hippocampus,1,8,,,H,,868,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%"
14331,,,10576,,,,BAO_0000221,F,10000000.0,CHEMBL615924,,,Autocuration,Hippocampus,1,8,,,H,,869,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
14331,,,10576,,,,BAO_0000221,F,10000000.0,CHEMBL615925,,,Autocuration,Hippocampus,1,8,,,H,,870,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus
14178,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL615926,,,Expert,,1,9,,Rattus norvegicus,D,,871,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor
10639,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL615927,,,Expert,,1,9,,Rattus norvegicus,D,,872,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor
12306,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615928,,,Autocuration,Hippocampus,1,8,,,H,,873,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
1348,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL615929,,,Expert,,1,9,,Rattus norvegicus,D,,874,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype
13605,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615930,,,Autocuration,Hippocampus,1,8,,,H,,875,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615931,,,Autocuration,,1,8,,,H,,876,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615932,,,Autocuration,,1,8,,,H,,877,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL615933,,,Autocuration,,1,8,,,H,,878,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor
15267,,,51,,,,BAO_0000357,B,,CHEMBL615934,,,Autocuration,,1,8,,,H,,879,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
16532,,,51,,,,BAO_0000357,B,,CHEMBL615935,,,Autocuration,,1,8,,,H,,880,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested
6563,,,51,,,,BAO_0000019,F,,CHEMBL615936,,,Autocuration,,1,8,,,H,,881,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay"
4751,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615937,,,Autocuration,,1,8,,,H,,882,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM
15463,,,51,,,,BAO_0000357,B,,CHEMBL615938,,,Autocuration,,1,8,,,H,,883,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor
3805,,,51,,,,BAO_0000357,B,,CHEMBL615797,,,Autocuration,,1,8,,,H,,884,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM)
5640,,,51,,,,BAO_0000357,B,,CHEMBL615798,,,Autocuration,,1,8,,,H,,885,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
6563,,,51,,,,BAO_0000357,B,,CHEMBL872870,,,Autocuration,,1,8,,,H,,886,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration
5548,,,51,,,,BAO_0000357,B,,CHEMBL615799,,,Autocuration,,1,8,,,H,,887,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration
6347,,,51,,,,BAO_0000357,B,,CHEMBL615800,,,Autocuration,,1,8,,,H,,888,Percent binding affinity against 5-hydroxytryptamine 1A receptor
17296,722.0,HEK293,51,,,,BAO_0000219,F,,CHEMBL615801,,,Autocuration,,1,8,,,H,,889,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
13047,,,51,,,,BAO_0000019,B,,CHEMBL615802,,,Autocuration,,1,8,,,H,,890,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium
15740,,,51,,,,BAO_0000357,B,,CHEMBL615803,,,Autocuration,,1,8,,,H,,891,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor
5640,,,51,,,,BAO_0000019,F,,CHEMBL835002,,,Expert,,1,8,,,H,,892,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors."
5640,,,51,,,,BAO_0000019,F,,CHEMBL615804,,,Autocuration,,1,8,,,H,,893,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined"
17211,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL615805,,,Expert,,1,8,,,H,,894,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor
4751,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615806,,,Autocuration,,1,8,,,H,,895,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor
6491,,,51,9606.0,,,BAO_0000357,B,,CHEMBL615807,,,Expert,,1,9,,Homo sapiens,D,,896,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor
4707,,,51,,,,BAO_0000357,B,,CHEMBL615808,,,Autocuration,,1,8,,,H,,897,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand
13910,,,51,9606.0,,,BAO_0000357,B,,CHEMBL615809,,,Expert,,1,9,,Homo sapiens,D,,898,Binding affinity against 5-hydroxytryptamine 1A receptor
16190,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL615810,,,Autocuration,,1,8,,,H,,899,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT
16633,,,51,,,,BAO_0000357,B,,CHEMBL615811,,,Autocuration,,1,8,,,H,,900,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
11898,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615812,,,Autocuration,,1,8,,,H,,901,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells
11898,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615751,,,Autocuration,,1,8,,,H,,902,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
14331,,,51,,,,BAO_0000357,B,,CHEMBL615752,,,Autocuration,,1,8,,,H,,903,Binding affinity against human 5-hydroxytryptamine 1A receptor
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615753,,,Expert,,1,8,,,H,,904,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand
17624,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL615754,,,Autocuration,,1,8,,,H,,905,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined
3307,,,51,,,,BAO_0000357,B,,CHEMBL615755,,,Autocuration,,1,8,,,H,,906,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor
6563,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL615756,,,Expert,,1,9,,Homo sapiens,D,,907,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
14165,,,51,,,,BAO_0000019,B,,CHEMBL615757,,,Autocuration,,1,8,,,H,,908,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand
5732,,,51,,,,BAO_0000357,B,,CHEMBL615758,,,Autocuration,,1,8,,,H,,909,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
13366,,,51,,,,BAO_0000357,B,,CHEMBL615759,,,Expert,,1,8,,,H,,910,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
17626,,,51,,,,BAO_0000357,B,,CHEMBL615760,,,Autocuration,,1,8,,,H,,911,Binding affinity towards human 5-hydroxytryptamine 1A receptor
6588,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL615761,,,Expert,,1,8,,,H,,912,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells
16209,,,51,,,,BAO_0000357,B,,CHEMBL872104,,,Autocuration,,1,8,,,H,,913,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand
15463,,,51,,,,BAO_0000357,B,,CHEMBL615762,,,Autocuration,,1,8,,,H,,914,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
15463,,,51,,,,BAO_0000357,B,,CHEMBL615763,,,Autocuration,,1,8,,,H,,915,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
14770,,,51,,,,BAO_0000357,B,,CHEMBL615764,,,Autocuration,,1,8,,,H,,916,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.
16245,1167.0,Cell line,51,,,,BAO_0000219,B,,CHEMBL615765,,,Autocuration,,1,8,,,H,,917,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La)
16245,,,51,,,,BAO_0000019,B,,CHEMBL615766,,,Autocuration,,1,8,,,H,,918,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La)
5548,,,51,,,,BAO_0000357,B,,CHEMBL615767,,,Autocuration,,1,8,,,H,,919,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand
5548,,,51,,,,BAO_0000357,B,,CHEMBL615768,,,Expert,,1,8,,,H,,920,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
5548,,,51,,,,BAO_0000357,B,,CHEMBL615769,,,Autocuration,,1,8,,,H,,921,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
6876,,,51,,,,BAO_0000357,B,,CHEMBL615770,,,Expert,,1,8,,,H,,922,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT
2598,,,51,,,,BAO_0000357,B,,CHEMBL615771,,,Autocuration,,1,8,,,H,,923,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
17785,,,51,,,,BAO_0000357,B,,CHEMBL615772,,,Expert,,1,8,,,H,,924,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand
6013,,,51,,,,BAO_0000357,B,,CHEMBL615773,,,Autocuration,,1,8,,,H,,925,Binding affinity towards 5-hydroxytryptamine 1A receptor
5929,,,51,,,,BAO_0000357,B,,CHEMBL615774,,,Expert,,1,8,,,H,,926,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
16633,,,51,,,,BAO_0000357,B,,CHEMBL615775,,,Autocuration,,1,8,,,H,,927,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
1558,,,51,,,,BAO_0000357,B,,CHEMBL615776,,,Autocuration,,1,8,,,H,,928,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined
16026,,,51,,,,BAO_0000357,B,,CHEMBL615777,,,Expert,,1,8,,,H,,929,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
12469,,,51,,,,BAO_0000219,B,,CHEMBL615778,,,Autocuration,,1,8,,,H,,930,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT
15874,,,51,9606.0,,,BAO_0000357,B,,CHEMBL615779,,,Expert,,1,9,,Homo sapiens,D,,931,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
15874,,,51,,,,BAO_0000357,B,,CHEMBL615780,,,Autocuration,,1,8,,,H,,932,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
3935,,,51,,,,BAO_0000357,B,,CHEMBL616298,,,Autocuration,,1,8,,,H,,933,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor
15818,,,51,,,,BAO_0000357,B,,CHEMBL616299,,,Autocuration,,1,8,,,H,,934,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor
13706,485.0,CHO-K1,51,,,,BAO_0000219,B,,CHEMBL616300,,,Autocuration,,1,8,,,H,,935,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.
13729,485.0,CHO-K1,51,,,,BAO_0000219,F,,CHEMBL616301,,,Expert,,1,8,,,H,,936,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells
15413,,,51,,,,BAO_0000019,B,,CHEMBL616302,,,Autocuration,,1,8,,,H,,937,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor
15413,,,51,,,,BAO_0000019,B,,CHEMBL616117,,,Autocuration,,1,8,,,H,,938,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1)
15413,,,51,,,,BAO_0000019,B,,CHEMBL616118,,,Autocuration,,1,8,,,H,,939,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2)
15413,,,51,,,,BAO_0000019,B,,CHEMBL616119,,,Autocuration,,1,8,,,H,,940,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay
3445,308.0,HeLa,51,9606.0,,,BAO_0000219,B,,CHEMBL616120,,,Expert,,1,9,,Homo sapiens,D,,941,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells
15740,,,51,,,,BAO_0000357,B,,CHEMBL616121,,,Autocuration,,1,8,,,H,,942,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
15740,,,51,,,,BAO_0000357,B,,CHEMBL616122,,,Autocuration,,1,8,,,H,,943,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor
17626,,,51,,,,BAO_0000357,B,,CHEMBL616123,,,Autocuration,,1,8,,,H,,944,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor
4234,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616124,,,Expert,,1,9,,Homo sapiens,D,,945,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor
5640,,,51,,,,BAO_0000357,B,,CHEMBL616125,,,Expert,,1,8,,,H,,946,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.
5272,,,51,10116.0,,,BAO_0000357,B,,CHEMBL616126,,,Expert,,1,8,,Rattus norvegicus,H,,947,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT
4622,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL616127,,,Autocuration,,1,8,,,H,,948,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand
17085,,,51,,,,BAO_0000019,B,,CHEMBL616128,,,Expert,,1,8,,,H,,949,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor
3025,,,51,,,,BAO_0000357,B,,CHEMBL616129,,,Autocuration,,1,8,,,H,,950,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand
15315,,,51,,,,BAO_0000357,B,,CHEMBL616130,,,Expert,,1,8,,,H,,951,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor
15267,,,51,,,,BAO_0000357,B,,CHEMBL616131,,,Autocuration,,1,8,,,H,,952,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant
17158,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL616132,,,Autocuration,,1,8,,,H,,953,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells
14214,308.0,HeLa,51,9606.0,,,BAO_0000219,B,,CHEMBL616133,,,Expert,,1,9,,Homo sapiens,D,,954,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells
17133,,,51,,,,BAO_0000357,B,,CHEMBL616134,,,Autocuration,,1,8,,,H,,955,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
16532,,,51,,,,BAO_0000357,B,,CHEMBL616135,,,Autocuration,,1,8,,,H,,956,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT
2391,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616136,,,Expert,,1,9,,Homo sapiens,D,,957,Affinity for 5-hydroxytryptamine 1A receptor subtype
14447,,,51,,,,BAO_0000019,B,,CHEMBL616137,,,Autocuration,,1,8,,,H,,958,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes
14447,,,51,,,,BAO_0000019,B,,CHEMBL872105,,,Autocuration,,1,8,,,H,,959,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.
15086,,,51,,,,BAO_0000357,B,,CHEMBL616138,,,Autocuration,,1,8,,,H,,960,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor
13051,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616139,,,Expert,,1,9,,Homo sapiens,D,,961,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor
16026,,,51,,,,BAO_0000019,F,,CHEMBL616140,,,Autocuration,,1,8,,,H,,962,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active"
17085,,,51,,,,BAO_0000019,B,,CHEMBL616141,,,Expert,,1,8,,,H,,963,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined
17133,,,51,,,,BAO_0000357,B,,CHEMBL616142,,,Autocuration,,1,8,,,H,,964,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
17133,,,51,,,,BAO_0000357,B,,CHEMBL616143,,,Autocuration,,1,8,,,H,,965,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined
17211,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL616144,,,Autocuration,,1,8,,,H,,966,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
17211,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL616145,,,Autocuration,,1,8,,,H,,967,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested
17211,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL616012,,,Autocuration,,1,8,,,H,,968,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
17211,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL616013,,,Autocuration,,1,8,,,H,,969,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested
16394,,,51,,,,BAO_0000019,F,,CHEMBL616014,,,Autocuration,,1,8,,,H,,970,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
16394,,,51,,,,BAO_0000019,F,,CHEMBL616015,,,Autocuration,,1,8,,,H,,971,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
16394,,,51,,,,BAO_0000019,F,,CHEMBL616016,,,Autocuration,,1,8,,,H,,972,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested"
16394,,,51,,,,BAO_0000218,F,,CHEMBL616017,,,Autocuration,,1,8,,,H,In vivo,973,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested
16394,,,51,,,,BAO_0000019,B,,CHEMBL616018,,,Autocuration,,1,8,,,H,,974,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested
15740,,,51,,,,BAO_0000019,F,,CHEMBL616019,,,Autocuration,,1,8,,,H,,975,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested
15740,,,51,,,,BAO_0000019,F,,CHEMBL616020,,,Autocuration,,1,8,,,H,,976,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested
15740,,,51,,,,BAO_0000357,B,,CHEMBL858018,,,Autocuration,,1,8,,,H,,977,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor
17296,722.0,HEK293,51,,,,BAO_0000219,F,,CHEMBL616021,,,Autocuration,,1,8,,,H,,978,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
5640,,,51,,,,BAO_0000019,F,,CHEMBL616022,,,Expert,,1,8,,,H,,979,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM."
5640,,,51,,,,BAO_0000019,F,,CHEMBL616023,,,Autocuration,,1,8,,,H,,980,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined"
5640,,,51,,,,BAO_0000019,F,,CHEMBL616024,,,Autocuration,,1,8,,,H,,981,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined"
5640,,,51,,,,BAO_0000019,F,,CHEMBL616025,,,Autocuration,,1,8,,,H,,982,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined"
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL616026,,,Autocuration,,1,8,,,H,,983,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor
16394,,,51,,,,BAO_0000019,F,,CHEMBL616027,,,Autocuration,,1,8,,,H,,984,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT"
16394,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616028,,,Expert,,1,9,,Homo sapiens,D,,985,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT"
3445,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616029,,,Expert,,1,9,,Homo sapiens,D,,986,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response
4316,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL616030,,,Expert,,1,8,,,H,,987,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT
4316,,,51,,,,BAO_0000019,B,,CHEMBL616031,,,Expert,,1,8,,,H,,988,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.
15180,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616032,,,Expert,,1,9,,Homo sapiens,D,,989,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
15180,,,51,9606.0,,,BAO_0000019,F,,CHEMBL616033,,,Expert,,1,9,,Homo sapiens,D,,990,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype
15042,,,51,,,,BAO_0000019,F,,CHEMBL616034,,,Autocuration,,1,8,,,H,,991,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
15042,,,51,,,,BAO_0000019,F,,CHEMBL616035,,,Autocuration,,1,8,,,H,,992,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
15042,,,51,,,,BAO_0000019,F,,CHEMBL616036,,,Autocuration,,1,8,,,H,,993,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
15042,,,51,,,,BAO_0000019,F,,CHEMBL616037,,,Autocuration,,1,8,,,H,,994,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
15042,,,51,,,,BAO_0000019,F,,CHEMBL616038,,,Autocuration,,1,8,,,H,,995,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
15042,,,51,,,,BAO_0000019,F,,CHEMBL616039,,,Autocuration,,1,8,,,H,,996,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.
15042,,,51,,,,BAO_0000019,F,,CHEMBL616040,,,Autocuration,,1,8,,,H,,997,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor
15180,308.0,HeLa,51,9606.0,,,BAO_0000219,F,,CHEMBL616041,,,Expert,,1,9,,Homo sapiens,D,,998,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
15180,308.0,HeLa,51,9606.0,,,BAO_0000219,F,,CHEMBL616042,,,Expert,,1,9,,Homo sapiens,D,,999,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
15180,308.0,HeLa,51,9606.0,,,BAO_0000219,F,,CHEMBL616043,,,Expert,,1,9,,Homo sapiens,D,,1000,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells
16245,,,51,,,,BAO_0000019,F,,CHEMBL616044,,,Autocuration,,1,8,,,H,,1001,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor"
16026,,,51,,,,BAO_0000019,F,,CHEMBL616045,,,Autocuration,,1,8,,,H,,1002,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
17296,722.0,HEK293,51,,,,BAO_0000219,F,,CHEMBL616046,,,Autocuration,,1,8,,,H,,1003,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL616047,,,Autocuration,,1,8,,,H,,1004,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL616048,,,Autocuration,,1,8,,,H,,1005,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells
2759,449.0,CHO,51,9606.0,,,BAO_0000219,F,,CHEMBL616049,,,Expert,,1,9,,Homo sapiens,D,,1006,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1)
2759,449.0,CHO,51,,,,BAO_0000219,F,,CHEMBL616050,,,Autocuration,,1,8,,,H,,1007,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2)
15419,,,51,,,,BAO_0000219,F,,CHEMBL616051,,,Expert,,1,8,,,H,,1008,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor
15419,,,51,,,,BAO_0000219,F,,CHEMBL616212,,,Autocuration,,1,8,,,H,,1009,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested
16026,,,51,,,,BAO_0000019,F,,CHEMBL616213,,,Autocuration,,1,8,,,H,,1010,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor"
1414,,,51,,,,BAO_0000219,B,,CHEMBL616214,,,Expert,,1,8,,,H,In vitro,1011,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells
1414,,,51,,,,BAO_0000219,B,,CHEMBL616215,,,Expert,,1,8,,,H,In vitro,1012,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells
12861,,,51,,,,BAO_0000357,B,,CHEMBL616216,,,Autocuration,,1,8,,,H,,1013,Binding activity radioligand.
12861,,,51,,,,BAO_0000019,B,,CHEMBL616217,,,Autocuration,,1,8,,,H,,1014,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
5104,,,51,,,,BAO_0000357,B,,CHEMBL616218,,,Autocuration,,1,8,,,H,,1015,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
5105,,,51,,,,BAO_0000357,B,,CHEMBL616219,,,Autocuration,,1,8,,,H,,1016,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor
16312,,,51,,,,BAO_0000357,B,,CHEMBL616220,,,Autocuration,,1,8,,,H,,1017,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor
15180,,,51,9606.0,,,BAO_0000357,B,,CHEMBL833493,,,Expert,,1,9,,Homo sapiens,D,,1018,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor
5033,,,51,,,,BAO_0000357,B,,CHEMBL616221,,,Autocuration,,1,8,,,H,,1019,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor
16909,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL616222,,,Expert,,1,9,,Homo sapiens,D,,1020,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
2590,,,51,,,,BAO_0000019,F,,CHEMBL616223,,,Autocuration,,1,8,,,H,,1021,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor
2590,,,51,,,,BAO_0000019,F,,CHEMBL616224,,,Autocuration,,1,8,,,H,,1022,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined
16394,,,51,,,,BAO_0000019,B,,CHEMBL616225,,,Expert,,1,8,,,H,,1023,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line
4540,722.0,HEK293,51,9606.0,,,BAO_0000219,B,,CHEMBL616226,,,Expert,,1,9,,Homo sapiens,D,,1024,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand
17296,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616227,,,Autocuration,,1,8,,,H,,1025,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells
17296,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616228,,,Autocuration,,1,8,,,H,,1026,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand
15779,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616229,,,Autocuration,,1,8,,,H,,1027,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
15779,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616230,,,Autocuration,,1,8,,,H,,1028,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data
15779,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616231,,,Autocuration,,1,8,,,H,,1029,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.
6166,,,51,,,,BAO_0000357,B,,CHEMBL616232,,,Autocuration,,1,8,,,H,,1030,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand
15779,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616233,,,Autocuration,,1,8,,,H,,1031,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;
4199,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL857973,,,Autocuration,,1,8,,,H,,1032,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand
15316,,,51,,,,BAO_0000219,B,,CHEMBL616234,,,Autocuration,,1,8,,,H,,1033,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells
14875,,,51,,,,BAO_0000357,B,,CHEMBL616235,,,Autocuration,,1,8,,,H,,1034,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor
14727,308.0,HeLa,51,,,,BAO_0000219,B,,CHEMBL616236,,,Expert,,1,8,,,H,,1035,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
14727,,,51,,,,BAO_0000019,B,,CHEMBL616237,,,Expert,,1,8,,,H,,1036,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.
15146,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616238,,,Autocuration,,1,8,,,H,,1037,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT
5213,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616239,,,Autocuration,,1,8,,,H,,1038,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand
16429,,,51,,,,BAO_0000219,B,,CHEMBL616240,,,Autocuration,,1,8,,,H,,1039,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand
15042,308.0,HeLa,51,9606.0,,,BAO_0000219,B,,CHEMBL616241,,,Expert,,1,9,,Homo sapiens,D,,1040,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.
14818,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616242,,,Autocuration,,1,8,,,H,,1041,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.
4829,722.0,HEK293,51,,,,BAO_0000219,B,,CHEMBL616243,,,Autocuration,,1,8,,,H,,1042,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand"
17200,,,51,,,,BAO_0000357,B,,CHEMBL616244,,,Expert,,1,9,,,D,,1043,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor
13051,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616245,,,Autocuration,,1,9,,Homo sapiens,D,,1044,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor
5486,,,106,,,,BAO_0000357,B,,CHEMBL616246,,,Autocuration,,1,8,,,H,,1045,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
5254,,,105,,,,BAO_0000357,B,,CHEMBL616247,,,Autocuration,,1,8,,,H,,1046,Binding affinity against 5-HT1D receptor
5254,,,105,,,,BAO_0000357,B,,CHEMBL616248,,,Autocuration,,1,8,,,H,,1047,Binding affinity against 5-hydroxytryptamine 1A receptor
15331,,,107,,,,BAO_0000357,B,,CHEMBL616249,,,Autocuration,,1,8,,,H,,1048,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique
13506,,,10576,9606.0,,,BAO_0000357,B,,CHEMBL616250,,,Autocuration,,1,8,,Homo sapiens,H,,1049,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
15267,,,51,,,,BAO_0000357,B,,CHEMBL616251,,,Autocuration,,1,8,,,H,,1050,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor
16616,,,11863,,,,BAO_0000218,F,,CHEMBL616252,,,Autocuration,,1,8,,,H,In vivo,1051,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound
16616,,,11863,,,,BAO_0000218,F,,CHEMBL616253,,,Autocuration,,1,8,,,H,In vivo,1052,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound
16616,,,11863,,,,BAO_0000218,F,,CHEMBL616254,,,Autocuration,,1,8,,,H,In vivo,1053,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound
16616,,,11863,10090.0,,,BAO_0000218,F,,CHEMBL616255,,,Expert,,1,9,,Mus musculus,D,,1054,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min
16616,,,11863,10090.0,,,BAO_0000218,F,,CHEMBL832872,,,Expert,,1,9,,Mus musculus,D,,1055,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min
16616,,,11863,10090.0,,,BAO_0000218,F,,CHEMBL616256,,,Expert,,1,9,,Mus musculus,D,,1056,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min
16616,,,11863,10090.0,,,BAO_0000218,F,,CHEMBL616257,,,Expert,,1,9,,Mus musculus,D,,1057,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min
16616,,,11863,10090.0,,,BAO_0000218,F,,CHEMBL616258,,,Expert,,1,9,,Mus musculus,D,,1058,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min
16616,,,11863,10090.0,,,BAO_0000218,F,,CHEMBL616384,,,Expert,,1,9,,Mus musculus,D,,1059,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min
10297,,,11863,,,,BAO_0000221,B,10000000.0,CHEMBL616385,,,Autocuration,Hippocampus,1,8,,,H,,1060,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
13704,,,11863,,,,BAO_0000357,B,,CHEMBL616386,,,Expert,,1,8,,,H,,1061,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.
10297,,,11863,10090.0,,,BAO_0000221,B,10000000.0,CHEMBL616387,,,Expert,Hippocampus,1,9,,Mus musculus,D,,1062,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
10297,,,11863,,,,BAO_0000221,B,10000000.0,CHEMBL616388,,,Autocuration,Hippocampus,1,8,,,H,,1063,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
10297,,,11863,10090.0,,,BAO_0000221,B,10000000.0,CHEMBL616389,,,Expert,Hippocampus,1,9,,Mus musculus,D,,1064,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus
10297,,,11863,,,,BAO_0000221,B,10000000.0,CHEMBL616390,,,Autocuration,Hippocampus,1,8,,,H,,1065,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined
217,,,11863,,,,BAO_0000357,B,,CHEMBL616391,,,Autocuration,,1,8,,,H,,1066,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand
10297,,,11863,10090.0,,,BAO_0000221,B,10000000.0,CHEMBL616392,,,Expert,Hippocampus,1,9,,Mus musculus,D,,1067,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus
4921,,,51,9823.0,,,BAO_0000357,B,,CHEMBL616393,,,Autocuration,,1,8,,Sus scrofa,H,,1068,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor
4921,,,51,9823.0,,,BAO_0000357,B,,CHEMBL616394,,,Autocuration,,1,8,,Sus scrofa,H,,1069,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined
4996,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616395,,,Autocuration,,1,8,,Sus scrofa,H,,1070,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates
12918,,,51,9823.0,,,BAO_0000357,B,,CHEMBL616396,,,Autocuration,,1,8,,Sus scrofa,H,,1071,Compound was evaluated for the binding affinity at 5- HT1A receptor
5333,,,51,9823.0,,,BAO_0000019,B,,CHEMBL872907,,,Autocuration,,1,8,,Sus scrofa,H,,1072,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate
4437,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616397,,,Autocuration,,1,8,,Sus scrofa,H,,1073,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate
1742,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616398,,,Autocuration,,1,8,,Sus scrofa,H,,1074,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex
16688,,,51,9823.0,,,BAO_0000357,B,,CHEMBL616399,,,Expert,,1,8,,Sus scrofa,H,,1075,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor
12861,,,51,9823.0,,,BAO_0000357,B,,CHEMBL857065,,,Autocuration,,1,8,,Sus scrofa,H,,1076,Binding activity radioligand.
12861,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616400,,,Expert,,1,8,,Sus scrofa,H,,1077,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
12861,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616401,,,Autocuration,,1,8,,Sus scrofa,H,,1078,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.
12490,,,10624,,,,BAO_0000019,B,,CHEMBL616402,,,Expert,,1,8,,,H,,1079,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex
11828,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616403,,,Expert,,1,8,,Sus scrofa,H,,1080,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor
11866,,,51,9823.0,,,BAO_0000221,B,10000000.0,CHEMBL616404,,,Autocuration,Hippocampus,1,8,,Sus scrofa,H,,1081,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT
12827,,,51,9823.0,,,BAO_0000249,B,,CHEMBL616405,,,Autocuration,,1,8,,Sus scrofa,H,,1082,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT
12918,,,51,9823.0,,,BAO_0000019,B,,CHEMBL616406,,,Autocuration,,1,8,,Sus scrofa,H,,1083,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT
12919,,,51,9823.0,,,BAO_0000019,F,,CHEMBL616407,,,Expert,,1,8,,Sus scrofa,H,,1084,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT
13047,,,51,9986.0,,,BAO_0000019,B,,CHEMBL616408,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1085,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium
15796,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL616409,,,Expert,,1,9,,Rattus norvegicus,D,,1086,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays
3651,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616410,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1087,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active"
188,,,10576,,,,BAO_0000357,B,,CHEMBL616411,,,Autocuration,,1,8,,,H,,1088,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity
16616,,,10576,10116.0,,,BAO_0000249,F,,CHEMBL616412,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1089,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
16616,,,10576,10116.0,,,BAO_0000249,F,10000000.0,CHEMBL616413,,Membranes,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1090,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
12306,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616414,,,Autocuration,Hippocampus,1,8,,,H,,1091,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
17167,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616415,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1092,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding
14776,,,10576,,,,BAO_0000019,B,,CHEMBL616416,,,Autocuration,,1,8,,,H,,1093,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.
12158,,,10576,,,,BAO_0000357,B,,CHEMBL616417,,,Expert,,1,8,,,H,,1094,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.
13481,,,10576,,,,BAO_0000357,B,,CHEMBL616418,,,Autocuration,,1,8,,,H,,1095,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay
13427,,,10576,,,,BAO_0000219,B,,CHEMBL616419,,,Autocuration,,1,8,,,H,In vitro,1096,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
10210,,,10576,,,,BAO_0000357,B,,CHEMBL616420,,,Autocuration,,1,8,,,H,,1097,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT
10205,,,10576,,,,BAO_0000249,B,,CHEMBL616421,,Membranes,Autocuration,,1,8,,,H,,1098,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
10205,,,10576,,,,BAO_0000249,B,,CHEMBL616422,,Membranes,Autocuration,,1,8,,,H,,1099,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes
10205,,,10576,,,,BAO_0000249,B,,CHEMBL616423,,Membranes,Expert,,1,8,,,H,,1100,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.
12280,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616424,,,Expert,,1,9,,Rattus norvegicus,D,,1101,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT
17386,,,10576,,,,BAO_0000357,B,,CHEMBL616425,,,Expert,,1,8,,,H,,1102,Binding affinity to the rat 5-hydroxytryptamine 1A receptor
13654,,,10576,,,,BAO_0000357,B,,CHEMBL616426,,,Expert,,1,8,,,H,,1103,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.
14423,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616427,,,Autocuration,Hippocampus,1,8,,,H,,1104,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.
15412,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616428,,,Autocuration,Hippocampus,1,8,,,H,,1105,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.
12073,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616290,,,Autocuration,Hippocampus,1,8,,,H,,1106,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
4101,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616052,,,Expert,,1,9,,Rattus norvegicus,D,,1107,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor
10062,,,10576,,,,BAO_0000357,B,,CHEMBL616053,,,Autocuration,,1,8,,,H,,1108,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor
6238,,,10576,,,,BAO_0000249,B,,CHEMBL616054,,,Autocuration,,1,8,,,H,,1109,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand
16273,,,10576,,,,BAO_0000357,B,,CHEMBL616055,,,Autocuration,,1,8,,,H,,1110,Binding affinity towards 5-hydroxytryptamine 1A receptor
11139,,,10576,,,,BAO_0000357,B,,CHEMBL616056,,,Autocuration,,1,8,,,H,,1111,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay
16796,,,10576,,,,BAO_0000019,B,,CHEMBL616057,,,Expert,,1,8,,,H,,1112,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
9548,,,10576,10116.0,,,BAO_0000221,B,955.0,CHEMBL616058,,,Expert,Brain,1,9,,Rattus norvegicus,D,,1113,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
10381,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616059,,,Autocuration,Brain,1,8,,,H,,1114,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
13408,,,10576,,,,BAO_0000249,B,,CHEMBL616060,,,Autocuration,,1,8,,,H,,1115,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand
13825,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616061,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1116,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT
11147,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616062,,,Expert,Hippocampus,1,8,,,H,,1117,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand
10552,,,10576,,,,BAO_0000249,B,,CHEMBL616063,,,Autocuration,,1,8,,,H,,1118,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand
10552,,,10576,,,,BAO_0000249,B,2435.0,CHEMBL616064,,,Autocuration,Striatum,1,8,,,H,,1119,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
17136,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL616065,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1120,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes
5778,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL616066,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1121,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes
13481,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616067,,,Autocuration,Hippocampus,1,8,,,H,,1122,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
13481,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616068,,,Autocuration,Hippocampus,1,8,,,H,,1123,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested
13630,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616069,,,Intermediate,Hippocampus,1,8,,,H,,1124,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand
16245,,,10576,,,,BAO_0000249,B,,CHEMBL616070,,,Expert,,1,8,,,H,,1125,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
14509,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616071,,,Autocuration,Hippocampus,1,8,,,H,,1126,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand
14509,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616072,,,Expert,Hippocampus,1,8,,,H,,1127,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.
14509,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616073,,,Autocuration,Hippocampus,1,8,,,H,,1128,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined
14509,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616074,,,Autocuration,Hippocampus,1,8,,,H,,1129,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined
14256,,,10576,,,,BAO_0000019,B,,CHEMBL616075,,,Expert,,1,8,,,H,,1130,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.
11139,,,10576,,,,BAO_0000357,B,,CHEMBL616076,,,Autocuration,,1,8,,,H,,1131,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor
11047,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616077,,,Expert,,1,9,,Rattus norvegicus,D,,1132,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined
11047,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616078,,,Expert,,1,9,,Rattus norvegicus,D,,1133,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes
11047,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616079,,,Expert,,1,9,,Rattus norvegicus,D,,1134,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined
2395,485.0,CHO-K1,10576,10116.0,,,BAO_0000219,B,,CHEMBL616080,,,Expert,,1,9,,Rattus norvegicus,D,,1135,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
9699,,,10576,,,,BAO_0000357,B,,CHEMBL616081,,,Autocuration,,1,8,,,H,,1136,Binding affinity towards 5-hydroxytryptamine 1A receptor
12028,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616082,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1137,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain
12028,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616083,,,Autocuration,Hippocampus,1,8,,,H,,1138,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain
5815,,,10576,,,,BAO_0000019,B,,CHEMBL616084,,,Autocuration,,1,8,,,H,,1139,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex
16616,,,10576,,,,BAO_0000019,B,,CHEMBL616085,,,Expert,,1,8,,,H,,1140,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates
5815,,,10576,,,,BAO_0000019,B,,CHEMBL616086,,,Autocuration,,1,8,,,H,,1141,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT
2761,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616087,,,Autocuration,Hippocampus,1,8,,,H,,1142,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate"
13133,,,10576,,,,BAO_0000357,B,,CHEMBL616088,,,Expert,,1,8,,,H,,1143,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101
10444,,,10576,,,,BAO_0000019,B,,CHEMBL616089,,,Autocuration,,1,8,,,H,,1144,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.
13278,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616090,,,Expert,,1,9,,Rattus norvegicus,D,,1145,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides
15874,,,10576,,,,BAO_0000357,B,,CHEMBL616091,,,Autocuration,,1,8,,,H,,1146,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT
10552,,,10576,,,,BAO_0000249,B,2435.0,CHEMBL616092,,Membranes,Autocuration,Striatum,1,8,,,H,,1147,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand"
11130,,,10576,,,,BAO_0000357,B,,CHEMBL616093,,,Autocuration,,1,8,,,H,,1148,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro)
11130,,,10576,,,,BAO_0000218,B,,CHEMBL616094,,,Autocuration,,1,8,,,H,In vivo,1149,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo)
14542,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616095,,,Autocuration,Brain,1,8,,,H,,1150,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex
13670,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616096,,,Expert,,1,9,,Rattus norvegicus,D,,1151,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
9888,,,10576,,,,BAO_0000249,B,,CHEMBL616097,,,Expert,,1,8,,,H,,1152,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes
3678,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL616098,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1153,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes
11332,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616099,,,Autocuration,Hippocampus,1,8,,,H,,1154,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
11332,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616100,,,Autocuration,Hippocampus,1,8,,,H,,1155,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand
1185,,,10576,,,,BAO_0000357,B,,CHEMBL616101,,,Expert,,1,8,,,H,,1156,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
2014,,,10576,,,,BAO_0000249,B,,CHEMBL616102,,,Expert,,1,8,,,H,,1157,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.
1185,,,10576,,,,BAO_0000357,B,,CHEMBL616103,,,Autocuration,,1,8,,,H,,1158,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor
14429,,,10576,,,,BAO_0000019,B,,CHEMBL616104,,,Expert,,1,8,,,H,,1159,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex
16288,,,10576,,,,BAO_0000019,B,,CHEMBL616105,,,Expert,,1,8,,,H,,1160,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand"
5432,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616106,,,Expert,,1,9,,Rattus norvegicus,D,,1161,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor
14429,,,10576,,,,BAO_0000019,B,,CHEMBL616107,,,Autocuration,,1,8,,,H,,1162,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex
13672,,,10576,,,,BAO_0000357,B,,CHEMBL616108,,,Expert,,1,8,,,H,,1163,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.
11296,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616109,,,Expert,Hippocampus,1,8,,,H,,1164,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
11296,,,10576,,,,BAO_0000357,B,,CHEMBL616110,,,Autocuration,,1,8,,,H,,1165,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.
14749,449.0,CHO,10576,,,,BAO_0000219,B,,CHEMBL616111,,,Expert,,1,8,,,H,,1166,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.
15086,,,10576,,,,BAO_0000019,B,,CHEMBL616112,,,Expert,,1,8,,,H,,1167,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand
13462,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616113,,,Autocuration,Hippocampus,1,8,,,H,,1168,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.
15363,,,10576,,,,BAO_0000019,B,,CHEMBL616114,,,Autocuration,,1,8,,,H,,1169,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
15363,,,10576,,,,BAO_0000019,B,,CHEMBL616115,,,Autocuration,,1,8,,,H,,1170,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor
10796,,,10576,,,,BAO_0000357,B,,CHEMBL616116,,,Autocuration,,1,8,,,H,,1171,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor
12816,,,10576,,,,BAO_0000221,B,955.0,CHEMBL615844,,,Expert,Brain,1,8,,,H,,1172,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand
13542,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615939,,,Expert,Hippocampus,1,8,,,H,,1173,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
13308,,,10576,,,,BAO_0000019,B,,CHEMBL615940,,,Expert,,1,8,,,H,,1174,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.
13541,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615941,,,Expert,Hippocampus,1,8,,,H,,1175,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615942,,,Autocuration,Hippocampus,1,8,,,H,,1176,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615943,,,Autocuration,Hippocampus,1,8,,,H,,1177,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615944,,,Autocuration,Hippocampus,1,8,,,H,,1178,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615945,,,Autocuration,Hippocampus,1,8,,,H,,1179,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615946,,,Autocuration,Hippocampus,1,8,,,H,,1180,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615947,,,Autocuration,Hippocampus,1,8,,,H,,1181,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615948,,,Autocuration,Hippocampus,1,8,,,H,,1182,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615949,,,Autocuration,Hippocampus,1,8,,,H,,1183,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615950,,,Autocuration,Hippocampus,1,8,,,H,,1184,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615951,,,Autocuration,Hippocampus,1,8,,,H,,1185,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615952,,,Autocuration,Hippocampus,1,8,,,H,,1186,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615953,,,Autocuration,Hippocampus,1,8,,,H,,1187,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615954,,,Autocuration,Hippocampus,1,8,,,H,,1188,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13
10058,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL615955,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1189,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615956,,,Autocuration,Hippocampus,1,8,,,H,,1190,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL615957,,,Autocuration,Hippocampus,1,8,,,H,,1191,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27
12879,,,10576,,,,BAO_0000019,B,,CHEMBL615958,,,Expert,,1,8,,,H,,1192,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.
11964,,,10576,,,,BAO_0000019,B,,CHEMBL615959,,,Expert,,1,8,,,H,,1193,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate
11964,,,10576,,,,BAO_0000019,B,,CHEMBL615960,,,Autocuration,,1,8,,,H,,1194,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1)
11964,,,10576,,,,BAO_0000019,B,,CHEMBL615961,,,Autocuration,,1,8,,,H,,1195,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2)
9548,,,10576,,,,BAO_0000221,B,955.0,CHEMBL615962,,,Expert,Brain,1,8,,,H,,1196,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain
9098,,,10576,,,,BAO_0000019,B,,CHEMBL615963,,,Expert,,1,8,,,H,,1197,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.
9098,,,10576,,,,BAO_0000019,B,,CHEMBL615964,,,Autocuration,,1,8,,,H,,1198,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.
9098,,,10576,,,,BAO_0000019,B,,CHEMBL615965,,,Autocuration,,1,8,,,H,,1199,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data
13248,449.0,CHO,10576,,,,BAO_0000219,B,,CHEMBL615966,,,Expert,,1,8,,,H,,1200,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells
3147,,,10576,,,,BAO_0000249,B,,CHEMBL615967,,,Expert,,1,8,,,H,,1201,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes
13949,,,10576,,,,BAO_0000019,B,,CHEMBL615968,,,Expert,,1,8,,,H,,1202,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
11883,449.0,CHO,10576,,,,BAO_0000218,B,,CHEMBL615969,,,Autocuration,,1,8,,,H,,1203,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc)
11883,,,10576,,,,BAO_0000218,B,,CHEMBL615970,,,Autocuration,,1,8,,,H,,1204,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc)
11883,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL615971,,,Expert,,1,9,,Rattus norvegicus,D,,1205,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT
15535,,,10576,,,,BAO_0000249,B,,CHEMBL615972,,Membranes,Expert,,1,8,,,H,,1206,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
15535,,,10576,,,,BAO_0000249,B,,CHEMBL615973,,,Autocuration,,1,8,,,H,,1207,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex
15535,,,10576,,,,BAO_0000249,B,,CHEMBL615974,,,Autocuration,,1,8,,,H,,1208,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex
16372,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL615975,,,Expert,,1,9,,Homo sapiens,D,,1209,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells
14608,,,10576,,,,BAO_0000249,B,,CHEMBL615976,,,Expert,,1,8,,,H,,1210,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.
4795,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL872106,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1211,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus
13863,,,10576,,,,BAO_0000357,B,,CHEMBL615977,,,Autocuration,,1,8,,,H,,1212,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
13863,,,10576,,,,BAO_0000357,B,,CHEMBL615978,,,Autocuration,,1,8,,,H,,1213,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616166,,,Autocuration,,1,8,,,H,,1214,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616167,,,Autocuration,,1,8,,,H,,1215,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616168,,,Autocuration,,1,8,,,H,,1216,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616169,,,Autocuration,,1,8,,,H,,1217,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616170,,,Autocuration,,1,8,,,H,,1218,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616171,,,Autocuration,,1,8,,,H,,1219,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616172,,,Autocuration,,1,8,,,H,,1220,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616173,,,Autocuration,,1,8,,,H,,1221,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616174,,,Autocuration,,1,8,,,H,,1222,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616175,,,Autocuration,,1,8,,,H,,1223,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616176,,,Autocuration,,1,8,,,H,,1224,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616177,,,Autocuration,,1,8,,,H,,1225,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616178,,,Autocuration,,1,8,,,H,,1226,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2
9742,,,10576,,,,BAO_0000019,B,,CHEMBL616179,,,Autocuration,,1,8,,,H,,1227,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat
12073,,,10576,,,,BAO_0000357,B,,CHEMBL616180,,,Autocuration,,1,8,,,H,,1228,Inhibitory concentration against 5-hydroxytryptamine 1A receptor
4101,,,10576,,,,BAO_0000357,B,,CHEMBL616181,,,Autocuration,,1,8,,,H,,1229,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT
15360,,,10576,,,,BAO_0000019,B,,CHEMBL616182,,,Autocuration,,1,8,,,H,,1230,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat
11576,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616183,,,Autocuration,Hippocampus,1,8,,,H,,1231,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
5834,,,10576,,,,BAO_0000019,B,,CHEMBL615874,,,Expert,,1,8,,,H,,1232,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe
2395,485.0,CHO-K1,10576,10116.0,,,BAO_0000219,B,,CHEMBL615875,,,Expert,,1,9,,Rattus norvegicus,D,,1233,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells
1375,,,10576,,,,BAO_0000019,B,,CHEMBL615876,,,Autocuration,,1,8,,,H,,1234,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand
1375,,,10576,,,,BAO_0000019,B,,CHEMBL615877,,,Autocuration,,1,8,,,H,,1235,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested
3967,,,10576,,,,BAO_0000357,B,,CHEMBL615878,,,Autocuration,,1,8,,,H,,1236,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats)
12884,,,10576,,,,BAO_0000357,B,,CHEMBL615879,,,Expert,,1,8,,,H,,1237,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. 
2343,,,10576,,,,BAO_0000357,B,,CHEMBL615880,,,Expert,,1,8,,,H,,1238,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay
11511,,,10576,,,,BAO_0000019,B,,CHEMBL615881,,,Autocuration,,1,8,,,H,,1239,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
11511,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL615882,,,Expert,,1,9,,Rattus norvegicus,D,,1240,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand"
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615883,,,Autocuration,,1,8,,,H,In vivo,1241,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615884,,,Autocuration,,1,8,,,H,In vivo,1242,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615885,,,Autocuration,,1,8,,,H,In vivo,1243,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615886,,,Autocuration,,1,8,,,H,In vivo,1244,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615887,,,Autocuration,,1,8,,,H,In vivo,1245,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615888,,,Autocuration,,1,8,,,H,In vivo,1246,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615889,,,Autocuration,,1,8,,,H,In vivo,1247,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615890,,,Autocuration,,1,8,,,H,In vivo,1248,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615891,,,Autocuration,,1,8,,,H,In vivo,1249,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615892,,,Autocuration,,1,8,,,H,In vivo,1250,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615893,,,Autocuration,,1,8,,,H,In vivo,1251,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615894,,,Autocuration,,1,8,,,H,In vivo,1252,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615895,,,Autocuration,,1,8,,,H,In vivo,1253,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615896,,,Autocuration,,1,8,,,H,In vivo,1254,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5)
16394,,,10576,,,,BAO_0000218,F,,CHEMBL615897,,,Autocuration,,1,8,,,H,In vivo,1255,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable
16616,,,10576,10116.0,,,BAO_0000249,F,,CHEMBL615898,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1256,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes"
16796,,,10576,,,,BAO_0000019,B,,CHEMBL615899,,,Autocuration,,1,8,,,H,,1257,% inhibition towards 5-HT1A receptor from rat hippocampal membranes
16796,,,10576,,,,BAO_0000019,B,,CHEMBL616291,,,Autocuration,,1,8,,,H,,1258,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes
15629,,,10576,,,,BAO_0000357,B,,CHEMBL616292,,,Autocuration,,1,8,,,H,,1259,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.
13241,,,10576,,,,BAO_0000249,F,,CHEMBL616293,,,Autocuration,,1,8,,,H,,1260,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor"
12073,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616294,,,Expert,Hippocampus,1,8,,,H,,1261,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus
14286,,,10576,,,,BAO_0000249,B,10000000.0,CHEMBL616295,,,Autocuration,Hippocampus,1,8,,,H,,1262,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane
14542,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616296,,,Autocuration,Brain,1,8,,,H,,1263,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616297,,,Autocuration,,1,8,,,H,,1264,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616605,,,Autocuration,,1,8,,,H,,1265,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616606,,,Autocuration,,1,8,,,H,,1266,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616607,,,Autocuration,,1,8,,,H,,1267,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616608,,,Expert,,1,8,,,H,,1268,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616609,,,Autocuration,,1,8,,,H,,1269,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.
13630,,,10576,10116.0,,,BAO_0000019,F,,CHEMBL616610,,,Expert,,1,9,,Rattus norvegicus,D,,1270,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616611,,,Autocuration,,1,8,,,H,,1271,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616612,,,Expert,,1,8,,,H,,1272,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616613,,,Autocuration,,1,8,,,H,,1273,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616614,,,Expert,,1,8,,,H,,1274,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616615,,,Autocuration,,1,8,,,H,,1275,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616616,,,Expert,,1,8,,,H,,1276,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616617,,,Autocuration,,1,8,,,H,,1277,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616618,,,Autocuration,,1,8,,,H,,1278,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616619,,,Autocuration,,1,8,,,H,,1279,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616620,,,Expert,,1,8,,,H,,1280,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616621,,,Expert,,1,8,,,H,,1281,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616622,,,Autocuration,,1,8,,,H,,1282,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616146,,,Expert,,1,8,,,H,,1283,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL832873,,,Autocuration,,1,8,,,H,,1284,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616147,,,Autocuration,,1,8,,,H,,1285,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM
13630,,,10576,,,,BAO_0000019,F,,CHEMBL872872,,,Autocuration,,1,8,,,H,,1286,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616148,,,Autocuration,,1,8,,,H,,1287,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM
9783,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616149,,,Autocuration,Hippocampus,1,8,,,H,,1288,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue
9783,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616150,,,Expert,Hippocampus,1,8,,,H,,1289,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM
14331,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL616151,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1290,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M
15260,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL872873,,,Expert,Hippocampus,1,8,,,H,,1291,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM
15260,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616670,,,Autocuration,Hippocampus,1,8,,,H,,1292,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration
15260,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616671,,,Autocuration,Hippocampus,1,8,,,H,,1293,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration
16616,,,10576,10116.0,,,BAO_0000249,F,,CHEMBL884861,,,Expert,,1,9,,Rattus norvegicus,D,,1294,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes"
15629,,,10576,,,,BAO_0000357,B,,CHEMBL616672,,,Autocuration,,1,8,,,H,,1295,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor
15086,,,10576,,,,BAO_0000019,B,,CHEMBL616673,,,Autocuration,,1,8,,,H,,1296,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
5717,,,10576,,,,BAO_0000019,F,,CHEMBL616674,,,Expert,,1,8,,,H,,1297,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.
12652,,,10576,,,,BAO_0000357,B,,CHEMBL616675,,,Autocuration,,1,8,,,H,,1298,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
14608,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616676,,,Autocuration,Hippocampus,1,8,,,H,,1299,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations
12306,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616677,,,Autocuration,Hippocampus,1,8,,,H,,1300,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
12306,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616678,,,Autocuration,Hippocampus,1,8,,,H,,1301,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
15247,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616679,,,Expert,,1,9,,Rattus norvegicus,D,,1302,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
17529,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616680,,,Expert,Hippocampus,1,8,,,H,,1303,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand
14826,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616681,,,Autocuration,Hippocampus,1,8,,,H,,1304,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
14826,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616682,,,Autocuration,Hippocampus,1,8,,,H,,1305,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus
13241,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616683,,,Autocuration,Hippocampus,1,8,,,H,,1306,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor
14093,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616684,,,Autocuration,Hippocampus,1,8,,,H,,1307,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor
14093,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616685,,,Autocuration,Hippocampus,1,8,,,H,,1308,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested
14442,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616686,,,Autocuration,Brain,1,8,,,H,,1309,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined
9919,,,10576,,,,BAO_0000357,B,,CHEMBL616687,,,Autocuration,,1,8,,,H,,1310,Affinity for 5-hydroxytryptamine 1A receptor site
9919,,,10576,,,,BAO_0000357,B,,CHEMBL616688,,,Autocuration,,1,8,,,H,,1311,Affinity for 5-hydroxytryptamine 1A receptor site
11440,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616689,,,Autocuration,Hippocampus,1,8,,,H,,1312,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.
11257,,,10576,,,,BAO_0000357,B,,CHEMBL616690,,,Autocuration,,1,8,,,H,,1313,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT
10330,,,10576,,,,BAO_0000357,B,,CHEMBL616691,,,Expert,,1,8,,,H,,1314,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand
17331,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616692,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1315,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes
16567,,,10576,,,,BAO_0000249,B,,CHEMBL616693,,,Expert,,1,8,,,H,,1316,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane
12058,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616694,,,Expert,,1,9,,Rattus norvegicus,D,,1317,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
9699,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616695,,,Autocuration,Hippocampus,1,8,,,H,,1318,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue
9547,,,10576,,,,BAO_0000357,B,,CHEMBL616696,,,Autocuration,,1,8,,,H,,1319,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay
10330,,,10576,,,,BAO_0000357,B,,CHEMBL616697,,,Autocuration,,1,8,,,H,,1320,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand
14331,,,10576,,,,BAO_0000357,B,,CHEMBL616698,,,Autocuration,,1,8,,,H,,1321,Binding affinity against rat 5-hydroxytryptamine 1A receptor
14060,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616949,,,Expert,,1,9,,Rattus norvegicus,D,,1322,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor
14744,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616950,,,Autocuration,Hippocampus,1,8,,,H,,1323,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates
13506,,,10576,,,,BAO_0000357,B,,CHEMBL832875,,,Autocuration,,1,8,,,H,,1324,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay
10862,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616951,,,Expert,Brain,1,8,,,H,,1325,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
10862,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616952,,,Expert,Brain,1,8,,,H,,1326,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
10062,,,10576,,,,BAO_0000357,B,,CHEMBL616953,,,Expert,,1,8,,,H,,1327,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.
12073,,,10576,,,,BAO_0000357,B,,CHEMBL616954,,,Autocuration,,1,8,,,H,,1328,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat
14875,,,106,,,,BAO_0000357,B,,CHEMBL616955,,,Autocuration,,1,8,,,H,,1329,GTPgammaS radioligand binding assay
2391,,,106,,,,BAO_0000357,B,,CHEMBL616956,,,Autocuration,,1,8,,,H,,1330,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
2391,,,106,,,,BAO_0000019,F,,CHEMBL616957,,,Autocuration,,1,8,,,H,,1331,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist
2391,,,106,,,,BAO_0000019,F,,CHEMBL616958,,,Autocuration,,1,8,,,H,,1332,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist
2391,,,106,,,,BAO_0000357,B,,CHEMBL616959,,,Autocuration,,1,8,,,H,,1333,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
2391,,,106,,,,BAO_0000357,B,,CHEMBL616960,,,Autocuration,,1,8,,,H,,1334,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined
2391,,,106,,,,BAO_0000019,F,,CHEMBL616961,,,Autocuration,,1,8,,,H,,1335,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist
17211,308.0,HeLa,106,,,,BAO_0000219,B,,CHEMBL616962,,,Expert,,1,8,,,H,,1336,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor
17211,308.0,HeLa,106,,,,BAO_0000219,B,,CHEMBL616963,,,Autocuration,,1,8,,,H,,1337,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor
6491,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616524,,,Expert,,1,9,,Homo sapiens,D,,1338,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor
16190,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616525,,,Autocuration,,1,8,,,H,,1339,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
14165,,,106,,,,BAO_0000019,B,,CHEMBL872908,,,Autocuration,,1,8,,,H,,1340,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand
14165,,,106,,,,BAO_0000019,B,,CHEMBL616526,,,Autocuration,,1,8,,,H,,1341,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand
4234,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616527,,,Expert,,1,9,,Homo sapiens,D,,1342,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor
6328,,,106,,,,BAO_0000219,B,,CHEMBL616528,,,Expert,,1,8,,,H,,1343,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
14770,,,106,,,,BAO_0000357,B,,CHEMBL616529,,,Autocuration,,1,8,,,H,,1344,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
2598,,,106,,,,BAO_0000357,B,,CHEMBL616530,,,Autocuration,,1,8,,,H,,1345,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand
6897,,,106,,,,BAO_0000357,B,,CHEMBL616531,,,Expert,,1,8,,,H,,1346,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
6897,,,106,,,,BAO_0000357,B,,CHEMBL616532,,,Autocuration,,1,8,,,H,,1347,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor
6013,,,106,,,,BAO_0000357,B,,CHEMBL616533,,,Autocuration,,1,8,,,H,,1348,Binding affinity towards 5-hydroxytryptamine 1B receptor
5843,,,106,,,,BAO_0000357,B,,CHEMBL616534,,,Expert,,1,8,,,H,,1349,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
14454,,,106,,,,BAO_0000357,B,,CHEMBL616535,,,Expert,,1,8,,,H,,1350,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand
16209,,,106,,,,BAO_0000357,B,,CHEMBL616536,,,Autocuration,,1,8,,,H,,1351,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand
3935,,,106,,,,BAO_0000357,B,,CHEMBL616537,,,Autocuration,,1,8,,,H,,1352,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor
13729,485.0,CHO-K1,106,,,,BAO_0000219,F,,CHEMBL616538,,,Expert,,1,8,,,H,,1353,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells
14251,,,106,,,,BAO_0000019,F,,CHEMBL616539,,,Expert,,1,8,,,H,,1354,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor
17085,,,106,,,,BAO_0000019,B,,CHEMBL616540,,,Expert,,1,8,,,H,,1355,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor
3025,,,106,,,,BAO_0000357,B,,CHEMBL616429,,,Autocuration,,1,8,,,H,,1356,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
15315,,,106,,,,BAO_0000357,B,,CHEMBL616430,,,Expert,,1,8,,,H,,1357,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor
14214,,,106,9606.0,,,BAO_0000219,B,,CHEMBL616431,,,Expert,,1,9,,Homo sapiens,D,,1358,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells
3804,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616432,,,Expert,,1,9,,Homo sapiens,D,,1359,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor
2391,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616433,,,Expert,,1,9,,Homo sapiens,D,,1360,Affinity for 5-hydroxytryptamine 1B receptor subtype
4175,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616434,,,Expert,,1,9,,Homo sapiens,D,,1361,Binding affinity for human 5-hydroxytryptamine 1B receptor
17296,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616435,,,Autocuration,,1,8,,,H,,1362,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined
17085,,,106,,,,BAO_0000019,B,,CHEMBL616436,,,Expert,,1,8,,,H,,1363,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined
17211,308.0,HeLa,106,,,,BAO_0000219,B,,CHEMBL616437,,,Autocuration,,1,8,,,H,,1364,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
17211,308.0,HeLa,106,,,,BAO_0000219,B,,CHEMBL616438,,,Autocuration,,1,8,,,H,,1365,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested
17211,308.0,HeLa,106,,,,BAO_0000219,B,,CHEMBL616439,,,Autocuration,,1,8,,,H,,1366,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested
15926,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616440,,,Expert,,1,9,,Homo sapiens,D,,1367,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested
16312,485.0,CHO-K1,106,,,,BAO_0000219,B,,CHEMBL616441,,,Autocuration,,1,8,,,H,,1368,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested
5843,,,106,,,,BAO_0000357,B,,CHEMBL616442,,,Expert,,1,8,,,H,,1369,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor
5843,,,106,,,,BAO_0000357,B,,CHEMBL616443,,,Autocuration,,1,8,,,H,,1370,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor
16312,485.0,CHO-K1,106,,,,BAO_0000219,B,,CHEMBL616444,,,Expert,,1,8,,,H,,1371,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor
15926,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616445,,,Expert,,1,9,,Homo sapiens,D,,1372,Binding activity against human 5-hydroxytryptamine 1B receptor
15926,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616446,,,Expert,,1,9,,Homo sapiens,D,,1373,Binding activity against human 5-hydroxytryptamine 1B receptor
4540,449.0,CHO,106,9606.0,,,BAO_0000219,B,,CHEMBL616447,,,Expert,,1,9,,Homo sapiens,D,,1374,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand
6166,,,106,,,,BAO_0000357,B,,CHEMBL616448,,,Autocuration,,1,8,,,H,,1375,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined
17296,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616449,,,Autocuration,,1,8,,,H,,1376,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand
17296,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616450,,,Autocuration,,1,8,,,H,,1377,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells
17296,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL857974,,,Autocuration,,1,8,,,H,,1378,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand
15779,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616451,,,Autocuration,,1,8,,,H,,1379,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
15779,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616452,,,Autocuration,,1,8,,,H,,1380,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
15779,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616453,,,Autocuration,,1,8,,,H,,1381,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.
4199,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616454,,,Autocuration,,1,8,,,H,,1382,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand
14875,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616455,,,Expert,,1,9,,Homo sapiens,D,,1383,Binding affinity for human 5-hydroxytryptamine 1B receptor
15146,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616456,,,Autocuration,,1,8,,,H,,1384,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
5213,,,106,,,,BAO_0000357,B,,CHEMBL616457,,,Autocuration,,1,8,,,H,,1385,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand
14818,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616458,,,Autocuration,,1,8,,,H,,1386,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT
4829,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616459,,,Autocuration,,1,8,,,H,,1387,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand"
14454,,,106,,,,BAO_0000019,F,,CHEMBL616460,,,Expert,,1,8,,,H,,1388,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM
14454,,,106,,,,BAO_0000019,F,,CHEMBL616461,,,Expert,,1,8,,,H,,1389,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM
14875,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616462,,,Autocuration,,1,8,,,H,,1390,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor"
14875,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616463,,,Autocuration,,1,8,,,H,,1391,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor"
15250,,,105,,,,BAO_0000019,F,,CHEMBL616464,,,Autocuration,,1,8,,,H,,1392,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT."
15250,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616465,,,Autocuration,,1,8,,,H,,1393,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.
15086,,,17105,,,,BAO_0000357,B,,CHEMBL832874,,,Autocuration,,1,8,,,H,,1394,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
3025,,,106,9986.0,,,BAO_0000019,F,,CHEMBL616184,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1395,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model
14998,,,106,9986.0,,,BAO_0000019,B,,CHEMBL616185,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1396,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).
14998,,,106,9986.0,,,BAO_0000019,B,,CHEMBL616186,,,Intermediate,,1,8,,Oryctolagus cuniculus,H,,1397,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)"
14998,,,106,9986.0,,,BAO_0000019,B,,CHEMBL616187,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1398,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).
13969,,,10577,,,,BAO_0000357,B,,CHEMBL616188,,,Expert,,1,8,,,H,,1399,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand
13392,,,10577,,,,BAO_0000357,B,,CHEMBL873475,,,Intermediate,,1,9,,,D,,1400,Binding affinity for 5-hydroxytryptamine 1B receptor
3651,,,10577,10116.0,,,BAO_0000019,B,2435.0,CHEMBL616189,,,Expert,Striatum,1,9,,Rattus norvegicus,D,,1401,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active
10025,,,10577,,,,BAO_0000357,B,,CHEMBL616190,,,Expert,,1,8,,,H,,1402,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616191,,,Autocuration,,1,8,,,H,,1403,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616192,,,Autocuration,,1,8,,,H,,1404,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616193,,,Autocuration,,1,8,,,H,,1405,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616194,,,Autocuration,,1,8,,,H,,1406,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616195,,,Autocuration,,1,8,,,H,,1407,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130
13863,,,10576,,,,BAO_0000357,B,,CHEMBL616196,,,Autocuration,,1,8,,,H,,1408,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280
4622,,,10576,,,,BAO_0000249,B,10000000.0,CHEMBL616197,,,Autocuration,Hippocampus,1,8,,,H,,1409,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.
14911,,,10576,,,,BAO_0000019,B,,CHEMBL616198,,,Intermediate,,1,8,,,H,,1410,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand
12678,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616199,,,Autocuration,Hippocampus,1,8,,,H,,1411,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate
12678,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616200,,,Expert,Hippocampus,1,8,,,H,,1412,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.
14235,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616201,,,Expert,Hippocampus,1,8,,,H,,1413,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand
14949,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616202,,,Expert,Hippocampus,1,8,,,H,,1414,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
14949,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616203,,,Expert,Hippocampus,1,8,,,H,,1415,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates
14949,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616204,,,Expert,Hippocampus,1,8,,,H,,1416,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined
14949,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616205,,,Expert,Hippocampus,1,8,,,H,,1417,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined
14949,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616206,,,Expert,Hippocampus,1,8,,,H,,1418,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined
16118,,,10576,,,,BAO_0000249,B,,CHEMBL616207,,,Expert,,1,8,,,H,,1419,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes
3268,,,10576,,,,BAO_0000249,B,,CHEMBL616208,,,Autocuration,,1,8,,,H,,1420,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes
3268,,,10576,,,,BAO_0000249,B,,CHEMBL616209,,,Autocuration,,1,8,,,H,,1421,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive
16117,,,10576,,,,BAO_0000357,B,,CHEMBL616210,,,Expert,,1,8,,,H,,1422,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT
9783,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616211,,,Expert,Hippocampus,1,8,,,H,,1423,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.
9783,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616504,,,Autocuration,Hippocampus,1,8,,,H,,1424,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested
14356,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616505,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1425,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
15740,,,10576,,,,BAO_0000019,F,,CHEMBL616506,,,Autocuration,,1,8,,,H,,1426,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor
12306,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL872107,,,Autocuration,Hippocampus,1,8,,,H,,1427,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates
13348,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616507,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1428,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin
10394,,,10576,,,,BAO_0000249,B,,CHEMBL616303,,,Autocuration,,1,8,,,H,,1429,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand
15260,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616304,,,Autocuration,Hippocampus,1,8,,,H,,1430,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue
10046,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616305,,,Expert,Hippocampus,1,8,,,H,,1431,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
15260,,,10576,,,,BAO_0000221,F,10000000.0,CHEMBL616306,,,Intermediate,Hippocampus,1,8,,,H,,1432,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor
12851,,,10576,,,,BAO_0000357,B,,CHEMBL616307,,,Autocuration,,1,8,,,H,,1433,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor
2148,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL881829,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1434,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus
13134,,,10576,,,,BAO_0000357,B,,CHEMBL616308,,,Expert,,1,8,,,H,,1435,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.
12462,,,10576,,,,BAO_0000019,B,,CHEMBL616309,,,Autocuration,,1,8,,,H,,1436,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain
12462,,,10576,,,,BAO_0000019,B,,CHEMBL616310,,,Expert,,1,8,,,H,,1437,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue
12462,449.0,CHO,10576,,,,BAO_0000219,B,,CHEMBL616311,,,Autocuration,,1,8,,,H,,1438,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells
11933,,,10576,,,,BAO_0000357,B,,CHEMBL616312,,,Expert,,1,8,,,H,,1439,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand
11933,,,10576,,,,BAO_0000357,B,,CHEMBL616313,,,Autocuration,,1,8,,,H,,1440,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined
403,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616314,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1441,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor
15538,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616315,,,Autocuration,Hippocampus,1,8,,,H,,1442,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus
15538,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616567,,,Autocuration,Hippocampus,1,8,,,H,,1443,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active
15538,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616568,,,Autocuration,Hippocampus,1,8,,,H,,1444,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined
12464,,,10576,,,,BAO_0000019,B,,CHEMBL616569,,,Intermediate,,1,8,,,H,,1445,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates
1455,,,10576,,,,BAO_0000357,B,,CHEMBL616570,,,Expert,,1,8,,,H,,1446,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.
12652,,,10576,,,,BAO_0000357,B,,CHEMBL616571,,,Autocuration,,1,8,,,H,,1447,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT
12639,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616572,,,Autocuration,Hippocampus,1,8,,,H,,1448,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal
13949,,,10576,,,,BAO_0000249,B,,CHEMBL616573,,,Expert,,1,8,,,H,,1449,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.
12463,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616574,,,Expert,,1,9,,Rattus norvegicus,D,,1450,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT
14829,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616575,,,Expert,Hippocampus,1,8,,,H,,1451,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation
14829,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL872108,,,Autocuration,Hippocampus,1,8,,,H,,1452,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined
12092,,,10576,,,,BAO_0000357,B,,CHEMBL616576,,,Autocuration,,1,8,,,H,,1453,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.
403,,,10576,,,,BAO_0000249,B,,CHEMBL616577,,,Autocuration,,1,8,,,H,,1454,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2
403,,,10576,,,,BAO_0000249,B,,CHEMBL616578,,,Autocuration,,1,8,,,H,,1455,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S
3967,,,10576,,,,BAO_0000357,B,,CHEMBL616579,,,Expert,,1,8,,,H,,1456,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.
12771,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616580,,,Expert,,1,9,,Rattus norvegicus,D,,1457,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations
15086,,,10576,,,,BAO_0000019,B,,CHEMBL616581,,,Autocuration,,1,8,,,H,,1458,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.
14909,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616582,,,Autocuration,Hippocampus,1,8,,,H,,1459,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
14949,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616583,,,Expert,Hippocampus,1,8,,,H,,1460,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus
2309,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616584,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1461,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT
4170,,,10576,,,,BAO_0000357,B,,CHEMBL616585,,,Expert,,1,8,,,H,,1462,Binding affinity towards 5-hydroxytryptamine 1A receptor
11642,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616586,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1463,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus
11642,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616587,,,Autocuration,Hippocampus,1,8,,,H,,1464,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus
12953,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616588,,,Autocuration,Hippocampus,1,8,,,H,,1465,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand
12953,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616589,,,Autocuration,Hippocampus,1,8,,,H,,1466,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.
12953,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616590,,,Expert,Hippocampus,1,8,,,H,,1467,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand
12903,449.0,CHO,10576,,,,BAO_0000219,B,,CHEMBL616591,,,Expert,,1,8,,,H,,1468,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand."
12536,,,10576,,,,BAO_0000357,B,,CHEMBL616592,,,Expert,,1,8,,,H,,1469,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
10058,,,10576,,,,BAO_0000357,B,,CHEMBL616593,,,Autocuration,,1,8,,,H,,1470,The inhibition activity of 5-HT1A at 1 uM
12902,485.0,CHO-K1,10576,,,,BAO_0000219,B,,CHEMBL616594,,,Expert,,1,8,,,H,,1471,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand."
14057,,,10576,,,,BAO_0000249,B,,CHEMBL616595,,,Expert,,1,8,,,H,,1472,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane
11296,,,10576,,,,BAO_0000357,B,,CHEMBL616596,,,Autocuration,,1,8,,,H,,1473,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.
11296,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616597,,,Autocuration,Hippocampus,1,8,,,H,,1474,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
11296,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616598,,,Expert,Hippocampus,1,8,,,H,,1475,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus
16616,,,10576,10116.0,,,BAO_0000249,F,,CHEMBL616599,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1476,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes
16616,,,10576,10116.0,,,BAO_0000249,F,10000000.0,CHEMBL616600,,Membranes,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1477,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes"
16567,,,10576,,,,BAO_0000019,B,,CHEMBL616601,,,Autocuration,,1,8,,,H,,1478,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.
16567,,,10576,,,,BAO_0000019,B,,CHEMBL616602,,,Autocuration,,1,8,,,H,,1479,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.
16567,,,10576,,,,BAO_0000019,B,,CHEMBL616603,,,Autocuration,,1,8,,,H,,1480,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.
16567,,,10576,,,,BAO_0000019,B,,CHEMBL616604,,,Autocuration,,1,8,,,H,,1481,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.
17136,,,10576,,,,BAO_0000249,B,,CHEMBL616316,,,Autocuration,,1,8,,,H,,1482,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data
17136,,,10576,,,,BAO_0000249,B,,CHEMBL616317,,,Autocuration,,1,8,,,H,,1483,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined
16616,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616318,,,Expert,,1,9,,Rattus norvegicus,D,,1484,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data
17331,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616319,,,Autocuration,Hippocampus,1,8,,,H,,1485,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes
17331,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616320,,,Autocuration,Hippocampus,1,8,,,H,,1486,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested
17167,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616321,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1487,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested
15740,,,10576,,,,BAO_0000019,F,,CHEMBL616322,,,Autocuration,,1,8,,,H,,1488,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
15740,,,10576,,,,BAO_0000019,F,,CHEMBL616323,,,Autocuration,,1,8,,,H,,1489,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested
4671,,,10576,,,,BAO_0000357,B,,CHEMBL616324,,,Autocuration,,1,8,,,H,,1490,Ratio of binding affinity to 5-HT 1A and D2 receptor
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616325,,,Autocuration,Hippocampus,1,8,,,H,,1491,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616326,,,Autocuration,Hippocampus,1,8,,,H,,1492,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM
10058,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616327,,,Autocuration,Hippocampus,1,8,,,H,,1493,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.
12073,,,10576,,,,BAO_0000357,B,,CHEMBL616328,,,Autocuration,,1,8,,,H,,1494,Percentage inhibition against 5-hydroxytryptamine 1A receptor
2759,,,10576,,,,BAO_0000249,B,,CHEMBL858110,,,Autocuration,,1,8,,,H,,1495,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
2759,,,10576,,,,BAO_0000249,F,,CHEMBL616329,,,Autocuration,,1,8,,,H,,1496,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1)
2759,,,10576,,,,BAO_0000249,B,,CHEMBL616330,,,Autocuration,,1,8,,,H,,1497,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
2759,,,10576,,,,BAO_0000249,F,,CHEMBL616331,,,Autocuration,,1,8,,,H,,1498,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2)
2759,,,10576,,,,BAO_0000249,F,,CHEMBL616332,,,Autocuration,,1,8,,,H,,1499,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
9737,,,10576,,,,BAO_0000249,B,955.0,CHEMBL857063,,,Autocuration,Brain,1,8,,,H,,1500,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
9737,,,10576,,,,BAO_0000019,B,,CHEMBL616333,,,Autocuration,,1,8,,,H,,1501,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand
5717,,,10576,,,,BAO_0000019,F,,CHEMBL616334,,,Expert,,1,8,,,H,,1502,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.
12253,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616335,,,Autocuration,Hippocampus,1,8,,,H,,1503,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
14025,,,10576,,,,BAO_0000019,B,,CHEMBL616336,,,Autocuration,,1,8,,,H,,1504,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.
10425,,,10576,,,,BAO_0000249,B,,CHEMBL616337,,,Expert,,1,8,,,H,,1505,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.
14998,,,10576,,,,BAO_0000019,B,,CHEMBL616338,,,Autocuration,,1,8,,,H,,1506,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.
13694,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616339,,,Autocuration,Hippocampus,1,8,,,H,,1507,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay
13694,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616340,,,Autocuration,Hippocampus,1,8,,,H,,1508,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay
4342,,,10576,,,,BAO_0000357,B,,CHEMBL616341,,,Autocuration,,1,8,,,H,,1509,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined
12936,,,10576,10116.0,,,BAO_0000357,B,,CHEMBL616342,,,Expert,,1,9,,Rattus norvegicus,D,,1510,Binding affinity against rat 5-hydroxytryptamine 1A receptor
13144,,,10576,10116.0,,,BAO_0000019,B,,CHEMBL616343,,,Expert,,1,9,,Rattus norvegicus,D,,1511,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates
13343,,,10576,,,,BAO_0000019,B,,CHEMBL616344,,,Expert,,1,8,,,H,,1512,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement
12132,,,10576,,,,BAO_0000357,B,,CHEMBL616345,,,Expert,,1,8,,,H,,1513,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
15419,,,10576,,,,BAO_0000019,B,,CHEMBL616346,,,Expert,,1,8,,,H,,1514,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand
1479,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616347,,,Autocuration,Hippocampus,1,8,,,H,,1515,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus
14287,,,10576,,,,BAO_0000019,B,,CHEMBL616348,,,Expert,,1,8,,,H,,1516,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane
13116,,,10576,,,,BAO_0000357,B,,CHEMBL616349,,,Expert,,1,8,,,H,,1517,Binding affinity at 5-hydroxytryptamine 1A receptor
2759,,,10576,10116.0,,,BAO_0000249,B,,CHEMBL616152,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,1518,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes
2759,,,10576,,,,BAO_0000249,B,,CHEMBL616153,,,Autocuration,,1,8,,,H,,1519,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.
14748,,,10576,,,,BAO_0000019,B,,CHEMBL616154,,,Expert,,1,8,,,H,,1520,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand"
12304,,,10576,,,,BAO_0000019,B,,CHEMBL616155,,,Autocuration,,1,8,,,H,,1521,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex
12409,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616156,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1522,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT
12409,,,10576,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL616157,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,1523,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT
13267,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL616158,,,Autocuration,Hippocampus,1,8,,,H,,1524,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand
15194,,,10576,,,,BAO_0000357,B,,CHEMBL616159,,,Autocuration,,1,8,,,H,,1525,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.
14256,,,10576,,,,BAO_0000357,B,,CHEMBL616160,,,Expert,,1,8,,,H,,1526,pKi value against rat 5-hydroxytryptamine 1A receptor.
16567,,,10576,,,,BAO_0000019,B,,CHEMBL616161,,,Autocuration,,1,8,,,H,,1527,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.
15740,,,10576,,,,BAO_0000019,F,,CHEMBL616162,,,Autocuration,,1,8,,,H,,1528,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested
13278,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL616163,,,Expert,,1,9,,Rattus norvegicus,D,,1529,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
1970,,,10626,,,,BAO_0000249,B,,CHEMBL616164,,Membranes,Expert,,1,8,,,H,,1530,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes
10034,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616165,,,Autocuration,Brain,1,8,,,H,,1531,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated
13348,,,51,10116.0,,,BAO_0000019,B,,CHEMBL616355,,,Autocuration,,1,8,,Rattus norvegicus,H,,1532,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker
13630,,,10576,,,,BAO_0000019,F,,CHEMBL616356,,,Autocuration,,1,8,,,H,,1533,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.
10862,,,10576,,,,BAO_0000221,B,955.0,CHEMBL616357,,,Autocuration,Brain,1,8,,,H,,1534,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.
12058,,,10576,,,,BAO_0000019,B,,CHEMBL616358,,,Autocuration,,1,8,,,H,,1535,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand"
4639,,,51,,,,BAO_0000357,B,,CHEMBL616359,,,Autocuration,,1,8,,,H,,1536,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor
15453,,,51,,,,BAO_0000357,B,,CHEMBL616360,,,Expert,,1,8,,,H,,1537,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT
4820,,,51,,,,BAO_0000357,B,,CHEMBL616361,,,Expert,,1,8,,,H,,1538,Binding affinity towards 5-hydroxytryptamine 1A receptor
1089,,,51,,,,BAO_0000357,B,,CHEMBL616362,,,Autocuration,,1,8,,,H,,1539,Tested for binding affinity for 5-hydroxytryptamine 1A receptor
386,,,51,,,,BAO_0000249,B,,CHEMBL616363,,Brain membranes,Autocuration,,1,8,,,H,,1540,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes
6011,,,51,,,,BAO_0000357,B,,CHEMBL616364,,,Autocuration,,1,8,,,H,,1541,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration
5014,,,51,,,,BAO_0000357,B,,CHEMBL616365,,,Autocuration,,1,8,,,H,,1542,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor
4402,,,51,,,,BAO_0000357,B,,CHEMBL616366,,,Expert,,1,8,,,H,,1543,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand
17066,,,51,,,,BAO_0000357,B,,CHEMBL872906,,,Expert,,1,8,,,H,,1544,Binding affinity towards 5-hydroxytryptamine 1A receptor
17515,,,51,,,,BAO_0000357,B,,CHEMBL616367,,,Autocuration,,1,8,,,H,,1545,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM
2474,,,51,,,,BAO_0000357,B,,CHEMBL616368,,,Autocuration,,1,8,,,H,,1546,Binding affinity against 5-hydroxytryptamine 1A receptor
4775,,,51,,,,BAO_0000357,B,,CHEMBL616369,,,Autocuration,,1,8,,,H,,1547,Binding affinity to 5-hydroxytryptamine 1A receptor was determined
14294,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616370,,,Expert,,1,9,,Homo sapiens,D,,1548,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.
14294,,,51,9606.0,,,BAO_0000357,B,,CHEMBL616371,,,Expert,,1,9,,Homo sapiens,D,,1549,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive
12249,449.0,CHO,51,,,,BAO_0000219,B,,CHEMBL616372,,,Autocuration,,1,8,,,H,,1550,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
11376,,,51,,,,BAO_0000219,B,,CHEMBL616373,,,Expert,,1,8,,,H,,1551,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes
2474,,,51,,,,BAO_0000218,B,,CHEMBL616374,,,Autocuration,,1,8,,,H,In vivo,1552,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand
13311,,,51,,,,BAO_0000221,B,10000000.0,CHEMBL616375,,,Autocuration,Hippocampus,1,8,,,H,,1553,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus
4373,,,51,,,,BAO_0000357,B,,CHEMBL616376,,,Autocuration,,1,8,,,H,,1554,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined
1633,,,51,,,,BAO_0000357,B,,CHEMBL857064,,,Expert,,1,8,,,H,,1555,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.
11866,,,51,,,,BAO_0000357,B,,CHEMBL616377,,,Autocuration,,1,8,,,H,,1556,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
4373,,,51,,,,BAO_0000357,B,,CHEMBL616378,,,Autocuration,,1,8,,,H,,1557,Binding affinity for 5-hydroxytryptamine 1A receptor was determined
4687,,,51,,,,BAO_0000357,B,,CHEMBL616379,,,Autocuration,,1,8,,,H,,1558,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor
16946,,,11863,,,,BAO_0000357,B,,CHEMBL616380,,,Autocuration,,1,8,,,H,,1559,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor
13291,,,11863,,,,BAO_0000357,B,,CHEMBL616381,,,Autocuration,,1,8,,,H,,1560,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand
14159,,,11863,,,,BAO_0000357,B,,CHEMBL616382,,,Autocuration,,1,8,,,H,,1561,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor
10812,,,11863,,,,BAO_0000357,B,,CHEMBL616383,,,Autocuration,,1,8,,,H,,1562,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand
3032,449.0,CHO,11863,10090.0,,,BAO_0000219,B,,CHEMBL616350,,,Expert,,1,9,,Mus musculus,D,,1563,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells
16655,,,11863,,,,BAO_0000357,B,,CHEMBL616351,,,Autocuration,,1,8,,,H,,1564,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor
14532,,,11863,,,,BAO_0000357,B,,CHEMBL616352,,,Autocuration,,1,8,,,H,,1565,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration
13944,,,11863,,,,BAO_0000357,B,,CHEMBL616353,,,Autocuration,,1,8,,,H,,1566,Binding affinity against 5-hydroxytryptamine 1A receptor
13033,,,11863,,,,BAO_0000357,B,,CHEMBL616354,,,Autocuration,,1,8,,,H,,1567,Binding affinity against serotonergic 5-HT1a receptor
10321,,,11863,,,,BAO_0000357,B,,CHEMBL616508,,,Autocuration,,1,8,,,H,,1568,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand
2968,,,11863,10090.0,,,BAO_0000357,B,,CHEMBL616559,,,Expert,,1,9,,Mus musculus,D,,1569,Binding affinity for 5-hydroxytryptamine 1A receptor
13964,,,11863,,,,BAO_0000357,B,,CHEMBL616560,,,Autocuration,,1,8,,,H,,1570,Binding affinity at 5-hydroxytryptamine 1A receptor
15527,,,11863,,,,BAO_0000357,B,,CHEMBL616561,,,Autocuration,,1,8,,,H,,1571,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand."
12248,449.0,CHO,11863,,,,BAO_0000219,B,,CHEMBL616562,,,Autocuration,,1,8,,,H,,1572,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
12249,449.0,CHO,11863,,,,BAO_0000219,B,,CHEMBL616563,,,Autocuration,,1,8,,,H,,1573,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells
15120,,,11863,,,,BAO_0000357,B,,CHEMBL616564,,,Autocuration,,1,8,,,H,,1574,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor
13313,,,11863,,,,BAO_0000357,B,,CHEMBL616565,,,Autocuration,,1,8,,,H,,1575,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand
2613,,,11863,,,,BAO_0000218,B,,CHEMBL616566,,,Autocuration,,1,8,,,H,,1576,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor
16700,,,11863,,,,BAO_0000357,B,,CHEMBL616989,,,Autocuration,,1,8,,,H,,1577,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity
2201,,,11863,,,,BAO_0000357,B,,CHEMBL857975,,,Autocuration,,1,8,,,H,,1578,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor
1274,,,11863,10090.0,,,BAO_0000357,B,,CHEMBL616990,,,Expert,,1,9,,Mus musculus,D,,1579,Binding affinity against 5-hydroxytryptamine 1A receptor
1317,,,11863,,,,BAO_0000357,B,,CHEMBL616991,,,Autocuration,,1,8,,,H,,1580,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay
12146,,,11863,,,,BAO_0000357,B,,CHEMBL616992,,,Autocuration,,1,8,,,H,,1581,Tested against 5-hydroxytryptamine 1A receptor
14059,,,11863,,,,BAO_0000357,B,,CHEMBL616993,,,Autocuration,,1,8,,,H,,1582,The compound's binding affinity against 5-hydroxytryptamine 1A receptor
14025,,,106,9986.0,,,BAO_0000019,B,,CHEMBL616994,,,Expert,,1,8,,Oryctolagus cuniculus,H,,1583,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein
14025,,,106,9986.0,,,BAO_0000019,B,,CHEMBL616995,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1584,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable
14447,722.0,HEK293,105571,9593.0,,,BAO_0000219,B,,CHEMBL616996,,,Intermediate,,1,9,,Gorilla gorilla,D,,1585,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
3025,,,106,10141.0,,,BAO_0000218,F,,CHEMBL616997,,,Autocuration,,1,8,,Cavia porcellus,H,In vivo,1586,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
3025,,,106,10141.0,,,BAO_0000218,F,,CHEMBL616998,,,Autocuration,,1,8,,Cavia porcellus,H,In vivo,1587,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration
15329,,,106,10141.0,,,BAO_0000019,F,,CHEMBL616999,,,Autocuration,,1,8,,Cavia porcellus,H,,1588,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery
15329,,,106,10141.0,,,BAO_0000019,F,,CHEMBL617000,,,Autocuration,,1,8,,Cavia porcellus,H,,1589,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined
15847,,,106,10141.0,,,BAO_0000019,F,,CHEMBL617001,,,Autocuration,,1,8,,Cavia porcellus,H,,1590,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig
15847,,,106,10141.0,,,BAO_0000019,F,,CHEMBL858111,,,Autocuration,,1,8,,Cavia porcellus,H,,1591,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done
14165,,,106,,,,BAO_0000019,F,,CHEMBL617002,,,Autocuration,,1,8,,,H,,1592,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding
14214,,,106,,,,BAO_0000019,F,,CHEMBL617003,,,Autocuration,,1,8,,,H,,1593,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT)
14214,,,106,,,,BAO_0000019,F,,CHEMBL617004,,,Autocuration,,1,8,,,H,,1594,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT)
14214,,,106,9606.0,,,BAO_0000019,F,,CHEMBL617005,,,Expert,,1,9,,Homo sapiens,D,,1595,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation
13729,485.0,CHO-K1,106,9606.0,,,BAO_0000219,F,,CHEMBL616623,,,Expert,,1,9,,Homo sapiens,D,,1596,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells
3025,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616624,,,Autocuration,,1,8,,,H,,1597,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines
2391,,,106,,,,BAO_0000357,B,,CHEMBL883243,,,Autocuration,,1,8,,,H,,1598,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor
2391,,,106,,,,BAO_0000019,F,,CHEMBL616625,,,Autocuration,,1,8,,,H,,1599,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist
14956,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616626,,,Expert,,1,8,,,H,,1600,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor"
2598,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616627,,,Autocuration,,1,8,,,H,,1601,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line
2598,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616628,,,Autocuration,,1,8,,,H,,1602,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist
2598,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616629,,,Autocuration,,1,8,,,H,,1603,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist
2598,449.0,CHO,106,,,,BAO_0000219,F,,CHEMBL616630,,,Autocuration,,1,8,,,H,,1604,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist
14956,,,106,,,,BAO_0000019,F,,CHEMBL616631,,,Expert,,1,8,,,H,,1605,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand"
14956,,,106,,,,BAO_0000019,F,,CHEMBL616632,,,Autocuration,,1,8,,,H,,1606,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand"
14214,,,106,9606.0,,,BAO_0000357,B,,CHEMBL616633,,,Expert,,1,9,,Homo sapiens,D,,1607,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor
3463,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616634,,,Expert,,1,8,,,H,,1608,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro
15331,,,106,,,,BAO_0000357,B,,CHEMBL616635,,,Autocuration,,1,8,,,H,,1609,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique
16146,,,106,9606.0,,,BAO_0000357,B,,CHEMBL885358,,,Expert,,1,9,,Homo sapiens,D,,1610,Binding affinity against 5-hydroxytryptamine 1B receptor
14159,449.0,CHO,106,9606.0,,,BAO_0000219,B,,CHEMBL616636,,,Expert,,1,9,,Homo sapiens,D,,1611,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells
14158,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616637,,,Expert,,1,8,,,H,,1612,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.
14159,,,106,,,,BAO_0000357,B,,CHEMBL616638,,,Autocuration,,1,8,,,H,,1613,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor
15250,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616639,,,Expert,,1,8,,,H,,1614,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
15250,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616640,,,Expert,,1,8,,,H,,1615,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.
15331,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616641,,,Expert,,1,8,,,H,,1616,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells
15332,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616642,,,Expert,,1,8,,,H,,1617,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.
14956,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616643,,,Expert,,1,8,,,H,,1618,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells
3805,,,106,,,,BAO_0000357,B,,CHEMBL616644,,,Autocuration,,1,8,,,H,,1619,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM)
14875,,,106,,,,BAO_0000357,B,,CHEMBL616645,,,Autocuration,,1,8,,,H,,1620,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response
14454,,,105,9986.0,,,BAO_0000019,F,,CHEMBL616646,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1621,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
14454,,,105,9986.0,,,BAO_0000019,F,,CHEMBL616647,,,Expert,,1,8,,Oryctolagus cuniculus,H,,1622,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
16288,,,105,,,,BAO_0000357,B,,CHEMBL616509,,,Autocuration,,1,8,,,H,,1623,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9)
16288,,,105,,,,BAO_0000357,B,,CHEMBL616510,,,Autocuration,,1,8,,,H,,1624,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9)
16312,,,105,,,,BAO_0000357,B,,CHEMBL616511,,,Autocuration,,1,8,,,H,,1625,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor
1348,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616512,,,Expert,,1,8,,Bos taurus,H,,1626,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype
5834,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616513,,,Autocuration,,1,8,,Bos taurus,H,,1627,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT
13366,,,105,9913.0,,,BAO_0000019,B,2435.0,CHEMBL616514,,,Autocuration,Striatum,1,8,,Bos taurus,H,,1628,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
1414,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616515,,,Expert,,1,8,,Bos taurus,H,,1629,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra
14998,,,105,9913.0,,,BAO_0000019,B,,CHEMBL616516,,,Autocuration,,1,8,,Bos taurus,H,,1630,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.
11473,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616517,,,Autocuration,,1,8,,Bos taurus,H,,1631,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
11473,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616518,,,Autocuration,,1,8,,Bos taurus,H,,1632,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand
10639,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616519,,,Autocuration,,1,8,,Bos taurus,H,,1633,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
10639,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616520,,,Autocuration,,1,8,,Bos taurus,H,,1634,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand
1375,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616521,,,Autocuration,,1,8,,Bos taurus,H,,1635,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand
1375,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616522,,,Autocuration,,1,8,,Bos taurus,H,,1636,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested
16532,,,105,9913.0,,,BAO_0000357,B,,CHEMBL884531,,,Autocuration,,1,8,,Bos taurus,H,,1637,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
11147,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616523,,,Autocuration,,1,8,,Bos taurus,H,,1638,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand
13366,,,105,9913.0,,,BAO_0000019,B,2435.0,CHEMBL616731,,,Autocuration,Striatum,1,8,,Bos taurus,H,,1639,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate
10444,,,105,9913.0,,,BAO_0000019,B,,CHEMBL616732,,,Autocuration,,1,8,,Bos taurus,H,,1640,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate
16532,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616733,,,Autocuration,,1,8,,Bos taurus,H,,1641,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT
16532,,,105,9913.0,,,BAO_0000357,B,,CHEMBL616734,,,Autocuration,,1,8,,Bos taurus,H,,1642,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested
12827,,,105,9913.0,,,BAO_0000249,B,,CHEMBL616735,,,Autocuration,,1,8,,Bos taurus,H,,1643,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP
12827,,,105,9913.0,,,BAO_0000249,B,,CHEMBL616736,,,Autocuration,,1,8,,Bos taurus,H,,1644,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined
12919,,,105,9913.0,,,BAO_0000019,F,,CHEMBL616737,,,Expert,,1,8,,Bos taurus,H,,1645,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
14025,,,105,9913.0,,,BAO_0000019,B,,CHEMBL616738,,,Autocuration,,1,8,,Bos taurus,H,,1646,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate
12919,,,105,9913.0,,,BAO_0000019,F,,CHEMBL616739,,,Expert,,1,8,,Bos taurus,H,,1647,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
12919,,,105,9913.0,,,BAO_0000019,F,,CHEMBL616740,,,Expert,,1,8,,Bos taurus,H,,1648,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
12919,,,105,9913.0,,,BAO_0000019,F,,CHEMBL616741,,,Expert,,1,8,,Bos taurus,H,,1649,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI
14447,722.0,HEK293,105,9593.0,,,BAO_0000219,B,,CHEMBL616742,,,Autocuration,,1,8,,Gorilla gorilla,H,,1650,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells
1375,,,105570,10141.0,,,BAO_0000019,B,,CHEMBL616743,,,Intermediate,,1,9,,Cavia porcellus,D,,1651,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra
1375,,,105570,10141.0,,,BAO_0000019,B,,CHEMBL616744,,,Intermediate,,1,9,,Cavia porcellus,D,,1652,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested
12409,,,105570,10141.0,,,BAO_0000019,F,,CHEMBL616745,,,Intermediate,,1,9,,Cavia porcellus,D,,1653,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611
12409,,,105570,10141.0,,,BAO_0000019,F,,CHEMBL616746,,,Intermediate,,1,9,,Cavia porcellus,D,,1654,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
12409,,,105570,10141.0,,,BAO_0000019,F,,CHEMBL616747,,,Intermediate,,1,9,,Cavia porcellus,D,,1655,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9
12409,,,105570,10141.0,,,BAO_0000019,F,,CHEMBL616748,,,Intermediate,,1,9,,Cavia porcellus,D,,1656,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4
12409,,,105570,10141.0,,,BAO_0000019,F,,CHEMBL616648,,,Intermediate,,1,9,,Cavia porcellus,D,,1657,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2
11574,,,105570,10141.0,,,BAO_0000357,B,,CHEMBL616649,,,Intermediate,,1,9,,Cavia porcellus,D,,1658,Binding affinity against 5-hydroxytryptamine 1D receptor
1558,,,105570,10141.0,,,BAO_0000357,B,,CHEMBL616650,,,Intermediate,,1,9,,Cavia porcellus,D,,1659,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined
12409,,,105570,10141.0,,,BAO_0000218,F,,CHEMBL616651,,,Intermediate,,1,9,,Cavia porcellus,D,,1660,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
12409,,,105570,10141.0,,,BAO_0000218,F,,CHEMBL616652,,,Intermediate,,1,9,,Cavia porcellus,D,,1661,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
12409,,,105570,10141.0,,,BAO_0000218,F,,CHEMBL616653,,,Intermediate,,1,9,,Cavia porcellus,D,,1662,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611
12409,,,105570,10141.0,,,BAO_0000218,F,,CHEMBL616654,,,Intermediate,,1,9,,Cavia porcellus,D,,1663,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig
12253,,,105570,10141.0,,,BAO_0000019,B,,CHEMBL616655,,,Intermediate,,1,9,,Cavia porcellus,D,,1664,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex
12936,,,105570,10141.0,,,BAO_0000357,B,,CHEMBL616656,,,Intermediate,,1,9,,Cavia porcellus,D,,1665,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor
13181,,,105,10141.0,,,BAO_0000019,B,,CHEMBL616657,,,Autocuration,,1,8,,Cavia porcellus,H,,1666,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes
12409,,,105570,10141.0,,,BAO_0000357,B,2435.0,CHEMBL616658,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,1667,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine
10639,,,105570,10141.0,,,BAO_0000357,B,,CHEMBL616659,,,Intermediate,,1,9,,Cavia porcellus,D,,1668,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra
5254,,,51,,,,BAO_0000357,B,,CHEMBL616660,,,Autocuration,,1,8,,,H,,1669,Binding affinity against 5-hydroxytryptamine 1D receptor
13051,,,106,,,,BAO_0000357,B,,CHEMBL616661,,,Autocuration,,1,8,,,H,,1670,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta
3463,,,105,,,,BAO_0000019,F,,CHEMBL616662,,,Expert,,1,8,,,H,,1671,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor
15315,,,105,,,,BAO_0000019,F,,CHEMBL616663,,,Autocuration,,1,8,,,H,,1672,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor
6011,,,105,,,,BAO_0000019,F,,CHEMBL616664,,,Autocuration,,1,8,,,H,,1673,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor
14159,449.0,CHO,105,9606.0,,,BAO_0000219,F,,CHEMBL881820,,,Expert,,1,9,,Homo sapiens,D,,1674,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor"
14159,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL616665,,,Autocuration,,1,8,,,H,,1675,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor."
15250,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616666,,,Expert,,1,8,,,H,,1676,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
15250,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616667,,,Autocuration,,1,8,,,H,,1677,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor
15331,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL616668,,,Expert,,1,8,,,H,,1678,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
15332,449.0,CHO,105,9606.0,,,BAO_0000219,F,,CHEMBL616669,,,Expert,,1,9,,Homo sapiens,D,,1679,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor"
15332,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL617040,,,Expert,,1,8,,,H,,1680,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor."
3294,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL617041,,,Autocuration,,1,8,,,H,,1681,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor"
14158,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL617042,,,Expert,,1,8,,,H,,1682,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor."
14956,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL617043,,,Expert,,1,8,,,H,,1683,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor"
12469,,,105,,,,BAO_0000019,F,,CHEMBL617044,,,Autocuration,,1,8,,,H,,1684,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor
3463,449.0,CHO,105,,,,BAO_0000219,F,,CHEMBL617045,,,Expert,,1,8,,,H,,1685,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor
15250,449.0,CHO,105,9606.0,,,BAO_0000219,F,,CHEMBL617046,,,Expert,,1,9,,Homo sapiens,D,,1686,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
15250,449.0,CHO,105,9606.0,,,BAO_0000219,F,,CHEMBL617047,,,Expert,,1,9,,Homo sapiens,D,,1687,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT"
14956,,,105,,,,BAO_0000019,F,,CHEMBL617048,,,Expert,,1,8,,,H,,1688,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand"
14159,,,105,,,,BAO_0000019,F,,CHEMBL616897,,,Autocuration,,1,8,,,H,,1689,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor."
14159,,,105,9606.0,,,BAO_0000019,F,,CHEMBL616898,,,Expert,,1,9,,Homo sapiens,D,,1690,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT"
14499,449.0,CHO,105,9606.0,,,BAO_0000219,F,,CHEMBL858201,,,Expert,,1,9,,Homo sapiens,D,,1691,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor
15315,,,105,,,,BAO_0000019,F,,CHEMBL616899,,,Autocuration,,1,8,,,H,,1692,Intrinsic activity for 5-hydroxytryptamine 1D receptor
3294,,,105,,,,BAO_0000219,B,,CHEMBL616900,,,Autocuration,,1,8,,,H,In vitro,1693,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells)
3463,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616901,,,Expert,,1,8,,,H,,1694,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro
15331,,,105,,,,BAO_0000357,B,,CHEMBL616902,,,Autocuration,,1,8,,,H,,1695,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique
14159,449.0,CHO,105,9606.0,,,BAO_0000219,B,,CHEMBL616903,,,Expert,,1,9,,Homo sapiens,D,,1696,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
14158,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616904,,,Expert,,1,8,,,H,,1697,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.
14159,,,105,,,,BAO_0000357,B,,CHEMBL616905,,,Autocuration,,1,8,,,H,,1698,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor
15250,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616906,,,Expert,,1,8,,,H,,1699,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.
15250,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616907,,,Expert,,1,8,,,H,,1700,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
15331,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616908,,,Expert,,1,8,,,H,,1701,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
15332,449.0,CHO,105,9606.0,,,BAO_0000219,B,,CHEMBL616909,,,Expert,,1,9,,Homo sapiens,D,,1702,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
14499,449.0,CHO,105,9606.0,,,BAO_0000219,B,,CHEMBL616910,,,Expert,,1,9,,Homo sapiens,D,,1703,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells
15332,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616911,,,Expert,,1,8,,,H,,1704,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells
14956,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616912,,,Expert,,1,8,,,H,,1705,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells
3805,,,105,,,,BAO_0000357,B,,CHEMBL616913,,,Autocuration,,1,8,,,H,,1706,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM)
6011,449.0,CHO,105,9606.0,,,BAO_0000219,B,,CHEMBL616914,,,Expert,,1,9,,Homo sapiens,D,,1707,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM
16190,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616915,,,Autocuration,,1,8,,,H,,1708,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
14165,,,105,,,,BAO_0000019,B,,CHEMBL616916,,,Autocuration,,1,8,,,H,,1709,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand
4234,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616917,,,Expert,,1,9,,Homo sapiens,D,,1710,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor
15527,,,105,,,,BAO_0000357,B,,CHEMBL616918,,,Autocuration,,1,8,,,H,,1711,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand."
6328,,,105,,,,BAO_0000219,B,,CHEMBL616919,,,Expert,,1,8,,,H,,1712,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand
16209,,,105,,,,BAO_0000357,B,,CHEMBL616920,,,Autocuration,,1,8,,,H,,1713,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand
14770,,,105,,,,BAO_0000357,B,,CHEMBL872914,,,Autocuration,,1,8,,,H,,1714,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.
2598,,,105,,,,BAO_0000357,B,,CHEMBL616921,,,Autocuration,,1,8,,,H,,1715,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand
6897,,,105,,,,BAO_0000357,B,,CHEMBL616922,,,Expert,,1,8,,,H,,1716,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor
6013,,,105,,,,BAO_0000357,B,,CHEMBL616923,,,Autocuration,,1,8,,,H,,1717,Binding affinity towards 5-hydroxytryptamine 1D receptor
5843,,,105,,,,BAO_0000357,B,,CHEMBL616924,,,Expert,,1,8,,,H,,1718,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
14454,,,105,,,,BAO_0000357,B,,CHEMBL875909,,,Expert,,1,8,,,H,,1719,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand
14454,,,105,,,,BAO_0000357,B,,CHEMBL616925,,,Autocuration,,1,8,,,H,,1720,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined
14454,,,105,,,,BAO_0000357,B,,CHEMBL616926,,,Autocuration,,1,8,,,H,,1721,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined
15818,,,105,,,,BAO_0000357,B,,CHEMBL616927,,,Autocuration,,1,8,,,H,,1722,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor
13729,485.0,CHO-K1,105,,,,BAO_0000219,F,,CHEMBL616928,,,Expert,,1,8,,,H,,1723,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells
6011,,,105,9606.0,,,BAO_0000219,B,,CHEMBL616929,,,Expert,,1,9,,Homo sapiens,D,In vitro,1724,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells)
4234,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616930,,,Expert,,1,9,,Homo sapiens,D,,1725,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor
17085,,,105,,,,BAO_0000019,B,,CHEMBL616931,,,Expert,,1,8,,,H,,1726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
3025,,,105,,,,BAO_0000357,B,,CHEMBL616932,,,Autocuration,,1,8,,,H,,1727,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
15315,,,105,,,,BAO_0000357,B,,CHEMBL616933,,,Expert,,1,8,,,H,,1728,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor
14214,,,105,9606.0,,,BAO_0000219,B,,CHEMBL616934,,,Expert,,1,9,,Homo sapiens,D,,1729,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells
3804,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616935,,,Expert,,1,9,,Homo sapiens,D,,1730,Binding affinity for human 5-hydroxytryptamine 1D receptor
16700,,,105,,,,BAO_0000357,B,,CHEMBL616936,,,Autocuration,,1,8,,,H,,1731,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity
2391,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616937,,,Expert,,1,9,,Homo sapiens,D,,1732,Affinity for 5-hydroxytryptamine 1D receptor subtype
4175,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616938,,,Expert,,1,9,,Homo sapiens,D,,1733,Binding affinity for human 5-hydroxytryptamine 1D receptor
17085,,,105,,,,BAO_0000019,B,,CHEMBL616939,,,Autocuration,,1,8,,,H,,1734,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor
17085,,,105,,,,BAO_0000019,B,,CHEMBL616940,,,Expert,,1,8,,,H,,1735,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined
15926,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616941,,,Expert,,1,9,,Homo sapiens,D,,1736,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested
16312,485.0,CHO-K1,105,,,,BAO_0000219,B,,CHEMBL616942,,,Autocuration,,1,8,,,H,,1737,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested
16312,485.0,CHO-K1,105,,,,BAO_0000219,B,,CHEMBL616943,,,Autocuration,,1,8,,,H,,1738,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested
14956,449.0,CHO,104802,,,,BAO_0000219,B,,CHEMBL616944,,,Autocuration,,1,4,,,H,,1739,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells
3294,,,105,,,,BAO_0000019,F,,CHEMBL616945,,,Autocuration,,1,8,,,H,,1740,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT"
12861,,,105,,,,BAO_0000357,B,,CHEMBL616946,,,Autocuration,,1,8,,,H,,1741,Binding activity radioligand.
12861,,,105,,,,BAO_0000019,B,,CHEMBL616947,,,Autocuration,,1,8,,,H,,1742,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
16312,485.0,CHO-K1,105,,,,BAO_0000219,B,,CHEMBL616948,,,Expert,,1,8,,,H,,1743,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor
5104,,,105,,,,BAO_0000357,B,,CHEMBL616851,,,Autocuration,,1,8,,,H,,1744,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
5105,,,105,,,,BAO_0000357,B,,CHEMBL616852,,,Autocuration,,1,8,,,H,,1745,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor
14499,,,105,,,,BAO_0000357,B,,CHEMBL616853,,,Autocuration,,1,8,,,H,,1746,Measured as -log Ka on 5-hydroxytryptamine 1D receptor
15926,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616854,,,Expert,,1,9,,Homo sapiens,D,,1747,Binding activity against human 5-hydroxytryptamine 1D receptor
4540,449.0,CHO,105,9606.0,,,BAO_0000219,B,,CHEMBL616855,,,Expert,,1,9,,Homo sapiens,D,,1748,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand
15779,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616856,,,Autocuration,,1,8,,,H,,1749,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.
15779,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616857,,,Autocuration,,1,8,,,H,,1750,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
6166,,,105,,,,BAO_0000357,B,,CHEMBL616858,,,Autocuration,,1,8,,,H,,1751,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor
15779,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616859,,,Autocuration,,1,8,,,H,,1752,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.
15779,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616860,,,Autocuration,,1,8,,,H,,1753,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.
17451,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL616861,,,Autocuration,,1,8,,,H,,1754,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
17451,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL616541,,,Autocuration,,1,8,,,H,,1755,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand
17451,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL616542,,,Autocuration,,1,8,,,H,,1756,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined
4199,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616543,,,Autocuration,,1,8,,,H,,1757,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand
14875,,,105,9606.0,,,BAO_0000357,B,,CHEMBL616544,,,Expert,,1,9,,Homo sapiens,D,,1758,Binding affinity for human 5-hydroxytryptamine 1D receptor
15146,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616545,,,Autocuration,,1,8,,,H,,1759,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT
5213,,,105,,,,BAO_0000357,B,,CHEMBL616546,,,Autocuration,,1,8,,,H,,1760,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand
14818,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616547,,,Autocuration,,1,8,,,H,,1761,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.
4829,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL616548,,,Autocuration,,1,8,,,H,,1762,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand"
14454,,,105,,,,BAO_0000019,F,,CHEMBL616549,,,Expert,,1,8,,,H,,1763,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM
14454,,,105,,,,BAO_0000019,F,,CHEMBL616550,,,Expert,,1,8,,,H,,1764,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM
5254,,,108,,,,BAO_0000357,B,,CHEMBL857066,,,Autocuration,,1,8,,,H,,1765,Binding affinity against 5-HT2C receptor
5254,,,108,,,,BAO_0000357,B,,CHEMBL616551,,,Autocuration,,1,8,,,H,,1766,Binding affinity against 5-hydroxytryptamine 1D receptor
10639,,,10577,,,,BAO_0000357,B,,CHEMBL616552,,,Autocuration,,1,8,,,H,,1767,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
10639,,,10577,,,,BAO_0000019,F,,CHEMBL832876,,,Autocuration,,1,8,,,H,,1768,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra
12352,,,10577,,,,BAO_0000019,B,,CHEMBL616553,,,Expert,,1,8,,,H,,1769,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus"
9098,,,10577,,,,BAO_0000357,B,,CHEMBL616554,,,Autocuration,,1,8,,,H,,1770,Binding affinity towards 5-HT1B was determined
14430,,,10577,,,,BAO_0000019,B,,CHEMBL616555,,,Expert,,1,8,,,H,,1771,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT
13657,,,10577,,,,BAO_0000019,B,,CHEMBL616556,,,Expert,,1,8,,,H,,1772,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB"
13657,,,10577,,,,BAO_0000019,B,,CHEMBL616557,,,Autocuration,,1,8,,,H,,1773,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB."
15854,,,10577,,,,BAO_0000019,B,,CHEMBL616558,,,Expert,,1,8,,,H,,1774,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
10639,,,10577,10116.0,,,BAO_0000019,B,,CHEMBL616749,,,Expert,,1,9,,Rattus norvegicus,D,,1775,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT
10025,,,10577,,,,BAO_0000357,B,,CHEMBL616750,,,Autocuration,,1,8,,,H,,1776,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM
10025,,,10577,,,,BAO_0000357,B,,CHEMBL616751,,,Autocuration,,1,8,,,H,,1777,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM"
14286,,,10577,,,,BAO_0000249,B,,CHEMBL616752,,,Autocuration,,1,8,,,H,,1778,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
3651,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616753,,,Autocuration,Striatum,1,8,,,H,,1779,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%
14178,,,10577,10116.0,,,BAO_0000357,B,,CHEMBL616754,,,Expert,,1,9,,Rattus norvegicus,D,,1780,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor
10639,,,10577,,,,BAO_0000019,B,,CHEMBL616755,,,Autocuration,,1,8,,,H,,1781,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.
13605,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616756,,,Autocuration,Striatum,1,8,,,H,,1782,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum
5834,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616757,,,Autocuration,Striatum,1,8,,,H,,1783,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT
10922,,,10577,,,,BAO_0000357,B,2435.0,CHEMBL616758,,,Autocuration,Striatum,1,8,,,H,,1784,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue
14286,,,10577,,,,BAO_0000249,B,,CHEMBL616759,,,Autocuration,,1,8,,,H,,1785,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane
11825,,,10577,,,,BAO_0000357,B,,CHEMBL616760,,,Autocuration,,1,8,,,H,,1786,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M
14826,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616761,,,Autocuration,Striatum,1,8,,,H,,1787,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum
9699,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616762,,,Autocuration,Striatum,1,8,,,H,,1788,Binding affinity against 5-HT1B serotonin receptor in rat striatum
14423,,,10577,,,,BAO_0000019,B,,CHEMBL616763,,,Autocuration,,1,8,,,H,,1789,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex
10062,,,10577,,,,BAO_0000357,B,,CHEMBL872909,,,Expert,,1,8,,,H,,1790,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.
10062,,,10577,,,,BAO_0000357,B,,CHEMBL616764,,,Autocuration,,1,8,,,H,,1791,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
12280,,,10577,10116.0,,,BAO_0000357,B,,CHEMBL616765,,,Expert,,1,9,,Rattus norvegicus,D,,1792,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor
15412,,,10577,,,,BAO_0000357,B,2435.0,CHEMBL616766,,,Autocuration,Striatum,1,8,,,H,,1793,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum
15412,,,10577,,,,BAO_0000357,B,2435.0,CHEMBL616767,,,Autocuration,Striatum,1,8,,,H,,1794,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.
10062,,,10577,,,,BAO_0000357,B,,CHEMBL616768,,,Autocuration,,1,8,,,H,,1795,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor
11147,,,10577,,,,BAO_0000357,B,,CHEMBL616769,,,Autocuration,,1,8,,,H,,1796,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
9547,,,10577,,,,BAO_0000019,B,,CHEMBL616770,,,Autocuration,,1,8,,,H,,1797,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay
10444,,,10577,,,,BAO_0000019,B,,CHEMBL616771,,,Autocuration,,1,8,,,H,,1798,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.
12469,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616772,,,Autocuration,Striatum,1,8,,,H,,1799,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT
9098,,,10577,,,,BAO_0000019,B,,CHEMBL616773,,,Expert,,1,8,,,H,,1800,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.
9098,,,10577,,,,BAO_0000019,B,,CHEMBL616774,,,Autocuration,,1,8,,,H,,1801,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.
9699,,,10577,,,,BAO_0000357,B,,CHEMBL616775,,,Autocuration,,1,8,,,H,,1802,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor
10394,,,10577,,,,BAO_0000249,B,,CHEMBL616776,,,Autocuration,,1,8,,,H,,1803,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand
12092,,,10577,,,,BAO_0000357,B,,CHEMBL616777,,,Autocuration,,1,8,,,H,,1804,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.
16700,,,10577,,,,BAO_0000357,B,,CHEMBL616778,,,Autocuration,,1,8,,,H,,1805,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity
403,,,10577,10116.0,,,BAO_0000249,B,,CHEMBL616779,,,Expert,,1,9,,Rattus norvegicus,D,,1806,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand
12771,,,10577,10116.0,,,BAO_0000357,B,,CHEMBL616780,,,Expert,,1,9,,Rattus norvegicus,D,,1807,Binding affinity towards 5-hydroxytryptamine 1B receptor
11642,,,10577,,,,BAO_0000019,B,,CHEMBL616781,,,Autocuration,,1,8,,,H,,1808,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex
12953,,,10577,,,,BAO_0000357,B,,CHEMBL616782,,,Autocuration,,1,8,,,H,,1809,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand
12953,,,10577,,,,BAO_0000357,B,,CHEMBL616783,,,Autocuration,,1,8,,,H,,1810,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.
12953,,,10577,,,,BAO_0000019,B,2435.0,CHEMBL616784,,,Expert,Striatum,1,8,,,H,,1811,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand
12953,,,10577,,,,BAO_0000357,B,,CHEMBL616785,,,Autocuration,,1,8,,,H,,1812,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM
9737,,,10577,,,,BAO_0000249,B,955.0,CHEMBL857067,,,Autocuration,Brain,1,8,,,H,,1813,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
9737,,,10577,,,,BAO_0000019,B,,CHEMBL616786,,,Autocuration,,1,8,,,H,,1814,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand
9737,,,10577,,,,BAO_0000249,B,955.0,CHEMBL616787,,,Autocuration,Brain,1,8,,,H,,1815,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
12827,,,10577,,,,BAO_0000357,B,,CHEMBL616788,,,Autocuration,,1,8,,,H,,1816,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine
5033,,,10577,,,,BAO_0000357,B,,CHEMBL616789,,,Autocuration,,1,8,,,H,,1817,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor
9786,,,10577,10116.0,,,BAO_0000019,B,,CHEMBL616790,,,Expert,,1,9,,Rattus norvegicus,D,,1818,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate
13116,,,10577,,,,BAO_0000357,B,,CHEMBL616791,,,Expert,,1,8,,,H,,1819,Binding affinity at 5-hydroxytryptamine 1B receptor
16429,,,10577,,,,BAO_0000019,B,,CHEMBL616792,,,Autocuration,,1,8,,,H,,1820,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand
12409,,,10577,10116.0,,,BAO_0000249,B,,CHEMBL616793,,,Expert,,1,9,,Rattus norvegicus,D,,1821,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol
15194,,,10577,,,,BAO_0000357,B,,CHEMBL616794,,,Autocuration,,1,8,,,H,,1822,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand
15194,,,10577,,,,BAO_0000357,B,,CHEMBL616795,,,Autocuration,,1,8,,,H,,1823,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
5486,,,104686,,,,BAO_0000019,B,,CHEMBL616796,,,Autocuration,,1,4,,,H,,1824,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex
4639,,,106,,,,BAO_0000357,B,,CHEMBL616797,,,Autocuration,,1,8,,,H,,1825,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor
386,,,106,,,,BAO_0000249,B,,CHEMBL616798,,Brain membranes,Autocuration,,1,8,,,H,,1826,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes
2474,,,106,,,,BAO_0000357,B,,CHEMBL616799,,,Autocuration,,1,8,,,H,,1827,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand
6011,,,106,,,,BAO_0000357,B,,CHEMBL616800,,,Autocuration,,1,8,,,H,,1828,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration
5014,,,106,,,,BAO_0000357,B,,CHEMBL616801,,,Autocuration,,1,8,,,H,,1829,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor
17515,,,106,,,,BAO_0000357,B,,CHEMBL616802,,,Autocuration,,1,8,,,H,,1830,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM
4373,,,106,,,,BAO_0000357,B,,CHEMBL616803,,,Autocuration,,1,8,,,H,,1831,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined
1633,,,106,,,,BAO_0000357,B,,CHEMBL857068,,,Expert,,1,8,,,H,,1832,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.
1633,,,106,,,,BAO_0000357,B,,CHEMBL616804,,,Autocuration,,1,8,,,H,,1833,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.
4373,,,106,,,,BAO_0000357,B,,CHEMBL616805,,,Autocuration,,1,8,,,H,,1834,Binding affinity for 5-hydroxytryptamine 1B receptor was determined
4687,,,106,,,,BAO_0000357,B,,CHEMBL616806,,,Autocuration,,1,8,,,H,,1835,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor
11574,,,106,,,,BAO_0000357,B,,CHEMBL616807,,,Autocuration,,1,8,,,H,,1836,Binding affinity against 5-hydroxytryptamine 1B receptor
10321,,,106,,,,BAO_0000357,B,,CHEMBL616808,,,Autocuration,,1,8,,,H,,1837,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand
15527,,,106,,,,BAO_0000357,B,,CHEMBL616809,,,Autocuration,,1,8,,,H,,1838,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.
17200,,,106,,,,BAO_0000357,B,,CHEMBL616810,,,Autocuration,,1,8,,,H,,1839,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand
14423,,,104802,,,,BAO_0000224,B,,CHEMBL616811,,,Autocuration,,1,4,,,H,,1840,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.
5834,,,108,9913.0,,,BAO_0000357,B,,CHEMBL616812,,,Autocuration,,1,8,,Bos taurus,H,,1841,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine
11473,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616813,,,Autocuration,,1,8,,Sus scrofa,H,,1842,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
11473,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616814,,,Autocuration,,1,8,,Sus scrofa,H,,1843,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand
10639,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616815,,,Autocuration,,1,8,,Sus scrofa,H,,1844,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
10639,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616816,,,Autocuration,,1,8,,Sus scrofa,H,,1845,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand
14331,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616817,,,Autocuration,,1,8,,Sus scrofa,H,,1846,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined
10796,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616818,,,Autocuration,,1,8,,Sus scrofa,H,,1847,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor
9098,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616819,,,Expert,,1,8,,Sus scrofa,H,,1848,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.
14331,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616820,,,Expert,,1,8,,Sus scrofa,H,,1849,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus
11828,,,108,9823.0,,,BAO_0000019,B,,CHEMBL616821,,,Expert,,1,8,,Sus scrofa,H,,1850,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor
11866,,,108,9823.0,,,BAO_0000357,B,,CHEMBL616822,,,Autocuration,,1,8,,Sus scrofa,H,,1851,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT
13047,,,108,9986.0,,,BAO_0000019,B,,CHEMBL616823,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1852,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
188,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616824,,,Autocuration,,1,9,,Rattus norvegicus,D,,1853,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity
11825,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616825,,,Autocuration,,1,9,,Rattus norvegicus,D,,1854,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
11825,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616826,,,Autocuration,,1,9,,Rattus norvegicus,D,,1855,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M
11624,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL616827,,,Expert,,1,9,,Rattus norvegicus,D,,1856,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand
11139,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616828,,,Autocuration,,1,9,,Rattus norvegicus,D,,1857,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay
11147,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616829,,,Autocuration,,1,9,,Rattus norvegicus,D,,1858,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand
10444,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL616830,,,Autocuration,,1,9,,Rattus norvegicus,D,,1859,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.
11624,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616831,,,Expert,,1,9,,Rattus norvegicus,D,,1860,Binding affinity against 5-hydroxytryptamine 1C receptor
11662,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL616832,,,Autocuration,,1,9,,Rattus norvegicus,D,,1861,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
11662,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL616833,,,Autocuration,,1,9,,Rattus norvegicus,D,,1862,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
11662,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL616834,,,Expert,,1,9,,Rattus norvegicus,D,,1863,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
11662,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL829595,,,Autocuration,,1,9,,Rattus norvegicus,D,,1864,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand"
9098,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616835,,,Autocuration,,1,9,,Rattus norvegicus,D,,1865,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.
10394,,,12689,10116.0,,,BAO_0000249,B,,CHEMBL872910,,,Autocuration,,1,9,,Rattus norvegicus,D,,1866,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand
11933,,,12689,,,,BAO_0000357,B,,CHEMBL616836,,,Expert,,1,8,,,H,,1867,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand
12092,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL616837,,,Autocuration,,1,9,,Rattus norvegicus,D,,1868,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.
12253,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL616466,,,Autocuration,,1,9,,Rattus norvegicus,D,,1869,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex
12253,722.0,HEK293,12689,10116.0,,,BAO_0000219,B,,CHEMBL616467,,,Autocuration,,1,9,,Rattus norvegicus,D,,1870,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells
1558,,,108,,,,BAO_0000357,B,,CHEMBL616468,,,Autocuration,,1,8,,,H,,1871,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
2474,,,108,,,,BAO_0000357,B,,CHEMBL616469,,,Autocuration,,1,8,,,H,,1872,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
2474,,,108,,,,BAO_0000357,B,,CHEMBL616470,,,Autocuration,,1,8,,,H,,1873,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand
11574,,,12689,,,,BAO_0000357,B,,CHEMBL616471,,,Autocuration,,1,8,,,H,,1874,Binding affinity against 5-hydroxytryptamine 1C receptor
1558,,,12689,,,,BAO_0000357,B,,CHEMBL616472,,,Autocuration,,1,8,,,H,,1875,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor
13944,,,12689,,,,BAO_0000357,B,,CHEMBL616473,,,Autocuration,,1,8,,,H,,1876,Binding affinity against 5-hydroxytryptamine 1C receptor
13033,,,12689,,,,BAO_0000357,B,,CHEMBL616474,,,Autocuration,,1,8,,,H,,1877,Binding affinity against serotonergic 5-HT1c receptor
10321,,,12689,,,,BAO_0000357,B,,CHEMBL616475,,,Autocuration,,1,8,,,H,,1878,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand
11866,,,12689,,,,BAO_0000357,B,,CHEMBL616476,,,Autocuration,,1,8,,,H,,1879,Binding affinity for 5-hydroxytryptamine 1C receptor was determined
14454,,,105,9986.0,,,BAO_0000019,B,,CHEMBL616477,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1880,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV)
11574,,,104686,,,,BAO_0000224,B,,CHEMBL616478,,,Autocuration,,1,4,,,H,,1881,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.
11574,,,104686,,,,BAO_0000224,B,,CHEMBL616479,,,Autocuration,,1,4,,,H,,1882,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.
13631,,,104686,,,,BAO_0000019,B,,CHEMBL616480,,,Autocuration,,1,4,,,H,,1883,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand
9630,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL616481,,,Autocuration,,1,5,,Rattus norvegicus,D,,1884,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein
8822,,,104686,10116.0,,,BAO_0000249,B,,CHEMBL616482,,,Autocuration,,1,5,,Rattus norvegicus,D,,1885,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes
9064,,,104686,10116.0,,,BAO_0000221,B,955.0,CHEMBL884713,,,Autocuration,Brain,1,5,,Rattus norvegicus,D,,1886,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol
8868,,,104686,,,,BAO_0000224,B,,CHEMBL616483,,,Autocuration,,1,4,,,H,,1887,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay
9064,,,104686,,,,BAO_0000224,B,,CHEMBL616484,,,Autocuration,,1,4,,,H,,1888,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol
9806,,,104686,,,,BAO_0000019,B,,CHEMBL616485,,,Autocuration,,1,4,,,H,,1889,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.
9098,,,104686,,,,BAO_0000224,B,,CHEMBL616486,,,Autocuration,,1,4,,,H,,1890,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
8868,,,104686,,,,BAO_0000224,B,,CHEMBL616487,,,Autocuration,,1,4,,,H,,1891,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay
12765,,,104686,,,,BAO_0000224,B,,CHEMBL616488,,,Autocuration,,1,4,,,H,,1892,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616489,,,Autocuration,,1,4,,,H,,1893,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616490,,,Autocuration,,1,4,,,H,,1894,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616491,,,Autocuration,,1,4,,,H,,1895,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616492,,,Autocuration,,1,4,,,H,,1896,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616493,,,Autocuration,,1,4,,,H,,1897,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
11473,,,104686,,,,BAO_0000019,B,,CHEMBL616494,,,Autocuration,,1,4,,,H,,1898,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand
11473,,,104686,,,,BAO_0000019,B,,CHEMBL616495,,,Autocuration,,1,4,,,H,,1899,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand
3086,,,104686,,,,BAO_0000019,B,,CHEMBL616496,,,Autocuration,,1,4,,,H,,1900,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616497,,,Autocuration,,1,4,,,H,,1901,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
11049,,,104686,,,,BAO_0000019,B,,CHEMBL616498,,,Autocuration,,1,4,,,H,,1902,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.
10639,,,104686,,,,BAO_0000019,B,,CHEMBL616499,,,Autocuration,,1,4,,,H,,1903,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand
10922,,,104686,,,,BAO_0000019,B,,CHEMBL616500,,,Autocuration,,1,4,,,H,,1904,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.
9064,,,104686,10116.0,,,BAO_0000221,B,955.0,CHEMBL616501,,,Autocuration,Brain,1,5,,Rattus norvegicus,D,,1905,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
10748,,,104686,,,,BAO_0000221,B,955.0,CHEMBL616502,,,Autocuration,Brain,1,4,,,H,,1906,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.
11614,,,104686,,,,BAO_0000249,B,,CHEMBL884529,,Membranes,Autocuration,,1,4,,,H,,1907,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.
11615,,,104686,,,,BAO_0000249,B,,CHEMBL616503,,Membranes,Autocuration,,1,4,,,H,,1908,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
11615,,,104686,,,,BAO_0000224,B,,CHEMBL616964,,,Autocuration,,1,4,,,H,,1909,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor
11614,,,104686,,,,BAO_0000249,B,,CHEMBL616965,,Membranes,Autocuration,,1,4,,,H,,1910,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.
11702,,,104686,,,,BAO_0000224,B,,CHEMBL616966,,,Autocuration,,1,4,,,H,,1911,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.
11702,,,104686,,,,BAO_0000224,B,,CHEMBL616967,,,Autocuration,,1,4,,,H,,1912,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested
11702,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL616968,,,Autocuration,,1,5,,Rattus norvegicus,D,,1913,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor
11702,,,104686,,,,BAO_0000224,B,,CHEMBL616969,,,Autocuration,,1,4,,,H,,1914,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested
13346,,,104686,,,,BAO_0000019,B,,CHEMBL884530,,,Autocuration,,1,4,,,H,,1915,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.
10025,,,104686,,,,BAO_0000224,B,,CHEMBL616970,,,Autocuration,,1,4,,,H,,1916,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor
10025,,,104686,,,,BAO_0000224,B,,CHEMBL616971,,,Autocuration,,1,4,,,H,,1917,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
10025,,,104686,,,,BAO_0000224,B,,CHEMBL616972,,,Autocuration,,1,4,,,H,,1918,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
9036,,,104686,,,,BAO_0000224,B,,CHEMBL616973,,,Autocuration,,1,4,,,H,,1919,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone
9036,,,104686,,,,BAO_0000224,B,,CHEMBL616974,,,Autocuration,,1,4,,,H,,1920,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive
9161,,,104686,,,,BAO_0000019,B,,CHEMBL616975,,,Autocuration,,1,4,,,H,,1921,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.
12304,,,104686,,,,BAO_0000019,B,,CHEMBL616976,,,Autocuration,,1,4,,,H,,1922,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex
13276,,,104686,,,,BAO_0000224,B,,CHEMBL616977,,,Autocuration,,1,4,,,H,,1923,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.
11825,,,104686,,,,BAO_0000224,B,,CHEMBL616978,,,Autocuration,,1,4,,,H,,1924,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
12443,,,104686,,,,BAO_0000224,B,,CHEMBL616979,,,Autocuration,,1,4,,,H,,1925,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin
13830,,,104686,,,,BAO_0000224,B,,CHEMBL616980,,,Autocuration,,1,4,,,H,,1926,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor
9592,,,104686,,,,BAO_0000249,B,,CHEMBL616981,,Membranes,Autocuration,,1,4,,,H,,1927,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes
9592,,,104686,,,,BAO_0000249,B,,CHEMBL616982,,Membranes,Autocuration,,1,4,,,H,,1928,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested
10881,,,104686,,,,BAO_0000224,B,,CHEMBL616983,,,Autocuration,,1,4,,,H,,1929,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.
13605,,,104686,,,,BAO_0000019,B,,CHEMBL616984,,,Autocuration,,1,4,,,H,,1930,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex
11624,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL616985,,,Autocuration,,1,5,,Rattus norvegicus,D,,1931,Inhibitory activity against 5-hydroxytryptamine 2 receptor
4101,,,104686,,,,BAO_0000224,B,,CHEMBL616986,,,Autocuration,,1,4,,,H,,1932,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
4101,,,104686,,,,BAO_0000224,B,,CHEMBL616987,,,Autocuration,,1,4,,,H,,1933,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin
15360,,,104686,,,,BAO_0000019,B,,CHEMBL616988,,,Autocuration,,1,4,,,H,,1934,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat
11576,,,104686,,,,BAO_0000019,B,,CHEMBL617243,,,Autocuration,,1,4,,,H,,1935,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex
5834,,,104686,,,,BAO_0000019,B,,CHEMBL617244,,,Autocuration,,1,4,,,H,,1936,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone
2395,485.0,CHO-K1,104686,10116.0,,,BAO_0000219,B,,CHEMBL617245,,,Autocuration,,1,5,,Rattus norvegicus,D,,1937,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
11965,,,104686,,,,BAO_0000249,B,,CHEMBL617246,,Membranes,Autocuration,,1,4,,,H,,1938,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes
3967,,,104686,,,,BAO_0000224,B,,CHEMBL617546,,,Autocuration,,1,4,,,H,,1939,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats)
11130,,,104686,,,,BAO_0000249,B,,CHEMBL617547,,Brain membranes,Autocuration,,1,4,,,H,,1940,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro)
13427,,,104686,,,,BAO_0000219,B,,CHEMBL617548,,,Autocuration,,1,4,,,H,In vitro,1941,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
9443,,,104686,,,,BAO_0000224,B,,CHEMBL617549,,,Autocuration,,1,4,,,H,,1942,Binding affinity towards 5-hydroxytryptamine 2 receptor
9443,,,104686,,,,BAO_0000224,B,,CHEMBL617550,,,Autocuration,,1,4,,,H,,1943,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
11825,,,104686,,,,BAO_0000224,B,,CHEMBL617551,,,Autocuration,,1,4,,,H,,1944,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M
12120,,,104686,,,,BAO_0000249,B,,CHEMBL617552,,Membranes,Autocuration,,1,4,,,H,,1945,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M
12120,,,104686,,,,BAO_0000249,B,,CHEMBL617553,,Membranes,Autocuration,,1,4,,,H,,1946,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.
11963,,,104686,,,,BAO_0000019,F,1515.0,CHEMBL617554,,,Autocuration,Thoracic aorta,1,4,,,H,,1947,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta
9069,,,104686,,,,BAO_0000019,B,,CHEMBL617555,,,Autocuration,,1,4,,,H,,1948,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor
8868,,,104686,,,,BAO_0000224,B,,CHEMBL617556,,,Autocuration,,1,4,,,H,,1949,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
17200,,,10624,,,,BAO_0000357,B,,CHEMBL617557,,,Autocuration,,1,8,,,H,,1950,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand
17200,,,10624,,,,BAO_0000357,B,,CHEMBL617558,,,Autocuration,,1,8,,,H,,1951,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand
13969,,,17106,,,,BAO_0000357,B,,CHEMBL617559,,,Expert,,1,8,,,H,,1952,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand
13392,,,17106,,,,BAO_0000357,B,,CHEMBL617560,,,Expert,,1,9,,,D,,1953,Binding affinity for 5-hydroxytryptamine 1D receptor
1742,,,17106,,,,BAO_0000249,B,,CHEMBL617561,,,Autocuration,,1,8,,,H,,1954,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
1742,,,17106,,,,BAO_0000249,B,,CHEMBL617562,,,Autocuration,,1,8,,,H,,1955,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
14331,,,17106,,,,BAO_0000357,B,2435.0,CHEMBL617563,,,Autocuration,Striatum,1,8,,,H,,1956,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex
12861,,,17106,,,,BAO_0000019,F,,CHEMBL617564,,,Autocuration,,1,8,,,H,,1957,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor
12861,,,17106,,,,BAO_0000019,B,,CHEMBL617565,,,Expert,,1,8,,,H,,1958,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand
12861,,,17106,,,,BAO_0000357,B,,CHEMBL856076,,,Autocuration,,1,8,,,H,,1959,Binding activity radioligand.
12861,,,17106,,,,BAO_0000019,B,,CHEMBL617566,,,Autocuration,,1,8,,,H,,1960,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
12861,,,17106,,,,BAO_0000019,B,,CHEMBL875911,,,Expert,,1,8,,,H,,1961,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
12861,,,17106,,,,BAO_0000019,B,,CHEMBL617567,,,Autocuration,,1,8,,,H,,1962,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
675,,,17106,,,,BAO_0000249,B,,CHEMBL617568,,,Autocuration,,1,8,,,H,,1963,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes
12490,,,17106,,,,BAO_0000019,B,,CHEMBL617569,,,Expert,,1,8,,,H,,1964,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane
11828,,,17106,,,,BAO_0000249,B,,CHEMBL617570,,,Expert,,1,8,,,H,,1965,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane
11866,,,17106,,,,BAO_0000357,B,,CHEMBL617571,,,Autocuration,,1,8,,,H,,1966,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT
773,,,105,9823.0,,,BAO_0000357,B,,CHEMBL617572,,,Autocuration,,1,8,,Sus scrofa,H,,1967,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate
13047,,,105,9986.0,,,BAO_0000357,B,,CHEMBL617573,,,Expert,,1,8,,Oryctolagus cuniculus,H,,1968,The compound was tested for intrinsic activity against 5-HT1D receptor
13047,,,105,9986.0,,,BAO_0000019,B,,CHEMBL617574,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,1969,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.
13047,,,105,9986.0,,,BAO_0000357,B,,CHEMBL617575,,,Expert,,1,8,,Oryctolagus cuniculus,H,,1970,The compound was tested for binding affinity against 5-HT1D receptor
188,,,10578,,,,BAO_0000357,B,,CHEMBL617576,,,Autocuration,,1,8,,,H,,1971,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity
10639,,,10578,,,,BAO_0000019,F,,CHEMBL617577,,,Autocuration,,1,8,,,H,,1972,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra
12438,,,10578,,,,BAO_0000019,F,,CHEMBL617578,,,Autocuration,,1,8,,,H,,1973,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor
12438,,,10578,,,,BAO_0000357,B,,CHEMBL617579,,,Autocuration,,1,8,,,H,,1974,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor
15854,,,10578,,,,BAO_0000019,B,,CHEMBL617580,,,Expert,,1,8,,,H,,1975,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.
10394,,,10578,,,,BAO_0000249,B,,CHEMBL617581,,,Autocuration,,1,8,,,H,,1976,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand
12092,,,10578,,,,BAO_0000357,B,,CHEMBL617582,,,Autocuration,,1,8,,,H,,1977,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.
3389,,,10578,,,,BAO_0000019,B,,CHEMBL617583,,,Expert,,1,8,,,H,,1978,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.
6011,,,105,,,,BAO_0000357,B,,CHEMBL617584,,,Autocuration,,1,8,,,H,,1979,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration
4639,,,105,,,,BAO_0000357,B,,CHEMBL617585,,,Autocuration,,1,8,,,H,,1980,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor
2474,,,105,,,,BAO_0000357,B,,CHEMBL875912,,,Autocuration,,1,8,,,H,,1981,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand
5014,,,105,,,,BAO_0000357,B,,CHEMBL617586,,,Autocuration,,1,8,,,H,,1982,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor
17515,,,105,,,,BAO_0000357,B,,CHEMBL617587,,,Autocuration,,1,8,,,H,,1983,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM
11866,,,105,,,,BAO_0000357,B,,CHEMBL617588,,,Autocuration,,1,8,,,H,,1984,Binding affinity for 5-hydroxytryptamine 1D receptor was determined
4687,,,105,,,,BAO_0000357,B,,CHEMBL857980,,,Autocuration,,1,8,,,H,,1985,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor
12146,,,105,,,,BAO_0000357,B,,CHEMBL617589,,,Autocuration,,1,8,,,H,,1986,Tested against 5-hydroxytryptamine 1D receptor
10321,,,105,,,,BAO_0000357,B,,CHEMBL617590,,,Autocuration,,1,8,,,H,,1987,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand
13267,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL617591,,,Autocuration,,1,8,,,H,,1988,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
1274,,,105,9606.0,,,BAO_0000357,B,,CHEMBL617592,,,Expert,,1,9,,Homo sapiens,D,,1989,Binding affinity against 5-Hydroxytryptamine 1D receptor
15250,,,105,,,,BAO_0000357,B,,CHEMBL617593,,,Autocuration,,1,8,,,H,,1990,
13706,485.0,CHO-K1,106,,,,BAO_0000219,B,,CHEMBL617594,,,Autocuration,,1,8,,,H,,1991,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
13706,485.0,CHO-K1,105,,,,BAO_0000219,B,,CHEMBL617595,,,Autocuration,,1,8,,,H,,1992,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
13706,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL617596,,,Autocuration,,1,8,,,H,,1993,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.
13706,722.0,HEK293,105,,,,BAO_0000219,B,,CHEMBL617597,,,Autocuration,,1,8,,,H,,1994,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
13047,,,105,,,,BAO_0000019,B,,CHEMBL617598,,,Autocuration,,1,8,,,H,,1995,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
13366,,,105,,,,BAO_0000357,B,,CHEMBL872916,,,Autocuration,,1,8,,,H,,1996,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human
13366,,,105,,,,BAO_0000357,B,,CHEMBL617599,,,Expert,,1,8,,,H,,1997,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.
1558,,,105,,,,BAO_0000357,B,,CHEMBL617091,,,Autocuration,,1,8,,,H,,1998,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined
12902,485.0,CHO-K1,105,,,,BAO_0000219,B,,CHEMBL617092,,,Expert,,1,8,,,H,,1999,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand."
13706,485.0,CHO-K1,105,,,,BAO_0000219,B,,CHEMBL617093,,,Autocuration,,1,8,,,H,,2000,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.
13706,,,105,,,,BAO_0000019,F,,CHEMBL617094,,,Autocuration,,1,8,,,H,,2001,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.
13706,,,105,,,,BAO_0000019,F,,CHEMBL617095,,,Autocuration,,1,8,,,H,,2002,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
14251,,,105,,,,BAO_0000019,F,,CHEMBL617096,,,Autocuration,,1,8,,,H,,2003,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
14251,,,105,,,,BAO_0000019,F,,CHEMBL617097,,,Autocuration,,1,8,,,H,,2004,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
14251,,,105,,,,BAO_0000019,F,,CHEMBL617098,,,Autocuration,,1,8,,,H,,2005,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.
13313,,,105,,,,BAO_0000357,B,,CHEMBL617301,,,Autocuration,,1,8,,,H,,2006,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand
13313,,,105,,,,BAO_0000357,B,,CHEMBL617302,,,Autocuration,,1,8,,,H,,2007,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand
13366,,,105,,,,BAO_0000357,B,,CHEMBL617303,,,Autocuration,,1,8,,,H,,2008,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha
13051,,,105,,,,BAO_0000357,B,,CHEMBL617304,,,Expert,,1,8,,,H,,2009,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha
12903,449.0,CHO,105,,,,BAO_0000219,B,,CHEMBL617305,,,Expert,,1,8,,,H,,2010,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand"
12469,,,105,9606.0,,,BAO_0000219,B,,CHEMBL617306,,,Autocuration,,1,9,,Homo sapiens,D,,2011,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT
5619,,,17106,,,,BAO_0000357,B,,CHEMBL617307,,,Autocuration,,1,8,,,H,,2012,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay
13047,,,105,9986.0,,,BAO_0000019,B,,CHEMBL617308,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,2013,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.
16633,,,105,,,,BAO_0000357,B,,CHEMBL617309,,,Autocuration,,1,8,,,H,,2014,Binding affinities against 5-hydroxytryptamine 1D receptor alpha
16633,,,105,,,,BAO_0000357,B,,CHEMBL617310,,,Autocuration,,1,8,,,H,,2015,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
16633,,,105,,,,BAO_0000357,B,,CHEMBL617311,,,Autocuration,,1,8,,,H,,2016,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha
16633,,,105,,,,BAO_0000357,B,,CHEMBL617312,,,Autocuration,,1,8,,,H,,2017,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand
3269,,,105,,,,BAO_0000357,B,,CHEMBL617313,,,Autocuration,,1,8,,,H,,2018,Affinity against 5-hydroxytryptamine 1D receptor alpha
12409,,,105,,,,BAO_0000357,B,,CHEMBL617314,,,Expert,,1,8,,,H,,2019,Binding affinity against 5-hydroxytryptamine 1D receptor alpha
13706,,,106,,,,BAO_0000019,F,,CHEMBL617315,,,Autocuration,,1,8,,,H,,2020,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
13706,722.0,HEK293,106,,,,BAO_0000219,B,,CHEMBL617316,,,Autocuration,,1,8,,,H,,2021,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.
13706,722.0,HEK293,106,,,,BAO_0000219,B,,CHEMBL617317,,,Autocuration,,1,8,,,H,,2022,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested
12903,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL617318,,,Autocuration,,1,8,,,H,,2023,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
13047,,,106,,,,BAO_0000019,B,,CHEMBL617319,,,Autocuration,,1,8,,,H,,2024,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.
13366,,,106,,,,BAO_0000357,B,,CHEMBL617320,,,Expert,,1,9,,,D,,2025,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
13366,,,106,,,,BAO_0000357,B,,CHEMBL617321,,,Expert,,1,9,,,D,,2026,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
13366,,,106,,,,BAO_0000357,B,,CHEMBL617322,,,Expert,,1,9,,,D,,2027,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta
13366,,,106,,,,BAO_0000357,B,,CHEMBL616862,,,Autocuration,,1,8,,,H,,2028,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand
13366,,,106,,,,BAO_0000357,B,,CHEMBL616863,,,Autocuration,,1,8,,,H,,2029,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand
12469,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616864,,,Autocuration,,1,8,,,H,,2030,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT
13706,485.0,CHO-K1,106,,,,BAO_0000219,B,,CHEMBL616865,,,Autocuration,,1,8,,,H,,2031,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.
13706,485.0,CHO-K1,106,,,,BAO_0000219,B,,CHEMBL616866,,,Autocuration,,1,8,,,H,,2032,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.
13706,,,106,,,,BAO_0000019,F,,CHEMBL616867,,,Autocuration,,1,8,,,H,,2033,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.
12902,485.0,CHO-K1,106,,,,BAO_0000219,B,,CHEMBL616868,,,Expert,,1,8,,,H,,2034,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand."
13051,,,105,,,,BAO_0000357,B,,CHEMBL616869,,,Expert,,1,8,,,H,,2035,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta
12903,449.0,CHO,106,,,,BAO_0000219,B,,CHEMBL616870,,,Expert,,1,8,,,H,,2036,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand"
1558,485.0,CHO-K1,105,,,,BAO_0000219,F,,CHEMBL616871,,,Autocuration,,1,8,,,H,,2037,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55
1558,485.0,CHO-K1,105,,,,BAO_0000219,F,,CHEMBL616872,,,Autocuration,,1,8,,,H,,2038,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0
1558,485.0,CHO-K1,105,,,,BAO_0000219,F,,CHEMBL616873,,,Autocuration,,1,8,,,H,,2039,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5
1558,485.0,CHO-K1,105,,,,BAO_0000219,F,,CHEMBL616838,,,Autocuration,,1,8,,,H,,2040,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70
1558,,,105,,,,BAO_0000357,B,,CHEMBL616839,,,Autocuration,,1,8,,,H,,2041,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined
13047,,,106,9986.0,,,BAO_0000019,B,,CHEMBL616840,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,2042,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.
13313,,,105,,,,BAO_0000357,B,,CHEMBL616841,,,Autocuration,,1,8,,,H,,2043,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand
13313,,,105,,,,BAO_0000357,B,,CHEMBL616842,,,Autocuration,,1,8,,,H,,2044,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand
12409,,,105,,,,BAO_0000357,B,,CHEMBL857976,,,Expert,,1,8,,,H,,2045,Binding affinity against 5-hydroxytryptamine 1D receptor beta
15250,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616843,,,Autocuration,,1,8,,,H,,2046,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells
1348,,,10618,9606.0,,,BAO_0000357,B,,CHEMBL616844,,,Expert,,1,9,,Homo sapiens,D,,2047,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype
1348,,,10618,,,,BAO_0000357,B,,CHEMBL616845,,,Autocuration,,1,8,,,H,,2048,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available
4234,,,10618,9606.0,,,BAO_0000357,B,,CHEMBL616846,,,Expert,,1,9,,Homo sapiens,D,,2049,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor
16209,,,10618,,,,BAO_0000357,B,,CHEMBL616847,,,Autocuration,,1,8,,,H,,2050,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand
10444,,,10618,,,,BAO_0000019,B,,CHEMBL616848,,,Autocuration,,1,8,,,H,,2051,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate
3935,,,10618,,,,BAO_0000357,B,,CHEMBL616849,,,Autocuration,,1,8,,,H,,2052,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor
15818,,,10618,,,,BAO_0000357,B,,CHEMBL872911,,,Autocuration,,1,8,,,H,,2053,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor
17085,,,10618,,,,BAO_0000019,B,,CHEMBL616850,,,Autocuration,,1,8,,,H,,2054,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor
12936,449.0,CHO,10618,9606.0,,,BAO_0000219,B,,CHEMBL616699,,,Expert,,1,9,,Homo sapiens,D,,2055,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells
6166,,,10618,,,,BAO_0000357,B,,CHEMBL616700,,,Autocuration,,1,8,,,H,,2056,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined
15779,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616701,,,Autocuration,,1,8,,,H,,2057,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
15779,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616702,,,Autocuration,,1,8,,,H,,2058,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.
15779,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616703,,,Autocuration,,1,8,,,H,,2059,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.
13181,,,10618,,,,BAO_0000357,B,,CHEMBL616704,,,Autocuration,,1,8,,,H,,2060,Binding affinity was determined against 5-hydroxytryptamine 1D receptor
4199,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616705,,,Autocuration,,1,8,,,H,,2061,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand
14875,,,10618,,,,BAO_0000357,B,,CHEMBL616706,,,Autocuration,,1,8,,,H,,2062,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor
15146,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616707,,,Autocuration,,1,8,,,H,,2063,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT
5213,,,10618,,,,BAO_0000357,B,,CHEMBL616708,,,Autocuration,,1,8,,,H,,2064,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand
12146,,,10618,,,,BAO_0000357,B,,CHEMBL616709,,,Autocuration,,1,8,,,H,,2065,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand
13267,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616710,,,Autocuration,,1,8,,,H,,2066,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand
14818,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616711,,,Autocuration,,1,8,,,H,,2067,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.
4829,449.0,CHO,10618,,,,BAO_0000219,B,,CHEMBL616712,,,Autocuration,,1,8,,,H,,2068,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand"
4373,,,10618,,,,BAO_0000357,B,,CHEMBL616713,,,Autocuration,,1,8,,,H,,2069,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined
4373,,,10618,,,,BAO_0000357,B,,CHEMBL616714,,,Autocuration,,1,8,,,H,,2070,Binding affinity for 5-hydroxytryptamine 1E receptor was determined
14159,,,10618,,,,BAO_0000357,B,,CHEMBL616715,,,Autocuration,,1,8,,,H,,2071,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor
16633,,,10618,,,,BAO_0000357,B,,CHEMBL616716,,,Autocuration,,1,8,,,H,,2072,Binding affinity towards 5-hydroxytryptamine 1E receptor
17085,,,279,,,,BAO_0000019,F,,CHEMBL616717,,,Autocuration,,1,8,,,H,,2073,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor"
17085,,,279,,,,BAO_0000019,F,,CHEMBL616718,,,Expert,,1,8,,,H,,2074,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor"
16209,,,279,,,,BAO_0000019,F,,CHEMBL875905,,,Autocuration,,1,8,,,H,,2075,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor
16209,,,279,,,,BAO_0000019,F,,CHEMBL616719,,,Autocuration,,1,8,,,H,,2076,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor
17085,,,279,,,,BAO_0000019,F,,CHEMBL616720,,,Expert,,1,8,,,H,,2077,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor"
14159,,,279,,,,BAO_0000357,B,,CHEMBL616721,,,Autocuration,,1,8,,,H,,2078,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor
15250,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL616722,,,Autocuration,,1,8,,,H,,2079,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells
3805,,,279,,,,BAO_0000357,B,,CHEMBL616723,,,Autocuration,,1,8,,,H,,2080,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM)
16190,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL616724,,,Autocuration,,1,8,,,H,,2081,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand
16190,,,279,,,,BAO_0000357,B,,CHEMBL616725,,,Autocuration,,1,8,,,H,,2082,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand
16209,,,279,,,,BAO_0000357,B,,CHEMBL616726,,,Autocuration,,1,8,,,H,,2083,Binding affinity towards human 5-hydroxytryptamine 1F receptor
16209,,,279,,,,BAO_0000357,B,,CHEMBL616727,,,Autocuration,,1,8,,,H,,2084,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined
16209,,,279,,,,BAO_0000357,B,,CHEMBL616728,,,Autocuration,,1,8,,,H,,2085,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand
6866,,,279,,,,BAO_0000357,B,,CHEMBL616729,,,Autocuration,,1,8,,,H,,2086,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor
17085,,,279,,,,BAO_0000019,B,,CHEMBL616730,,,Expert,,1,8,,,H,,2087,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor
16312,,,279,,,,BAO_0000357,B,,CHEMBL617125,,,Autocuration,,1,8,,,H,,2088,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor
6166,,,279,,,,BAO_0000357,B,,CHEMBL857977,,,Autocuration,,1,8,,,H,,2089,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined
15779,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL617126,,,Autocuration,,1,8,,,H,,2090,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.
4199,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL617127,,,Autocuration,,1,8,,,H,,2091,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand
14875,,,279,,,,BAO_0000357,B,,CHEMBL617128,,,Autocuration,,1,8,,,H,,2092,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor
15146,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL617129,,,Autocuration,,1,8,,,H,,2093,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT
5213,,,279,,,,BAO_0000357,B,,CHEMBL617130,,,Autocuration,,1,8,,,H,,2094,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand
14818,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL617131,,,Autocuration,,1,8,,,H,,2095,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.
4829,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL617132,,,Autocuration,,1,8,,,H,,2096,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
4829,449.0,CHO,279,,,,BAO_0000219,B,,CHEMBL617133,,,Autocuration,,1,8,,,H,,2097,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand"
4373,,,279,,,,BAO_0000357,B,,CHEMBL617134,,,Autocuration,,1,8,,,H,,2098,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined
4373,,,279,,,,BAO_0000357,B,,CHEMBL617135,,,Autocuration,,1,8,,,H,,2099,Binding affinity for 5-hydroxytryptamine 1F receptor was determined
5014,,,279,,,,BAO_0000357,B,,CHEMBL617136,,,Autocuration,,1,8,,,H,,2100,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor
11662,,,104686,,,,BAO_0000019,B,,CHEMBL617137,,,Autocuration,,1,4,,,H,,2101,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand"
11662,,,104686,,,,BAO_0000019,B,,CHEMBL617138,,,Autocuration,,1,4,,,H,,2102,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
11662,,,104686,,,,BAO_0000019,B,,CHEMBL617139,,,Autocuration,,1,4,,,H,,2103,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
14093,,,12687,,,,BAO_0000019,B,,CHEMBL617140,,,Autocuration,,1,8,,,H,,2104,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
11200,,,104686,,,,BAO_0000218,F,,CHEMBL617141,,,Autocuration,,1,4,,,H,In vivo,2105,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration"
11200,,,104686,,,,BAO_0000019,F,,CHEMBL858112,,,Autocuration,,1,4,,,H,,2106,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
12352,,,17005,,,,BAO_0000019,B,,CHEMBL617142,,,Intermediate,,1,8,,,H,,2107,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex
13657,,,22226,9913.0,,,BAO_0000019,B,,CHEMBL617143,,,Autocuration,,1,0,,Bos taurus,U,,2108,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB"
14331,,,22226,9913.0,,,BAO_0000019,B,,CHEMBL617144,,,Autocuration,,1,0,,Bos taurus,U,,2109,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M
14331,,,22226,9913.0,,,BAO_0000019,B,,CHEMBL617145,,,Autocuration,,1,0,,Bos taurus,U,,2110,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex
14331,,,22226,,,,BAO_0000019,B,,CHEMBL617146,,,Autocuration,,1,0,,,U,,2111,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined
12685,,,104784,10141.0,,,BAO_0000019,B,,CHEMBL617147,,,Autocuration,,1,4,,Cavia porcellus,H,,2112,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex
14389,,,104784,10141.0,,,BAO_0000019,B,,CHEMBL617148,,,Autocuration,,1,4,,Cavia porcellus,H,,2113,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes
14386,,,104784,10141.0,,,BAO_0000019,B,,CHEMBL617149,,,Autocuration,,1,4,,Cavia porcellus,H,,2114,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex
5732,,,104784,,,,BAO_0000224,B,,CHEMBL617150,,,Autocuration,,1,4,,,H,,2115,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined
16293,,,104784,,,,BAO_0000224,B,,CHEMBL617151,,,Autocuration,,1,4,,,H,,2116,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
2078,,,104784,,,,BAO_0000224,B,,CHEMBL617201,,,Autocuration,,1,4,,,H,,2117,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor
5486,,,10209,,,,BAO_0000357,B,,CHEMBL617202,,,Autocuration,,1,8,,,H,,2118,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell
11820,,,104826,,,,BAO_0000218,B,,CHEMBL617203,,,Autocuration,,1,4,,,H,In vivo,2119,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
10297,,,104826,,,,BAO_0000019,B,,CHEMBL617204,,,Autocuration,,1,4,,,H,,2120,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
13704,,,104826,,,,BAO_0000224,B,,CHEMBL617205,,,Autocuration,,1,4,,,H,,2121,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.
10297,,,104826,10090.0,,,BAO_0000019,B,,CHEMBL617206,,,Autocuration,,1,5,,Mus musculus,D,,2122,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex
11820,,,104826,,,,BAO_0000218,B,,CHEMBL617207,,,Autocuration,,1,4,,,H,In vivo,2123,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin
10297,,,104826,10090.0,,,BAO_0000019,B,,CHEMBL617208,,,Autocuration,,1,5,,Mus musculus,D,,2124,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex
11555,,,104826,,,,BAO_0000224,B,,CHEMBL617209,,,Autocuration,,1,4,,,H,,2125,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor
11555,,,104826,,,,BAO_0000224,B,,CHEMBL617210,,,Autocuration,,1,4,,,H,,2126,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors
11555,,,104826,,,,BAO_0000224,B,,CHEMBL617211,,,Autocuration,,1,4,,,H,,2127,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data
10297,,,104826,10090.0,,,BAO_0000019,B,,CHEMBL617212,,,Autocuration,,1,5,,Mus musculus,D,,2128,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex
16688,,,104784,9823.0,,,BAO_0000224,B,,CHEMBL617213,,,Autocuration,,1,4,,Sus scrofa,H,,2129,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin
16688,,,104784,9823.0,,,BAO_0000224,B,,CHEMBL617214,,,Autocuration,,1,4,,Sus scrofa,H,,2130,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin
5333,,,22226,,,,BAO_0000221,B,,CHEMBL617215,,,Autocuration,,1,0,,,U,,2131,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate
4437,,,22226,,,,BAO_0000221,B,,CHEMBL617216,,,Autocuration,,1,0,,,U,,2132,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate
5033,,,17005,9823.0,,,BAO_0000357,B,,CHEMBL617217,,,Autocuration,,1,8,,Sus scrofa,H,,2133,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor
15267,,,104686,,,,BAO_0000019,B,,CHEMBL617218,,,Autocuration,,1,4,,,H,,2134,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
15267,,,104686,,,,BAO_0000019,B,,CHEMBL872913,,,Autocuration,,1,4,,,H,,2135,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor
11820,,,104826,,,,BAO_0000019,B,,CHEMBL617219,,,Autocuration,,1,4,,,H,,2136,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.
9069,,,104686,,,,BAO_0000224,B,,CHEMBL873482,,,Autocuration,,1,4,,,H,,2137,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
9162,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617220,,,Autocuration,,1,5,,Rattus norvegicus,D,,2138,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data
9162,,,104686,,,,BAO_0000019,B,,CHEMBL617221,,,Autocuration,,1,4,,,H,,2139,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.
9162,,,104686,,,,BAO_0000019,B,,CHEMBL617222,,,Autocuration,,1,4,,,H,,2140,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity
10428,,,104686,,,,BAO_0000019,F,,CHEMBL875906,,,Autocuration,,1,4,,,H,,2141,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein
9628,,,104686,,,,BAO_0000019,B,,CHEMBL617223,,,Autocuration,,1,4,,,H,,2142,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein
12704,,,104686,,,,BAO_0000224,B,,CHEMBL617224,,,Autocuration,,1,4,,,H,,2143,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor
15453,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617225,,,Autocuration,,1,5,,Rattus norvegicus,D,,2144,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
188,,,104686,,,,BAO_0000224,B,,CHEMBL617226,,,Autocuration,,1,4,,,H,,2145,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity
10349,,,104686,,,,BAO_0000224,B,,CHEMBL617227,,,Autocuration,,1,4,,,H,,2146,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.
10349,,,104686,,,,BAO_0000224,B,,CHEMBL617228,,,Autocuration,,1,4,,,H,,2147,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.
8868,,,104686,,,,BAO_0000224,B,,CHEMBL617229,,,Autocuration,,1,4,,,H,,2148,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis
10025,,,104686,,,,BAO_0000224,B,,CHEMBL617230,,,Autocuration,,1,4,,,H,,2149,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM
10025,,,104686,,,,BAO_0000224,B,,CHEMBL617231,,,Autocuration,,1,4,,,H,,2150,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM"
11702,,,104686,,,,BAO_0000224,B,,CHEMBL617232,,,Autocuration,,1,4,,,H,,2151,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor
11702,,,104686,,,,BAO_0000224,B,,CHEMBL617233,,,Autocuration,,1,4,,,H,,2152,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor
11702,,,104686,,,,BAO_0000224,B,,CHEMBL617234,,,Autocuration,,1,4,,,H,,2153,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested
11702,,,104686,,,,BAO_0000019,F,,CHEMBL617235,,,Autocuration,,1,4,,,H,,2154,Compound was tested for the inhibition of quipazine induced head twitches in rats
11702,,,104686,,,,BAO_0000019,F,,CHEMBL617236,,,Autocuration,,1,4,,,H,,2155,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested
10085,,,104686,,,,BAO_0000221,B,10000000.0,CHEMBL617237,,,Autocuration,Hippocampus,1,4,,,H,,2156,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone
10085,,,104686,,,,BAO_0000221,B,10000000.0,CHEMBL617238,,,Autocuration,Hippocampus,1,4,,,H,,2157,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone
9630,,,104686,10116.0,,,BAO_0000221,B,955.0,CHEMBL617239,,,Autocuration,Brain,1,5,,Rattus norvegicus,D,,2158,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain
11070,,,104686,,,,BAO_0000019,B,,CHEMBL617240,,,Autocuration,,1,4,,,H,,2159,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex
9841,,,104686,,,,BAO_0000249,B,,CHEMBL617241,,Membranes,Autocuration,,1,4,,,H,,2160,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
9841,,,104686,,,,BAO_0000249,B,,CHEMBL875907,,Membranes,Autocuration,,1,4,,,H,,2161,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes
13291,,,104686,,,,BAO_0000019,B,,CHEMBL617242,,,Autocuration,,1,4,,,H,,2162,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.
10590,,,104686,,,,BAO_0000019,F,,CHEMBL617152,,,Autocuration,,1,4,,,H,,2163,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.
9064,,,104686,10116.0,,,BAO_0000221,B,955.0,CHEMBL617153,,,Autocuration,Brain,1,5,,Rattus norvegicus,D,,2164,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol
12268,,,104686,10116.0,,,BAO_0000249,B,,CHEMBL617154,,Membranes,Autocuration,,1,5,,Rattus norvegicus,D,,2165,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes
13508,,,104686,,,,BAO_0000221,B,955.0,CHEMBL617155,,,Autocuration,Brain,1,4,,,H,,2166,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand
11279,,,104686,,,,BAO_0000019,F,,CHEMBL617156,,,Autocuration,,1,4,,,H,,2167,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
11200,,,104686,,,,BAO_0000019,F,,CHEMBL617157,,,Autocuration,,1,4,,,H,,2168,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips
11200,,,104686,,,,BAO_0000019,F,,CHEMBL617158,,,Autocuration,,1,4,,,H,,2169,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
11200,,,104686,,,,BAO_0000019,F,,CHEMBL617159,,,Autocuration,,1,4,,,H,,2170,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
11200,,,104686,,,,BAO_0000019,F,,CHEMBL617160,,,Autocuration,,1,4,,,H,,2171,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism
11200,,,104686,,,,BAO_0000019,F,,CHEMBL858113,,,Autocuration,,1,4,,,H,,2172,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
9231,,,104686,,,,BAO_0000220,B,955.0,CHEMBL617247,,,Autocuration,Brain,1,4,,,H,,2173,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes
9737,,,104686,,,,BAO_0000019,B,,CHEMBL617248,,,Autocuration,,1,4,,,H,,2174,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
9737,,,104686,,,,BAO_0000249,B,955.0,CHEMBL617249,,,Autocuration,Brain,1,4,,,H,,2175,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.
9737,,,104686,,,,BAO_0000019,B,,CHEMBL617250,,,Autocuration,,1,4,,,H,,2176,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex
9737,,,104686,,,,BAO_0000019,B,,CHEMBL617251,,,Autocuration,,1,4,,,H,,2177,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand
11828,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617252,,,Autocuration,,1,5,,Rattus norvegicus,D,,2178,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor
12253,,,104686,,,,BAO_0000019,B,,CHEMBL617006,,,Autocuration,,1,4,,,H,,2179,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex
12253,,,104686,,,,BAO_0000019,B,,CHEMBL617007,,,Autocuration,,1,4,,,H,,2180,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex
11279,,,104686,,,,BAO_0000019,F,,CHEMBL617008,,,Autocuration,,1,4,,,H,,2181,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery."
11866,,,104686,,,,BAO_0000019,B,,CHEMBL617009,,,Autocuration,,1,4,,,H,,2182,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin
14424,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617010,,,Autocuration,,1,5,,Rattus norvegicus,D,,2183,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta
15180,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL857978,,,Autocuration,,1,5,,Rattus norvegicus,D,,2184,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
15180,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617011,,,Autocuration,,1,5,,Rattus norvegicus,D,,2185,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor
9786,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617012,,,Autocuration,,1,5,,Rattus norvegicus,D,,2186,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate
12132,,,104686,,,,BAO_0000224,B,,CHEMBL617013,,,Autocuration,,1,4,,,H,,2187,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.
5486,,,104686,,,,BAO_0000249,B,,CHEMBL617014,,,Autocuration,,1,4,,,H,,2188,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane
15316,,,104686,,,,BAO_0000019,B,,CHEMBL617015,,,Autocuration,,1,4,,,H,,2189,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor
16429,,,104686,,,,BAO_0000019,B,,CHEMBL617016,,,Autocuration,,1,4,,,H,,2190,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand
14617,,,104686,,,,BAO_0000224,B,,CHEMBL617017,,,Autocuration,,1,4,,,H,,2191,pKi value for 5-hydroxytryptamine 2 receptor binding site
11351,,,104686,,,,BAO_0000221,B,955.0,CHEMBL617018,,,Autocuration,Brain,1,4,,,H,,2192,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.
11279,,,104686,,,,BAO_0000019,F,,CHEMBL617019,,,Autocuration,,1,4,,,H,,2193,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.
9523,,,105075,,,,BAO_0000019,B,,CHEMBL617020,,,Autocuration,,1,4,,,H,,2194,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
9523,,,105075,,,,BAO_0000019,B,,CHEMBL617021,,,Autocuration,,1,4,,,H,,2195,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
9523,,,105075,,,,BAO_0000019,B,,CHEMBL617022,,,Autocuration,,1,4,,,H,,2196,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
9523,,,105075,,,,BAO_0000019,B,,CHEMBL617023,,,Autocuration,,1,4,,,H,,2197,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
9523,,,105075,,,,BAO_0000019,B,,CHEMBL617024,,,Autocuration,,1,4,,,H,,2198,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex
9523,,,105075,,,,BAO_0000019,B,,CHEMBL617025,,,Autocuration,,1,4,,,H,,2199,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex
9523,,,105075,,,,BAO_0000224,B,,CHEMBL617026,,,Autocuration,,1,4,,,H,,2200,Hill coefficient of compound was determined
4771,,,22226,,,,BAO_0000019,B,,CHEMBL617027,,,Autocuration,,1,0,,,U,,2201,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor
5033,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617028,,,Autocuration,,1,5,,Rattus norvegicus,D,,2202,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane
10845,,,12687,,,,BAO_0000019,B,,CHEMBL617029,,,Expert,,1,8,,,H,,2203,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand
10845,,,12687,,,,BAO_0000019,B,,CHEMBL875908,,,Expert,,1,8,,,H,,2204,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive
16288,,,12687,,,,BAO_0000357,B,,CHEMBL617030,,,Autocuration,,1,8,,,H,,2205,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09)
16288,,,12687,,,,BAO_0000019,B,,CHEMBL617031,,,Autocuration,,1,8,,,H,,2206,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09)
16190,,,12687,,,,BAO_0000019,B,,CHEMBL617032,,,Autocuration,,1,8,,,H,,2207,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand
12463,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617033,,,Autocuration,,1,5,,Rattus norvegicus,D,,2208,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin
9699,,,104686,,,,BAO_0000224,B,,CHEMBL617034,,,Autocuration,,1,4,,,H,,2209,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand"
9699,,,104686,,,,BAO_0000224,B,,CHEMBL617035,,,Autocuration,,1,4,,,H,,2210,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand
11662,,,104686,,,,BAO_0000019,B,,CHEMBL617036,,,Autocuration,,1,4,,,H,,2211,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
1205,,,104784,,,,BAO_0000224,B,,CHEMBL617037,,,Autocuration,,1,4,,,H,,2212,Inhibitory concentration against 5-hydroxytryptamine 2 receptor
11376,,,22226,,,,BAO_0000219,B,,CHEMBL617038,,,Autocuration,,1,0,,,U,,2213,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand
11376,,,104784,,,,BAO_0000219,B,,CHEMBL617039,,,Autocuration,,1,4,,,H,,2214,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)"
4639,,,104784,,,,BAO_0000224,B,,CHEMBL617161,,,Autocuration,,1,4,,,H,,2215,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor
2222,,,104784,,,,BAO_0000224,B,,CHEMBL617162,,,Autocuration,,1,4,,,H,,2216,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor
1558,,,104784,,,,BAO_0000224,B,,CHEMBL617163,,,Autocuration,,1,4,,,H,,2217,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor
1089,,,104784,,,,BAO_0000224,B,,CHEMBL617164,,,Autocuration,,1,4,,,H,,2218,Tested for binding affinity for 5-hydroxytryptamine 2 receptor
386,,,104784,,,,BAO_0000249,B,,CHEMBL617165,,Brain membranes,Autocuration,,1,4,,,H,,2219,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes
2474,,,104784,,,,BAO_0000224,B,,CHEMBL617166,,,Autocuration,,1,4,,,H,,2220,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand
17066,,,104784,,,,BAO_0000224,B,,CHEMBL617167,,,Autocuration,,1,4,,,H,,2221,Binding affinity towards 5-HT2 receptor
959,,,104784,,,,BAO_0000224,B,,CHEMBL872912,,,Autocuration,,1,4,,,H,,2222,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
6398,,,104784,,,,BAO_0000224,B,,CHEMBL617168,,,Autocuration,,1,4,,,H,,2223,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding
11889,,,104686,,,,BAO_0000224,B,,CHEMBL617169,,,Autocuration,,1,4,,,H,,2224,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.
4221,,,104784,,,,BAO_0000224,B,,CHEMBL617170,,,Autocuration,,1,4,,,H,,2225,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
11026,,,104784,,,,BAO_0000224,B,,CHEMBL617171,,,Autocuration,,1,4,,,H,,2226,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand
11866,,,104784,,,,BAO_0000224,B,,CHEMBL617172,,,Autocuration,,1,4,,,H,,2227,Binding affinity for 5-hydroxytryptamine 2 receptor was determined
4221,,,104784,,,,BAO_0000224,B,,CHEMBL617173,,,Autocuration,,1,4,,,H,,2228,In vitro binding affinity for 5-hydroxytryptamine 2 receptor
13950,,,22226,,,,BAO_0000019,B,,CHEMBL617174,,,Autocuration,,1,0,,,U,,2229,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor
1263,,,104784,,,,BAO_0000224,B,,CHEMBL617175,,,Autocuration,,1,4,,,H,,2230,5-hydroxytryptamine 2 receptor binding affinity
13291,,,17005,,,,BAO_0000357,B,,CHEMBL617176,,,Autocuration,,1,8,,,H,,2231,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand
10812,,,17005,,,,BAO_0000357,B,,CHEMBL617177,,,Autocuration,,1,8,,,H,,2232,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand
13020,,,104784,,,,BAO_0000224,B,,CHEMBL617178,,,Autocuration,,1,4,,,H,,2233,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
13021,,,104784,,,,BAO_0000224,B,,CHEMBL617179,,,Autocuration,,1,4,,,H,,2234,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system
13020,,,104784,,,,BAO_0000224,B,,CHEMBL617180,,,Autocuration,,1,4,,,H,,2235,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M
14532,,,17005,,,,BAO_0000357,B,,CHEMBL617181,,,Autocuration,,1,8,,,H,,2236,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration
13944,,,17005,,,,BAO_0000357,B,,CHEMBL617182,,,Autocuration,,1,8,,,H,,2237,Binding affinity against 5-hydroxytryptamine 2 receptor
14331,,,17005,,,,BAO_0000357,B,,CHEMBL617183,,,Autocuration,,1,8,,,H,,2238,Binding affinity against 5-hydroxytryptamine 2 receptor
14118,,,17005,,,,BAO_0000357,B,,CHEMBL617184,,,Autocuration,,1,8,,,H,,2239,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
13033,,,17005,,,,BAO_0000357,B,,CHEMBL617185,,,Autocuration,,1,8,,,H,,2240,Binding affinity against serotonergic 5-HT2 receptor
10321,,,17005,,,,BAO_0000357,B,,CHEMBL617186,,,Autocuration,,1,8,,,H,,2241,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand
12918,,,17005,,,,BAO_0000357,B,,CHEMBL617187,,,Autocuration,,1,8,,,H,,2242,Compound was evaluated for the binding affinity at 5- HT2 receptor
15120,,,17005,,,,BAO_0000357,B,,CHEMBL617188,,,Autocuration,,1,8,,,H,,2243,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor
2613,,,17005,,,,BAO_0000218,B,,CHEMBL617189,,,Autocuration,,1,8,,,H,,2244,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor
13378,,,104784,9606.0,,,BAO_0000224,B,,CHEMBL617190,,,Autocuration,,1,5,,Homo sapiens,D,,2245,Inhibitory activity against cloned human 5-HT2 receptor
2331,449.0,CHO,104784,9606.0,,,BAO_0000219,B,,CHEMBL617191,,,Autocuration,,1,5,,Homo sapiens,D,,2246,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells"
2331,449.0,CHO,104784,9606.0,,,BAO_0000219,B,,CHEMBL617192,,,Autocuration,,1,5,,Homo sapiens,D,,2247,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells."
2331,449.0,CHO,104784,9606.0,,,BAO_0000219,B,,CHEMBL617193,,,Autocuration,,1,5,,Homo sapiens,D,,2248,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive"
2331,449.0,CHO,104784,9606.0,,,BAO_0000219,B,,CHEMBL617194,,,Autocuration,,1,5,,Homo sapiens,D,,2249,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested"
4170,,,104784,,,,BAO_0000224,B,,CHEMBL617195,,,Autocuration,,1,4,,,H,,2250,Binding affinity towards 5-hydroxytryptamine 2 receptor
15453,,,104784,,,,BAO_0000224,B,,CHEMBL881830,,,Autocuration,,1,4,,,H,,2251,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin
1479,,,17005,,,,BAO_0000357,B,,CHEMBL617196,,,Autocuration,,1,8,,,H,,2252,Binding affinity towards 5-hydroxytryptamine 2 receptor
11139,,,104686,,,,BAO_0000224,B,,CHEMBL617197,,,Autocuration,,1,4,,,H,,2253,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay
13969,,,17005,,,,BAO_0000357,B,,CHEMBL617198,,,Expert,,1,8,,,H,,2254,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand
13392,,,17005,,,,BAO_0000357,B,,CHEMBL873476,,,Expert,,1,8,,,H,,2255,Binding affinity towards 5-hydroxytryptamine 2A receptor
14430,,,17005,,,,BAO_0000019,B,,CHEMBL617199,,,Expert,,1,8,,,H,,2256,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin
13181,,,107,10141.0,,,BAO_0000357,B,,CHEMBL617200,,,Autocuration,,1,8,,Cavia porcellus,H,,2257,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
17200,,,51,,,,BAO_0000357,B,,CHEMBL617484,,,Autocuration,,1,8,,,H,,2258,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
17200,,,107,,,,BAO_0000357,B,,CHEMBL617485,,,Autocuration,,1,8,,,H,,2259,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
17200,,,51,,,,BAO_0000357,B,,CHEMBL617486,,,Autocuration,,1,8,,,H,,2260,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
13463,,,107,,,,BAO_0000357,B,,CHEMBL858022,,,Autocuration,,1,8,,,H,,2261,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand
6347,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617049,,,Autocuration,,1,8,,,H,,2262,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
6857,449.0,CHO,107,9606.0,,,BAO_0000219,F,,CHEMBL617050,,,Expert,,1,9,,Homo sapiens,D,,2263,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader
4176,,,107,,,,BAO_0000219,F,,CHEMBL617051,,,Autocuration,,1,8,,,H,,2264,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
4176,,,107,,,,BAO_0000219,F,,CHEMBL617052,,,Autocuration,,1,8,,,H,,2265,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data
4176,,,107,,,,BAO_0000219,F,,CHEMBL617053,,,Autocuration,,1,8,,,H,,2266,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line
6347,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617054,,,Autocuration,,1,8,,,H,,2267,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax"
6347,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617055,,,Autocuration,,1,8,,,H,,2268,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax"
15331,,,107,,,,BAO_0000357,B,,CHEMBL882924,,,Autocuration,,1,8,,,H,,2269,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique
16146,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617056,,,Expert,,1,9,,Homo sapiens,D,,2270,Inhibition of human 5-hydroxytryptamine 2A receptor
15250,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617057,,,Autocuration,,1,8,,,H,,2271,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
13631,,,107,,,,BAO_0000219,B,,CHEMBL617058,,,Expert,,1,8,,,H,,2272,Inhibitory concentration against human 5-HT2A receptor in BEK cells
3805,,,107,,,,BAO_0000357,B,,CHEMBL617059,,,Autocuration,,1,8,,,H,,2273,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM)
4011,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617060,,,Autocuration,,1,8,,,H,,2274,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined
4012,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617061,,,Expert,,1,8,,,H,,2275,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.
6366,307.0,L929,107,,,,BAO_0000219,B,,CHEMBL617062,,,Expert,,1,8,,,H,,2276,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells
15949,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617063,,,Expert,,1,8,,,H,,2277,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
14093,,,107,,,,BAO_0000019,F,,CHEMBL617064,,,Autocuration,,1,8,,,H,,2278,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand
13481,,,107,,,,BAO_0000019,F,,CHEMBL617065,,,Autocuration,,1,8,,,H,,2279,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
6347,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617066,,,Autocuration,,1,8,,,H,,2280,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand
6347,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617067,,,Autocuration,,1,8,,,H,,2281,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done
14093,,,107,,,,BAO_0000019,F,,CHEMBL617068,,,Autocuration,,1,8,,,H,,2282,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand
14093,,,107,,,,BAO_0000019,F,,CHEMBL617069,,,Autocuration,,1,8,,,H,,2283,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested
13481,,,107,,,,BAO_0000019,F,,CHEMBL617070,,,Autocuration,,1,8,,,H,,2284,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
14442,,,107,,,,BAO_0000357,B,,CHEMBL617071,,,Autocuration,,1,8,,,H,,2285,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand
14442,,,107,,,,BAO_0000357,B,,CHEMBL872915,,,Autocuration,,1,8,,,H,,2286,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
14755,,,107,,,,BAO_0000357,B,,CHEMBL617072,,,Autocuration,,1,8,,,H,,2287,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.
16441,,,107,,,,BAO_0000357,B,,CHEMBL617073,,,Autocuration,,1,8,,,H,,2288,Binding affinity against 5-hydroxytryptamine 2A receptor in humans
14744,,,107,,,,BAO_0000357,B,,CHEMBL617074,,,Autocuration,,1,8,,,H,,2289,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand
16659,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617075,,,Expert,,1,8,,,H,,2290,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
3307,,,107,,,,BAO_0000357,B,,CHEMBL617076,,,Autocuration,,1,8,,,H,,2291,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor
6857,,,107,9606.0,,,BAO_0000019,B,,CHEMBL617077,,,Expert,,1,9,,Homo sapiens,D,,2292,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line
5635,,,107,,,,BAO_0000357,B,,CHEMBL617078,,,Expert,,1,8,,,H,,2293,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.
4234,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617079,,,Expert,,1,9,,Homo sapiens,D,,2294,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor
15527,,,107,,,,BAO_0000357,B,,CHEMBL617080,,,Autocuration,,1,8,,,H,,2295,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
6588,449.0,CHO,107,,,,BAO_0000219,B,,CHEMBL617081,,,Expert,,1,8,,,H,,2296,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells
13631,,,107,,,,BAO_0000219,B,,CHEMBL617082,,,Expert,,1,8,,,H,,2297,Binding affinity towards human 5-HT2A receptor in BEK cells
17723,,,107,,,,BAO_0000357,B,,CHEMBL617083,,,Autocuration,,1,8,,,H,,2298,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor
14770,,,107,,,,BAO_0000357,B,,CHEMBL617084,,,Autocuration,,1,8,,,H,,2299,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.
16293,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617085,,,Expert,,1,9,,Homo sapiens,D,,2300,Binding affinity for human 5-hydroxytryptamine 2A receptor
16209,,,107,,,,BAO_0000357,B,,CHEMBL617086,,,Autocuration,,1,8,,,H,,2301,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
12469,,,107,,,,BAO_0000219,B,,CHEMBL617087,,,Autocuration,,1,8,,,H,,2302,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin
15363,,,107,,,,BAO_0000357,B,,CHEMBL617088,,,Autocuration,,1,8,,,H,,2303,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor
15363,,,107,,,,BAO_0000357,B,,CHEMBL617089,,,Autocuration,,1,8,,,H,,2304,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor
16441,,,107,,,,BAO_0000019,B,,CHEMBL617090,,,Expert,,1,8,,,H,,2305,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand"
8,,,107,,,,BAO_0000357,B,,CHEMBL617513,,,Autocuration,,1,8,,,H,,2306,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand
4176,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL617514,,,Autocuration,,1,8,,,H,,2307,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand
17085,,,107,,,,BAO_0000019,B,,CHEMBL617515,,,Autocuration,,1,8,,,H,,2308,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor
17200,,,107,,,,BAO_0000357,B,,CHEMBL617516,,,Autocuration,,1,8,,,H,,2309,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
17200,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617517,,,Expert,,1,9,,Homo sapiens,D,,2310,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand
4013,449.0,CHO,107,9606.0,,,BAO_0000219,B,,CHEMBL617518,,,Expert,,1,9,,Homo sapiens,D,,2311,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells
5088,,,107,,,,BAO_0000357,B,,CHEMBL617519,,,Autocuration,,1,8,,,H,,2312,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor
5088,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617520,,,Expert,,1,9,,Homo sapiens,D,,2313,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor
5088,,,107,,,,BAO_0000357,B,,CHEMBL617521,,,Autocuration,,1,8,,,H,,2314,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained
5088,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617522,,,Expert,,1,9,,Homo sapiens,D,,2315,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor
5088,,,107,,,,BAO_0000357,B,,CHEMBL617523,,,Autocuration,,1,8,,,H,,2316,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand
5088,,,107,,,,BAO_0000357,B,,CHEMBL617524,,,Autocuration,,1,8,,,H,,2317,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
9786,,,104686,,,,BAO_0000019,B,,CHEMBL617525,,,Autocuration,,1,4,,,H,,2318,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate
9205,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617526,,,Autocuration,,1,5,,Rattus norvegicus,D,,2319,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat
11257,,,104686,,,,BAO_0000224,B,,CHEMBL617527,,,Autocuration,,1,4,,,H,,2320,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI
9362,,,104686,,,,BAO_0000019,B,,CHEMBL617528,,,Autocuration,,1,4,,,H,,2321,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
9362,,,104686,,,,BAO_0000019,B,,CHEMBL617529,,,Autocuration,,1,4,,,H,,2322,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates
10590,,,104686,,,,BAO_0000224,B,,CHEMBL617530,,,Autocuration,,1,4,,,H,,2323,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.
10468,,,104686,,,,BAO_0000019,B,,CHEMBL617531,,,Autocuration,,1,4,,,H,,2324,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
13050,,,104686,,,,BAO_0000019,B,,CHEMBL617532,,,Autocuration,,1,4,,,H,,2325,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand
11624,,,104686,,,,BAO_0000019,B,,CHEMBL617533,,,Autocuration,,1,4,,,H,,2326,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand
10468,,,104686,,,,BAO_0000019,B,,CHEMBL617534,,,Autocuration,,1,4,,,H,,2327,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand
10330,,,104686,,,,BAO_0000224,B,,CHEMBL617535,,,Autocuration,,1,4,,,H,,2328,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand
10062,,,104686,,,,BAO_0000224,B,,CHEMBL617536,,,Autocuration,,1,4,,,H,,2329,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.
11642,,,104686,,,,BAO_0000224,B,,CHEMBL617537,,,Autocuration,,1,4,,,H,,2330,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
10062,,,104686,,,,BAO_0000224,B,,CHEMBL617538,,,Autocuration,,1,4,,,H,,2331,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor
13427,,,104686,,,,BAO_0000219,B,,CHEMBL617539,,,Autocuration,,1,4,,,H,In vitro,2332,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.
12280,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617540,,,Autocuration,,1,5,,Rattus norvegicus,D,,2333,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor
4101,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617541,,,Autocuration,,1,5,,Rattus norvegicus,D,,2334,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin
10062,,,104686,,,,BAO_0000224,B,,CHEMBL617542,,,Autocuration,,1,4,,,H,,2335,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor
11147,,,104686,,,,BAO_0000224,B,,CHEMBL617543,,,Autocuration,,1,4,,,H,,2336,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as
2395,485.0,CHO-K1,104686,10116.0,,,BAO_0000219,B,,CHEMBL617544,,,Autocuration,,1,5,,Rattus norvegicus,D,,2337,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
2395,485.0,CHO-K1,104686,10116.0,,,BAO_0000219,B,,CHEMBL617545,,,Autocuration,,1,5,,Rattus norvegicus,D,,2338,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells
9098,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617413,,,Autocuration,,1,5,,Rattus norvegicus,D,,2339,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617414,,,Autocuration,,1,4,,,H,,2340,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.
9098,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617415,,,Autocuration,,1,5,,Rattus norvegicus,D,,2341,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.
9443,,,104686,,,,BAO_0000224,B,,CHEMBL617416,,,Autocuration,,1,4,,,H,,2342,Binding affinity towards 5-hydroxytryptamine 2 receptor
9443,,,104686,,,,BAO_0000224,B,,CHEMBL617417,,,Autocuration,,1,4,,,H,,2343,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration
9699,,,104686,,,,BAO_0000019,B,,CHEMBL617418,,,Autocuration,,1,4,,,H,,2344,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex"
9699,,,104686,,,,BAO_0000019,B,,CHEMBL617419,,,Autocuration,,1,4,,,H,,2345,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex
9098,,,104686,,,,BAO_0000224,B,,CHEMBL617420,,,Autocuration,,1,4,,,H,,2346,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined
3070,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617421,,,Autocuration,,1,5,,Rattus norvegicus,D,,2347,Affinity for 5-hydroxytryptamine 2 receptor
9547,,,104686,,,,BAO_0000224,B,,CHEMBL617422,,,Autocuration,,1,4,,,H,,2348,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay
10444,,,104686,,,,BAO_0000019,B,,CHEMBL617423,,,Autocuration,,1,4,,,H,,2349,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.
14617,,,104686,,,,BAO_0000019,B,,CHEMBL617424,,,Autocuration,,1,4,,,H,,2350,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate
14617,,,104686,,,,BAO_0000019,B,,CHEMBL617425,,,Autocuration,,1,4,,,H,,2351,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate
11130,,,104686,,,,BAO_0000224,B,,CHEMBL617426,,,Autocuration,,1,4,,,H,,2352,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro)
11130,,,104686,,,,BAO_0000218,B,,CHEMBL617427,,,Autocuration,,1,4,,,H,In vivo,2353,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo)
14542,,,104686,,,,BAO_0000221,B,955.0,CHEMBL617428,,,Autocuration,Brain,1,4,,,H,,2354,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain
2797,,,104686,,,,BAO_0000224,B,,CHEMBL617429,,,Autocuration,,1,4,,,H,,2355,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat
11332,,,104686,,,,BAO_0000019,B,,CHEMBL617430,,,Autocuration,,1,4,,,H,,2356,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
11332,,,104686,,,,BAO_0000019,B,,CHEMBL617431,,,Autocuration,,1,4,,,H,,2357,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand
10752,,,104686,,,,BAO_0000019,B,1870.0,CHEMBL617432,,,Autocuration,Frontal cortex,1,4,,,H,,2358,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.
1185,,,104686,,,,BAO_0000224,B,,CHEMBL617433,,,Autocuration,,1,4,,,H,,2359,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
1185,,,104686,,,,BAO_0000224,B,,CHEMBL617434,,,Autocuration,,1,4,,,H,,2360,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor
11624,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617435,,,Autocuration,,1,5,,Rattus norvegicus,D,,2361,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor
1344,,,104686,,,,BAO_0000019,B,,CHEMBL617436,,,Autocuration,,1,4,,,H,,2362,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay
15453,,,104686,10116.0,,,BAO_0000019,B,2435.0,CHEMBL617437,,,Autocuration,Striatum,1,5,,Rattus norvegicus,D,,2363,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203
11662,,,104686,,,,BAO_0000019,B,,CHEMBL617438,,,Autocuration,,1,4,,,H,,2364,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand"
11662,,,104686,,,,BAO_0000019,B,,CHEMBL617439,,,Autocuration,,1,4,,,H,,2365,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined"
10796,,,104686,,,,BAO_0000224,B,,CHEMBL617440,,,Autocuration,,1,4,,,H,,2366,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor
9069,,,104686,,,,BAO_0000224,B,,CHEMBL617441,,,Autocuration,,1,4,,,H,,2367,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor
8814,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL872918,,,Autocuration,,1,5,,Rattus norvegicus,D,,2368,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates
8908,,,104686,10116.0,,,BAO_0000019,B,,CHEMBL617442,,,Autocuration,,1,5,,Rattus norvegicus,D,,2369,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617443,,,Autocuration,,1,4,,,H,,2370,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617444,,,Autocuration,,1,4,,,H,,2371,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617445,,,Autocuration,,1,4,,,H,,2372,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617446,,,Autocuration,,1,4,,,H,,2373,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.
9098,,,104686,,,,BAO_0000249,B,,CHEMBL617447,,,Autocuration,,1,4,,,H,,2374,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617448,,,Autocuration,,1,4,,,H,,2375,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined
9098,,,104686,,,,BAO_0000019,B,,CHEMBL617449,,,Autocuration,,1,4,,,H,,2376,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617450,,,Autocuration,,1,4,,,H,,2377,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617451,,,Autocuration,,1,4,,,H,,2378,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617452,,,Autocuration,,1,4,,,H,,2379,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617453,,,Autocuration,,1,4,,,H,,2380,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617660,,,Autocuration,,1,4,,,H,,2381,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617661,,,Autocuration,,1,4,,,H,,2382,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617662,,,Autocuration,,1,4,,,H,,2383,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66
9161,,,104686,,,,BAO_0000019,B,,CHEMBL872919,,,Autocuration,,1,4,,,H,,2384,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617663,,,Autocuration,,1,4,,,H,,2385,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617664,,,Autocuration,,1,4,,,H,,2386,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617665,,,Autocuration,,1,4,,,H,,2387,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132
9161,,,104686,,,,BAO_0000019,B,,CHEMBL617666,,,Autocuration,,1,4,,,H,,2388,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75
12094,,,104686,,,,BAO_0000019,B,,CHEMBL617667,,,Autocuration,,1,4,,,H,,2389,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells
12018,,,104686,,,,BAO_0000249,B,,CHEMBL617668,,,Autocuration,,1,4,,,H,,2390,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.
10394,,,104686,,,,BAO_0000249,B,,CHEMBL617669,,,Autocuration,,1,4,,,H,,2391,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand
15260,,,104686,,,,BAO_0000224,B,,CHEMBL617670,,,Autocuration,,1,4,,,H,,2392,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor
11624,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617671,,,Autocuration,,1,5,,Rattus norvegicus,D,,2393,Inhibitory constant against 5-hydroxytryptamine 2 receptor
13654,,,104686,,,,BAO_0000224,B,,CHEMBL617672,,,Autocuration,,1,4,,,H,,2394,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor
9541,,,104686,,,,BAO_0000019,B,,CHEMBL617673,,,Autocuration,,1,4,,,H,,2395,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum
11933,,,104686,,,,BAO_0000224,B,,CHEMBL617674,,,Autocuration,,1,4,,,H,,2396,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand
15538,,,104686,,,,BAO_0000019,B,,CHEMBL617675,,,Autocuration,,1,4,,,H,,2397,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex
15538,,,104686,,,,BAO_0000019,B,,CHEMBL617676,,,Autocuration,,1,4,,,H,,2398,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active
15538,,,104686,,,,BAO_0000019,B,,CHEMBL617677,,,Autocuration,,1,4,,,H,,2399,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined
8841,,,104686,,,,BAO_0000019,B,,CHEMBL617678,,,Autocuration,,1,5,,,D,,2400,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor
1455,,,104686,,,,BAO_0000224,B,,CHEMBL617679,,,Autocuration,,1,4,,,H,,2401,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.
1455,,,104686,,,,BAO_0000224,B,,CHEMBL617680,,,Autocuration,,1,4,,,H,,2402,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay
11752,,,104686,,,,BAO_0000019,B,,CHEMBL617681,,,Autocuration,,1,4,,,H,,2403,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain
11642,,,104686,,,,BAO_0000221,B,955.0,CHEMBL617682,,,Autocuration,Brain,1,4,,,H,,2404,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue
12092,,,104686,,,,BAO_0000224,B,,CHEMBL617683,,,Autocuration,,1,4,,,H,,2405,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.
3967,,,104686,,,,BAO_0000224,B,,CHEMBL617684,,,Autocuration,,1,4,,,H,,2406,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.
12771,,,104686,10116.0,,,BAO_0000224,B,,CHEMBL617685,,,Autocuration,,1,5,,Rattus norvegicus,D,,2407,Binding affinity towards 5-hydroxytryptamine 2 receptor
11642,,,104686,,,,BAO_0000019,B,,CHEMBL617686,,,Autocuration,,1,4,,,H,,2408,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex
11628,,,104686,,,,BAO_0000224,B,,CHEMBL617687,,,Autocuration,,1,4,,,H,,2409,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand
13654,,,104686,,,,BAO_0000224,B,,CHEMBL617688,,,Autocuration,,1,4,,,H,,2410,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor
11200,,,104686,,,,BAO_0000019,F,,CHEMBL617689,,,Autocuration,,1,4,,,H,,2411,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
11200,,,104686,,,,BAO_0000019,F,,CHEMBL617690,,,Autocuration,,1,4,,,H,,2412,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips
11200,,,104686,,,,BAO_0000218,F,,CHEMBL617691,,,Autocuration,,1,4,,,H,In vivo,2413,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
11200,,,104686,,,,BAO_0000218,F,,CHEMBL617692,,,Autocuration,,1,4,,,H,In vivo,2414,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
11200,,,104686,,,,BAO_0000218,F,,CHEMBL617693,,,Autocuration,,1,4,,,H,In vivo,2415,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration"
11200,,,104686,,,,BAO_0000218,F,,CHEMBL617694,,,Autocuration,,1,4,,,H,In vivo,2416,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration"
15436,,,12687,,,,BAO_0000221,B,955.0,CHEMBL857985,,,Expert,Brain,1,8,,,H,,2417,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin
15436,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617695,,,Expert,,1,9,,Rattus norvegicus,D,,2418,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
14025,,,12687,,,,BAO_0000019,B,,CHEMBL617696,,,Autocuration,,1,8,,,H,,2419,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates
4342,,,12687,,,,BAO_0000357,B,,CHEMBL617697,,,Autocuration,,1,8,,,H,,2420,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined
13735,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617257,,,Expert,,1,9,,Rattus norvegicus,D,,2421,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex
5816,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL617258,,,Expert,,1,9,,Rattus norvegicus,D,,2422,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
14287,,,12687,,,,BAO_0000019,B,,CHEMBL617259,,,Expert,,1,8,,,H,,2423,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane
15738,,,12687,,,,BAO_0000357,B,,CHEMBL617260,,,Autocuration,,1,8,,,H,,2424,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor
15738,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL617261,,,Expert,,1,9,,Rattus norvegicus,D,,2425,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor
15026,,,12687,,,,BAO_0000019,B,,CHEMBL617262,,,Autocuration,,1,8,,,H,,2426,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand
16647,,,12687,,,,BAO_0000019,B,,CHEMBL617263,,,Expert,,1,8,,,H,,2427,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
16647,,,12687,,,,BAO_0000019,B,,CHEMBL617264,,,Autocuration,,1,8,,,H,,2428,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate
13345,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617265,,,Expert,,1,9,,Rattus norvegicus,D,,2429,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor
1543,,,12687,,,,BAO_0000249,B,,CHEMBL617266,,Membranes,Autocuration,,1,8,,,H,,2430,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor
12444,,,12687,,,,BAO_0000019,B,,CHEMBL617267,,,Autocuration,,1,8,,,H,,2431,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane
16404,,,12687,,,,BAO_0000019,B,,CHEMBL617268,,,Expert,,1,8,,,H,,2432,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex
16404,449.0,CHO,12687,,,,BAO_0000219,B,,CHEMBL617269,,,Autocuration,,1,8,,,H,,2433,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
15577,,,12687,,,,BAO_0000357,B,,CHEMBL617323,,,Expert,,1,8,,,H,,2434,Kinetic inhibition constant evaluated by measuring serotonergic activity
15577,,,12687,,,,BAO_0000357,B,,CHEMBL617324,,,Autocuration,,1,8,,,H,,2435,Serotonergic activity of the compound.
2495,,,12687,,,,BAO_0000249,B,,CHEMBL617325,,,Autocuration,,1,8,,,H,,2436,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes
15042,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617326,,,Expert,,1,9,,Rattus norvegicus,D,,2437,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.
15026,,,12687,,,,BAO_0000249,B,,CHEMBL617327,,,Expert,,1,8,,,H,,2438,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.
12919,,,12687,10116.0,,,BAO_0000019,F,,CHEMBL617328,,,Expert,,1,9,,Rattus norvegicus,D,,2439,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
12919,,,12687,10116.0,,,BAO_0000019,F,,CHEMBL617329,,,Expert,,1,9,,Rattus norvegicus,D,,2440,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
12919,,,12687,10116.0,,,BAO_0000019,F,,CHEMBL617330,,,Expert,,1,9,,Rattus norvegicus,D,,2441,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
15194,,,12687,,,,BAO_0000357,B,,CHEMBL617331,,,Autocuration,,1,8,,,H,,2442,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
15194,,,12687,,,,BAO_0000357,B,,CHEMBL617332,,,Autocuration,,1,8,,,H,,2443,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.
4820,,,107,,,,BAO_0000357,B,,CHEMBL617333,,,Expert,,1,8,,,H,,2444,Binding affinity towards 5-hydroxytryptamine 2A receptor
6736,,,107,,,,BAO_0000357,B,,CHEMBL617334,,,Autocuration,,1,8,,,H,,2445,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin
5163,,,107,,,,BAO_0000357,B,,CHEMBL617335,,,Autocuration,,1,8,,,H,,2446,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L
5163,,,107,,,,BAO_0000357,B,,CHEMBL617336,,,Autocuration,,1,8,,,H,,2447,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L
6011,,,107,,,,BAO_0000357,B,,CHEMBL617337,,,Autocuration,,1,8,,,H,,2448,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration
14294,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617338,,,Expert,,1,9,,Homo sapiens,D,,2449,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM
5014,,,107,,,,BAO_0000357,B,,CHEMBL617339,,,Autocuration,,1,8,,,H,,2450,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor
17066,,,107,,,,BAO_0000357,B,,CHEMBL617340,,,Expert,,1,8,,,H,,2451,Binding affinity towards 5-hydroxytryptamine 2A receptor
17515,,,107,,,,BAO_0000357,B,,CHEMBL617341,,,Autocuration,,1,8,,,H,,2452,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM
6736,,,107,,,,BAO_0000357,B,,CHEMBL617342,,,Expert,,1,8,,,H,,2453,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor
5163,,,107,,,,BAO_0000357,B,,CHEMBL617343,,,Expert,,1,8,,,H,,2454,Affinity for 5-hydroxytryptamine 2A receptor
16911,723.0,NIH3T3,107,,,,BAO_0000219,B,,CHEMBL617344,,,Expert,,1,8,,,H,,2455,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).
6841,,,107,,,,BAO_0000357,B,,CHEMBL617345,,,Expert,,1,8,,,H,,2456,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin
6119,,,107,,,,BAO_0000357,B,,CHEMBL617346,,,Expert,,1,8,,,H,,2457,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.
3962,,,107,,,,BAO_0000357,B,,CHEMBL617347,,,Autocuration,,1,8,,,H,,2458,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor
4373,,,107,,,,BAO_0000357,B,,CHEMBL617348,,,Autocuration,,1,8,,,H,,2459,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined
4373,,,107,,,,BAO_0000357,B,,CHEMBL617349,,,Autocuration,,1,8,,,H,,2460,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined
3962,,,107,,,,BAO_0000019,F,,CHEMBL617350,,,Autocuration,,1,8,,,H,,2461,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor
1633,,,107,,,,BAO_0000357,B,,CHEMBL872339,,,Expert,,1,8,,,H,,2462,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin
4373,,,107,,,,BAO_0000357,B,,CHEMBL617351,,,Autocuration,,1,8,,,H,,2463,Binding affinity for 5-hydroxytryptamine 2A receptor was determined
6576,,,107,,,,BAO_0000357,B,,CHEMBL617352,,,Expert,,1,8,,,H,,2464,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor
4687,,,107,,,,BAO_0000357,B,,CHEMBL617353,,,Autocuration,,1,8,,,H,,2465,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor
16946,,,107,,,,BAO_0000357,B,,CHEMBL617354,,,Autocuration,,1,8,,,H,,2466,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor
14159,,,107,,,,BAO_0000357,B,,CHEMBL617355,,,Autocuration,,1,8,,,H,,2467,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor
3032,449.0,CHO,107,10090.0,,,BAO_0000219,B,,CHEMBL617356,,,Expert,,1,8,,Mus musculus,H,,2468,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells
16655,,,107,,,,BAO_0000357,B,,CHEMBL617357,,,Autocuration,,1,8,,,H,,2469,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor
13964,,,107,,,,BAO_0000357,B,,CHEMBL617358,,,Autocuration,,1,8,,,H,,2470,Binding affinity at 5-hydroxytryptamine 2A receptor
16989,,,107,,,,BAO_0000357,B,,CHEMBL617359,,,Expert,,1,8,,,H,,2471,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor
16117,,,107,,,,BAO_0000357,B,,CHEMBL617360,,,Autocuration,,1,8,,,H,,2472,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined
16700,,,107,,,,BAO_0000357,B,,CHEMBL875913,,,Autocuration,,1,8,,,H,,2473,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity
3269,,,107,,,,BAO_0000357,B,,CHEMBL617361,,,Autocuration,,1,8,,,H,,2474,Affinity against 5-hydroxytryptamine 2A receptor
1274,,,107,9606.0,,,BAO_0000357,B,,CHEMBL617362,,,Expert,,1,9,,Homo sapiens,D,,2475,Binding affinity against 5-Hydroxytryptamine 2A receptor
1317,,,107,,,,BAO_0000357,B,,CHEMBL617363,,,Autocuration,,1,8,,,H,,2476,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay
12146,,,107,,,,BAO_0000357,B,,CHEMBL617364,,,Autocuration,,1,8,,,H,,2477,Tested against 5-hydroxytryptamine 2A receptor
12652,,,105075,,,,BAO_0000224,B,,CHEMBL617365,,,Autocuration,,1,4,,,H,,2478,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
12652,,,105075,,,,BAO_0000224,B,,CHEMBL617366,,,Autocuration,,1,4,,,H,,2479,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin
12652,,,105075,,,,BAO_0000224,B,,CHEMBL617367,,,Autocuration,,1,4,,,H,,2480,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI
12652,,,105075,,,,BAO_0000224,B,,CHEMBL617368,,,Autocuration,,1,4,,,H,,2481,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin
16647,,,107,,,,BAO_0000357,B,,CHEMBL617369,,,Autocuration,,1,8,,,H,,2482,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 )
15851,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617370,,,Expert,,1,9,,Homo sapiens,D,,2483,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data
6857,449.0,CHO,227,9606.0,,,BAO_0000219,F,,CHEMBL617371,,,Expert,,1,9,,Homo sapiens,D,,2484,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader
3805,,,227,,,,BAO_0000357,B,,CHEMBL617372,,,Autocuration,,1,8,,,H,,2485,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM)
6491,,,227,9606.0,,,BAO_0000357,B,,CHEMBL617373,,,Expert,,1,9,,Homo sapiens,D,,2486,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor
14093,,,227,,,,BAO_0000019,F,,CHEMBL617374,,,Autocuration,,1,8,,,H,,2487,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand
13481,,,227,,,,BAO_0000019,F,,CHEMBL617375,,,Autocuration,,1,8,,,H,,2488,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand
14093,,,227,,,,BAO_0000019,F,,CHEMBL617376,,,Autocuration,,1,8,,,H,,2489,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand
14093,,,227,,,,BAO_0000019,F,,CHEMBL617377,,,Autocuration,,1,8,,,H,,2490,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested
14093,,,227,,,,BAO_0000019,F,,CHEMBL617378,,,Autocuration,,1,8,,,H,,2491,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand
13481,,,227,,,,BAO_0000019,F,,CHEMBL617379,,,Autocuration,,1,8,,,H,,2492,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
14442,,,227,,,,BAO_0000357,B,,CHEMBL617380,,,Autocuration,,1,8,,,H,,2493,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand
14442,,,227,,,,BAO_0000357,B,,CHEMBL617381,,,Autocuration,,1,8,,,H,,2494,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand
14442,,,227,,,,BAO_0000357,B,,CHEMBL617382,,,Autocuration,,1,8,,,H,,2495,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand
12369,,,107,,,,BAO_0000357,B,,CHEMBL617383,,,Autocuration,,1,8,,,H,,2496,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor
12369,,,107,,,,BAO_0000357,B,,CHEMBL617384,,,Expert,,1,8,,,H,,2497,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.
12369,,,107,,,,BAO_0000357,B,,CHEMBL617385,,,Expert,,1,8,,,H,,2498,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.
14447,,,107,,,,BAO_0000019,B,,CHEMBL617386,,,Autocuration,,1,8,,,H,,2499,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes
14447,,,107,,,,BAO_0000019,B,,CHEMBL617387,,,Autocuration,,1,8,,,H,,2500,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.
17451,723.0,NIH3T3,107,,,,BAO_0000219,B,,CHEMBL617388,,,Autocuration,,1,8,,,H,,2501,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
6857,449.0,CHO,107,,,,BAO_0000219,F,,CHEMBL617389,,,Autocuration,,1,8,,,H,,2502,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
6857,449.0,CHO,107,9606.0,,,BAO_0000219,F,,CHEMBL617390,,,Expert,,1,9,,Homo sapiens,D,,2503,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
5635,,,104817,,,,BAO_0000224,B,,CHEMBL617391,,,Autocuration,,1,4,,,H,,2504,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.
12861,,,107,,,,BAO_0000357,B,,CHEMBL617392,,,Autocuration,,1,8,,,H,,2505,Binding activity radioligand.
12861,,,107,,,,BAO_0000019,B,,CHEMBL617393,,,Autocuration,,1,8,,,H,,2506,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
5105,307.0,L929,107,,,,BAO_0000219,B,,CHEMBL617394,,,Autocuration,,1,8,,,H,,2507,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand
5104,307.0,L929,107,,,,BAO_0000219,B,,CHEMBL617395,,,Expert,,1,8,,,H,,2508,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand
5105,307.0,L929,107,,,,BAO_0000219,B,,CHEMBL617396,,,Expert,,1,8,,,H,,2509,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.
5105,307.0,L929,107,,,,BAO_0000219,B,,CHEMBL617397,,,Autocuration,,1,8,,,H,,2510,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested
5254,,,107,,,,BAO_0000357,B,,CHEMBL617398,,,Autocuration,,1,8,,,H,,2511,Binding affinity against 5-HT2A receptor
5254,,,107,,,,BAO_0000357,B,,CHEMBL617399,,,Autocuration,,1,8,,,H,,2512,Binding affinity against 5-hydroxytryptamine 2A receptor
13267,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL617400,,,Autocuration,,1,8,,,H,,2513,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand
13267,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL617401,,,Autocuration,,1,8,,,H,,2514,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
14157,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL617402,,,Expert,,1,9,,Homo sapiens,D,,2515,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells
12936,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL617403,,,Expert,,1,9,,Homo sapiens,D,,2516,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
14068,,,107,,,,BAO_0000357,B,,CHEMBL617404,,,Expert,,1,8,,,H,,2517,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT
12936,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL857981,,,Expert,,1,9,,Homo sapiens,D,,2518,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
12936,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL617405,,,Expert,,1,9,,Homo sapiens,D,,2519,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
4540,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL617253,,,Expert,,1,9,,Homo sapiens,D,,2520,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand
6166,,,107,,,,BAO_0000357,B,,CHEMBL617254,,,Expert,,1,8,,,H,,2521,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.
17296,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL617255,,,Autocuration,,1,8,,,H,,2522,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
17296,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL617256,,,Autocuration,,1,8,,,H,,2523,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand
17296,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616874,,,Autocuration,,1,8,,,H,,2524,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand
15779,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL616875,,,Expert,,1,9,,Homo sapiens,D,,2525,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.
14391,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616876,,,Expert,,1,8,,,H,,2526,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand
15851,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616877,,,Expert,,1,8,,,H,,2527,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand."
15851,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL616878,,,Expert,,1,9,,Homo sapiens,D,,2528,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble
3832,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616879,,,Expert,,1,8,,,H,,2529,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin
3833,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616880,,,Expert,,1,8,,,H,,2530,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.
12936,722.0,HEK293,107,9606.0,,,BAO_0000219,B,,CHEMBL616881,,,Expert,,1,9,,Homo sapiens,D,,2531,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin
17451,723.0,NIH3T3,107,,,,BAO_0000219,B,,CHEMBL616882,,,Autocuration,,1,8,,,H,,2532,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand
17451,723.0,NIH3T3,107,,,,BAO_0000219,B,,CHEMBL616883,,,Autocuration,,1,8,,,H,,2533,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
17451,723.0,NIH3T3,107,,,,BAO_0000219,B,,CHEMBL616884,,,Autocuration,,1,8,,,H,,2534,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
4199,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616885,,,Autocuration,,1,8,,,H,,2535,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand
1883,485.0,CHO-K1,107,,,,BAO_0000219,B,,CHEMBL616886,,,Autocuration,,1,8,,,H,,2536,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells
1883,485.0,CHO-K1,107,,,,BAO_0000219,B,,CHEMBL616887,,,Expert,,1,8,,,H,,2537,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.
14875,,,107,9606.0,,,BAO_0000357,B,,CHEMBL616888,,,Expert,,1,9,,Homo sapiens,D,,2538,Binding affinity for human 5-hydroxytryptamine 2A receptor
15146,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616889,,,Autocuration,,1,8,,,H,,2539,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin
5213,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616890,,,Autocuration,,1,8,,,H,,2540,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand
16404,449.0,CHO,107,9606.0,,,BAO_0000219,B,,CHEMBL616891,,,Expert,,1,9,,Homo sapiens,D,,2541,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells
14818,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616892,,,Autocuration,,1,8,,,H,,2542,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.
4829,722.0,HEK293,107,,,,BAO_0000219,B,,CHEMBL616893,,,Autocuration,,1,8,,,H,,2543,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand"
12652,723.0,NIH3T3,10620,,,,BAO_0000219,F,,CHEMBL616894,,,Autocuration,,1,8,,,H,,2544,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells
4682,723.0,NIH3T3,107,,,,BAO_0000219,B,,CHEMBL616895,,,Expert,,1,8,,,H,,2545,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells
12652,,,10620,,,,BAO_0000019,F,,CHEMBL616896,,,Autocuration,,1,8,,,H,,2546,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor
4921,,,10621,,,,BAO_0000357,B,,CHEMBL617099,,,Autocuration,,1,8,,,H,,2547,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor
4921,,,10621,,,,BAO_0000357,B,,CHEMBL617100,,,Autocuration,,1,8,,,H,,2548,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined
16312,,,107,9986.0,,,BAO_0000357,B,,CHEMBL884532,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,2549,Binding affinity against rabbit aorta 5-HT2A receptor
14998,,,107,9986.0,,,BAO_0000357,B,,CHEMBL617101,,,Expert,,1,8,,Oryctolagus cuniculus,H,,2550,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations
14025,,,107,9986.0,,,BAO_0000357,B,,CHEMBL617102,,,Expert,,1,8,,Oryctolagus cuniculus,H,,2551,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta
13047,,,107,9986.0,,,BAO_0000019,B,,CHEMBL617103,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,2552,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.
13047,,,107,9986.0,,,BAO_0000357,B,,CHEMBL617104,,,Expert,,1,8,,Oryctolagus cuniculus,H,,2553,The compound was tested for binding affinity against 5-HT2A receptor
1883,485.0,CHO-K1,10576,,,,BAO_0000219,B,,CHEMBL857979,,,Autocuration,,1,8,,,H,,2554,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.
13463,,,12687,,,,BAO_0000019,B,,CHEMBL857502,,,Autocuration,,1,8,,,H,,2555,Binding affinity analysed towards 5-HT 2A in rat jugular vein
13463,,,12687,,,,BAO_0000019,B,,CHEMBL617105,,,Autocuration,,1,8,,,H,,2556,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
13463,,,12687,,,,BAO_0000019,B,945.0,CHEMBL858021,,,Autocuration,Stomach,1,8,,,H,,2557,Binding affinity analysed on 5-HT 2A in rat stomach fundus.
13463,,,12687,10116.0,,,BAO_0000019,B,945.0,CHEMBL875910,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2558,Binding affinity for 5-HT 2A in rat stomach fundus
13463,,,12687,,,,BAO_0000019,B,,CHEMBL617106,,,Autocuration,,1,8,,,H,,2559,Binding affinity analysed towards 5-HT 2A in rat jugular vein.
16326,723.0,NIH3T3,12687,,,,BAO_0000219,B,,CHEMBL617107,,,Expert,,1,8,,,H,,2560,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor
14093,,,12687,,,,BAO_0000019,F,,CHEMBL617108,,,Autocuration,,1,8,,,H,,2561,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor
14093,,,12687,,,,BAO_0000019,F,,CHEMBL617109,,,Autocuration,,1,8,,,H,,2562,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor
15740,,,12687,,,,BAO_0000357,B,,CHEMBL617110,,,Autocuration,,1,8,,,H,,2563,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
16633,,,12687,,,,BAO_0000357,B,,CHEMBL617111,,,Autocuration,,1,8,,,H,,2564,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation
17200,,,12687,10116.0,,,BAO_0000019,F,,CHEMBL617112,,,Expert,,1,9,,Rattus norvegicus,D,,2565,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells
17133,,,12687,,,,BAO_0000357,B,,CHEMBL617113,,,Autocuration,,1,8,,,H,,2566,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
17133,,,12687,,,,BAO_0000357,B,,CHEMBL617114,,,Autocuration,,1,8,,,H,,2567,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
17133,,,12687,,,,BAO_0000357,B,,CHEMBL617115,,,Autocuration,,1,8,,,H,,2568,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor
17200,,,12687,,,,BAO_0000219,F,,CHEMBL617116,,,Autocuration,,1,8,,,H,,2569,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
15363,,,12687,,,,BAO_0000019,F,,CHEMBL617117,,,Autocuration,,1,8,,,H,,2570,Efficacy at 5-hydroxytryptamine 2A receptor
17200,,,12687,,,,BAO_0000357,B,,CHEMBL617118,,,Autocuration,,1,8,,,H,,2571,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
17200,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL617119,,,Expert,,1,9,,Rattus norvegicus,D,,2572,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax)
17200,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL617120,,,Expert,,1,9,,Rattus norvegicus,D,,2573,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax)
17200,,,12687,10116.0,,,BAO_0000219,F,,CHEMBL617121,,,Expert,,1,9,,Rattus norvegicus,D,,2574,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
17200,,,12687,,,,BAO_0000219,F,,CHEMBL617122,,,Autocuration,,1,8,,,H,,2575,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells
17211,,,12687,,,,BAO_0000019,B,,CHEMBL617123,,,Autocuration,,1,8,,,H,,2576,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor
17331,,,12687,,,,BAO_0000019,B,,CHEMBL617124,,,Expert,,1,8,,,H,,2577,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes
13565,,,12687,,,,BAO_0000249,B,,CHEMBL617600,,,Expert,,1,8,,,H,,2578,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes
13730,,,12687,,,,BAO_0000357,B,,CHEMBL617601,,,Expert,,1,8,,,H,,2579,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand
12416,,,12687,,,,BAO_0000019,B,,CHEMBL882923,,,Expert,,1,8,,,H,,2580,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex
15295,,,12687,,,,BAO_0000357,B,,CHEMBL617602,,,Autocuration,,1,8,,,H,,2581,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor
1742,,,12687,,,,BAO_0000019,B,,CHEMBL617603,,,Autocuration,,1,8,,,H,,2582,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates
15295,,,12687,,,,BAO_0000357,B,,CHEMBL617604,,,Autocuration,,1,8,,,H,,2583,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor
14970,,,12687,,,,BAO_0000019,B,,CHEMBL617605,,,Expert,,1,8,,,H,,2584,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand
16693,,,12687,,,,BAO_0000019,B,,CHEMBL617606,,,Expert,,1,8,,,H,,2585,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand
14776,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617607,,,Expert,,1,9,,Rattus norvegicus,D,,2586,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor
14286,,,12687,,,,BAO_0000249,B,,CHEMBL617455,,,Autocuration,,1,8,,,H,,2587,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane
17200,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617456,,,Expert,,1,9,,Rattus norvegicus,D,,2588,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
15306,,,12687,,,,BAO_0000357,B,,CHEMBL617457,,,Expert,,1,8,,,H,,2589,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration)
14178,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL617458,,,Expert,,1,9,,Rattus norvegicus,D,,2590,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor
14229,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617459,,,Expert,,1,9,,Rattus norvegicus,D,,2591,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain
12884,,,12687,,,,BAO_0000357,B,,CHEMBL617460,,,Expert,,1,8,,,H,,2592,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. 
13149,,,12687,,,,BAO_0000357,B,,CHEMBL617461,,,Expert,,1,8,,,H,,2593,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values."
15295,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617462,,,Expert,,1,9,,Rattus norvegicus,D,,2594,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M
15740,,,12687,,,,BAO_0000357,B,,CHEMBL617463,,,Autocuration,,1,8,,,H,,2595,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.
15185,,,12687,,,,BAO_0000019,B,,CHEMBL617464,,,Autocuration,,1,8,,,H,,2596,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI)."
15185,,,12687,,,,BAO_0000019,B,,CHEMBL617465,,,Autocuration,,1,8,,,H,,2597,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate."
17529,,,12687,,,,BAO_0000019,B,,CHEMBL617466,,,Expert,,1,8,,,H,,2598,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand
14826,,,12687,,,,BAO_0000019,B,,CHEMBL617467,,,Autocuration,,1,8,,,H,,2599,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
17211,,,12687,,,,BAO_0000019,B,,CHEMBL617468,,,Expert,,1,8,,,H,,2600,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors
14826,,,12687,,,,BAO_0000019,B,,CHEMBL617469,,,Autocuration,,1,8,,,H,,2601,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex
14093,,,12687,,,,BAO_0000019,B,,CHEMBL617470,,,Autocuration,,1,8,,,H,,2602,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor
14093,,,12687,,,,BAO_0000019,B,,CHEMBL617471,,,Autocuration,,1,8,,,H,,2603,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested
13246,723.0,NIH3T3,12687,,,,BAO_0000219,B,,CHEMBL617472,,,Expert,,1,8,,,H,,2604,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes
13246,,,12687,,,,BAO_0000357,B,,CHEMBL617473,,,Expert,,1,8,,,H,,2605,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.
15436,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617474,,,Expert,,1,9,,Rattus norvegicus,D,,2606,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
15436,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617475,,,Expert,,1,9,,Rattus norvegicus,D,,2607,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin
14442,,,12687,,,,BAO_0000221,B,955.0,CHEMBL617476,,,Autocuration,Brain,1,8,,,H,,2608,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined
12457,,,12687,,,,BAO_0000357,B,,CHEMBL617477,,,Expert,,1,8,,,H,,2609,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor
12457,723.0,NIH3T3,12687,,,,BAO_0000219,B,,CHEMBL617478,,,Expert,,1,8,,,H,,2610,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor
14755,,,12687,,,,BAO_0000221,F,,CHEMBL617479,,,Autocuration,,1,8,,,H,,2611,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates."
4707,,,12687,,,,BAO_0000357,B,,CHEMBL617480,,,Autocuration,,1,8,,,H,,2612,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand
13297,,,12687,,,,BAO_0000357,B,,CHEMBL617481,,,Expert,,1,8,,,H,,2613,Binding affinity against 5-hydroxytryptamine 2A receptor
17331,,,12687,,,,BAO_0000019,B,,CHEMBL617482,,,Expert,,1,8,,,H,,2614,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes
4664,,,12687,,,,BAO_0000019,B,,CHEMBL617483,,,Autocuration,,1,8,,,H,,2615,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand
16633,,,12687,,,,BAO_0000357,B,,CHEMBL621528,,,Autocuration,,1,8,,,H,,2616,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
4664,723.0,NIH3T3,12687,10116.0,,,BAO_0000219,B,,CHEMBL621529,,,Expert,,1,9,,Rattus norvegicus,D,,2617,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin
16133,,,12687,,,,BAO_0000357,B,,CHEMBL621530,,,Expert,,1,8,,,H,,2618,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
16133,,,12687,,,,BAO_0000357,B,,CHEMBL621531,,,Expert,,1,8,,,H,,2619,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
14060,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL621532,,,Expert,,1,9,,Rattus norvegicus,D,,2620,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor
16326,,,12687,,,,BAO_0000357,B,,CHEMBL621533,,,Expert,,1,8,,,H,,2621,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
16659,449.0,CHO,12687,,,,BAO_0000219,B,,CHEMBL621534,,,Expert,,1,8,,,H,,2622,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells
14776,,,12687,,,,BAO_0000019,B,,CHEMBL621535,,,Autocuration,,1,8,,,H,,2623,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.
13481,,,12687,,,,BAO_0000357,B,,CHEMBL621536,,,Autocuration,,1,8,,,H,,2624,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay
17386,,,12687,,,,BAO_0000357,B,,CHEMBL621537,,,Autocuration,,1,8,,,H,,2625,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor
6611,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL621538,,,Expert,,1,9,,Rattus norvegicus,D,,2626,Binding affinity for 5-hydroxytryptamine 2A receptor
14423,,,12687,,,,BAO_0000019,B,,CHEMBL621539,,,Autocuration,,1,8,,,H,,2627,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.
15412,,,12687,,,,BAO_0000019,B,,CHEMBL621540,,,Autocuration,,1,8,,,H,,2628,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex
15412,,,12687,,,,BAO_0000019,B,,CHEMBL621541,,,Autocuration,,1,8,,,H,,2629,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.
6238,,,12687,,,,BAO_0000019,B,,CHEMBL621542,,,Autocuration,,1,8,,,H,,2630,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand
6648,,,12687,,,,BAO_0000357,B,,CHEMBL621543,,,Expert,,1,8,,,H,,2631,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.
5667,,,12687,,,,BAO_0000357,B,,CHEMBL621544,,,Expert,,1,8,,,H,,2632,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand
6611,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL621545,,,Expert,,1,9,,Rattus norvegicus,D,,2633,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor
13481,,,12687,,,,BAO_0000357,B,,CHEMBL621546,,,Autocuration,,1,8,,,H,,2634,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
13481,,,12687,,,,BAO_0000357,B,,CHEMBL621547,,,Autocuration,,1,8,,,H,,2635,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested
15558,723.0,NIH3T3,12687,,,,BAO_0000219,B,,CHEMBL618692,,,Expert,,1,8,,,H,,2636,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor
6013,,,12687,,,,BAO_0000357,B,,CHEMBL618693,,,Autocuration,,1,8,,,H,,2637,Binding affinity towards 5-hydroxytryptamine 2A receptor
16633,,,12687,,,,BAO_0000357,B,,CHEMBL872922,,,Autocuration,,1,8,,,H,,2638,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand
6013,,,12687,,,,BAO_0000357,B,,CHEMBL618694,,,Autocuration,,1,8,,,H,,2639,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand
6013,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL618695,,,Expert,,1,9,,Rattus norvegicus,D,,2640,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB
6013,,,12687,,,,BAO_0000357,B,,CHEMBL618696,,,Autocuration,,1,8,,,H,,2641,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data
6013,,,12687,,,,BAO_0000357,B,,CHEMBL618697,,,Expert,,1,8,,,H,,2642,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.
6013,,,12687,,,,BAO_0000357,B,,CHEMBL618892,,,Autocuration,,1,8,,,H,,2643,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand
6013,,,12687,,,,BAO_0000357,B,,CHEMBL618893,,,Autocuration,,1,8,,,H,,2644,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand
16293,,,12687,,,,BAO_0000357,B,,CHEMBL618894,,,Autocuration,,1,8,,,H,,2645,Binding affinity towards rat 5-hydroxytryptamine 2A receptor
17175,723.0,NIH3T3,12687,,,,BAO_0000219,B,,CHEMBL618895,,,Expert,,1,8,,,H,,2646,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand
13278,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL618896,,,Expert,,1,9,,Rattus norvegicus,D,,2647,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides
3682,,,12687,,,,BAO_0000019,B,5383.0,CHEMBL618897,,,Autocuration,Caudate-putamen,1,8,,,H,,2648,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain
2014,,,12687,,,,BAO_0000357,B,,CHEMBL618898,,,Autocuration,,1,8,,,H,,2649,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand
2014,,,12687,,,,BAO_0000357,B,,CHEMBL618899,,,Autocuration,,1,8,,,H,,2650,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined
4932,,,12687,,,,BAO_0000357,B,,CHEMBL618900,,,Autocuration,,1,8,,,H,,2651,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture
4932,,,12687,,,,BAO_0000019,B,,CHEMBL618901,,,Autocuration,,1,8,,,H,,2652,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate
3935,,,12687,,,,BAO_0000357,B,,CHEMBL618902,,,Autocuration,,1,8,,,H,,2653,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor
5432,,,12687,10116.0,,,BAO_0000221,B,10000000.0,CHEMBL618903,,,Expert,Hippocampus,1,9,,Rattus norvegicus,D,,2654,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor
15818,,,12687,,,,BAO_0000357,B,,CHEMBL618904,,,Autocuration,,1,8,,,H,,2655,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor
13672,,,12687,,,,BAO_0000357,B,,CHEMBL618905,,,Autocuration,,1,8,,,H,,2656,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.
13672,,,12687,,,,BAO_0000357,B,,CHEMBL618906,,,Autocuration,,1,8,,,H,,2657,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.
14749,723.0,NIH3T3,12687,,,,BAO_0000219,B,,CHEMBL618907,,,Expert,,1,8,,,H,,2658,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.
13462,,,12687,,,,BAO_0000019,B,,CHEMBL618908,,,Autocuration,,1,8,,,H,,2659,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.
15740,,,12687,,,,BAO_0000357,B,,CHEMBL617909,,,Autocuration,,1,8,,,H,,2660,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor
16647,,,12687,,,,BAO_0000019,B,,CHEMBL617910,,,Expert,,1,8,,,H,,2661,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate
13345,,,12687,,,,BAO_0000221,B,955.0,CHEMBL617911,,,Autocuration,Brain,1,8,,,H,,2662,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.
16740,,,12687,,,,BAO_0000249,B,,CHEMBL872923,,,Autocuration,,1,8,,,H,,2663,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
16740,,,12687,,,,BAO_0000249,B,,CHEMBL617912,,,Autocuration,,1,8,,,H,,2664,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
15535,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617913,,,Expert,,1,9,,Rattus norvegicus,D,,2665,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex
16740,,,12687,,,,BAO_0000249,B,,CHEMBL617914,,,Expert,,1,8,,,H,,2666,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
16740,,,12687,,,,BAO_0000249,B,,CHEMBL617915,,,Autocuration,,1,8,,,H,,2667,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane
16740,,,12687,,,,BAO_0000249,B,,CHEMBL617916,,,Autocuration,,1,8,,,H,,2668,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane
4795,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617917,,,Expert,,1,9,,Rattus norvegicus,D,,2669,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor
8,,,12687,,,,BAO_0000019,B,,CHEMBL617918,,,Expert,,1,8,,,H,,2670,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand
8,,,12687,,,,BAO_0000019,B,,CHEMBL617919,,,Autocuration,,1,8,,,H,,2671,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M
17200,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617920,,,Expert,,1,9,,Rattus norvegicus,D,,2672,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex
2148,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617921,,,Expert,,1,9,,Rattus norvegicus,D,,2673,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex
13345,,,105102,10116.0,,,BAO_0000224,B,,CHEMBL617922,,,Expert,,1,5,,Rattus norvegicus,D,,2674,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki"
5088,,,12687,,,,BAO_0000357,B,,CHEMBL617923,,,Autocuration,,1,8,,,H,,2675,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand
5088,,,12687,,,,BAO_0000357,B,,CHEMBL617924,,,Autocuration,,1,8,,,H,,2676,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand
17133,,,12687,,,,BAO_0000357,B,,CHEMBL617925,,,Autocuration,,1,8,,,H,,2677,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand
17133,,,12687,10116.0,,,BAO_0000357,B,,CHEMBL617926,,,Expert,,1,9,,Rattus norvegicus,D,,2678,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI
16532,,,12687,,,,BAO_0000357,B,,CHEMBL617927,,,Autocuration,,1,8,,,H,,2679,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin
15086,,,12687,,,,BAO_0000357,B,,CHEMBL617928,,,Autocuration,,1,8,,,H,,2680,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor
2309,,,12687,10116.0,,,BAO_0000019,B,,CHEMBL617929,,,Expert,,1,9,,Rattus norvegicus,D,,2681,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin
12953,,,12687,,,,BAO_0000019,B,,CHEMBL617930,,,Expert,,1,8,,,H,,2682,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.
12953,,,12687,,,,BAO_0000019,B,,CHEMBL617931,,,Autocuration,,1,8,,,H,,2683,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM
12953,,,12687,,,,BAO_0000019,B,,CHEMBL617932,,,Autocuration,,1,8,,,H,,2684,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM
16659,449.0,CHO,12687,,,,BAO_0000219,B,,CHEMBL617933,,,Autocuration,,1,8,,,H,,2685,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data
16740,,,12687,,,,BAO_0000019,B,,CHEMBL617934,,,Autocuration,,1,8,,,H,,2686,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
16740,,,12687,,,,BAO_0000019,B,,CHEMBL617935,,,Autocuration,,1,8,,,H,,2687,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data
17133,,,12687,,,,BAO_0000357,B,,CHEMBL617936,,,Autocuration,,1,8,,,H,,2688,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined
17211,,,12687,,,,BAO_0000019,B,,CHEMBL617937,,,Autocuration,,1,8,,,H,,2689,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested
17331,,,12687,,,,BAO_0000019,B,,CHEMBL617938,,,Autocuration,,1,8,,,H,,2690,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested
16633,,,12687,,,,BAO_0000218,B,,CHEMBL617939,,,Autocuration,,1,8,,,H,,2691,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63
16633,,,12687,,,,BAO_0000218,B,,CHEMBL617940,,,Autocuration,,1,8,,,H,,2692,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg
16633,,,12687,,,,BAO_0000218,B,,CHEMBL617941,,,Autocuration,,1,8,,,H,,2693,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg
15026,,,12687,,,,BAO_0000357,B,,CHEMBL617942,,,Expert,,1,8,,,H,,2694,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor
15026,,,12687,,,,BAO_0000357,B,,CHEMBL617943,,,Expert,,1,8,,,H,,2695,Ratio of pKi of 5-HT2A to that of D2 receptor
16404,,,105093,,,,BAO_0000224,B,,CHEMBL617944,,,Expert,,1,4,,,H,,2696,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
16404,,,105093,,,,BAO_0000224,B,,CHEMBL617945,,,Expert,,1,4,,,H,,2697,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor
16404,,,105075,,,,BAO_0000224,B,,CHEMBL617946,,,Expert,,1,4,,,H,,2698,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor
16404,,,12687,,,,BAO_0000357,B,,CHEMBL617947,,,Autocuration,,1,8,,,H,,2699,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data
16326,,,12687,,,,BAO_0000357,B,,CHEMBL617948,,,Expert,,1,8,,,H,,2700,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM
15847,,,12687,,,,BAO_0000019,F,,CHEMBL858116,,,Autocuration,,1,8,,,H,,2701,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat
15847,,,12687,,,,BAO_0000019,F,,CHEMBL617949,,,Autocuration,,1,8,,,H,,2702,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done
15329,,,12687,,,,BAO_0000019,F,,CHEMBL617950,,,Autocuration,,1,8,,,H,,2703,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery
16404,,,12687,,,,BAO_0000019,F,1515.0,CHEMBL617951,,,Expert,Thoracic aorta,1,8,,,H,,2704,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta
16404,,,12687,,,,BAO_0000019,F,1515.0,CHEMBL617952,,,Expert,Thoracic aorta,1,8,,,H,,2705,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta
16404,,,12687,,,,BAO_0000019,F,1515.0,CHEMBL617953,,,Autocuration,Thoracic aorta,1,8,,,H,,2706,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.
12861,,,12687,,,,BAO_0000357,B,,CHEMBL617954,,,Autocuration,,1,8,,,H,,2707,Binding activity radioligand.
12861,,,12687,,,,BAO_0000019,B,,CHEMBL617955,,,Expert,,1,8,,,H,,2708,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
12861,,,12687,,,,BAO_0000019,B,,CHEMBL857071,,,Autocuration,,1,8,,,H,,2709,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
12490,,,12687,,,,BAO_0000019,B,,CHEMBL617270,,,Expert,,1,8,,,H,,2710,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate
12827,339.0,N1E-115,12687,,,,BAO_0000219,B,,CHEMBL617271,,,Autocuration,,1,8,,,H,,2711,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930
12827,339.0,N1E-115,12687,,,,BAO_0000219,B,,CHEMBL617272,,,Autocuration,,1,8,,,H,,2712,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined
12918,,,12687,,,,BAO_0000019,B,,CHEMBL617273,,,Autocuration,,1,8,,,H,,2713,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin
12919,,,12687,10116.0,,,BAO_0000019,F,,CHEMBL617274,,,Expert,,1,9,,Rattus norvegicus,D,,2714,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin
17723,,,108,,,,BAO_0000357,B,,CHEMBL617275,,,Autocuration,,1,8,,,H,,2715,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor
6013,,,108,,,,BAO_0000357,B,,CHEMBL617276,,,Autocuration,,1,8,,,H,,2716,Binding affinity towards 5-hydroxytryptamine 2C receptor
16293,,,108,,,,BAO_0000357,B,,CHEMBL617277,,,Autocuration,,1,8,,,H,,2717,Binding affinity towards human 5-hydroxytryptamine 2C receptor
3857,,,108,,,,BAO_0000019,B,,CHEMBL617278,,,Expert,,1,8,,,H,,2718,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
3857,,,108,,,,BAO_0000019,B,,CHEMBL617279,,,Expert,,1,8,,,H,,2719,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined
3857,,,108,,,,BAO_0000019,B,,CHEMBL617280,,,Expert,,1,8,,,H,,2720,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor
15363,,,108,,,,BAO_0000357,B,,CHEMBL617281,,,Autocuration,,1,8,,,H,,2721,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
15363,,,108,,,,BAO_0000357,B,,CHEMBL617282,,,Autocuration,,1,8,,,H,,2722,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor
16441,,,108,,,,BAO_0000019,B,,CHEMBL617283,,,Expert,,1,8,,,H,,2723,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine
16441,,,108,,,,BAO_0000019,B,,CHEMBL617284,,,Expert,,1,8,,,H,,2724,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.
4176,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617285,,,Autocuration,,1,8,,,H,,2725,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand
17085,,,108,,,,BAO_0000019,B,,CHEMBL617286,,,Autocuration,,1,8,,,H,,2726,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor
17200,,,108,9606.0,,,BAO_0000357,B,,CHEMBL617287,,,Expert,,1,9,,Homo sapiens,D,,2727,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand
5088,,,108,,,,BAO_0000357,B,,CHEMBL617288,,,Expert,,1,8,,,H,,2728,Binding affinity towards human 5-hydroxytryptamine 2C receptor.
5088,,,108,,,,BAO_0000357,B,,CHEMBL617289,,,Autocuration,,1,8,,,H,,2729,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand
5088,,,108,,,,BAO_0000357,B,,CHEMBL872917,,,Autocuration,,1,8,,,H,,2730,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
5088,,,108,,,,BAO_0000357,B,,CHEMBL617290,,,Autocuration,,1,8,,,H,,2731,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
16659,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617291,,,Autocuration,,1,8,,,H,,2732,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
16659,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617292,,,Autocuration,,1,8,,,H,,2733,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data
17451,723.0,NIH3T3,108,,,,BAO_0000219,B,,CHEMBL617293,,,Autocuration,,1,8,,,H,,2734,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined
6857,449.0,CHO,108,9606.0,,,BAO_0000219,F,,CHEMBL617294,,,Expert,,1,9,,Homo sapiens,D,,2735,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
3857,,,108,,,,BAO_0000019,B,,CHEMBL617295,,,Expert,,1,8,,,H,,2736,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
12861,,,108,,,,BAO_0000357,B,,CHEMBL617296,,,Autocuration,,1,8,,,H,,2737,Binding activity radioligand.
12861,,,108,,,,BAO_0000019,B,,CHEMBL617297,,,Autocuration,,1,8,,,H,,2738,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.
5104,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617298,,,Expert,,1,8,,,H,,2739,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand
5105,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617299,,,Expert,,1,8,,,H,,2740,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.
5105,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617300,,,Autocuration,,1,8,,,H,,2741,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested
5254,,,108,,,,BAO_0000357,B,,CHEMBL617454,,,Autocuration,,1,8,,,H,,2742,Binding affinity against 5-HT2C receptor
13267,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617505,,,Autocuration,,1,8,,,H,,2743,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand
14157,722.0,HEK293,108,9606.0,,,BAO_0000219,B,,CHEMBL617506,,,Expert,,1,9,,Homo sapiens,D,,2744,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells
12936,722.0,HEK293,108,9606.0,,,BAO_0000219,B,,CHEMBL617507,,,Expert,,1,9,,Homo sapiens,D,,2745,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
14068,,,108,,,,BAO_0000357,B,,CHEMBL617508,,,Expert,,1,8,,,H,,2746,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB
12936,722.0,HEK293,108,9606.0,,,BAO_0000219,B,,CHEMBL857982,,,Expert,,1,9,,Homo sapiens,D,,2747,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine
4540,722.0,HEK293,108,9606.0,,,BAO_0000219,B,,CHEMBL617509,,,Expert,,1,9,,Homo sapiens,D,,2748,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand
4540,722.0,HEK293,108,9606.0,,,BAO_0000219,B,,CHEMBL617510,,,Expert,,1,9,,Homo sapiens,D,,2749,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined
6166,,,108,,,,BAO_0000357,B,,CHEMBL617511,,,Autocuration,,1,8,,,H,,2750,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined
17296,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617512,,,Autocuration,,1,8,,,H,,2751,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand
17296,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617749,,,Autocuration,,1,8,,,H,,2752,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand
15779,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617750,,,Autocuration,,1,8,,,H,,2753,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
15779,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617751,,,Autocuration,,1,8,,,H,,2754,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
14391,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617752,,,Expert,,1,8,,,H,,2755,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand
15779,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617753,,,Autocuration,,1,8,,,H,,2756,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand"
15851,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617754,,,Expert,,1,8,,,H,,2757,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand."
15851,722.0,HEK293,108,9606.0,,,BAO_0000219,B,,CHEMBL617755,,,Expert,,1,9,,Homo sapiens,D,,2758,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble
15779,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617756,,,Autocuration,,1,8,,,H,,2759,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data"
3832,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617757,,,Expert,,1,8,,,H,,2760,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine
3833,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617758,,,Expert,,1,8,,,H,,2761,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.
17451,723.0,NIH3T3,108,,,,BAO_0000219,B,,CHEMBL617759,,,Autocuration,,1,8,,,H,,2762,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand
4199,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617760,,,Autocuration,,1,8,,,H,,2763,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand
1883,485.0,CHO-K1,108,,,,BAO_0000219,B,,CHEMBL617761,,,Expert,,1,8,,,H,,2764,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells
4321,,,108,9606.0,,,BAO_0000357,B,,CHEMBL617762,,,Expert,,1,9,,Homo sapiens,D,,2765,Binding affinity against 5-hydroxytryptamine 2C receptor
14875,,,108,,,,BAO_0000357,B,,CHEMBL617763,,,Autocuration,,1,8,,,H,,2766,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor
15146,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL857983,,,Autocuration,,1,8,,,H,,2767,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine
5213,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617764,,,Autocuration,,1,8,,,H,,2768,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand
16404,308.0,HeLa,108,,,,BAO_0000219,B,,CHEMBL617765,,,Autocuration,,1,8,,,H,,2769,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells
13267,,,108,,,,BAO_0000019,F,,CHEMBL617766,,,Autocuration,,1,8,,,H,,2770,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor
13267,,,108,,,,BAO_0000221,F,10000000.0,CHEMBL617767,,,Autocuration,Hippocampus,1,8,,,H,,2771,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand
14818,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617768,,,Autocuration,,1,8,,,H,,2772,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.
4829,722.0,HEK293,108,,,,BAO_0000219,B,,CHEMBL617769,,,Autocuration,,1,8,,,H,,2773,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand"
13463,,,11864,,,,BAO_0000357,B,,CHEMBL858023,,,Autocuration,,1,8,,,H,,2774,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand
13463,,,11864,,,,BAO_0000019,B,945.0,CHEMBL617770,,,Autocuration,Stomach,1,8,,,H,,2775,Binding affinity analysed on 5-HT 2C in rat stomach fundus
13463,,,11864,,,,BAO_0000019,B,945.0,CHEMBL617771,,,Autocuration,Stomach,1,8,,,H,,2776,Binding affinity analysed towards 5-HT 2C in rat stomach fundus
12652,625.0,A9,11864,,,,BAO_0000219,F,,CHEMBL617772,,,Autocuration,,1,8,,,H,,2777,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells
4682,723.0,NIH3T3,11864,,,,BAO_0000219,B,,CHEMBL617773,,,Autocuration,,1,8,,,H,,2778,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
4682,723.0,NIH3T3,11864,,,,BAO_0000219,B,,CHEMBL617850,,,Autocuration,,1,8,,,H,,2779,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells
4682,723.0,NIH3T3,11864,,,,BAO_0000219,B,,CHEMBL617851,,,Autocuration,,1,8,,,H,,2780,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells
12652,,,11864,,,,BAO_0000019,F,,CHEMBL617852,,,Autocuration,,1,8,,,H,,2781,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor
13463,,,12689,10090.0,,,BAO_0000019,B,945.0,CHEMBL858024,,,Autocuration,Stomach,1,8,,Mus musculus,H,,2782,Binding affinity analysed on 5-HT 2C in rat stomach fundus.
13463,,,12689,10116.0,,,BAO_0000019,B,945.0,CHEMBL617853,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2783,Binding affinity towards 5-HT 2C receptor in rat stomach fundus
13969,,,108,,,,BAO_0000357,B,,CHEMBL617854,,,Expert,,1,8,,,H,,2784,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand
13392,,,108,9823.0,,,BAO_0000357,B,,CHEMBL873477,,,Expert,,1,8,,Sus scrofa,H,,2785,Binding affinity for 5-hydroxytryptamine 2C receptor
13392,,,108,,,,BAO_0000357,B,,CHEMBL617855,,,Expert,,1,8,,,H,,2786,Binding affinity towards 5-hydroxytryptamine 2C receptor
14430,,,108,,,,BAO_0000019,B,,CHEMBL617856,,,Expert,,1,8,,,H,,2787,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine
1742,,,108,,,,BAO_0000019,B,,CHEMBL617857,,,Autocuration,,1,8,,,H,,2788,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex
14286,,,108,,,,BAO_0000249,B,,CHEMBL617858,,,Autocuration,,1,8,,,H,,2789,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane
5619,,,108,,,,BAO_0000357,B,,CHEMBL617859,,,Autocuration,,1,8,,,H,,2790,Binding affinity towards pig 5-hydroxytryptamine 2C receptor
15086,,,108,,,,BAO_0000357,B,,CHEMBL617860,,,Autocuration,,1,8,,,H,,2791,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
12861,,,108,,,,BAO_0000357,B,,CHEMBL617861,,,Autocuration,,1,8,,,H,,2792,Binding activity radioligand.
12861,,,108,,,,BAO_0000019,B,,CHEMBL617862,,,Expert,,1,8,,,H,,2793,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
12861,,,108,,,,BAO_0000019,B,,CHEMBL617863,,,Autocuration,,1,8,,,H,,2794,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available
12827,,,108,,,,BAO_0000249,B,,CHEMBL617864,,,Autocuration,,1,8,,,H,,2795,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT
12827,,,108,,,,BAO_0000249,B,,CHEMBL617649,,,Autocuration,,1,8,,,H,,2796,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined
12919,,,108,9823.0,,,BAO_0000019,F,,CHEMBL617650,,,Expert,,1,8,,Sus scrofa,H,,2797,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
12919,,,108,9823.0,,,BAO_0000019,F,,CHEMBL617651,,,Expert,,1,8,,Sus scrofa,H,,2798,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine
16429,,,108,9823.0,,,BAO_0000357,B,,CHEMBL617652,,,Autocuration,,1,8,,Sus scrofa,H,,2799,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand
773,,,108,9823.0,,,BAO_0000019,B,,CHEMBL857072,,,Autocuration,,1,8,,Sus scrofa,H,,2800,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex
5033,,,108,9823.0,,,BAO_0000357,B,,CHEMBL617653,,,Autocuration,,1,8,,Sus scrofa,H,,2801,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor
12861,,,12687,,,,BAO_0000019,B,,CHEMBL617654,,,Autocuration,,1,8,,,H,,2802,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.
14093,,,12689,,,,BAO_0000019,F,,CHEMBL617655,,,Autocuration,,1,8,,,H,,2803,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor
14970,,,12689,,,,BAO_0000357,B,,CHEMBL617656,,,Expert,,1,8,,,H,,2804,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand
14970,,,12689,,,,BAO_0000357,B,,CHEMBL617657,,,Autocuration,,1,8,,,H,,2805,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand
14970,,,12689,,,,BAO_0000357,B,,CHEMBL617658,,,Autocuration,,1,8,,,H,,2806,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested
14178,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL617659,,,Expert,,1,9,,Rattus norvegicus,D,,2807,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor
14178,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL617838,,,Expert,,1,9,,Rattus norvegicus,D,,2808,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor
14229,,,12689,10116.0,,,BAO_0000249,B,,CHEMBL617839,,Brain membranes,Expert,,1,9,,Rattus norvegicus,D,,2809,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes
16532,,,12689,,,,BAO_0000357,B,,CHEMBL617840,,,Autocuration,,1,8,,,H,,2810,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested
14826,,,12689,,,,BAO_0000019,B,,CHEMBL617841,,,Autocuration,,1,8,,,H,,2811,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex
17211,,,12689,,,,BAO_0000019,B,,CHEMBL875915,,,Autocuration,,1,8,,,H,,2812,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor
17211,,,12689,,,,BAO_0000219,B,,CHEMBL617842,,,Expert,,1,8,,,H,In vitro,2813,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells
13246,723.0,NIH3T3,12689,,,,BAO_0000219,B,,CHEMBL617843,,,Expert,,1,8,,,H,,2814,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes
13246,,,12689,,,,BAO_0000357,B,,CHEMBL617844,,,Expert,,1,8,,,H,,2815,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.
12457,,,12689,,,,BAO_0000357,B,,CHEMBL617845,,,Expert,,1,8,,,H,,2816,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor
12457,723.0,NIH3T3,12689,,,,BAO_0000219,B,,CHEMBL617846,,,Expert,,1,8,,,H,,2817,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor
4707,,,12689,,,,BAO_0000357,B,,CHEMBL617847,,,Autocuration,,1,8,,,H,,2818,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand
13297,,,12689,,,,BAO_0000357,B,,CHEMBL617848,,,Expert,,1,8,,,H,,2819,Binding affinity against 5-hydroxytryptamine 2C receptor
16633,,,12689,,,,BAO_0000357,B,,CHEMBL617849,,,Autocuration,,1,8,,,H,,2820,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
16133,,,12689,,,,BAO_0000357,B,,CHEMBL621507,,,Expert,,1,8,,,H,,2821,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
16326,,,12689,,,,BAO_0000357,B,,CHEMBL621508,,,Expert,,1,8,,,H,,2822,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand
14423,,,12689,,,,BAO_0000019,B,,CHEMBL621509,,,Autocuration,,1,8,,,H,,2823,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.
15412,,,12689,,,,BAO_0000019,B,,CHEMBL621510,,,Autocuration,,1,8,,,H,,2824,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex
15412,,,12689,,,,BAO_0000019,B,,CHEMBL621511,,,Autocuration,,1,8,,,H,,2825,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.
15558,625.0,A9,12689,,,,BAO_0000219,B,,CHEMBL621512,,,Expert,,1,8,,,H,,2826,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor
16633,,,12689,,,,BAO_0000357,B,,CHEMBL621513,,,Autocuration,,1,8,,,H,,2827,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
6013,,,12689,,,,BAO_0000357,B,,CHEMBL621514,,,Expert,,1,8,,,H,,2828,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.
17175,,,12689,,,,BAO_0000219,B,,CHEMBL621515,,,Expert,,1,8,,,H,In vitro,2829,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand
12469,,,12689,,,,BAO_0000219,B,,CHEMBL621516,,,Autocuration,,1,8,,,H,,2830,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine
3682,,,12689,,,,BAO_0000019,B,5383.0,CHEMBL621517,,,Autocuration,Caudate-putamen,1,8,,,H,,2831,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain
4932,,,12689,,,,BAO_0000357,B,,CHEMBL621518,,,Autocuration,,1,8,,,H,,2832,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture
4932,,,12689,,,,BAO_0000019,B,,CHEMBL621519,,,Autocuration,,1,8,,,H,,2833,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data
3935,,,12689,,,,BAO_0000357,B,,CHEMBL621520,,,Autocuration,,1,8,,,H,,2834,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor
15818,,,12689,,,,BAO_0000357,B,,CHEMBL621521,,,Autocuration,,1,8,,,H,,2835,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor
15818,,,12689,,,,BAO_0000357,B,,CHEMBL621522,,,Autocuration,,1,8,,,H,,2836,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor
14749,,,12689,,,,BAO_0000219,B,,CHEMBL621523,,,Expert,,1,8,,,H,,2837,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.
15740,,,12689,,,,BAO_0000357,B,,CHEMBL621524,,,Autocuration,,1,8,,,H,,2838,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor
17133,,,12689,10116.0,,,BAO_0000357,B,,CHEMBL621525,,,Expert,,1,9,,Rattus norvegicus,D,,2839,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI
16532,,,12689,,,,BAO_0000357,B,,CHEMBL872921,,,Autocuration,,1,8,,,H,,2840,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine
12369,,,12689,,,,BAO_0000357,B,,CHEMBL621526,,,Autocuration,,1,8,,,H,,2841,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor
12369,,,12689,,,,BAO_0000219,B,,CHEMBL621527,,,Expert,,1,8,,,H,,2842,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.
2309,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL617865,,,Expert,,1,9,,Rattus norvegicus,D,,2843,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine
12953,,,12689,,,,BAO_0000357,B,,CHEMBL617866,,,Autocuration,,1,8,,,H,,2844,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor
12953,,,12689,,,,BAO_0000019,B,,CHEMBL617867,,,Autocuration,,1,8,,,H,,2845,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM
12953,,,12689,,,,BAO_0000357,B,,CHEMBL617487,,,Autocuration,,1,8,,,H,,2846,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM
12953,,,12689,,,,BAO_0000357,B,,CHEMBL617488,,,Expert,,1,8,,,H,,2847,Binding affinity for 5-hydroxytryptamine 2C receptor
17133,,,12689,,,,BAO_0000357,B,,CHEMBL617489,,,Autocuration,,1,8,,,H,,2848,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined
17211,,,12689,,,,BAO_0000019,B,,CHEMBL617490,,,Autocuration,,1,8,,,H,,2849,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested
17211,,,12689,,,,BAO_0000019,B,,CHEMBL617491,,,Autocuration,,1,8,,,H,,2850,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested
14025,,,12689,,,,BAO_0000019,B,,CHEMBL617492,,,Autocuration,,1,8,,,H,,2851,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.
14998,,,12689,,,,BAO_0000019,B,,CHEMBL617493,,,Autocuration,,1,8,,,H,,2852,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.
4342,,,12689,,,,BAO_0000357,B,,CHEMBL617494,,,Autocuration,,1,8,,,H,,2853,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined
13735,,,12689,10116.0,,,BAO_0000019,B,,CHEMBL617495,,,Expert,,1,9,,Rattus norvegicus,D,,2854,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293
13181,,,12689,,,,BAO_0000357,B,,CHEMBL617496,,,Autocuration,,1,8,,,H,,2855,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand
1883,485.0,CHO-K1,12689,,,,BAO_0000219,B,,CHEMBL617497,,,Autocuration,,1,8,,,H,,2856,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.
15194,,,12689,,,,BAO_0000357,B,,CHEMBL617498,,,Autocuration,,1,8,,,H,,2857,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
15194,,,12689,,,,BAO_0000357,B,,CHEMBL617499,,,Autocuration,,1,8,,,H,,2858,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.
14579,,,12689,,,,BAO_0000019,F,,CHEMBL617500,,,Autocuration,,1,8,,,H,,2859,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor
4639,,,108,,,,BAO_0000357,B,,CHEMBL617501,,,Autocuration,,1,8,,,H,,2860,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor
4820,,,108,,,,BAO_0000357,B,,CHEMBL617502,,,Expert,,1,8,,,H,,2861,Binding affinity towards 5-hydroxytryptamine 2C receptor
14442,,,227,,,,BAO_0000357,B,,CHEMBL617503,,,Autocuration,,1,8,,,H,,2862,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested
14755,,,227,,,,BAO_0000357,B,,CHEMBL617504,,,Autocuration,,1,8,,,H,,2863,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.
14744,,,227,,,,BAO_0000357,B,,CHEMBL617406,,,Autocuration,,1,8,,,H,,2864,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand
6857,,,227,9606.0,,,BAO_0000019,B,,CHEMBL617407,,,Expert,,1,9,,Homo sapiens,D,,2865,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line
16209,,,227,,,,BAO_0000357,B,,CHEMBL617408,,,Autocuration,,1,8,,,H,,2866,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand
15363,,,227,,,,BAO_0000357,B,,CHEMBL617409,,,Autocuration,,1,8,,,H,,2867,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
15363,,,227,,,,BAO_0000357,B,,CHEMBL617410,,,Autocuration,,1,8,,,H,,2868,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor
15363,,,227,,,,BAO_0000357,B,,CHEMBL617411,,,Autocuration,,1,8,,,H,,2869,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor
17085,,,227,,,,BAO_0000019,B,,CHEMBL617412,,,Autocuration,,1,8,,,H,,2870,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor
17200,,,227,9606.0,,,BAO_0000357,B,,CHEMBL617774,,,Expert,,1,9,,Homo sapiens,D,,2871,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand
15851,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617775,,,Expert,,1,9,,Homo sapiens,D,,2872,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
15851,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617776,,,Expert,,1,9,,Homo sapiens,D,,2873,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data
6857,449.0,CHO,227,9606.0,,,BAO_0000219,F,,CHEMBL617777,,,Expert,,1,9,,Homo sapiens,D,,2874,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
6857,449.0,CHO,227,9606.0,,,BAO_0000219,F,,CHEMBL617778,,,Expert,,1,9,,Homo sapiens,D,,2875,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT
15779,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617779,,,Autocuration,,1,8,,,H,,2876,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
15851,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617780,,,Expert,,1,8,,,H,,2877,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.
15779,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617781,,,Autocuration,,1,8,,,H,,2878,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data"
14157,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617782,,,Expert,,1,9,,Homo sapiens,D,,2879,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells
4540,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617783,,,Expert,,1,9,,Homo sapiens,D,,2880,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand
6166,,,227,,,,BAO_0000357,B,,CHEMBL617784,,,Autocuration,,1,8,,,H,,2881,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined
15779,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617785,,,Autocuration,,1,8,,,H,,2882,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.
14391,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL857984,,,Expert,,1,8,,,H,,2883,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand
3832,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617786,,,Expert,,1,8,,,H,,2884,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT
3833,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617787,,,Expert,,1,8,,,H,,2885,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.
15851,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617788,,,Expert,,1,9,,Homo sapiens,D,,2886,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells
15851,722.0,HEK293,227,9606.0,,,BAO_0000219,B,,CHEMBL617789,,,Expert,,1,9,,Homo sapiens,D,,2887,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble
4199,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617790,,,Autocuration,,1,8,,,H,,2888,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand
1883,485.0,CHO-K1,227,,,,BAO_0000219,B,,CHEMBL617791,,,Expert,,1,8,,,H,,2889,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells
4321,,,227,,,,BAO_0000357,B,,CHEMBL617608,,,Expert,,1,8,,,H,,2890,Binding affinity against 5-hydroxytryptamine 2B receptor
15146,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617609,,,Autocuration,,1,8,,,H,,2891,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT
5213,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617610,,,Autocuration,,1,8,,,H,,2892,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand
14818,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617611,,,Autocuration,,1,8,,,H,,2893,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.
4829,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617612,,,Autocuration,,1,8,,,H,,2894,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
4829,722.0,HEK293,227,,,,BAO_0000219,B,,CHEMBL617613,,,Autocuration,,1,8,,,H,,2895,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand"
14025,,,227,9986.0,,,BAO_0000019,B,,CHEMBL617614,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,2896,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.
13463,,,12688,,,,BAO_0000019,B,945.0,CHEMBL617615,,,Expert,Stomach,1,8,,,H,,2897,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus
7259,,,12688,,,,BAO_0000357,B,945.0,CHEMBL858114,,,Expert,Stomach,1,8,,,H,,2898,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus
7259,,,12688,,,,BAO_0000357,B,945.0,CHEMBL617616,,,Autocuration,Stomach,1,8,,,H,,2899,Affinity against serotonergic receptor in the isolated rat stomach fundus
7185,,,12688,10116.0,,,BAO_0000019,F,945.0,CHEMBL617617,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2900,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation
7185,,,12688,10116.0,,,BAO_0000019,F,,CHEMBL875914,,,Expert,,1,9,,Rattus norvegicus,D,,2901,Antagonistic against 5-hydroxytryptamine 2B receptor
13267,,,12688,,,,BAO_0000019,F,945.0,CHEMBL617618,,,Autocuration,Stomach,1,8,,,H,,2902,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus
13735,,,12688,10116.0,,,BAO_0000357,B,945.0,CHEMBL617619,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2903,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus
15738,,,12688,,,,BAO_0000019,F,,CHEMBL617620,,,Autocuration,,1,8,,,H,,2904,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor
15738,,,12688,,,,BAO_0000019,F,,CHEMBL617621,,,Autocuration,,1,8,,,H,,2905,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data
15738,,,12688,,,,BAO_0000019,F,,CHEMBL617622,,,Autocuration,,1,8,,,H,,2906,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor
12936,,,12688,10116.0,,,BAO_0000357,B,945.0,CHEMBL617623,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2907,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
12936,,,12688,10116.0,,,BAO_0000357,B,945.0,CHEMBL617624,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2908,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
12936,,,12688,10116.0,,,BAO_0000357,B,945.0,CHEMBL617625,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2909,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
12936,,,12688,10116.0,,,BAO_0000357,B,945.0,CHEMBL617626,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2910,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor
16404,,,12688,,,,BAO_0000019,F,945.0,CHEMBL617627,,,Autocuration,Stomach,1,8,,,H,,2911,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
16404,,,12688,,,,BAO_0000019,F,945.0,CHEMBL617628,,,Expert,Stomach,1,8,,,H,,2912,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
16404,,,12688,,,,BAO_0000019,F,945.0,CHEMBL617629,,,Autocuration,Stomach,1,8,,,H,,2913,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.
16404,,,12688,,,,BAO_0000019,F,945.0,CHEMBL858115,,,Autocuration,Stomach,1,8,,,H,,2914,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.
16404,,,12688,10116.0,,,BAO_0000019,F,945.0,CHEMBL617630,,,Expert,Stomach,1,9,,Rattus norvegicus,D,,2915,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined
16404,,,12688,,,,BAO_0000019,F,1515.0,CHEMBL617631,,,Autocuration,Thoracic aorta,1,8,,,H,,2916,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined
7483,,,12688,,,,BAO_0000357,B,,CHEMBL617632,,,Autocuration,,1,8,,,H,,2917,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
7483,,,12688,,,,BAO_0000357,B,,CHEMBL617633,,,Expert,,1,8,,,H,,2918,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus
7483,,,12688,,,,BAO_0000357,B,,CHEMBL617634,,,Autocuration,,1,8,,,H,,2919,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot
7483,,,12688,,,,BAO_0000357,B,,CHEMBL617635,,,Autocuration,,1,8,,,H,,2920,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot
16404,,,12688,10116.0,,,BAO_0000019,F,945.0,CHEMBL617637,,,Autocuration,Stomach,1,9,,Rattus norvegicus,D,,2922,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus
6347,,,227,,,,BAO_0000357,B,,CHEMBL617638,,,Autocuration,,1,8,,,H,,2923,Binding affinity against 5-hydroxytryptamine 1A receptor
4373,,,227,,,,BAO_0000357,B,,CHEMBL617639,,,Autocuration,,1,8,,,H,,2924,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined
4373,,,227,,,,BAO_0000357,B,,CHEMBL617640,,,Autocuration,,1,8,,,H,,2925,Binding affinity for 5-hydroxytryptamine 2B receptor was determined
4687,,,227,,,,BAO_0000357,B,,CHEMBL617641,,,Autocuration,,1,8,,,H,,2926,Evaluated for the binding affinity to 5-HT 2B receptor
16946,,,227,,,,BAO_0000357,B,,CHEMBL617642,,,Autocuration,,1,8,,,H,,2927,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor
16633,,,227,,,,BAO_0000357,B,,CHEMBL617643,,,Autocuration,,1,8,,,H,,2928,Binding affinities against 5-hydroxytryptamine 2B receptor
16633,,,227,,,,BAO_0000357,B,,CHEMBL617644,,,Autocuration,,1,8,,,H,,2929,Binding affinities towards 5-hydroxytryptamine 2B receptor
16633,,,227,,,,BAO_0000357,B,,CHEMBL617645,,,Autocuration,,1,8,,,H,,2930,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand
15026,,,108,,,,BAO_0000357,B,,CHEMBL617646,,,Expert,,1,8,,,H,,2931,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
15738,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617647,,,Autocuration,,1,8,,Bos taurus,H,,2932,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
15738,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617648,,,Autocuration,,1,8,,Bos taurus,H,,2933,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M
15738,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617875,,,Autocuration,,1,8,,Bos taurus,H,,2934,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M
15738,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617876,,,Autocuration,,1,8,,Bos taurus,H,,2935,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M
16404,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617877,,,Expert,,1,8,,Bos taurus,H,,2936,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus
15026,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617878,,,Expert,,1,8,,Bos taurus,H,,2937,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.
15738,,,108,9913.0,,,BAO_0000357,B,,CHEMBL617879,,,Autocuration,,1,8,,Bos taurus,H,,2938,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor
16312,,,108,10141.0,,,BAO_0000019,B,,CHEMBL617880,,,Autocuration,,1,8,,Cavia porcellus,H,,2939,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine
5486,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL617881,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,2940,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum
5254,,,51,,,,BAO_0000357,B,,CHEMBL857073,,,Autocuration,,1,8,,,H,,2941,Binding affinity against 5-HT1A receptor
3857,449.0,CHO,108,,,,BAO_0000219,F,,CHEMBL617882,,,Expert,,1,8,,,H,,2942,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed
6857,449.0,CHO,108,9606.0,,,BAO_0000219,F,,CHEMBL617883,,,Expert,,1,9,,Homo sapiens,D,,2943,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader
4176,,,108,,,,BAO_0000219,F,,CHEMBL617884,,,Autocuration,,1,8,,,H,,2944,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line
6347,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617885,,,Autocuration,,1,8,,,H,,2945,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand
6347,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617886,,,Autocuration,,1,8,,,H,,2946,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax"
16146,,,108,9606.0,,,BAO_0000357,B,,CHEMBL617887,,,Expert,,1,9,,Homo sapiens,D,,2947,Inhibition of human 5-hydroxytryptamine 2C receptor
3805,,,108,,,,BAO_0000357,B,,CHEMBL617888,,,Autocuration,,1,8,,,H,,2948,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM)
3857,,,108,,,,BAO_0000019,B,,CHEMBL617889,,,Autocuration,,1,8,,,H,,2949,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM
5635,,,108,,,,BAO_0000357,B,,CHEMBL617890,,,Autocuration,,1,8,,,H,,2950,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor
5635,,,108,,,,BAO_0000357,B,,CHEMBL617891,,,Autocuration,,1,8,,,H,,2951,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
5635,,,108,,,,BAO_0000357,B,,CHEMBL617892,,,Autocuration,,1,8,,,H,,2952,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined
4012,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617893,,,Expert,,1,8,,,H,,2953,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.
6366,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617894,,,Expert,,1,8,,,H,,2954,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells
15949,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617895,,,Expert,,1,8,,,H,,2955,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
17211,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL617896,,,Autocuration,,1,8,,,H,,2956,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor
6491,,,108,9606.0,,,BAO_0000357,B,,CHEMBL617897,,,Expert,,1,9,,Homo sapiens,D,,2957,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor
14093,,,108,,,,BAO_0000019,F,,CHEMBL617898,,,Autocuration,,1,8,,,H,,2958,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand
13481,,,108,,,,BAO_0000019,F,,CHEMBL617899,,,Autocuration,,1,8,,,H,,2959,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand
6347,449.0,CHO,108,10116.0,,,BAO_0000219,B,,CHEMBL617900,,,Expert,,1,8,,Rattus norvegicus,H,,2960,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI 
14093,,,108,,,,BAO_0000019,F,,CHEMBL617901,,,Autocuration,,1,8,,,H,,2961,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand
14093,,,108,,,,BAO_0000019,F,,CHEMBL617902,,,Autocuration,,1,8,,,H,,2962,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested
13481,,,108,,,,BAO_0000019,F,,CHEMBL617903,,,Autocuration,,1,8,,,H,,2963,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
14442,,,108,,,,BAO_0000357,B,,CHEMBL617904,,,Autocuration,,1,8,,,H,,2964,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand
14442,,,108,,,,BAO_0000357,B,,CHEMBL617905,,,Autocuration,,1,8,,,H,,2965,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand
14442,,,108,,,,BAO_0000357,B,,CHEMBL617906,,,Autocuration,,1,8,,,H,,2966,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested
14755,,,108,,,,BAO_0000357,B,,CHEMBL617907,,,Autocuration,,1,8,,,H,,2967,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.
14744,,,108,,,,BAO_0000357,B,,CHEMBL617908,,,Autocuration,,1,8,,,H,,2968,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand
16659,449.0,CHO,108,,,,BAO_0000219,B,,CHEMBL620617,,,Expert,,1,8,,,H,,2969,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells
6857,,,108,9606.0,,,BAO_0000019,B,,CHEMBL620618,,,Expert,,1,9,,Homo sapiens,D,,2970,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line
5635,,,108,,,,BAO_0000357,B,,CHEMBL620619,,,Expert,,1,8,,,H,,2971,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.
4234,,,108,9606.0,,,BAO_0000357,B,,CHEMBL620620,,,Expert,,1,9,,Homo sapiens,D,,2972,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor
16209,,,108,,,,BAO_0000357,B,,CHEMBL620621,,,Autocuration,,1,8,,,H,,2973,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand
5778,,,104698,10116.0,,,BAO_0000249,B,,CHEMBL872920,,Membranes,Autocuration,,1,7,,Rattus norvegicus,D,,2974,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes
5094,,,104698,,,,BAO_0000223,B,,CHEMBL620622,,,Autocuration,,1,6,,,H,,2975,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated
809,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL620623,,,Autocuration,,1,7,,Rattus norvegicus,D,,2976,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex
1578,,,104698,,,,BAO_0000019,B,,CHEMBL620624,,,Autocuration,,1,6,,,H,,2977,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex
809,,,104698,,,,BAO_0000019,B,,CHEMBL620625,,,Autocuration,,1,6,,,H,,2978,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested
12469,,,104698,,,,BAO_0000219,B,,CHEMBL620626,,,Autocuration,,1,6,,,H,,2979,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630
14290,,,104698,,,,BAO_0000019,B,,CHEMBL621307,,,Autocuration,,1,6,,,H,,2980,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex
14290,,,104698,,,,BAO_0000019,B,,CHEMBL621308,,,Autocuration,,1,6,,,H,,2981,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.
10609,,,104698,,,,BAO_0000223,B,,CHEMBL621309,,,Autocuration,,1,6,,,H,,2982,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT
10609,,,104698,,,,BAO_0000223,B,,CHEMBL621310,,,Autocuration,,1,6,,,H,,2983,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630
10609,,,104698,,,,BAO_0000223,B,,CHEMBL621311,,,Autocuration,,1,6,,,H,,2984,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin
15253,,,104698,,,,BAO_0000249,B,,CHEMBL621502,,,Autocuration,,1,6,,,H,,2985,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
15253,,,104698,,,,BAO_0000249,B,,CHEMBL621503,,,Autocuration,,1,6,,,H,,2986,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes."
11683,,,104698,,,,BAO_0000249,B,,CHEMBL621504,,Membranes,Autocuration,,1,6,,,H,,2987,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.
12092,,,104698,,,,BAO_0000223,B,,CHEMBL621505,,,Autocuration,,1,6,,,H,,2988,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor
1946,,,104698,,,,BAO_0000019,B,,CHEMBL621506,,,Autocuration,,1,6,,,H,,2989,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
11623,,,104698,,,,BAO_0000223,B,,CHEMBL619781,,,Autocuration,,1,6,,,H,,2990,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.
11623,,,104698,,,,BAO_0000223,B,,CHEMBL619782,,,Autocuration,,1,6,,,H,,2991,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. 
14788,,,104698,,,,BAO_0000019,B,,CHEMBL619783,,,Autocuration,,1,6,,,H,,2992,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex
5432,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL619784,,,Autocuration,,1,7,,Rattus norvegicus,D,,2993,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor
14826,,,104698,,,,BAO_0000249,B,,CHEMBL619785,,,Autocuration,,1,6,,,H,,2994,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane
2222,,,104698,,,,BAO_0000223,B,,CHEMBL619786,,,Autocuration,,1,6,,,H,,2995,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
11963,,,104698,,,,BAO_0000019,B,,CHEMBL619787,,,Autocuration,,1,6,,,H,,2996,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex
14145,,,104698,,,,BAO_0000019,B,,CHEMBL872925,,,Autocuration,,1,6,,,H,,2997,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex
17819,,,104698,,,,BAO_0000019,B,,CHEMBL619788,,,Autocuration,,1,6,,,H,,2998,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.
10394,,,104698,,,,BAO_0000249,B,,CHEMBL619789,,,Autocuration,,1,6,,,H,,2999,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
10394,,,104698,,,,BAO_0000249,B,,CHEMBL619790,,,Autocuration,,1,6,,,H,,3000,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand
15034,,,104698,,,,BAO_0000019,B,,CHEMBL619791,,,Autocuration,,1,6,,,H,,3001,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
691,,,104698,,,,BAO_0000019,B,,CHEMBL619792,,,Autocuration,,1,6,,,H,,3002,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.
12092,,,104698,,,,BAO_0000249,B,,CHEMBL619793,,Membranes,Autocuration,,1,6,,,H,,3003,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes
11752,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL619794,,,Autocuration,,1,7,,Rattus norvegicus,D,,3004,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor
11752,,,104698,,,,BAO_0000221,B,955.0,CHEMBL619795,,,Autocuration,Brain,1,6,,,H,,3005,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices
301,,,104698,,,,BAO_0000019,B,,CHEMBL619796,,,Autocuration,,1,6,,,H,,3006,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.
16532,,,104698,,,,BAO_0000223,B,,CHEMBL620448,,,Autocuration,,1,6,,,H,,3007,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584
16532,,,104698,,,,BAO_0000223,B,,CHEMBL620449,,,Autocuration,,1,6,,,H,,3008,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
12092,,,104698,,,,BAO_0000223,B,,CHEMBL620450,,,Autocuration,,1,6,,,H,,3009,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.
11684,,,104698,,,,BAO_0000223,B,,CHEMBL620451,,,Autocuration,,1,6,,,H,,3010,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630
11684,,,104698,,,,BAO_0000223,B,,CHEMBL620631,,,Autocuration,,1,6,,,H,,3011,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.
12953,,,104698,,,,BAO_0000019,B,,CHEMBL620632,,,Autocuration,,1,6,,,H,,3012,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand
12953,,,104698,,,,BAO_0000019,B,,CHEMBL620633,,,Autocuration,,1,6,,,H,,3013,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active
12953,,,104698,,,,BAO_0000223,B,,CHEMBL620634,,,Autocuration,,1,6,,,H,,3014,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM
12861,,,104698,,,,BAO_0000019,B,,CHEMBL620635,,,Autocuration,,1,6,,,H,,3015,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620636,,,Autocuration,,1,6,,,H,In vivo,3016,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620637,,,Autocuration,,1,6,,,H,In vivo,3017,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620638,,,Autocuration,,1,6,,,H,In vivo,3018,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620639,,,Autocuration,,1,6,,,H,In vivo,3019,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620640,,,Autocuration,,1,6,,,H,In vivo,3020,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620641,,,Autocuration,,1,6,,,H,In vivo,3021,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620642,,,Autocuration,,1,6,,,H,In vivo,3022,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620643,,,Autocuration,,1,6,,,H,In vivo,3023,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620644,,,Autocuration,,1,6,,,H,In vivo,3024,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620645,,,Autocuration,,1,6,,,H,In vivo,3025,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620646,,,Autocuration,,1,6,,,H,In vivo,3026,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620647,,,Autocuration,,1,6,,,H,In vivo,3027,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620648,,,Autocuration,,1,6,,,H,In vivo,3028,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620649,,,Autocuration,,1,6,,,H,In vivo,3029,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620650,,,Autocuration,,1,6,,,H,In vivo,3030,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620651,,,Autocuration,,1,6,,,H,In vivo,3031,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL872875,,,Autocuration,,1,6,,,H,In vivo,3032,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL620652,,,Autocuration,,1,6,,,H,In vivo,3033,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats
10609,,,104698,,,,BAO_0000019,F,,CHEMBL620653,,,Autocuration,,1,6,,,H,,3034,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart
12861,,,104698,,,,BAO_0000019,B,,CHEMBL857076,,,Autocuration,,1,6,,,H,,3035,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.
12861,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL620654,,,Autocuration,,1,7,,Rattus norvegicus,D,,3036,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor
12861,,,104698,,,,BAO_0000223,B,,CHEMBL620655,,,Autocuration,,1,6,,,H,,3037,Binding activity radioligand.
10728,,,104698,,,,BAO_0000249,B,,CHEMBL620656,,Brain membranes,Autocuration,,1,6,,,H,,3038,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes
10728,,,104698,,,,BAO_0000249,B,,CHEMBL620657,,Brain membranes,Autocuration,,1,6,,,H,,3039,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.
5163,,,108,,,,BAO_0000357,B,,CHEMBL620658,,,Autocuration,,1,8,,,H,,3040,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L
5163,,,108,,,,BAO_0000357,B,,CHEMBL620659,,,Autocuration,,1,8,,,H,,3041,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L
6011,,,108,,,,BAO_0000357,B,,CHEMBL620660,,,Autocuration,,1,8,,,H,,3042,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration
5014,,,108,,,,BAO_0000357,B,,CHEMBL620661,,,Autocuration,,1,8,,,H,,3043,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor
5635,,,108,,,,BAO_0000357,B,,CHEMBL620662,,,Autocuration,,1,8,,,H,,3044,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor
5163,,,108,,,,BAO_0000357,B,,CHEMBL620663,,,Expert,,1,8,,,H,,3045,Affinity for 5-hydroxytryptamine 2C receptor
6841,,,108,,,,BAO_0000357,B,,CHEMBL620664,,,Autocuration,,1,8,,,H,,3046,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand
6119,,,108,,,,BAO_0000357,B,,CHEMBL620665,,,Expert,,1,8,,,H,,3047,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.
4373,,,108,,,,BAO_0000357,B,,CHEMBL620666,,,Autocuration,,1,8,,,H,,3048,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined
1633,,,108,,,,BAO_0000357,B,,CHEMBL620667,,,Autocuration,,1,8,,,H,,3049,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin
1633,,,108,,,,BAO_0000357,B,,CHEMBL620668,,,Expert,,1,8,,,H,,3050,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine
4373,,,108,,,,BAO_0000357,B,,CHEMBL620669,,,Autocuration,,1,8,,,H,,3051,Binding affinity for 5-hydroxytryptamine 2C receptor was determined
6576,,,108,,,,BAO_0000357,B,,CHEMBL620670,,,Expert,,1,8,,,H,,3052,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor
4687,,,108,,,,BAO_0000357,B,,CHEMBL620671,,,Autocuration,,1,8,,,H,,3053,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor
12146,,,108,,,,BAO_0000357,B,,CHEMBL620672,,,Autocuration,,1,8,,,H,,3054,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1
12146,,,108,,,,BAO_0000357,B,,CHEMBL620673,,,Autocuration,,1,8,,,H,,3055,Tested against 5-hydroxytryptamine 2C receptor in experiment 2
16946,,,108,,,,BAO_0000357,B,,CHEMBL620674,,,Autocuration,,1,8,,,H,,3056,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor
14159,,,108,,,,BAO_0000357,B,,CHEMBL620675,,,Autocuration,,1,8,,,H,,3057,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor
16700,,,108,,,,BAO_0000357,B,,CHEMBL620676,,,Autocuration,,1,8,,,H,,3058,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity
3269,,,108,,,,BAO_0000357,B,,CHEMBL621382,,,Autocuration,,1,8,,,H,,3059,Affinity against 5-hydroxytryptamine 2C receptor
1274,,,108,9606.0,,,BAO_0000357,B,,CHEMBL621383,,,Expert,,1,9,,Homo sapiens,D,,3060,Binding affinity against 5-hydroxytryptamine 2C receptor
1317,,,108,,,,BAO_0000357,B,,CHEMBL621384,,,Autocuration,,1,8,,,H,,3061,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay
5834,,,144,9913.0,,,BAO_0000357,B,,CHEMBL621385,,,Autocuration,,1,8,,Bos taurus,H,,3062,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630
11147,,,144,9913.0,,,BAO_0000357,B,,CHEMBL617989,,,Autocuration,,1,8,,Bos taurus,H,,3063,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand
14145,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617990,,,Expert,,1,4,,Cavia porcellus,H,,3064,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay
10561,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL875085,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3065,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
15847,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617991,,,Autocuration,,1,4,,Cavia porcellus,H,,3066,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig
15847,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617992,,,Autocuration,,1,4,,Cavia porcellus,H,,3067,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done
10561,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617993,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3068,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum
11454,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617994,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3069,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617995,,,Autocuration,,1,4,,Cavia porcellus,H,,3070,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617996,,,Autocuration,,1,4,,Cavia porcellus,H,,3071,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617997,,,Autocuration,,1,4,,Cavia porcellus,H,,3072,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617998,,,Autocuration,,1,4,,Cavia porcellus,H,,3073,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL617999,,,Autocuration,,1,4,,Cavia porcellus,H,,3074,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618000,,,Autocuration,,1,4,,Cavia porcellus,H,,3075,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM
15253,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617815,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3076,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum"
15253,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617816,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3077,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum."
11963,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617817,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3078,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum
1946,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617818,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3079,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum
1946,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617819,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3080,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested
12045,,,104714,10141.0,,,BAO_0000223,B,,CHEMBL617820,,,Autocuration,,1,4,,Cavia porcellus,H,,3081,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15
1559,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617821,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3082,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
273,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617822,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3083,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
273,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617823,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3084,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI)
188,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617824,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3085,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum
12919,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617825,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3086,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay
12918,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617826,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3087,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay
1559,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617827,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3088,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
273,,,104714,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617828,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3089,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
1559,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617829,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3090,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum
1559,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617830,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3091,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined
1559,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617831,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3092,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined
14424,,,104714,10141.0,,,BAO_0000221,B,2116.0,CHEMBL617832,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3093,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.
13181,,,22226,10141.0,,,BAO_0000019,B,,CHEMBL617833,,,Autocuration,,1,0,,Cavia porcellus,U,,3094,Binding affinity was determined against 5-hydroxytryptamine 2A receptor
5486,,,51,,,,BAO_0000357,B,,CHEMBL617834,,,Autocuration,,1,8,,,H,,3095,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell
6491,,,104714,9606.0,,,BAO_0000223,B,,CHEMBL617835,,,Expert,,1,5,,Homo sapiens,D,,3096,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor
6013,,,104714,,,,BAO_0000223,B,,CHEMBL617836,,,Autocuration,,1,4,,,H,,3097,Binding affinity towards 5-HT3 receptor
12861,,,104714,,,,BAO_0000223,B,,CHEMBL617837,,,Autocuration,,1,4,,,H,,3098,Binding activity radioligand.
12861,,,104714,,,,BAO_0000019,B,,CHEMBL620392,,,Autocuration,,1,4,,,H,,3099,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.
5104,,,104714,,,,BAO_0000223,B,,CHEMBL620393,,,Autocuration,,1,4,,,H,,3100,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
5105,,,104714,,,,BAO_0000223,B,,CHEMBL620394,,,Autocuration,,1,4,,,H,,3101,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor
5104,,,104714,,,,BAO_0000223,B,,CHEMBL620395,,,Autocuration,,1,4,,,H,,3102,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested
3935,,,22226,,,,BAO_0000019,B,,CHEMBL620396,,,Autocuration,,1,0,,,U,,3103,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor
13657,433.0,NG108-15,105030,,,,BAO_0000219,B,,CHEMBL620582,,,Expert,,1,4,,,H,,3104,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells
10369,,,105030,,,,BAO_0000218,B,,CHEMBL620583,,,Autocuration,,1,4,,,H,In vivo,3105,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)"
10369,,,105030,,,,BAO_0000019,B,,CHEMBL620584,,,Autocuration,,1,4,,,H,,3106,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
12918,,,105030,,,,BAO_0000224,B,,CHEMBL620585,,,Autocuration,,1,4,,,H,,3107,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype
12918,,,105030,,,,BAO_0000224,B,,CHEMBL620586,,,Autocuration,,1,4,,,H,,3108,Compound was evaluated for the binding affinity at 5- HT3 receptor
10369,,,105030,,,,BAO_0000019,B,,CHEMBL620587,,,Autocuration,,1,4,,,H,,3109,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro)
773,,,105030,,,,BAO_0000019,B,,CHEMBL620588,,,Autocuration,,1,4,,,H,,3110,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
12918,,,105030,,,,BAO_0000218,F,,CHEMBL620589,,,Autocuration,,1,4,,,H,,3111,5-hydroxytryptamine 3 receptor agonism in mouse
10561,,,105030,,,,BAO_0000219,B,,CHEMBL620590,,,Autocuration,,1,4,,,H,,3112,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells
12827,,,105030,,,,BAO_0000019,B,,CHEMBL617956,,,Autocuration,,1,4,,,H,,3113,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
12827,,,105030,,,,BAO_0000019,B,,CHEMBL617957,,,Autocuration,,1,4,,,H,,3114,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin
12918,,,105030,,,,BAO_0000224,B,,CHEMBL617958,,,Autocuration,,1,4,,,H,,3115,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron
273,,,105030,,,,BAO_0000219,B,,CHEMBL617959,,,Autocuration,,1,4,,,H,,3116,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
273,,,105030,,,,BAO_0000219,B,,CHEMBL617960,,,Autocuration,,1,4,,,H,,3117,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand
10561,,,105030,,,,BAO_0000224,B,,CHEMBL617961,,,Autocuration,,1,4,,,H,,3118,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
5033,,,105030,,,,BAO_0000219,B,,CHEMBL617962,,,Autocuration,,1,4,,,H,In vitro,3119,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells
16429,339.0,N1E-115,105030,,,,BAO_0000219,B,,CHEMBL617963,,,Autocuration,,1,4,,,H,,3120,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand
10322,,,11765,,,,BAO_0000019,B,,CHEMBL617964,,,Autocuration,,1,8,,,H,,3121,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
14331,,,11765,,,,BAO_0000219,B,,CHEMBL617965,,,Autocuration,,1,8,,,H,,3122,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15
13462,,,10630,10090.0,,,BAO_0000357,B,,CHEMBL617966,,,Autocuration,,1,9,,Mus musculus,D,,3123,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.
12861,,,17106,,,,BAO_0000019,B,,CHEMBL857074,,,Autocuration,,1,8,,,H,,3124,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.
15086,,,144,9823.0,,,BAO_0000357,B,,CHEMBL617967,,,Autocuration,,1,8,,Sus scrofa,H,,3125,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor
12861,,,144,9823.0,,,BAO_0000357,B,,CHEMBL617968,,,Autocuration,,1,8,,Sus scrofa,H,,3126,Binding activity radioligand.
10561,,,104714,9986.0,,,BAO_0000223,B,,CHEMBL617969,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3127,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus
10561,,,104714,9986.0,,,BAO_0000223,B,,CHEMBL617970,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3128,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart
10561,,,104714,9986.0,,,BAO_0000223,B,,CHEMBL617971,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3129,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart
10561,,,104714,9986.0,,,BAO_0000019,B,,CHEMBL617972,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3130,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
273,,,104714,9986.0,,,BAO_0000019,F,,CHEMBL617973,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3131,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
273,,,104714,9986.0,,,BAO_0000019,F,,CHEMBL617974,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3132,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
273,,,104714,9986.0,,,BAO_0000221,F,2116.0,CHEMBL617975,,,Autocuration,Ileum,1,4,,Oryctolagus cuniculus,H,,3133,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI)
273,,,104714,9986.0,,,BAO_0000019,F,,CHEMBL617976,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3134,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
273,,,104714,9986.0,,,BAO_0000019,F,,CHEMBL617977,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3135,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
273,,,104714,9986.0,,,BAO_0000019,F,,CHEMBL617978,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3136,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH)
273,,,104714,9986.0,,,BAO_0000019,F,,CHEMBL617979,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3137,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN)
13047,449.0,CHO,104714,9986.0,,,BAO_0000219,B,,CHEMBL617980,,,Autocuration,,1,4,,Oryctolagus cuniculus,H,,3138,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand
1650,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL617981,,,Autocuration,,1,7,,Rattus norvegicus,D,,3139,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor
16288,,,12020,,,,BAO_0000019,B,,CHEMBL617982,,,Autocuration,,1,8,,,H,,3140,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01)
16288,,,12020,,,,BAO_0000357,B,,CHEMBL617983,,,Autocuration,,1,8,,,H,,3141,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01)
10254,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL617984,,,Autocuration,,1,7,,Rattus norvegicus,D,,3142,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells
14532,,,104698,,,,BAO_0000019,B,,CHEMBL617985,,,Autocuration,,1,6,,,H,,3143,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630"
13392,,,104698,,,,BAO_0000218,F,948.0,CHEMBL617986,,,Autocuration,Heart,1,6,,,H,In vivo,3144,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
13392,,,104698,,,,BAO_0000019,F,948.0,CHEMBL617987,,,Autocuration,Heart,1,6,,,H,,3145,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
13392,,,104698,,,,BAO_0000019,F,948.0,CHEMBL617988,,,Autocuration,Heart,1,6,,,H,,3146,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate"
13392,,,104698,,,,BAO_0000019,F,948.0,CHEMBL617792,,,Autocuration,Heart,1,6,,,H,,3147,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate"
13392,,,104698,,,,BAO_0000019,F,948.0,CHEMBL617793,,,Autocuration,Heart,1,6,,,H,,3148,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate"
13392,,,104698,,,,BAO_0000019,F,,CHEMBL617794,,,Autocuration,,1,6,,,H,,3149,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia"
13392,,,104698,,,,BAO_0000019,F,,CHEMBL617795,,,Autocuration,,1,6,,,H,,3150,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
13392,,,104698,,,,BAO_0000019,F,,CHEMBL617796,,,Autocuration,,1,6,,,H,,3151,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia"
13392,,,104698,,,,BAO_0000019,F,,CHEMBL617797,,,Autocuration,,1,6,,,H,,3152,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia"
1089,,,104698,10116.0,,,BAO_0000218,F,,CHEMBL617798,,,Autocuration,,1,7,,Rattus norvegicus,D,In vivo,3153,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism)
1089,,,104698,,,,BAO_0000218,F,,CHEMBL617799,,,Autocuration,,1,6,,,H,In vivo,3154,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor)
11454,,,104698,10116.0,,,BAO_0000218,F,,CHEMBL617800,,,Autocuration,,1,7,,Rattus norvegicus,D,In vivo,3155,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
11454,,,104698,10116.0,,,BAO_0000019,F,,CHEMBL617801,,,Autocuration,,1,7,,Rattus norvegicus,D,,3156,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+
12205,,,104698,10116.0,,,BAO_0000218,F,,CHEMBL617802,,,Autocuration,,1,7,,Rattus norvegicus,D,In vivo,3157,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration
1089,,,104698,10116.0,,,BAO_0000019,F,,CHEMBL617803,,,Autocuration,,1,7,,Rattus norvegicus,D,,3158,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism)
5094,,,104698,,,,BAO_0000019,B,,CHEMBL617804,,,Autocuration,,1,6,,,H,,3159,Binding affinity towards 5-HT3 receptor in rat was evaluated
2622,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL617805,,,Autocuration,,1,7,,Rattus norvegicus,D,,3160,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor
245,,,104698,,,,BAO_0000223,B,,CHEMBL617806,,,Autocuration,,1,6,,,H,,3161,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor
14788,,,104698,,,,BAO_0000019,B,,CHEMBL617807,,,Autocuration,,1,6,,,H,,3162,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.
14788,,,104698,,,,BAO_0000019,B,,CHEMBL617808,,,Autocuration,,1,6,,,H,,3163,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex
3020,,,104698,,,,BAO_0000249,B,,CHEMBL617809,,,Autocuration,,1,6,,,H,,3164,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand
1742,,,104698,,,,BAO_0000019,B,,CHEMBL617810,,,Autocuration,,1,6,,,H,,3165,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates
17394,,,104698,,,,BAO_0000249,B,955.0,CHEMBL617811,,,Autocuration,Brain,1,6,,,H,,3166,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane
17394,,,104698,,,,BAO_0000221,B,955.0,CHEMBL617812,,,Autocuration,Brain,1,6,,,H,,3167,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane
17394,,,104698,,,,BAO_0000249,B,,CHEMBL617813,,,Autocuration,,1,6,,,H,,3168,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane
14286,,,104698,,,,BAO_0000249,B,,CHEMBL617814,,,Autocuration,,1,6,,,H,,3169,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane
14178,,,104698,,,,BAO_0000019,B,,CHEMBL617698,,,Autocuration,,1,6,,,H,,3170,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.
14178,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL617699,,,Autocuration,,1,7,,Rattus norvegicus,D,,3171,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm
14178,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL617700,,,Autocuration,,1,7,,Rattus norvegicus,D,,3172,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM
14178,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL617701,,,Autocuration,,1,7,,Rattus norvegicus,D,,3173,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor
15034,,,104698,,,,BAO_0000019,B,,CHEMBL617702,,,Autocuration,,1,6,,,H,,3174,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand
1089,,,104698,,,,BAO_0000249,B,,CHEMBL617703,,Membranes,Autocuration,,1,6,,,H,,3175,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50"
1089,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL617704,,,Autocuration,,1,7,,Rattus norvegicus,D,,3176,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor
16532,,,104698,,,,BAO_0000223,B,,CHEMBL617705,,,Autocuration,,1,6,,,H,,3177,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested
12801,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL617706,,,Autocuration,,1,7,,Rattus norvegicus,D,,3178,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor
15194,433.0,NG108-15,104698,,,,BAO_0000219,B,,CHEMBL617707,,,Autocuration,,1,6,,,H,,3179,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand)
15194,433.0,NG108-15,104698,,,,BAO_0000219,B,,CHEMBL617708,,,Autocuration,,1,6,,,H,,3180,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand
15194,,,104698,,,,BAO_0000019,B,,CHEMBL617709,,,Autocuration,,1,6,,,H,,3181,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand
15194,,,104698,,,,BAO_0000019,B,,CHEMBL617710,,,Autocuration,,1,6,,,H,,3182,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active
15194,,,104698,,,,BAO_0000019,B,,CHEMBL882925,,,Autocuration,,1,6,,,H,,3183,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active
15194,,,104698,,,,BAO_0000019,B,,CHEMBL617711,,,Autocuration,,1,6,,,H,,3184,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active
10610,,,104698,,,,BAO_0000019,F,,CHEMBL617712,,,Autocuration,,1,6,,,H,,3185,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats
10355,,,104698,10116.0,,,BAO_0000019,F,,CHEMBL617713,,,Autocuration,,1,7,,Rattus norvegicus,D,,3186,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat
691,,,104698,,,,BAO_0000019,F,,CHEMBL617714,,,Autocuration,,1,6,,,H,,3187,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously"
10611,,,104698,,,,BAO_0000218,F,,CHEMBL617715,,,Autocuration,,1,6,,,H,,3188,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats
12801,,,104698,,,,BAO_0000218,F,,CHEMBL617716,,,Autocuration,,1,6,,,H,In vivo,3189,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats
10609,,,104698,,,,BAO_0000218,F,,CHEMBL617717,,,Autocuration,,1,6,,,H,,3190,Inhibition of 5-HT evoked reflex bradycardia in rat.
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617718,,,Autocuration,,1,6,,,H,In vivo,3191,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617719,,,Autocuration,,1,6,,,H,In vivo,3192,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617720,,,Autocuration,,1,6,,,H,In vivo,3193,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats)
11454,,,104698,10116.0,,,BAO_0000218,F,,CHEMBL617721,,,Autocuration,,1,7,,Rattus norvegicus,D,In vivo,3194,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617722,,,Autocuration,,1,6,,,H,In vivo,3195,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617723,,,Autocuration,,1,6,,,H,In vivo,3196,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617724,,,Autocuration,,1,6,,,H,In vivo,3197,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617725,,,Autocuration,,1,6,,,H,In vivo,3198,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617726,,,Autocuration,,1,6,,,H,In vivo,3199,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617727,,,Autocuration,,1,6,,,H,In vivo,3200,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617728,,,Autocuration,,1,6,,,H,In vivo,3201,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617729,,,Autocuration,,1,6,,,H,In vivo,3202,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617730,,,Autocuration,,1,6,,,H,In vivo,3203,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617731,,,Autocuration,,1,6,,,H,In vivo,3204,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617732,,,Autocuration,,1,6,,,H,In vivo,3205,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617733,,,Autocuration,,1,6,,,H,In vivo,3206,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617734,,,Autocuration,,1,6,,,H,In vivo,3207,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL872874,,,Autocuration,,1,6,,,H,In vivo,3208,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617735,,,Autocuration,,1,6,,,H,In vivo,3209,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617736,,,Autocuration,,1,6,,,H,In vivo,3210,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617737,,,Autocuration,,1,6,,,H,In vivo,3211,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617738,,,Autocuration,,1,6,,,H,In vivo,3212,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617739,,,Autocuration,,1,6,,,H,In vivo,3213,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617740,,,Autocuration,,1,6,,,H,In vivo,3214,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617741,,,Autocuration,,1,6,,,H,In vivo,3215,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617742,,,Autocuration,,1,6,,,H,In vivo,3216,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617743,,,Autocuration,,1,6,,,H,In vivo,3217,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617744,,,Autocuration,,1,6,,,H,In vivo,3218,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats
11454,,,104698,,,,BAO_0000218,F,,CHEMBL617745,,,Autocuration,,1,6,,,H,In vivo,3219,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats
670,,,104698,,,,BAO_0000218,F,,CHEMBL617746,,,Autocuration,,1,6,,,H,,3220,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)"
670,,,104698,,,,BAO_0000218,F,,CHEMBL617747,,,Autocuration,,1,6,,,H,,3221,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested"
10321,,,104698,,,,BAO_0000218,F,,CHEMBL617748,,,Autocuration,,1,6,,,H,In vivo,3222,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg
10321,,,104698,,,,BAO_0000218,F,,CHEMBL618909,,,Autocuration,,1,6,,,H,In vivo,3223,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg
10321,,,104698,,,,BAO_0000218,F,,CHEMBL618910,,,Autocuration,,1,6,,,H,In vivo,3224,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg
10321,,,104698,,,,BAO_0000218,F,,CHEMBL618911,,,Autocuration,,1,6,,,H,In vivo,3225,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg
10321,,,104698,,,,BAO_0000218,F,,CHEMBL618912,,,Autocuration,,1,6,,,H,In vivo,3226,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg
10322,,,104698,,,,BAO_0000218,F,,CHEMBL618913,,,Autocuration,,1,6,,,H,In vivo,3227,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg)
15412,,,104698,,,,BAO_0000019,F,,CHEMBL618914,,,Autocuration,,1,6,,,H,,3228,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
15412,,,104698,,,,BAO_0000019,F,,CHEMBL618915,,,Autocuration,,1,6,,,H,,3229,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist
15412,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL618916,,,Autocuration,,1,7,,Rattus norvegicus,D,,3230,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor
15412,,,104698,,,,BAO_0000019,F,,CHEMBL618917,,,Autocuration,,1,6,,,H,,3231,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist
15412,,,104698,,,,BAO_0000221,B,10000000.0,CHEMBL618918,,,Intermediate,Hippocampus,1,7,,,D,,3232,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue
15412,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL618919,,,Autocuration,,1,7,,Rattus norvegicus,D,,3233,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane
17394,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL618920,,,Autocuration,,1,7,,Rattus norvegicus,D,,3234,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor
12457,,,104698,,,,BAO_0000223,B,,CHEMBL618921,,,Autocuration,,1,6,,,H,,3235,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor
12457,,,104698,,,,BAO_0000019,B,,CHEMBL618922,,,Autocuration,,1,6,,,H,,3236,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor
12205,,,104698,,,,BAO_0000019,B,,CHEMBL618923,,,Autocuration,,1,6,,,H,,3237,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.
14532,,,104698,,,,BAO_0000019,B,,CHEMBL618924,,,Autocuration,,1,6,,,H,,3238,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices
1122,,,104698,,,,BAO_0000019,B,,CHEMBL618925,,,Autocuration,,1,6,,,H,,3239,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand
5094,,,104698,,,,BAO_0000019,B,,CHEMBL618926,,,Autocuration,,1,6,,,H,,3240,Binding affinity towards 5-HT3 receptor in rat was evaluated
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL618927,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3241,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL618928,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3242,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL618929,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3243,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL618930,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3244,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL618931,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3245,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619594,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3246,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619595,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3247,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation"
13961,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619596,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3248,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.
13961,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619755,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3249,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619756,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3250,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619757,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3251,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619758,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3252,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619759,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3253,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619760,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3254,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619761,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3255,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619762,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3256,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619763,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3257,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
14290,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL617868,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3258,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested"
15034,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL617869,,,Intermediate,,1,9,,Cavia porcellus,D,,3259,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum
5094,,,20033,10141.0,,,BAO_0000249,B,2435.0,CHEMBL882926,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3260,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
5094,,,20033,10141.0,,,BAO_0000249,B,2435.0,CHEMBL617870,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3261,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
5399,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL617871,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3262,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand
17394,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL617872,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3263,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum
17394,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL617873,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3264,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum
17394,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL617874,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3265,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum
13961,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619067,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3266,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.
13961,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619068,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3267,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.
13961,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619069,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3268,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
16946,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619070,,,Intermediate,,1,9,,Cavia porcellus,D,,3269,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig
16946,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619071,,,Intermediate,,1,9,,Cavia porcellus,D,,3270,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig
15034,,,20033,10141.0,,,BAO_0000019,F,,CHEMBL619072,,,Intermediate,,1,9,,Cavia porcellus,D,,3271,Agonistic activity against 5-hydroxytryptamine 4 receptor
15034,,,20033,10141.0,,,BAO_0000019,F,,CHEMBL619073,,,Intermediate,,1,9,,Cavia porcellus,D,,3272,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested
12918,,,20033,10141.0,,,BAO_0000019,F,,CHEMBL619074,,,Intermediate,,1,9,,Cavia porcellus,D,,3273,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor
16946,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619075,,,Intermediate,,1,9,,Cavia porcellus,D,,3274,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor
17394,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL619076,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3275,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor
15034,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL619077,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3276,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand
5094,,,20033,10141.0,,,BAO_0000249,B,2435.0,CHEMBL619078,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3277,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated
5094,,,20033,10141.0,,,BAO_0000249,B,2435.0,CHEMBL619079,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3278,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated
17358,,,20033,10141.0,,,BAO_0000221,B,2116.0,CHEMBL619080,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3279,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.
12953,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619081,,,Expert,,1,9,,Cavia porcellus,D,,3280,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum
12953,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619082,,,Intermediate,,1,9,,Cavia porcellus,D,,3281,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
12953,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619083,,,Intermediate,,1,9,,Cavia porcellus,D,,3282,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.
12953,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619084,,,Intermediate,,1,9,,Cavia porcellus,D,,3283,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM
273,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL859397,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3284,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
12918,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619085,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3285,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay
12919,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619086,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3286,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation
273,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619087,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3287,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).
273,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619088,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3288,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.
13181,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619089,,,Intermediate,,1,9,,Cavia porcellus,D,,3289,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP
13181,,,168,10141.0,,,BAO_0000357,B,,CHEMBL619090,,,Autocuration,,1,8,,Cavia porcellus,H,,3290,Binding affinity was determined against 5-hydroxytryptamine 3 receptor
15034,,,20033,10141.0,,,BAO_0000019,F,,CHEMBL619091,,,Intermediate,,1,9,,Cavia porcellus,D,,3291,Antagonistic activity against 5-hydroxytryptamine 4 receptor
5033,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619092,,,Intermediate,,1,9,,Cavia porcellus,D,,3292,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor
1980,,,20033,10141.0,,,BAO_0000019,B,,CHEMBL619093,,,Intermediate,,1,9,,Cavia porcellus,D,,3293,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.
13181,722.0,HEK293,168,10141.0,,,BAO_0000219,B,,CHEMBL619094,,,Autocuration,,1,8,,Cavia porcellus,H,,3294,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine
14287,,,20033,10141.0,,,BAO_0000019,B,,CHEMBL619095,,,Intermediate,,1,9,,Cavia porcellus,D,,3295,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane
1317,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL857988,,,Intermediate,,1,9,,Cavia porcellus,D,,3296,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand
15316,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619096,,,Intermediate,,1,9,,Cavia porcellus,D,,3297,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.
16429,,,20033,10141.0,,,BAO_0000357,B,2435.0,CHEMBL619097,,,Intermediate,Striatum,1,9,,Cavia porcellus,D,,3298,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand
14818,,,20033,10141.0,,,BAO_0000221,B,10000000.0,CHEMBL619098,,,Intermediate,Hippocampus,1,9,,Cavia porcellus,D,,3299,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.
15194,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619751,,,Intermediate,,1,9,,Cavia porcellus,D,,3300,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand
15194,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619752,,,Intermediate,,1,9,,Cavia porcellus,D,,3301,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.
13961,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL875096,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3302,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.
5486,,,108,,,,BAO_0000357,B,,CHEMBL619004,,,Autocuration,,1,8,,,H,,3303,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell
16209,,,168,,,,BAO_0000357,B,,CHEMBL619005,,,Autocuration,,1,8,,,H,,3304,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand
17085,,,168,,,,BAO_0000019,B,,CHEMBL619006,,,Autocuration,,1,8,,,H,,3305,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor
4199,308.0,HeLa,168,,,,BAO_0000219,B,,CHEMBL619007,,,Autocuration,,1,8,,,H,,3306,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand
15146,,,168,,,,BAO_0000357,B,,CHEMBL619008,,,Autocuration,,1,8,,,H,,3307,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor
5213,,,168,,,,BAO_0000357,B,,CHEMBL619009,,,Autocuration,,1,8,,,H,,3308,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor
4829,308.0,HeLa,168,,,,BAO_0000219,B,,CHEMBL619010,,,Autocuration,,1,8,,,H,,3309,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand"
17358,,,10622,,,,BAO_0000357,B,,CHEMBL619011,,,Autocuration,,1,8,,,H,,3310,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons
17358,,,10622,,,,BAO_0000357,B,,CHEMBL619012,,,Autocuration,,1,8,,,H,,3311,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive
16946,,,10622,,,,BAO_0000219,B,,CHEMBL619013,,,Autocuration,,1,8,,,H,,3312,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells
17358,,,10622,,,,BAO_0000357,B,,CHEMBL619014,,,Autocuration,,1,8,,,H,,3313,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons
268,,,11249,,,,BAO_0000019,F,2081.0,CHEMBL857503,,,Autocuration,Cardiac atrium,1,8,,,H,,3314,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model
268,,,11249,,,,BAO_0000019,F,2081.0,CHEMBL619015,,,Autocuration,Cardiac atrium,1,8,,,H,,3315,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM
15086,,,11249,,,,BAO_0000357,B,,CHEMBL619016,,,Autocuration,,1,8,,,H,,3316,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor
14875,,,11249,,,,BAO_0000221,B,10000000.0,CHEMBL619017,,,Autocuration,Hippocampus,1,8,,,H,,3317,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor
13267,,,168,9823.0,,,BAO_0000221,B,10000000.0,CHEMBL619018,,,Autocuration,Hippocampus,1,8,,Sus scrofa,H,,3318,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand
13047,,,168,9986.0,,,BAO_0000019,B,,CHEMBL619019,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,3319,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.
1650,,,10623,10116.0,,,BAO_0000357,B,,CHEMBL619020,,,Expert,,1,9,,Rattus norvegicus,D,,3320,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor
567,,,10623,,,,BAO_0000019,F,,CHEMBL619021,,,Autocuration,,1,8,,,H,,3321,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
17358,,,10623,,,,BAO_0000357,B,,CHEMBL619022,,,Autocuration,,1,8,,,H,,3322,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus
188,,,10623,,,,BAO_0000357,B,,CHEMBL619023,,,Autocuration,,1,8,,,H,,3323,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity
670,,,10623,,,,BAO_0000019,F,,CHEMBL619024,,,Autocuration,,1,8,,,H,,3324,lntrinsic activity relative to 5-HT receptor
204,,,10623,,,,BAO_0000019,F,,CHEMBL619025,,,Autocuration,,1,8,,,H,,3325,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay
1946,,,10623,,,,BAO_0000019,F,,CHEMBL619026,,,Expert,,1,8,,,H,,3326,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.
6398,,,10623,,,,BAO_0000019,F,,CHEMBL619027,,,Autocuration,,1,8,,,H,,3327,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay
6398,,,10623,,,,BAO_0000019,F,,CHEMBL619028,,,Autocuration,,1,8,,,H,,3328,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive
17358,,,10623,,,,BAO_0000019,F,,CHEMBL619029,,,Autocuration,,1,8,,,H,,3329,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae
6398,,,10623,,,,BAO_0000019,F,,CHEMBL619030,,,Autocuration,,1,8,,,H,,3330,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture
11752,,,10623,,,,BAO_0000357,B,,CHEMBL619031,,,Expert,,1,8,,,H,,3331,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae
809,,,10623,,,,BAO_0000019,F,,CHEMBL619032,,,Autocuration,,1,8,,,H,,3332,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae
14178,,,10623,10116.0,,,BAO_0000357,B,,CHEMBL619033,,,Expert,,1,9,,Rattus norvegicus,D,,3333,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor
567,,,10623,,,,BAO_0000357,B,,CHEMBL619034,,,Autocuration,,1,8,,,H,,3334,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae
1946,,,10623,,,,BAO_0000357,B,,CHEMBL619035,,,Autocuration,,1,8,,,H,,3335,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.
1946,,,10623,,,,BAO_0000357,B,,CHEMBL619036,,,Autocuration,,1,8,,,H,,3336,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration
13961,,,10623,10116.0,,,BAO_0000019,B,,CHEMBL619037,,,Expert,,1,9,,Rattus norvegicus,D,,3337,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum
6238,,,10623,,,,BAO_0000249,B,2435.0,CHEMBL619038,,,Autocuration,Striatum,1,8,,,H,,3338,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand
14290,,,10623,,,,BAO_0000249,B,,CHEMBL619039,,,Autocuration,,1,8,,,H,,3339,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested
14290,,,10623,,,,BAO_0000249,B,,CHEMBL619040,,,Expert,,1,8,,,H,,3340,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand
809,,,10623,10116.0,,,BAO_0000019,B,2435.0,CHEMBL619041,,,Expert,Striatum,1,9,,Rattus norvegicus,D,,3341,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
1578,,,10623,,,,BAO_0000019,B,2435.0,CHEMBL619042,,,Autocuration,Striatum,1,8,,,H,,3342,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum
16709,,,10623,,,,BAO_0000249,B,2435.0,CHEMBL619043,,,Expert,Striatum,1,8,,,H,,3343,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane
1946,,,10623,,,,BAO_0000019,B,2435.0,CHEMBL619044,,,Expert,Striatum,1,8,,,H,,3344,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.
15253,,,10623,,,,BAO_0000249,B,2435.0,CHEMBL619045,,,Expert,Striatum,1,8,,,H,,3345,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.
4535,,,10623,,,,BAO_0000249,B,2435.0,CHEMBL619046,,,Expert,Striatum,1,8,,,H,,3346,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane
13961,,,10623,,,,BAO_0000249,B,,CHEMBL619047,,,Expert,,1,8,,,H,,3347,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.
17358,,,10623,,,,BAO_0000221,F,955.0,CHEMBL619048,,,Autocuration,Brain,1,8,,,H,,3348,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain
15847,,,10623,,,,BAO_0000019,F,,CHEMBL859398,,,Autocuration,,1,8,,,H,,3349,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat
15847,,,10623,,,,BAO_0000019,F,,CHEMBL619049,,,Autocuration,,1,8,,,H,,3350,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done
670,,,10623,,,,BAO_0000019,F,,CHEMBL857886,,,Autocuration,,1,8,,,H,,3351,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae
670,,,10623,,,,BAO_0000019,F,,CHEMBL619050,,,Autocuration,,1,8,,,H,,3352,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested
1317,,,10623,,,,BAO_0000019,F,,CHEMBL620591,,,Autocuration,,1,8,,,H,,3353,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae
12936,,,10623,10116.0,,,BAO_0000357,B,,CHEMBL620592,,,Expert,,1,9,,Rattus norvegicus,D,,3354,Binding affinity against rat 5-hydroxytryptamine 4 receptor
4535,,,10623,,,,BAO_0000249,B,2435.0,CHEMBL620593,,,Expert,Striatum,1,8,,,H,,3355,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane
14424,,,10623,10116.0,,,BAO_0000019,F,,CHEMBL620594,,,Expert,,1,9,,Rattus norvegicus,D,,3356,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.
14424,,,10623,,,,BAO_0000019,F,,CHEMBL875079,,,Expert,,1,8,,,H,,3357,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.
14424,,,10623,,,,BAO_0000019,F,,CHEMBL620595,,,Expert,,1,8,,,H,,3358,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
14424,,,10623,10116.0,,,BAO_0000019,F,,CHEMBL620596,,,Expert,,1,9,,Rattus norvegicus,D,,3359,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.
14424,,,10623,,,,BAO_0000019,F,,CHEMBL620597,,,Autocuration,,1,8,,,H,,3360,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.
14424,,,10623,,,,BAO_0000019,F,,CHEMBL620598,,,Expert,,1,8,,,H,,3361,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.
14424,,,10623,,,,BAO_0000218,F,,CHEMBL620599,,,Expert,,1,8,,,H,,3362,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.)
14424,,,10623,,,,BAO_0000019,F,,CHEMBL620600,,,Autocuration,,1,8,,,H,,3363,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.
1980,,,168,10116.0,,,BAO_0000019,F,,CHEMBL620601,,,Autocuration,,1,8,,Rattus norvegicus,H,,3364,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae
4639,,,168,,,,BAO_0000019,F,,CHEMBL620602,,,Autocuration,,1,8,,,H,,3365,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM
17358,,,168,,,,BAO_0000357,B,,CHEMBL620603,,,Autocuration,,1,8,,,H,,3366,Tested for affinity towards 5-hydroxytryptamine 4 receptor
17358,,,168,,,,BAO_0000357,B,,CHEMBL620604,,,Autocuration,,1,8,,,H,,3367,Tested for affinity towards 5-hydroxytryptamine 4 receptor.
17358,,,168,,,,BAO_0000357,B,,CHEMBL620605,,,Autocuration,,1,8,,,H,,3368,Compound was tested for 5-hydroxytryptamine 4 binding affinity
1558,,,168,,,,BAO_0000357,B,,CHEMBL620606,,,Autocuration,,1,8,,,H,,3369,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor
17358,,,168,,,,BAO_0000019,F,,CHEMBL620607,,,Autocuration,,1,8,,,H,,3370,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
16117,,,168,,,,BAO_0000357,B,,CHEMBL620608,,,Autocuration,,1,8,,,H,,3371,In vitro binding affinity towards 5-HT4 receptor was determined
17358,,,168,,,,BAO_0000019,F,,CHEMBL620609,,,Autocuration,,1,8,,,H,,3372,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
17358,,,168,,,,BAO_0000019,F,,CHEMBL620610,,,Autocuration,,1,8,,,H,,3373,Tested for agonist activity against 5-hydroxytryptamine 4 receptor
17358,,,168,,,,BAO_0000357,B,,CHEMBL620611,,,Autocuration,,1,8,,,H,,3374,Tested for selectivity for 5-hydroxytryptamine 4 receptor
17358,,,168,,,,BAO_0000357,B,,CHEMBL620612,,,Autocuration,,1,8,,,H,,3375,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride
17358,,,168,,,,BAO_0000357,B,,CHEMBL620613,,,Autocuration,,1,8,,,H,,3376,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride
17358,,,168,,,,BAO_0000357,B,,CHEMBL620614,,,Autocuration,,1,8,,,H,,3377,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride
1274,,,168,,,,BAO_0000357,B,,CHEMBL620615,,,Expert,,1,8,,,H,,3378,Binding affinity against 5-Hydroxytryptamine 4 receptor
10728,,,104698,,,,BAO_0000249,B,,CHEMBL857075,,Brain membranes,Autocuration,,1,6,,,H,,3379,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes
11695,,,104698,,,,BAO_0000249,B,,CHEMBL620616,,Brain membranes,Autocuration,,1,6,,,H,,3380,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes
11695,,,104698,,,,BAO_0000249,B,,CHEMBL619411,,Brain membranes,Autocuration,,1,6,,,H,,3381,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes
12490,,,104698,,,,BAO_0000019,B,,CHEMBL619412,,,Autocuration,,1,6,,,H,,3382,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate
11828,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL619413,,,Autocuration,,1,7,,Rattus norvegicus,D,,3383,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor
12253,,,104698,,,,BAO_0000221,B,10000000.0,CHEMBL619414,,,Autocuration,Hippocampus,1,6,,,H,,3384,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex
10561,,,104698,,,,BAO_0000019,B,,CHEMBL619415,,,Autocuration,,1,6,,,H,,3385,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex
10561,,,104698,,,,BAO_0000019,B,,CHEMBL619416,,,Autocuration,,1,6,,,H,,3386,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex
14432,,,104698,,,,BAO_0000019,F,,CHEMBL619417,,,Autocuration,,1,6,,,H,,3387,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist
12936,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL619418,,,Autocuration,,1,7,,Rattus norvegicus,D,,3388,Binding affinity against rat 5-hydroxytryptamine 3 receptor
1274,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL619419,,,Autocuration,,1,7,,Rattus norvegicus,D,,3389,Binding affinity against 5-Hydroxytryptamine 3 receptor
1980,,,104698,,,,BAO_0000019,B,,CHEMBL619420,,,Autocuration,,1,6,,,H,,3390,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex
670,,,104698,,,,BAO_0000249,B,,CHEMBL619421,,,Autocuration,,1,6,,,H,,3391,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.
968,,,104698,10116.0,,,BAO_0000019,B,,CHEMBL619422,,,Autocuration,,1,7,,Rattus norvegicus,D,,3392,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex
14287,,,104698,,,,BAO_0000019,B,,CHEMBL619423,,,Autocuration,,1,6,,,H,,3393,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex
567,,,104698,,,,BAO_0000019,B,,CHEMBL875080,,,Autocuration,,1,6,,,H,,3394,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex
13267,,,104698,,,,BAO_0000019,B,,CHEMBL619424,,,Autocuration,,1,6,,,H,,3395,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand
14826,,,104698,,,,BAO_0000249,B,,CHEMBL619425,,,Autocuration,,1,6,,,H,,3396,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.
15194,,,104698,,,,BAO_0000223,B,,CHEMBL619426,,,Autocuration,,1,6,,,H,,3397,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand
15194,,,104698,,,,BAO_0000223,B,,CHEMBL619427,,,Autocuration,,1,6,,,H,,3398,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.
10394,,,104698,10116.0,,,BAO_0000223,B,,CHEMBL619645,,,Autocuration,,1,7,,Rattus norvegicus,D,,3399,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor
13657,,,10576,,,,BAO_0000249,B,,CHEMBL619646,,,Expert,,1,9,,,D,,3400,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding"
1879,,,12020,,,,BAO_0000221,F,955.0,CHEMBL619647,,,Autocuration,Brain,1,8,,,H,,3401,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.
1879,,,12020,,,,BAO_0000019,F,,CHEMBL619648,,,Autocuration,,1,8,,,H,,3402,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor
1879,,,12020,,,,BAO_0000019,F,,CHEMBL619165,,,Autocuration,,1,8,,,H,,3403,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.
204,,,12020,,,,BAO_0000218,F,,CHEMBL620719,,,Autocuration,,1,8,,,H,In vivo,3404,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor
1879,,,12020,,,,BAO_0000019,B,,CHEMBL872924,,,Autocuration,,1,8,,,H,,3405,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
1879,,,12020,,,,BAO_0000357,B,,CHEMBL620720,,,Autocuration,,1,8,,,H,,3406,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor
1879,,,12020,,,,BAO_0000019,B,,CHEMBL620721,,,Autocuration,,1,8,,,H,,3407,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.
1879,,,12020,,,,BAO_0000019,B,,CHEMBL620722,,,Autocuration,,1,8,,,H,,3408,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.
10641,,,104698,,,,BAO_0000019,B,,CHEMBL620723,,,Autocuration,,1,6,,,H,,3409,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex"
773,,,12020,,,,BAO_0000019,B,,CHEMBL620724,,,Autocuration,,1,8,,,H,,3410,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates
11952,,,104698,,,,BAO_0000249,B,,CHEMBL620725,,,Autocuration,,1,6,,,H,,3411,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine
14145,,,12020,10116.0,,,BAO_0000019,F,,CHEMBL620726,,,Autocuration,,1,9,,Rattus norvegicus,D,,3412,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.
17066,,,144,,,,BAO_0000357,B,,CHEMBL620727,,,Expert,,1,8,,,H,,3413,Binding affinity towards 5-hydroxytryptamine 3 receptor
6398,,,104714,,,,BAO_0000223,B,,CHEMBL620728,,,Autocuration,,1,4,,,H,,3414,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding
10321,,,22226,,,,BAO_0000019,B,,CHEMBL620729,,,Autocuration,,1,0,,,U,,3415,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
511,,,104714,,,,BAO_0000019,F,,CHEMBL858288,,,Autocuration,,1,4,,,H,,3416,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex
4639,,,104714,,,,BAO_0000223,B,,CHEMBL620730,,,Autocuration,,1,4,,,H,,3417,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor
4639,,,104714,,,,BAO_0000223,B,,CHEMBL620731,,,Autocuration,,1,4,,,H,,3418,Binding affinity towards 5-hydroxytryptamine 3 receptor
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL620732,,,Autocuration,,1,4,,Cavia porcellus,H,,3419,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618042,,,Autocuration,,1,4,,Cavia porcellus,H,,3420,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618043,,,Autocuration,,1,4,,Cavia porcellus,H,,3421,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM
1558,,,104714,,,,BAO_0000223,B,,CHEMBL618044,,,Autocuration,,1,4,,,H,,3422,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
268,,,104714,,,,BAO_0000019,F,,CHEMBL618045,,,Autocuration,,1,4,,,H,,3423,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection
2474,,,104714,,,,BAO_0000223,B,,CHEMBL618046,,,Autocuration,,1,4,,,H,,3424,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand
5067,,,104714,,,,BAO_0000019,F,,CHEMBL618047,,,Autocuration,,1,4,,,H,,3425,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist
5067,,,104714,,,,BAO_0000019,F,,CHEMBL875084,,,Autocuration,,1,4,,,H,,3426,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist
5067,,,104714,,,,BAO_0000019,F,,CHEMBL618048,,,Autocuration,,1,4,,,H,,3427,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist
5067,,,104714,,,,BAO_0000223,B,,CHEMBL618049,,,Autocuration,,1,4,,,H,,3428,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available
5067,,,104714,,,,BAO_0000019,F,,CHEMBL619764,,,Autocuration,,1,4,,,H,,3429,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist
5067,,,104714,,,,BAO_0000019,F,,CHEMBL619765,,,Autocuration,,1,4,,,H,,3430,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist
5067,,,104714,,,,BAO_0000019,F,,CHEMBL619766,,,Autocuration,,1,4,,,H,,3431,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist
5067,,,104714,,,,BAO_0000223,B,,CHEMBL619767,,,Autocuration,,1,4,,,H,,3432,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active
5067,,,104714,,,,BAO_0000223,B,,CHEMBL619768,,,Autocuration,,1,4,,,H,,3433,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available
5067,,,104714,,,,BAO_0000019,F,,CHEMBL619769,,,Autocuration,,1,4,,,H,,3434,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist
5067,,,104714,,,,BAO_0000223,B,,CHEMBL619770,,,Autocuration,,1,4,,,H,,3435,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available
5067,,,104714,,,,BAO_0000223,B,,CHEMBL619771,,,Autocuration,,1,4,,,H,,3436,Binding affinity towards 5-hydroxytryptamine 3 receptor
14331,,,104714,,,,BAO_0000219,B,,CHEMBL619772,,,Autocuration,,1,4,,,H,,3437,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined
5067,,,104714,,,,BAO_0000223,B,,CHEMBL619773,,,Autocuration,,1,4,,,H,,3438,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active
6179,433.0,NG108-15,104714,,,,BAO_0000219,B,,CHEMBL619774,,,Autocuration,,1,4,,,H,,3439,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630
4265,,,104714,,,,BAO_0000019,B,,CHEMBL875083,,,Autocuration,,1,4,,,H,,3440,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.
4265,433.0,NG108-15,104714,,,,BAO_0000219,B,,CHEMBL620718,,,Autocuration,,1,4,,,H,,3441,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand
17358,,,104714,,,,BAO_0000223,B,,CHEMBL618127,,,Autocuration,,1,4,,,H,,3442,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
17358,,,104714,,,,BAO_0000223,B,,CHEMBL618128,,,Autocuration,,1,4,,,H,,3443,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity
13628,,,104714,,,,BAO_0000219,B,,CHEMBL618129,,,Autocuration,,1,4,,,H,In vitro,3444,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells
4612,,,104714,,,,BAO_0000223,B,,CHEMBL618130,,,Autocuration,,1,4,,,H,,3445,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined
17358,,,104714,,,,BAO_0000019,F,,CHEMBL618131,,,Autocuration,,1,4,,,H,,3446,Tested for 5-hydroxytryptamine 3 receptor antagonist activity
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618132,,,Autocuration,,1,4,,Cavia porcellus,H,,3447,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618133,,,Autocuration,,1,4,,Cavia porcellus,H,,3448,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618134,,,Autocuration,,1,4,,Cavia porcellus,H,,3449,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618135,,,Autocuration,,1,4,,Cavia porcellus,H,,3450,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM
511,,,104714,,,,BAO_0000223,B,,CHEMBL618136,,,Autocuration,,1,4,,,H,,3451,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.
1479,,,104714,,,,BAO_0000223,B,,CHEMBL618137,,,Autocuration,,1,4,,,H,,3452,Binding affinity towards 5-hydroxytryptamine 3 receptor
1317,,,104714,,,,BAO_0000223,B,,CHEMBL618138,,,Autocuration,,1,4,,,H,,3453,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay
12146,,,104714,,,,BAO_0000223,B,,CHEMBL618139,,,Autocuration,,1,4,,,H,,3454,Tested against 5-hydroxytryptamine 3 receptor in experiment 1
12146,,,104714,,,,BAO_0000223,B,,CHEMBL618140,,,Autocuration,,1,4,,,H,,3455,Tested against 5-hydroxytryptamine 3 receptor in experiment 2
13969,,,104714,,,,BAO_0000223,B,,CHEMBL618141,,,Autocuration,,1,4,,,H,,3456,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand
13392,,,108,,,,BAO_0000357,B,,CHEMBL873478,,,Expert,,1,8,,,H,,3457,Binding affinity for 5-hydroxytryptamine 2C receptor
13392,,,104698,,,,BAO_0000223,B,,CHEMBL618142,,,Autocuration,,1,6,,,H,,3458,Binding affinity towards 5-hydroxytryptamine 3 receptor
14159,,,144,,,,BAO_0000357,B,,CHEMBL618143,,,Autocuration,,1,8,,,H,,3459,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor
1558,,,144,,,,BAO_0000357,B,,CHEMBL618144,,,Autocuration,,1,8,,,H,,3460,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor
16655,,,144,,,,BAO_0000357,B,,CHEMBL618145,,,Autocuration,,1,8,,,H,,3461,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor
13020,,,104714,,,,BAO_0000223,B,,CHEMBL618146,,,Autocuration,,1,4,,,H,,3462,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
13021,,,104714,,,,BAO_0000223,B,,CHEMBL618147,,,Autocuration,,1,4,,,H,,3463,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system
13020,,,104714,,,,BAO_0000223,B,,CHEMBL618148,,,Autocuration,,1,4,,,H,,3464,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M
10321,,,144,,,,BAO_0000019,B,,CHEMBL618149,,,Autocuration,,1,8,,,H,,3465,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells
15818,,,144,,,,BAO_0000357,B,,CHEMBL872927,,,Autocuration,,1,8,,,H,,3466,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
15818,,,144,,,,BAO_0000357,B,,CHEMBL618150,,,Autocuration,,1,8,,,H,,3467,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor
17358,,,144,,,,BAO_0000357,B,,CHEMBL618151,,,Autocuration,,1,8,,,H,,3468,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity
2222,,,144,,,,BAO_0000357,B,,CHEMBL875094,,,Autocuration,,1,8,,,H,,3469,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor
10322,,,144,,,,BAO_0000019,B,,CHEMBL618152,,,Autocuration,,1,8,,,H,,3470,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells
16117,,,144,,,,BAO_0000357,B,,CHEMBL618153,,,Autocuration,,1,8,,,H,,3471,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined
17200,,,144,,,,BAO_0000357,B,,CHEMBL618888,,,Autocuration,,1,8,,,H,,3472,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand
17358,,,144,,,,BAO_0000019,F,,CHEMBL618889,,,Autocuration,,1,8,,,H,,3473,Tested for 5-hydroxytryptamine 3 receptor agonist activity
16700,,,144,,,,BAO_0000357,B,,CHEMBL618890,,,Autocuration,,1,8,,,H,,3474,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity
1980,,,144,,,,BAO_0000019,B,,CHEMBL618891,,,Autocuration,,1,8,,,H,,3475,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes
1980,,,144,,,,BAO_0000019,B,,CHEMBL619054,,,Autocuration,,1,8,,,H,,3476,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes
12409,,,104714,,,,BAO_0000223,B,,CHEMBL619055,,,Autocuration,,1,4,,,H,,3477,Binding affinity against the 5-hydroxytryptamine 3 receptor
4365,,,144,,,,BAO_0000357,B,,CHEMBL619056,,,Autocuration,,1,8,,,H,,3478,Binding affinity against human 5-hydroxytryptamine 3A receptor
4365,,,144,,,,BAO_0000019,F,,CHEMBL619057,,,Autocuration,,1,8,,,H,,3479,Percent efficacy against 5-hydroxytryptamine 3A receptor
4365,,,144,,,,BAO_0000357,B,,CHEMBL619058,,,Autocuration,,1,8,,,H,,3480,Binding affinity against human 5-hydroxytryptamine 3A receptor
6769,,Oocytes,12020,10116.0,,,BAO_0000219,F,,CHEMBL619059,,,Expert,,1,9,,Rattus norvegicus,D,,3481,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes
6769,,Oocytes,12020,10116.0,,,BAO_0000219,F,,CHEMBL619060,,,Expert,,1,9,,Rattus norvegicus,D,,3482,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes
6769,,Oocytes,12020,10116.0,,,BAO_0000219,F,,CHEMBL875095,,,Expert,,1,9,,Rattus norvegicus,D,,3483,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619061,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3484,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum
809,,,20033,10141.0,,,BAO_0000221,F,2116.0,CHEMBL619062,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3485,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum
14290,,,20033,10141.0,,,BAO_0000019,F,,CHEMBL619063,,,Intermediate,,1,9,,Cavia porcellus,D,,3486,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response
17358,,,20033,10141.0,,,BAO_0000221,B,2116.0,CHEMBL619064,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3487,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum
17358,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL619065,,,Intermediate,,1,9,,Cavia porcellus,D,,3488,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation
17358,,,20033,10141.0,,,BAO_0000221,B,2116.0,CHEMBL619066,,,Intermediate,Ileum,1,9,,Cavia porcellus,D,,3489,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation
17386,,,10209,,,,BAO_0000221,B,2116.0,CHEMBL619775,,,Autocuration,Ileum,1,8,,,H,,3490,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
3269,,,10209,,,,BAO_0000357,B,,CHEMBL619776,,,Autocuration,,1,8,,,H,,3491,Affinity against 5-hydroxytryptamine 7 receptor
7721,,,104841,10141.0,,,BAO_0000224,B,,CHEMBL619777,,,Autocuration,,1,4,,Cavia porcellus,H,,3492,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
7721,,,104841,10141.0,,,BAO_0000224,B,,CHEMBL619778,,,Autocuration,,1,4,,Cavia porcellus,H,,3493,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand
9117,,,104841,10141.0,,,BAO_0000221,B,2116.0,CHEMBL619779,,,Autocuration,Ileum,1,4,,Cavia porcellus,H,,3494,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect
7721,,,104841,10141.0,,,BAO_0000224,B,,CHEMBL619780,,,Autocuration,,1,4,,Cavia porcellus,H,,3495,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd."
7721,,,104841,10141.0,,,BAO_0000224,B,,CHEMBL619166,,,Autocuration,,1,4,,Cavia porcellus,H,,3496,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd."
15796,,,104841,10141.0,,,BAO_0000019,F,,CHEMBL619167,,,Autocuration,,1,4,,Cavia porcellus,H,,3497,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
15796,,,104841,10141.0,,,BAO_0000019,F,,CHEMBL619168,,,Autocuration,,1,4,,Cavia porcellus,H,,3498,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.
15650,,,168,9606.0,,,BAO_0000219,B,2081.0,CHEMBL619169,,,Expert,Cardiac atrium,1,9,,Homo sapiens,D,,3499,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes
15650,,,168,9606.0,,,BAO_0000219,B,2081.0,CHEMBL619170,,,Expert,Cardiac atrium,1,9,,Homo sapiens,D,,3500,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes
6866,,,104841,9606.0,,,BAO_0000019,F,,CHEMBL619171,,,Autocuration,,1,5,,Homo sapiens,D,,3501,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine"
15650,,,168,9606.0,,,BAO_0000219,F,2081.0,CHEMBL619172,,,Expert,Cardiac atrium,1,9,,Homo sapiens,D,,3502,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes"
10063,,,22226,10090.0,,,BAO_0000019,B,,CHEMBL619173,,,Autocuration,,1,0,,Mus musculus,U,,3503,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice
12665,,,22226,10090.0,,,BAO_0000019,B,,CHEMBL619174,,,Autocuration,,1,0,,Mus musculus,U,,3504,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration
7504,,,104705,,,,BAO_0000019,B,,CHEMBL619175,,,Autocuration,,1,4,,,H,,3505,5-hydroxytryptamine receptor binding affinity was determined in rats
7504,,,104705,,,,BAO_0000224,B,,CHEMBL619176,,,Autocuration,,1,4,,,H,,3506,Binding affinity at rat 5-hydroxytryptamine receptor.
7038,,,104705,,,,BAO_0000019,B,,CHEMBL619177,,,Autocuration,,1,4,,,H,,3507,Affinity against 5-hydroxytryptamine receptors in rat fundus model
7626,,,104705,,,,BAO_0000224,B,,CHEMBL619178,,,Autocuration,,1,4,,,H,,3508,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation
7626,,,104705,,,,BAO_0000224,B,,CHEMBL619179,,,Autocuration,,1,4,,,H,,3509,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined
7185,,,104705,,,,BAO_0000019,F,945.0,CHEMBL619180,,,Autocuration,Stomach,1,4,,,H,,3510,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation
7185,,,104705,,,,BAO_0000019,F,945.0,CHEMBL619181,,,Autocuration,Stomach,1,4,,,H,,3511,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).
7185,,,104705,,,,BAO_0000019,F,,CHEMBL619182,,,Autocuration,,1,4,,,H,,3512,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor
6960,,,104705,,,,BAO_0000224,B,,CHEMBL619183,,,Autocuration,,1,4,,,H,,3513,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2
6960,,,104705,,,,BAO_0000224,B,,CHEMBL619184,,,Autocuration,,1,4,,,H,,3514,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot."
12416,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL619185,,,Autocuration,Hippocampus,1,8,,,H,,3515,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus
15753,,,12198,,,,BAO_0000357,B,,CHEMBL619186,,,Expert,,1,8,,,H,,3516,Binding affinity for rat 5-hydroxytryptamine transporter.
8062,,,104705,,,,BAO_0000019,B,,CHEMBL619187,,,Autocuration,,1,4,,,H,,3517,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.
9036,,,104705,10116.0,,,BAO_0000019,B,,CHEMBL619188,,,Autocuration,,1,5,,Rattus norvegicus,D,,3518,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT
15067,,,104705,10116.0,,,BAO_0000224,B,,CHEMBL619189,,,Autocuration,,1,5,,Rattus norvegicus,D,,3519,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor
15753,,,12198,10116.0,,,BAO_0000019,F,955.0,CHEMBL619190,,,Expert,Brain,1,9,,Rattus norvegicus,D,,3520,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum
15753,,,12198,10116.0,,,BAO_0000221,F,2037.0,CHEMBL619191,,,Expert,Cerebellum,1,9,,Rattus norvegicus,D,,3521,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.
15295,,,104705,10116.0,,,BAO_0000019,B,,CHEMBL619192,,,Autocuration,,1,5,,Rattus norvegicus,D,,3522,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M
6347,,,104705,10116.0,,,BAO_0000224,B,,CHEMBL619193,,,Autocuration,,1,5,,Rattus norvegicus,D,,3523,Percent binding affinity against 5-hydroxytryptamine receptor
6763,,,22226,,,,BAO_0000019,B,,CHEMBL619194,,,Autocuration,,1,0,,,U,,3524,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex
12092,,,104705,10116.0,,,BAO_0000224,B,,CHEMBL619195,,,Autocuration,,1,5,,Rattus norvegicus,D,,3525,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.
1579,,,104705,10116.0,,,BAO_0000224,B,,CHEMBL619196,,,Autocuration,,1,5,,Rattus norvegicus,D,,3526,Affinity against 5-hydroxytryptamine receptor was determined
1579,,,104705,10116.0,,,BAO_0000019,B,945.0,CHEMBL619197,,,Autocuration,Stomach,1,5,,Rattus norvegicus,D,,3527,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip
5963,,,121,9606.0,,,BAO_0000219,B,,CHEMBL619198,,,Expert,,1,9,,Homo sapiens,D,In vitro,3528,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
5963,,,121,9606.0,,,BAO_0000219,B,,CHEMBL875081,,,Expert,,1,9,,Homo sapiens,D,In vitro,3529,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT
5030,,,18065,,,,BAO_0000357,B,,CHEMBL884712,,,Autocuration,,1,8,,,H,,3530,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete
15796,,,121,,,,BAO_0000357,B,,CHEMBL884710,,,Expert,,1,8,,,H,,3531,Inhibition of 5-hydroxytryptamine reuptake
15413,,,18065,,,,BAO_0000019,F,,CHEMBL619199,,,Autocuration,,1,8,,,H,,3532,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding"
15413,,,18065,,,,BAO_0000019,F,,CHEMBL619200,,,Autocuration,,1,8,,,H,,3533,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)"
15413,,,18065,,,,BAO_0000019,F,,CHEMBL619201,,,Autocuration,,1,8,,,H,,3534,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)"
12409,,,18065,,,,BAO_0000019,F,,CHEMBL619202,,,Autocuration,,1,8,,,H,,3535,Tested for 5-hydroxytryptamine receptor uptake
16909,449.0,CHO,51,9606.0,,,BAO_0000219,B,,CHEMBL619203,,,Expert,,1,9,,Homo sapiens,D,,3536,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A
16909,,,51,9606.0,,,BAO_0000019,F,,CHEMBL619204,,,Expert,,1,9,,Homo sapiens,D,,3537,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype
15629,,,10576,9606.0,,,BAO_0000249,B,,CHEMBL619205,,,Autocuration,,1,8,,Homo sapiens,H,,3538,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.
15629,,,10576,,,,BAO_0000357,B,,CHEMBL619206,,,Autocuration,,1,8,,,H,,3539,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A
15629,,,10576,,,,BAO_0000249,B,,CHEMBL619207,,,Expert,,1,8,,,H,,3540,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL619208,,,Autocuration,Striatum,1,8,,,H,,3541,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL619209,,,Autocuration,Striatum,1,8,,,H,,3542,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL619210,,,Autocuration,Striatum,1,8,,,H,,3543,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL619211,,,Autocuration,Striatum,1,8,,,H,,3544,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL619212,,,Autocuration,Striatum,1,8,,,H,,3545,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL620681,,,Autocuration,Striatum,1,8,,,H,,3546,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL620682,,,Autocuration,Striatum,1,8,,,H,,3547,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL620683,,,Autocuration,Striatum,1,8,,,H,,3548,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL620684,,,Autocuration,Striatum,1,8,,,H,,3549,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL620685,,,Autocuration,Striatum,1,8,,,H,,3550,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg
10034,,,10825,,,,BAO_0000019,F,2435.0,CHEMBL620686,,,Autocuration,Striatum,1,8,,,H,,3551,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620687,,,Autocuration,Limbic system,1,8,,,H,,3552,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620688,,,Autocuration,Limbic system,1,8,,,H,,3553,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620689,,,Autocuration,Limbic system,1,8,,,H,,3554,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620690,,,Autocuration,Limbic system,1,8,,,H,,3555,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620691,,,Autocuration,Limbic system,1,8,,,H,,3556,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620692,,,Autocuration,Limbic system,1,8,,,H,,3557,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL620693,,,Autocuration,Limbic system,1,8,,,H,,3558,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg
1274,,,168,,,,BAO_0000357,B,,CHEMBL620694,,,Expert,,1,8,,,H,,3559,Binding affinity against 5-hydroxytryptamine 4 receptor
17358,,,168,,,,BAO_0000019,F,,CHEMBL857986,,,Autocuration,,1,8,,,H,,3560,Tested for 5-hydroxytryptamine 4 receptor antagonist activity
14532,,,168,,,,BAO_0000357,B,,CHEMBL620695,,,Autocuration,,1,8,,,H,,3561,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration
16989,,,168,,,,BAO_0000357,B,,CHEMBL620696,,,Expert,,1,8,,,H,,3562,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor
17200,,,168,,,,BAO_0000357,B,,CHEMBL620697,,,Autocuration,,1,8,,,H,,3563,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand
15779,,,168,,,,BAO_0000357,B,,CHEMBL620698,,,Autocuration,,1,8,,,H,,3564,Binding affinity towards 5-hydroxytryptamine 4 receptor
15779,,,168,,,,BAO_0000357,B,,CHEMBL620699,,,Autocuration,,1,8,,,H,,3565,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
15779,,,168,,,,BAO_0000357,B,,CHEMBL620700,,,Autocuration,,1,8,,,H,,3566,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.
15650,643.0,COS-7,168,,,,BAO_0000219,B,,CHEMBL620701,,,Autocuration,,1,8,,,H,,3567,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells
15650,643.0,COS-7,168,,,,BAO_0000219,B,,CHEMBL875082,,,Autocuration,,1,8,,,H,,3568,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells
15650,643.0,COS-7,168,,,,BAO_0000219,B,,CHEMBL620702,,,Autocuration,,1,8,,,H,,3569,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells
15650,643.0,COS-7,168,,,,BAO_0000219,B,,CHEMBL620703,,,Autocuration,,1,8,,,H,,3570,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells
17046,673.0,C6,168,,,,BAO_0000219,B,,CHEMBL620704,,,Autocuration,,1,8,,,H,,3571,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
17046,673.0,C6,168,,,,BAO_0000219,B,,CHEMBL620705,,,Expert,,1,8,,,H,,3572,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand
15650,673.0,C6,168,,,,BAO_0000219,B,,CHEMBL620706,,,Expert,,1,8,,,H,,3573,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808
17046,673.0,C6,168,,,,BAO_0000219,B,,CHEMBL620707,,,Expert,,1,8,,,H,,3574,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined
17066,,,10624,,,,BAO_0000357,B,,CHEMBL620708,,,Expert,,1,8,,,H,,3575,Binding affinity towards 5-hydroxytryptamine 5 receptor
17200,,,105,,,,BAO_0000357,B,,CHEMBL620709,,,Autocuration,,1,8,,,H,,3576,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand
16146,,,10624,9606.0,,,BAO_0000357,B,,CHEMBL620710,,,Expert,,1,9,,Homo sapiens,D,,3577,Binding affinity against 5-hydroxytryptamine 5A receptor
15250,449.0,CHO,10624,,,,BAO_0000219,B,,CHEMBL620711,,,Autocuration,,1,8,,,H,,3578,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells
6491,,,10624,9606.0,,,BAO_0000357,B,,CHEMBL620712,,,Expert,,1,9,,Homo sapiens,D,,3579,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor
17066,,,10624,9606.0,,,BAO_0000357,B,,CHEMBL620713,,,Expert,,1,9,,Homo sapiens,D,,3580,Binding affinity towards human 5-hydroxytryptamine 5A receptor
17066,,,10624,9606.0,,,BAO_0000357,B,,CHEMBL620714,,,Expert,,1,9,,Homo sapiens,D,,3581,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand
4234,,,10624,9606.0,,,BAO_0000357,B,,CHEMBL620715,,,Expert,,1,9,,Homo sapiens,D,,3582,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor
6013,,,10624,,,,BAO_0000357,B,,CHEMBL620716,,,Autocuration,,1,8,,,H,,3583,Binding affinity towards 5-HT5A receptor
17175,,,10624,,,,BAO_0000357,B,,CHEMBL620717,,,Expert,,1,8,,,H,,3584,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand
15818,,,10624,,,,BAO_0000357,B,,CHEMBL618072,,,Autocuration,,1,8,,,H,,3585,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor
6166,,,10624,,,,BAO_0000357,B,,CHEMBL857987,,,Autocuration,,1,8,,,H,,3586,Binding affinity towards cloned human 5-HT5A receptor was determined
15779,722.0,HEK293,10624,,,,BAO_0000219,B,,CHEMBL618073,,,Autocuration,,1,8,,,H,,3587,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
15779,722.0,HEK293,10624,,,,BAO_0000219,B,,CHEMBL618074,,,Autocuration,,1,8,,,H,,3588,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
5213,722.0,HEK293,10624,,,,BAO_0000219,B,,CHEMBL618075,,,Autocuration,,1,8,,,H,,3589,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand )
17066,,,10625,10090.0,,,BAO_0000357,B,,CHEMBL618076,,,Expert,,1,9,,Mus musculus,D,,3590,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor
17066,,,10625,10090.0,,,BAO_0000357,B,,CHEMBL618077,,,Expert,,1,9,,Mus musculus,D,,3591,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand
17066,,,10625,10090.0,,,BAO_0000357,B,,CHEMBL618078,,,Expert,,1,9,,Mus musculus,D,,3592,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand
17066,,,10625,10090.0,,,BAO_0000357,B,,CHEMBL881821,,,Expert,,1,9,,Mus musculus,D,,3593,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand
17066,,,10625,10090.0,,,BAO_0000357,B,,CHEMBL618079,,,Expert,,1,9,,Mus musculus,D,,3594,Binding affinity towards murine 5-hydroxytryptamine 5A receptor
17175,,,10625,,,,BAO_0000357,B,,CHEMBL618080,,,Expert,,1,8,,,H,,3595,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand
16190,722.0,HEK293,10576,,,,BAO_0000219,B,,CHEMBL618081,,,Autocuration,,1,8,,,H,,3596,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
16190,722.0,HEK293,10626,,,,BAO_0000219,B,,CHEMBL618082,,,Autocuration,,1,8,,,H,,3597,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand
4820,,,10624,,,,BAO_0000357,B,,CHEMBL618083,,,Expert,,1,8,,,H,,3598,Binding affinity towards 5-HT5a receptor
17066,,,10624,9606.0,,,BAO_0000357,B,,CHEMBL618084,,,Expert,,1,9,,Homo sapiens,D,,3599,Binding affinity towards 5-hydroxytryptamine 5A receptor
17066,,,10624,,,,BAO_0000357,B,,CHEMBL618085,,,Expert,,1,8,,,H,,3600,Binding affinity for rodent 5-hydroxytryptamine 5A receptor
17175,,,10624,,,,BAO_0000357,B,,CHEMBL618086,,,Expert,,1,8,,,H,,3601,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand
16633,,,10624,,,,BAO_0000357,B,,CHEMBL875092,,,Autocuration,,1,8,,,H,,3602,Binding affinities against 5-hydroxytryptamine 5A receptor
16633,,,10624,,,,BAO_0000357,B,,CHEMBL618087,,,Autocuration,,1,8,,,H,,3603,Binding affinities towards 5-hydroxytryptamine 5A receptor
16700,,,10624,,,,BAO_0000357,B,,CHEMBL872926,,,Autocuration,,1,8,,,H,,3604,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity
4639,,,104714,10141.0,,,BAO_0000019,F,,CHEMBL618088,,,Autocuration,,1,4,,Cavia porcellus,H,,3605,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM
5486,,,104714,,,,BAO_0000223,B,,CHEMBL618089,,,Autocuration,,1,4,,,H,,3606,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell
16146,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618090,,,Expert,,1,9,,Homo sapiens,D,,3607,Inhibition of human 5-hydroxytryptamine 6 receptor
17273,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618091,,,Expert,,1,9,,Homo sapiens,D,,3608,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand
17687,,,10627,,,,BAO_0000357,B,,CHEMBL618092,,,Autocuration,,1,8,,,H,,3609,Inhibition against human 5-hydroxytryptamine 6 receptor
6491,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618093,,,Expert,,1,9,,Homo sapiens,D,,3610,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor
16190,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL618094,,,Expert,,1,8,,,H,,3611,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.
17066,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618095,,,Expert,,1,9,,Homo sapiens,D,,3612,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor
17066,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL875093,,,Expert,,1,9,,Homo sapiens,D,,3613,Binding affinity towards human 5-hydroxytryptamine 6 receptor
17066,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618096,,,Expert,,1,9,,Homo sapiens,D,,3614,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand
17066,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618118,,,Expert,,1,9,,Homo sapiens,D,,3615,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand
3555,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618119,,,Expert,,1,9,,Homo sapiens,D,,3616,Binding affinity against 5-hydroxytryptamine 6 receptor
5808,,,10627,,,,BAO_0000357,B,,CHEMBL618120,,,Expert,,1,8,,,H,,3617,Binding affinity towards human 5-hydroxytryptamine 6 receptor
6013,,,10627,,,,BAO_0000357,B,,CHEMBL618121,,,Autocuration,,1,8,,,H,,3618,Binding affinity towards human 5-hydroxytryptamine 6 receptor
15818,722.0,HEK293,10627,,,,BAO_0000219,B,,CHEMBL618122,,,Expert,,1,8,,,H,,3619,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand"
16209,,,10627,,,,BAO_0000357,B,,CHEMBL618123,,,Autocuration,,1,8,,,H,,3620,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand
3935,722.0,HEK293,10627,,,,BAO_0000219,B,,CHEMBL618124,,,Expert,,1,8,,,H,,3621,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand
15818,,,10627,,,,BAO_0000357,B,,CHEMBL618125,,,Autocuration,,1,8,,,H,,3622,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor
3805,722.0,HEK293,10627,9606.0,,,BAO_0000219,B,,CHEMBL618126,,,Expert,,1,9,,Homo sapiens,D,,3623,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
16441,,,10627,,,,BAO_0000019,B,,CHEMBL618236,,,Expert,,1,8,,,H,,3624,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD
16441,,,10627,,,,BAO_0000019,B,,CHEMBL618237,,,Expert,,1,8,,,H,,3625,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.
6786,643.0,COS-7,10627,,,,BAO_0000219,B,,CHEMBL618238,,,Expert,,1,8,,,H,,3626,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells
4234,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL618239,,,Expert,,1,9,,Homo sapiens,D,,3627,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor
17085,,,10627,,,,BAO_0000019,B,,CHEMBL618240,,,Autocuration,,1,8,,,H,,3628,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor
17200,,,10627,,,,BAO_0000357,B,,CHEMBL618241,,,Autocuration,,1,8,,,H,,3629,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand
17451,722.0,HEK293,10627,,,,BAO_0000219,B,,CHEMBL859399,,,Autocuration,,1,8,,,H,,3630,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells
3935,,,10627,,,,BAO_0000019,F,,CHEMBL618242,,,Autocuration,,1,8,,,H,,3631,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase
5033,,,10627,,,,BAO_0000357,B,,CHEMBL857991,,,Autocuration,,1,8,,,H,,3632,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor
4540,,,10627,,,,BAO_0000357,B,,CHEMBL619951,,,Expert,,1,8,,,H,,3633,Binding affinity against human 5-hydroxytryptamine 6 receptor
4540,308.0,HeLa,10627,9606.0,,,BAO_0000219,B,,CHEMBL619952,,,Expert,,1,9,,Homo sapiens,D,,3634,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand
4540,308.0,HeLa,10627,9606.0,,,BAO_0000219,B,,CHEMBL619953,,,Expert,,1,9,,Homo sapiens,D,,3635,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand
17296,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL619954,,,Autocuration,,1,8,,,H,,3636,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells
17296,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL619955,,,Autocuration,,1,8,,,H,,3637,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
17296,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL619956,,,Autocuration,,1,8,,,H,,3638,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand
15779,449.0,CHO,10627,,,,BAO_0000219,B,,CHEMBL619957,,,Autocuration,,1,8,,,H,,3639,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand
15779,722.0,HEK293,10627,,,,BAO_0000219,B,,CHEMBL619958,,,Autocuration,,1,8,,,H,,3640,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.
15779,722.0,HEK293,10627,,,,BAO_0000219,B,,CHEMBL620627,,,Autocuration,,1,8,,,H,,3641,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.
15779,722.0,HEK293,10627,,,,BAO_0000219,B,,CHEMBL620628,,,Autocuration,,1,8,,,H,,3642,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.
15779,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620629,,,Autocuration,,1,8,,,H,,3643,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.
6166,,,10627,,,,BAO_0000357,B,,CHEMBL620630,,,Autocuration,,1,8,,,H,,3644,Binding affinity towards human 5-hydroxytryptamine 6 receptor
17451,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620782,,,Autocuration,,1,8,,,H,,3645,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand
15316,,,10627,,,,BAO_0000357,B,,CHEMBL620783,,,Autocuration,,1,8,,,H,,3646,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor
4199,,,10627,,,,BAO_0000357,B,,CHEMBL620784,,,Expert,,1,8,,,H,,3647,Binding affinity against human 5-hydroxytryptamine 6 receptor
15146,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620785,,,Expert,,1,8,,,H,,3648,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD
5213,,,10627,,,,BAO_0000357,B,,CHEMBL857992,,,Autocuration,,1,8,,,H,,3649,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand )
16429,,,10627,,,,BAO_0000219,B,,CHEMBL620786,,,Autocuration,,1,8,,,H,,3650,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand
14818,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620787,,,Autocuration,,1,8,,,H,,3651,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.
4829,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620788,,,Autocuration,,1,8,,,H,,3652,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3"
4829,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620789,,,Autocuration,,1,8,,,H,,3653,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9"
4829,308.0,HeLa,10627,,,,BAO_0000219,B,,CHEMBL620790,,,Autocuration,,1,8,,,H,,3654,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3"
15250,449.0,CHO,10628,,,,BAO_0000219,B,,CHEMBL620791,,,Autocuration,,1,8,,,H,,3655,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells
14423,,,10628,,,,BAO_0000019,B,,CHEMBL620792,,,Autocuration,,1,8,,,H,,3656,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.
15086,,,10628,,,,BAO_0000357,B,,CHEMBL620793,,,Autocuration,,1,8,,,H,,3657,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor
4342,,,10628,,,,BAO_0000357,B,,CHEMBL620794,,,Autocuration,,1,8,,,H,,3658,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined
16190,308.0,HeLa,10627,9606.0,,,BAO_0000219,B,,CHEMBL620795,,,Autocuration,,1,9,,Homo sapiens,D,,3659,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells
4820,,,10627,,,,BAO_0000357,B,,CHEMBL620796,,,Expert,,1,8,,,H,,3660,Binding affinity towards human 5-hydroxytryptamine 6 receptor
4639,,,10627,,,,BAO_0000357,B,,CHEMBL620797,,,Autocuration,,1,8,,,H,,3661,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M
17066,,,10627,9606.0,,,BAO_0000019,F,,CHEMBL620798,,,Expert,,1,9,,Homo sapiens,D,,3662,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
6011,,,10627,,,,BAO_0000357,B,,CHEMBL620799,,,Autocuration,,1,8,,,H,,3663,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration
17066,,,10627,,,,BAO_0000357,B,,CHEMBL620800,,,Expert,,1,8,,,H,,3664,Binding affinity towards human 5-hydroxytryptamine 6 receptor
17515,,,10627,,,,BAO_0000357,B,,CHEMBL620801,,,Autocuration,,1,8,,,H,,3665,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM
5014,,,10627,,,,BAO_0000357,B,,CHEMBL875100,,,Autocuration,,1,8,,,H,,3666,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor
4373,,,10627,,,,BAO_0000357,B,,CHEMBL620802,,,Autocuration,,1,8,,,H,,3667,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined
17066,,,10627,,,,BAO_0000019,F,,CHEMBL620803,,,Expert,,1,8,,,H,,3668,Antagonistic activity towards 5-hydroxytryptamine 6 receptor
17066,,,10627,,,,BAO_0000019,F,,CHEMBL620804,,,Expert,,1,8,,,H,,3669,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay
4373,,,10627,,,,BAO_0000357,B,,CHEMBL620805,,,Autocuration,,1,8,,,H,,3670,Binding affinity for 5-hydroxytryptamine 6 receptor was determined
4687,,,10627,,,,BAO_0000357,B,,CHEMBL620806,,,Autocuration,,1,8,,,H,,3671,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor
16946,,,10627,,,,BAO_0000357,B,,CHEMBL620807,,,Autocuration,,1,8,,,H,,3672,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M
16946,,,10627,,,,BAO_0000357,B,,CHEMBL620808,,,Autocuration,,1,8,,,H,,3673,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M
16633,,,10627,,,,BAO_0000357,B,,CHEMBL620809,,,Autocuration,,1,8,,,H,,3674,Binding affinities against 5-hydroxytryptamine 6 receptor
16633,,,10627,,,,BAO_0000357,B,,CHEMBL620810,,,Autocuration,,1,8,,,H,,3675,Binding affinities towards 5-hydroxytryptamine 6 receptor
17066,,,10627,9606.0,,,BAO_0000357,B,,CHEMBL620811,,,Expert,,1,9,,Homo sapiens,D,,3676,Binding affinity towards 5-hydroxytryptamine 6 receptor
16700,,,10627,,,,BAO_0000357,B,,CHEMBL620812,,,Autocuration,,1,8,,,H,,3677,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity
3269,,,10627,,,,BAO_0000357,B,,CHEMBL620813,,,Autocuration,,1,8,,,H,,3678,Affinity against 5-hydroxytryptamine 6 receptor
5486,,,10627,,,,BAO_0000357,B,,CHEMBL620814,,,Autocuration,,1,8,,,H,,3679,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT]
16146,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL620815,,,Expert,,1,9,,Homo sapiens,D,,3680,Inhibition of human 5-hydroxytryptamine 7 receptor
5014,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL620816,,,Autocuration,,1,8,,,H,,3681,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD
15463,,,10209,,,,BAO_0000357,B,,CHEMBL620817,,,Autocuration,,1,8,,,H,,3682,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor
3805,,,10209,,,,BAO_0000357,B,,CHEMBL620818,,,Autocuration,,1,8,,,H,,3683,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM)
5014,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL620819,,,Expert,,1,8,,,H,,3684,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells
6491,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL620820,,,Expert,,1,9,,Homo sapiens,D,,3685,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor
16190,449.0,CHO,10209,,,,BAO_0000219,B,,CHEMBL620821,,,Autocuration,,1,8,,,H,,3686,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT
17066,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL620822,,,Expert,,1,9,,Homo sapiens,D,,3687,Binding affinity towards human 5-hydroxytryptamine 7 receptor
17066,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL620823,,,Expert,,1,9,,Homo sapiens,D,,3688,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor
3555,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL620824,,,Expert,,1,9,,Homo sapiens,D,,3689,Binding affinity against 5-hydroxytryptamine 7 receptor
6588,449.0,CHO,10209,,,,BAO_0000219,B,,CHEMBL620825,,,Expert,,1,8,,,H,,3690,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells
15463,,,10209,,,,BAO_0000357,B,,CHEMBL872930,,,Autocuration,,1,8,,,H,,3691,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand
6013,,,10209,,,,BAO_0000357,B,,CHEMBL620826,,,Autocuration,,1,8,,,H,,3692,Binding affinity towards 5-hydroxytryptamine 7 receptor
16209,,,10209,,,,BAO_0000357,B,,CHEMBL620827,,,Autocuration,,1,8,,,H,,3693,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
3935,,,10209,,,,BAO_0000357,B,,CHEMBL620828,,,Autocuration,,1,8,,,H,,3694,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor
15818,,,10209,,,,BAO_0000357,B,,CHEMBL620829,,,Autocuration,,1,8,,,H,,3695,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor
5014,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL620830,,,Expert,,1,8,,,H,,3696,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD
16441,,,10209,,,,BAO_0000019,B,,CHEMBL620831,,,Expert,,1,8,,,H,,3697,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD
16441,,,10209,,,,BAO_0000019,B,,CHEMBL620832,,,Expert,,1,8,,,H,,3698,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.
4234,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL621548,,,Expert,,1,9,,Homo sapiens,D,,3699,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor
17085,,,10209,,,,BAO_0000019,B,,CHEMBL621549,,,Autocuration,,1,8,,,H,,3700,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor
17200,,,10209,,,,BAO_0000357,B,,CHEMBL621550,,,Autocuration,,1,8,,,H,,3701,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand
17451,449.0,CHO,10209,,,,BAO_0000219,B,,CHEMBL621551,,,Autocuration,,1,8,,,H,,3702,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined
17085,,,10209,,,,BAO_0000019,B,,CHEMBL621552,,,Autocuration,,1,8,,,H,,3703,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined
5104,,,10209,,,,BAO_0000357,B,,CHEMBL857077,,,Autocuration,,1,8,,,H,,3704,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor
5104,,,10209,,,,BAO_0000357,B,,CHEMBL618158,,,Autocuration,,1,8,,,H,,3705,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested
5033,643.0,COS-7,10209,9606.0,,,BAO_0000219,B,,CHEMBL618159,,,Expert,,1,9,,Homo sapiens,D,,3706,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
5486,643.0,COS-7,10209,,,,BAO_0000219,B,,CHEMBL875101,,,Autocuration,,1,8,,,H,,3707,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells
4540,722.0,HEK293,10209,9606.0,,,BAO_0000219,B,,CHEMBL618160,,,Expert,,1,9,,Homo sapiens,D,,3708,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand
6166,,,10209,,,,BAO_0000357,B,,CHEMBL618161,,,Expert,,1,8,,,H,,3709,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.
17342,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL618162,,,Expert,,1,8,,,H,,3710,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand
17342,,,10209,,,,BAO_0000357,B,,CHEMBL618163,,,Expert,,1,8,,,H,,3711,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand
17296,,,10209,,,,BAO_0000357,B,,CHEMBL618164,,,Autocuration,,1,8,,,H,,3712,Binding affinity against 5-hydroxytryptamine 7 human receptors
16429,,,10209,,,,BAO_0000219,B,,CHEMBL618165,,,Expert,,1,8,,,H,,3713,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand
15779,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL618166,,,Autocuration,,1,8,,,H,,3714,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.
15779,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL857989,,,Autocuration,,1,8,,,H,,3715,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
15779,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619888,,,Autocuration,,1,8,,,H,,3716,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
15779,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619889,,,Autocuration,,1,8,,,H,,3717,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.
15779,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619890,,,Autocuration,,1,8,,,H,,3718,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.
17451,449.0,CHO,10209,,,,BAO_0000219,B,,CHEMBL619891,,,Autocuration,,1,8,,,H,,3719,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand
4199,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619892,,,Autocuration,,1,8,,,H,,3720,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3)
4199,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619893,,,Expert,,1,9,,,D,,3721,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells
4199,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619894,,,Autocuration,,1,8,,,H,,3722,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6)
3680,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619895,,,Intermediate,,1,9,,,D,,3723,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells
3680,,,10209,,,,BAO_0000357,B,,CHEMBL619896,,,Intermediate,,1,9,,,D,,3724,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand
15316,643.0,COS-7,10209,,,,BAO_0000219,B,,CHEMBL619897,,,Autocuration,,1,8,,,H,,3725,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.
15146,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619898,,,Autocuration,,1,8,,,H,,3726,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT
5213,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619899,,,Expert,,1,8,,,H,,3727,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand
5213,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL619900,,,Autocuration,,1,8,,,H,,3728,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand )
14818,722.0,HEK293,10209,9606.0,,,BAO_0000219,B,,CHEMBL619901,,,Expert,,1,9,,Homo sapiens,D,,3729,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT
14818,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL620580,,,Autocuration,,1,8,,,H,,3730,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. 
14818,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL620581,,,Autocuration,,1,8,,,H,,3731,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.
4829,722.0,HEK293,10209,,,,BAO_0000219,B,,CHEMBL620733,,,Autocuration,,1,8,,,H,,3732,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand"
17200,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL620734,,,Autocuration,,1,9,,Homo sapiens,D,,3733,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined
17066,,,10022,10090.0,,,BAO_0000357,B,,CHEMBL620735,,,Expert,,1,9,,Mus musculus,D,,3734,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
14025,,,10209,9986.0,,,BAO_0000019,B,,CHEMBL620736,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,3735,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.
15250,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620737,,,Autocuration,,1,8,,,H,,3736,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620738,,,Autocuration,,1,8,,,H,,3737,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620739,,,Autocuration,,1,8,,,H,,3738,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620740,,,Autocuration,,1,8,,,H,,3739,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620741,,,Autocuration,,1,8,,,H,,3740,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620742,,,Autocuration,,1,8,,,H,,3741,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620743,,,Autocuration,,1,8,,,H,,3742,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620744,,,Autocuration,,1,8,,,H,,3743,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620745,,,Autocuration,,1,8,,,H,,3744,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620746,,,Autocuration,,1,8,,,H,,3745,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620747,,,Autocuration,,1,8,,,H,,3746,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620748,,,Autocuration,,1,8,,,H,,3747,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620749,,,Autocuration,,1,8,,,H,,3748,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.
17066,,,11923,,,,BAO_0000357,B,,CHEMBL620750,,,Expert,,1,8,,,H,,3749,Binding affinity towards rat 5-hydroxytryptamine 7 receptor
17066,,,11923,10116.0,,,BAO_0000357,B,,CHEMBL620751,,,Expert,,1,9,,Rattus norvegicus,D,,3750,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand
17386,,,11923,,,,BAO_0000357,B,,CHEMBL620752,,,Expert,,1,8,,,H,,3751,Binding affinity to the rat 5-hydroxytryptamine 7 receptor
14423,,,11923,,,,BAO_0000019,B,,CHEMBL872929,,,Autocuration,,1,8,,,H,,3752,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.
15874,,,11923,10116.0,,,BAO_0000357,B,,CHEMBL620753,,,Expert,,1,9,,Rattus norvegicus,D,,3753,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT
15874,,,11923,10116.0,,,BAO_0000357,B,,CHEMBL620754,,,Expert,,1,9,,Rattus norvegicus,D,,3754,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor
16372,449.0,CHO,11923,10116.0,,,BAO_0000219,B,,CHEMBL620755,,,Expert,,1,9,,Rattus norvegicus,D,,3755,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells
4622,,,11923,,,,BAO_0000357,B,,CHEMBL620756,,,Autocuration,,1,8,,,H,,3756,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand
15086,,,11923,,,,BAO_0000357,B,,CHEMBL620757,,,Autocuration,,1,8,,,H,,3757,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620758,,,Autocuration,,1,8,,,H,,3758,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested"
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620759,,,Autocuration,,1,8,,,H,,3759,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested"
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620760,,,Autocuration,,1,8,,,H,,3760,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested
16372,449.0,CHO,11923,,,,BAO_0000219,B,,CHEMBL620761,,,Autocuration,,1,8,,,H,,3761,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested
17386,,,11923,,,,BAO_0000221,F,2116.0,CHEMBL620762,,,Autocuration,Ileum,1,8,,,H,,3762,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
17386,,,11923,,,,BAO_0000221,F,2116.0,CHEMBL620763,,,Autocuration,Ileum,1,8,,,H,,3763,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization
17386,,,11923,,,,BAO_0000221,F,2116.0,CHEMBL620764,,,Autocuration,Ileum,1,8,,,H,,3764,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization
5831,,,11923,10116.0,,,BAO_0000249,B,,CHEMBL857990,,Membranes,Expert,,1,9,,Rattus norvegicus,D,,3765,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes
4342,,,11923,,,,BAO_0000357,B,,CHEMBL620765,,,Autocuration,,1,8,,,H,,3766,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined
17319,,,11923,,,,BAO_0000357,B,,CHEMBL620766,,,Expert,,1,8,,,H,,3767,Binding affinity at rat 5-hydroxytryptamine 7 receptor.
17342,,,11923,,,,BAO_0000019,B,1898.0,CHEMBL620767,,,Expert,Hypothalamus,1,8,,,H,,3768,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.
17342,,,11923,,,,BAO_0000357,B,,CHEMBL620768,,,Autocuration,,1,8,,,H,,3769,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand
3680,,,11923,,,,BAO_0000249,B,1898.0,CHEMBL619051,,,Expert,Hypothalamus,1,8,,,H,,3770,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes
3680,,,11923,,,,BAO_0000357,B,,CHEMBL619052,,,Expert,,1,8,,,H,,3771,Binding affinity towards 5-hydroxytryptamine 7 receptor
17319,722.0,HEK293,11923,10116.0,,,BAO_0000219,F,,CHEMBL619053,,,Expert,,1,9,,Rattus norvegicus,D,,3772,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells
17319,722.0,HEK293,11923,10116.0,,,BAO_0000219,F,,CHEMBL619703,,,Expert,,1,9,,Rattus norvegicus,D,,3773,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active
17319,722.0,HEK293,11923,10116.0,,,BAO_0000219,F,,CHEMBL619704,,,Autocuration,,1,9,,Rattus norvegicus,D,,3774,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active
4820,,,10209,,,,BAO_0000357,B,,CHEMBL619851,,,Expert,,1,8,,,H,,3775,Binding affinity towards 5-hydroxytryptamine 7 receptor
4639,,,10209,,,,BAO_0000357,B,,CHEMBL619852,,,Autocuration,,1,8,,,H,,3776,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M
6011,,,10209,,,,BAO_0000357,B,,CHEMBL619853,,,Autocuration,,1,8,,,H,,3777,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration
17066,,,10209,9606.0,,,BAO_0000357,B,,CHEMBL619854,,,Expert,,1,9,,Homo sapiens,D,,3778,Binding affinity towards human 5-hydroxytryptamine 7 receptor
17066,,,10209,,,,BAO_0000357,B,,CHEMBL619855,,,Expert,,1,8,,,H,,3779,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor
17515,,,10209,,,,BAO_0000357,B,,CHEMBL619856,,,Autocuration,,1,8,,,H,,3780,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM
4373,,,10209,,,,BAO_0000357,B,,CHEMBL619857,,,Autocuration,,1,8,,,H,,3781,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
17066,,,10209,,,,BAO_0000019,F,,CHEMBL619858,,,Expert,,1,8,,,H,,3782,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay
4373,,,10209,,,,BAO_0000357,B,,CHEMBL619859,,,Autocuration,,1,8,,,H,,3783,Binding affinity for 5-hydroxytryptamine 7 receptor was determined
4373,,,10209,,,,BAO_0000357,B,,CHEMBL619860,,,Autocuration,,1,8,,,H,,3784,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined
4687,,,10209,,,,BAO_0000357,B,,CHEMBL619861,,,Autocuration,,1,8,,,H,,3785,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor
17342,,,10209,,,,BAO_0000357,B,,CHEMBL619862,,,Expert,,1,8,,,H,,3786,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor
16946,,,10209,,,,BAO_0000357,B,,CHEMBL619863,,,Autocuration,,1,8,,,H,,3787,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M
16946,,,10209,,,,BAO_0000357,B,,CHEMBL619864,,,Autocuration,,1,8,,,H,,3788,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M
16633,,,10209,,,,BAO_0000357,B,,CHEMBL872928,,,Autocuration,,1,8,,,H,,3789,Binding affinities against 5-hydroxytryptamine 7 receptor
16633,,,10209,,,,BAO_0000357,B,,CHEMBL619865,,,Autocuration,,1,8,,,H,,3790,Binding affinities towards 5-hydroxytryptamine 7 receptor
17066,,,10209,,,,BAO_0000357,B,,CHEMBL619866,,,Expert,,1,8,,,H,,3791,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor
16700,,,10209,,,,BAO_0000357,B,,CHEMBL619867,,,Autocuration,,1,8,,,H,,3792,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity
17386,,,10209,,,,BAO_0000221,B,2116.0,CHEMBL619868,,,Autocuration,Ileum,1,8,,,H,,3793,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization
14080,,,55,,,,BAO_0000019,F,,CHEMBL619869,,,Autocuration,,1,8,,,H,,3794,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay
14080,,,55,9606.0,,,BAO_0000019,F,,CHEMBL619870,,,Expert,,1,9,,Homo sapiens,D,,3795,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay
409,,,55,,,,BAO_0000357,B,,CHEMBL619871,,,Autocuration,,1,8,,,H,,3796,In vitro inhibition of human recombinant 5-lipoxygenase enzyme
409,,,55,,,,BAO_0000357,B,,CHEMBL619872,,,Autocuration,,1,8,,,H,,3797,In vitro inhibition of human recombinant lipoxygenase enzyme
409,,,55,,,,BAO_0000357,B,,CHEMBL619873,,,Autocuration,,1,8,,,H,,3798,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition
11090,,,55,,,,BAO_0000357,B,178.0,CHEMBL619874,,,Expert,Blood,1,8,,,H,,3799,Inhibition of 5-lipoxygenase in human whole blood.
11090,,,55,,,,BAO_0000357,B,178.0,CHEMBL619875,,,Expert,Blood,1,8,,,H,,3800,Inhibition of 5-lipoxygenase in human whole blood.
948,,,55,,,,BAO_0000357,B,,CHEMBL619876,,,Autocuration,,1,8,,,H,,3801,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE
948,,,55,,,,BAO_0000357,B,,CHEMBL619877,,,Autocuration,,1,8,,,H,,3802,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4)
13622,,,55,,,,BAO_0000219,F,,CHEMBL619878,,,Expert,,1,8,,,H,,3803,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.
13622,,,55,,,,BAO_0000019,F,178.0,CHEMBL619879,,,Autocuration,Blood,1,8,,,H,,3804,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood
9637,,,55,,,,BAO_0000357,B,,CHEMBL619880,,,Autocuration,,1,8,,,H,,3805,In vitro inhibition of 5-lipoxygenase from human polymorphs
11320,,,55,,,,BAO_0000357,B,,CHEMBL619881,,,Autocuration,,1,8,,,H,,3806,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase)
11320,,,55,,,,BAO_0000357,B,,CHEMBL619882,,,Expert,,1,8,,,H,,3807,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase
6838,,,55,,,,BAO_0000357,B,,CHEMBL619883,,,Autocuration,,1,8,,,H,,3808,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay
17667,,,55,9606.0,,,BAO_0000357,B,178.0,CHEMBL619884,,,Expert,Blood,1,9,,Homo sapiens,D,,3809,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB)
12703,,,55,,,,BAO_0000357,B,,CHEMBL619885,,,Autocuration,,1,8,,,H,,3810,In vitro potency against human 5-Lipoxygenase
14312,,,55,9606.0,,,BAO_0000019,F,,CHEMBL619886,,,Expert,,1,9,,Homo sapiens,D,,3811,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay
14312,,,55,,,,BAO_0000019,F,178.0,CHEMBL619887,,,Autocuration,Blood,1,8,,,H,,3812,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data
5364,,,55,,,,BAO_0000019,F,,CHEMBL875097,,,Autocuration,,1,8,,,H,,3813,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
951,,,55,,,,BAO_0000219,B,,CHEMBL618001,,,Autocuration,,1,8,,,H,,3814,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE
951,,,55,,,,BAO_0000219,B,,CHEMBL618002,,,Autocuration,,1,8,,,H,,3815,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active
951,,,55,,,,BAO_0000219,B,,CHEMBL618003,,,Autocuration,,1,8,,,H,,3816,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4
951,,,55,,,,BAO_0000219,B,,CHEMBL618004,,,Autocuration,,1,8,,,H,,3817,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active
12365,,,55,,,,BAO_0000219,B,,CHEMBL618005,,,Autocuration,,1,8,,,H,,3818,Inhibition of human 5-lipoxygenase in human cells
10603,,,55,,,,BAO_0000357,B,,CHEMBL618006,,,Expert,,1,8,,,H,,3819,Inhibition of human neutrophil 5-lipoxygenase
10501,,,55,,,,BAO_0000019,B,,CHEMBL875086,,,Autocuration,,1,8,,,H,,3820,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells
12281,,,55,,,,BAO_0000357,B,178.0,CHEMBL618007,,,Expert,Blood,1,8,,,H,,3821,Inhibition of 5-lipoxygenase from human whole blood
2567,,,55,,,,BAO_0000357,B,,CHEMBL618008,,,Autocuration,,1,8,,,H,,3822,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
2567,,,55,,,,BAO_0000219,B,,CHEMBL618009,,,Autocuration,,1,8,,,H,,3823,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils
10193,,,55,,,,BAO_0000357,B,,CHEMBL618010,,,Expert,,1,8,,,H,,3824,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase
10193,,,55,,,,BAO_0000357,B,,CHEMBL618011,,,Autocuration,,1,8,,,H,,3825,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
13623,,,55,,,,BAO_0000357,B,,CHEMBL618012,,,Expert,,1,8,,,H,,3826,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase
12780,,,55,,,,BAO_0000357,B,,CHEMBL882927,,,Autocuration,,1,8,,,H,,3827,Tested against 5-lipoxygenase
12780,,,55,,,,BAO_0000357,B,,CHEMBL618013,,,Autocuration,,1,8,,,H,,3828,Tested for activity against 5-Lipoxygenase (5-LO)
12780,,,55,,,,BAO_0000357,B,,CHEMBL618014,,,Autocuration,,1,8,,,H,,3829,Tested for activity against 5-lipoxygenase
11966,,,55,,,,BAO_0000357,B,,CHEMBL618015,,,Autocuration,,1,8,,,H,,3830,Tested for inhibition of 5-HPETE production by human 5-LO
5364,,,55,,,,BAO_0000019,F,,CHEMBL618016,,,Autocuration,,1,8,,,H,,3831,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.
13165,,,55,,,,BAO_0000357,B,,CHEMBL618017,,,Expert,,1,8,,,H,,3832,Inhibition of Human 5-lipoxygenase
5364,,,55,,,,BAO_0000019,B,,CHEMBL618018,,,Autocuration,,1,8,,,H,,3833,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells
11311,,,55,,,,BAO_0000219,B,,CHEMBL875087,,,Autocuration,,1,8,,,H,,3834,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS]
11311,,,55,,,,BAO_0000219,B,,CHEMBL618019,,,Autocuration,,1,8,,,H,,3835,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS]
14863,,,55,,,,BAO_0000019,B,,CHEMBL618020,,,Autocuration,,1,8,,,H,,3836,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.
14863,,,55,,,,BAO_0000019,B,,CHEMBL618021,,,Autocuration,,1,8,,,H,,3837,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested
11087,,,55,,,,BAO_0000357,B,178.0,CHEMBL618022,,,Autocuration,Blood,1,8,,,H,,3838,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL)
455,,,55,,,,BAO_0000357,B,,CHEMBL618023,,,Autocuration,,1,8,,,H,,3839,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils
13183,,,55,,,,BAO_0000357,B,,CHEMBL618024,,,Autocuration,,1,8,,,H,,3840,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
10319,,,55,,,,BAO_0000019,B,,CHEMBL873950,,,Expert,,1,8,,,H,,3841,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells
10193,,,55,,,,BAO_0000357,B,,CHEMBL618025,,,Autocuration,,1,8,,,H,,3842,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
951,,,55,,,,BAO_0000219,B,,CHEMBL618026,,,Autocuration,,1,8,,,H,,3843,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM
951,,,55,,,,BAO_0000219,B,,CHEMBL618027,,,Autocuration,,1,8,,,H,,3844,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive
951,,,55,,,,BAO_0000219,B,,CHEMBL618028,,,Autocuration,,1,8,,,H,,3845,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM
951,,,55,,,,BAO_0000219,B,,CHEMBL618029,,,Autocuration,,1,8,,,H,,3846,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive
9859,,,55,,,,BAO_0000357,B,,CHEMBL618030,,,Expert,,1,8,,,H,,3847,Inhibitory activity against 5-lipoxygenase at 10 uM concentration
9859,,,55,,,,BAO_0000357,B,,CHEMBL618031,,,Expert,,1,8,,,H,,3848,Inhibitory activity against 5-lipoxygenase at 1 uM concentration
9859,,,55,,,,BAO_0000357,B,,CHEMBL618032,,,Autocuration,,1,8,,,H,,3849,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration
2567,,,55,,,,BAO_0000357,B,,CHEMBL618033,,,Autocuration,,1,8,,,H,,3850,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils
10193,,,55,,,,BAO_0000357,B,,CHEMBL618034,,,Autocuration,,1,8,,,H,,3851,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM
10193,,,55,,,,BAO_0000357,B,,CHEMBL875088,,,Autocuration,,1,8,,,H,,3852,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM
949,,,55,,,,BAO_0000019,B,,CHEMBL618035,,,Autocuration,,1,8,,,H,,3853,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive
949,,,55,,,,BAO_0000019,B,,CHEMBL618036,,,Autocuration,,1,8,,,H,,3854,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90
10603,,,55,,,,BAO_0000357,B,,CHEMBL618037,,,Expert,,1,8,,,H,,3855,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM
10603,,,55,,,,BAO_0000357,B,,CHEMBL618038,,,Expert,,1,8,,,H,,3856,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
10603,,,55,,,,BAO_0000019,F,,CHEMBL618761,,,Autocuration,,1,8,,,H,,3857,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM
10603,,,55,,,,BAO_0000357,B,,CHEMBL618762,,,Expert,,1,8,,,H,,3858,Inhibition of lipoxygenase at the concentration of 0.1 uM
10603,,,55,,,,BAO_0000357,B,,CHEMBL618763,,,Expert,,1,8,,,H,,3859,Inhibition of lipoxygenase at the concentration of 1 uM
10193,,,55,,,,BAO_0000357,B,,CHEMBL618764,,,Autocuration,,1,8,,,H,,3860,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell
14580,,,55,9606.0,,,BAO_0000357,B,,CHEMBL618765,,,Expert,,1,9,,Homo sapiens,D,,3861,Inhibition of 5-Lipoxygenase (5-LOX)
11090,,,17087,,,,BAO_0000357,B,,CHEMBL618766,,,Expert,,1,8,,,H,,3862,Inhibition of 5-lipoxygenase in mouse macrophages.
11090,,,17087,,,,BAO_0000357,B,,CHEMBL618767,,,Expert,,1,8,,,H,,3863,Inhibition of 5-lipoxygenase in mouse macrophages.
6339,,,17087,,,,BAO_0000357,B,,CHEMBL619380,,,Autocuration,,1,8,,,H,,3864,Inhibitory activity against lipoxygenase-2 in mice
6339,,,17087,,,,BAO_0000357,B,,CHEMBL619381,,,Expert,,1,8,,,H,,3865,Inhibitory activity against murine lipoxygenase-2.
12281,,,17087,10090.0,,,BAO_0000357,B,,CHEMBL619382,,,Expert,,1,9,,Mus musculus,D,,3866,Inhibition of 5-lipoxygenase from mouse macrophage
11311,,,17087,,,,BAO_0000357,B,,CHEMBL619383,,,Autocuration,,1,8,,,H,,3867,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages
11089,,,55,9823.0,,,BAO_0000019,B,,CHEMBL619384,,,Autocuration,,1,8,,Sus scrofa,H,,3868,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.
10091,,,55,9823.0,,,BAO_0000019,B,,CHEMBL619385,,,Autocuration,,1,8,,Sus scrofa,H,,3869,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes
14352,,,55,9986.0,,,BAO_0000019,B,,CHEMBL882928,,,Autocuration,,1,8,,Oryctolagus cuniculus,H,,3870,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes
13329,,,12166,10116.0,,,BAO_0000019,B,,CHEMBL619386,,,Expert,,1,9,,Rattus norvegicus,D,,3871,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619387,,,Autocuration,,1,8,,,H,,3872,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. "
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619388,,,Autocuration,,1,8,,,H,,3873,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619389,,,Autocuration,,1,8,,,H,,3874,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4."
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619390,,,Expert,,1,8,,,H,,3875,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation)
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619391,,,Expert,,1,8,,,H,,3876,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM"
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619392,,,Autocuration,,1,8,,,H,,3877,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE
11311,,,12166,,,,BAO_0000019,B,,CHEMBL619393,,,Autocuration,,1,8,,,H,,3878,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo)
11311,,,12166,,,,BAO_0000019,B,,CHEMBL619394,,,Autocuration,,1,8,,,H,,3879,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration
105,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619395,,,Autocuration,,1,8,,,H,,3880,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
105,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619396,,,Autocuration,,1,8,,,H,,3881,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay"
9138,,,12166,,,,BAO_0000357,B,,CHEMBL619397,,,Autocuration,,1,8,,,H,,3882,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO)
9138,,,12166,,,,BAO_0000357,B,,CHEMBL619398,,,Autocuration,,1,8,,,H,,3883,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),"
9138,,,12166,,,,BAO_0000357,B,,CHEMBL619399,,,Autocuration,,1,8,,,H,,3884,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),"
14427,,,12166,,,,BAO_0000357,B,,CHEMBL619400,,,Autocuration,,1,8,,,H,,3885,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619401,,,Autocuration,,1,8,,,H,,3886,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE."
13329,,,12166,,,,BAO_0000019,B,,CHEMBL619402,,,Autocuration,,1,8,,,H,,3887,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. "
14427,663.0,RBL-2H3,12166,10116.0,,,BAO_0000219,B,,CHEMBL619403,,,Expert,,1,9,,Rattus norvegicus,D,,3888,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells
14427,,,12166,,,,BAO_0000357,B,,CHEMBL619404,,,Autocuration,,1,8,,,H,,3889,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined
14427,,,12166,,,,BAO_0000357,B,,CHEMBL619405,,,Autocuration,,1,8,,,H,,3890,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.
10293,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619406,,,Expert,,1,8,,,H,,3891,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line
338,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL619407,,,Expert,,1,9,,Rattus norvegicus,D,,3892,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells
303,,,12166,,,,BAO_0000357,B,,CHEMBL619408,,,Autocuration,,1,8,,,H,,3893,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase)
303,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619409,,,Autocuration,,1,8,,,H,,3894,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619410,,,Expert,,1,8,,,H,,3895,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619753,,,Autocuration,,1,8,,,H,,3896,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
137,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619754,,,Autocuration,,1,8,,,H,,3897,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase
11481,,,12166,,,,BAO_0000357,B,,CHEMBL619903,,,Expert,,1,8,,,H,,3898,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase
11481,,,12166,,,,BAO_0000357,B,,CHEMBL619904,,,Expert,,1,8,,,H,,3899,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration"
9029,,,12166,,,,BAO_0000357,B,,CHEMBL619905,,,Expert,,1,8,,,H,,3900,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro
1701,,,12166,,,,BAO_0000019,B,,CHEMBL619906,,,Autocuration,,1,8,,,H,,3901,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells
1701,,,12166,,,,BAO_0000019,B,,CHEMBL619907,,,Autocuration,,1,8,,,H,,3902,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active
1701,,,12166,,,,BAO_0000019,B,,CHEMBL619908,,,Autocuration,,1,8,,,H,,3903,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active
1701,,,12166,,,,BAO_0000019,B,,CHEMBL619909,,,Autocuration,,1,8,,,H,,3904,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data
13358,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL619910,,,Expert,,1,8,,,H,,3905,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant
1175,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL882929,,,Expert,,1,8,,,H,,3906,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells
8797,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619911,,,Expert,,1,8,,,H,,3907,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.
8797,,,12166,,,,BAO_0000019,B,,CHEMBL619912,,,Autocuration,,1,8,,,H,,3908,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data
577,,,12166,10116.0,,,BAO_0000357,B,,CHEMBL619913,,,Expert,,1,9,,Rattus norvegicus,D,,3909,Inhibition of rat basophilic leukemia cell 5-lipoxygenase
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619914,,,Expert,,1,8,,,H,,3910,In vitro inhibitory activity against RBL-1 5-LO
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619915,,,Autocuration,,1,8,,,H,,3911,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM)
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619916,,,Autocuration,,1,8,,,H,,3912,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent)
9295,,,12166,,,,BAO_0000218,B,,CHEMBL619917,,,Autocuration,,1,8,,,H,,3913,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.
9295,,,12166,,,,BAO_0000357,B,,CHEMBL619918,,,Autocuration,,1,8,,,H,,3914,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme
216,,,12166,,,,BAO_0000218,B,,CHEMBL619919,,,Autocuration,,1,8,,,H,,3915,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.
11090,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL883710,,,Autocuration,,1,8,,,H,,3916,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.
11090,,,12166,,,,BAO_0000019,B,178.0,CHEMBL619920,,,Autocuration,Blood,1,8,,,H,,3917,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.
10091,,,12166,,,,BAO_0000357,B,,CHEMBL619921,,,Expert,,1,8,,,H,,3918,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase
10274,,,12166,,,,BAO_0000019,F,,CHEMBL619922,,,Autocuration,,1,8,,,H,,3919,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.
13622,,,12166,,,,BAO_0000219,F,,CHEMBL619923,,,Autocuration,,1,8,,,H,,3920,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes
12118,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619924,,,Expert,,1,8,,,H,,3921,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined
12576,,,12166,,,,BAO_0000357,B,,CHEMBL619925,,,Expert,,1,8,,,H,,3922,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay
9546,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619926,,,Expert,,1,8,,,H,,3923,In vitro inhibition of 5-lipoxygenase from RBL-1 cells
9521,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619927,,,Autocuration,,1,8,,,H,,3924,In vitro inhibition of 5-lipoxygenase in RBL-1 cells
10626,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619928,,,Expert,,1,8,,,H,,3925,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619929,,,Autocuration,,1,8,,,H,,3926,In vitro inhibition of RBL-1 5-lipoxygenase
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL875089,,,Autocuration,,1,8,,,H,,3927,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619930,,,Autocuration,,1,8,,,H,,3928,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619931,,,Autocuration,,1,8,,,H,,3929,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619932,,,Autocuration,,1,8,,,H,,3930,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619933,,,Autocuration,,1,8,,,H,,3931,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619934,,,Autocuration,,1,8,,,H,,3932,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619935,,,Autocuration,,1,8,,,H,,3933,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619936,,,Autocuration,,1,8,,,H,,3934,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619937,,,Autocuration,,1,8,,,H,,3935,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619938,,,Autocuration,,1,8,,,H,,3936,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619939,,,Autocuration,,1,8,,,H,,3937,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619940,,,Autocuration,,1,8,,,H,,3938,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL875090,,,Autocuration,,1,8,,,H,,3939,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619941,,,Autocuration,,1,8,,,H,,3940,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619942,,,Autocuration,,1,8,,,H,,3941,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL883711,,,Autocuration,,1,8,,,H,,3942,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619943,,,Autocuration,,1,8,,,H,,3943,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619944,,,Autocuration,,1,8,,,H,,3944,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619945,,,Autocuration,,1,8,,,H,,3945,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619946,,,Autocuration,,1,8,,,H,,3946,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619947,,,Autocuration,,1,8,,,H,,3947,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619948,,,Autocuration,,1,8,,,H,,3948,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619949,,,Autocuration,,1,8,,,H,,3949,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8
9401,,,12166,,,,BAO_0000019,B,,CHEMBL619950,,,Expert,,1,8,,,H,,3950,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.
10325,,,12166,,,,BAO_0000019,B,,CHEMBL618050,,,Autocuration,,1,8,,,H,,3951,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay
1556,663.0,RBL-2H3,12166,,,,BAO_0000219,F,,CHEMBL875091,,,Expert,,1,8,,,H,,3952,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.
1556,663.0,RBL-2H3,12166,,,,BAO_0000219,F,,CHEMBL618051,,,Expert,,1,8,,,H,,3953,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested
961,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL618052,,,Expert,,1,9,,Rattus norvegicus,D,,3954,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells
6838,,,12166,,,,BAO_0000019,B,,CHEMBL618053,,,Autocuration,,1,8,,,H,,3955,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate
10325,,,12166,,,,BAO_0000019,B,,CHEMBL618054,,,Expert,,1,8,,,H,,3956,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay)
9209,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL618055,,,Expert,,1,9,,Rattus norvegicus,D,,3957,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
11520,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618056,,,Expert,,1,8,,,H,,3958,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.
137,,,12166,,,,BAO_0000357,B,,CHEMBL618057,,,Autocuration,,1,8,,,H,,3959,In vitro inhibitory activity against 5-lipoxygenase was determined
4717,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618058,,,Autocuration,,1,8,,,H,,3960,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells
10636,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618059,,,Expert,,1,8,,,H,,3961,Inhibition of 5-lipoxygenase in intact RBL-1 cell line
14312,,,12166,10116.0,,,BAO_0000019,F,,CHEMBL618060,,,Expert,,1,9,,Rattus norvegicus,D,,3962,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate
1203,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618061,,,Autocuration,,1,8,,,H,,3963,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells
1203,,,12166,,,,BAO_0000019,B,,CHEMBL618062,,,Autocuration,,1,8,,,H,,3964,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells
13622,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618063,,,Expert,,1,8,,,H,,3965,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation
9793,,,12166,,,,BAO_0000357,B,,CHEMBL618064,,,Autocuration,,1,8,,,H,,3966,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration
1143,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL618065,,,Expert,,1,9,,Rattus norvegicus,D,,3967,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes
11854,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL618066,,,Expert,,1,9,,Rattus norvegicus,D,,3968,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618067,,,Autocuration,,1,8,,,H,,3969,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618068,,,Autocuration,,1,8,,,H,,3970,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
10501,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL618069,,,Expert,,1,9,,Rattus norvegicus,D,,3971,Inhibition of 5-lipoxygenase in rat RBL-1 cells
12526,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618070,,,Expert,,1,8,,,H,,3972,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL618071,,,Autocuration,Limbic system,1,8,,,H,,3973,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg
10034,,,10825,,,,BAO_0000019,F,349.0,CHEMBL619247,,,Autocuration,Limbic system,1,8,,,H,,3974,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg
10034,,,10825,,,,BAO_0000019,F,,CHEMBL619248,,,Autocuration,,1,8,,,H,,3975,Approximate dose levels for a half maximal reduction of 5-HTP levels
10046,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL619249,,,Autocuration,Hippocampus,1,8,,,H,,3976,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
10046,,,10576,,,,BAO_0000221,B,10000000.0,CHEMBL619250,,,Autocuration,Hippocampus,1,8,,,H,,3977,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.
10046,,,10577,,,,BAO_0000019,B,,CHEMBL619251,,,Autocuration,,1,8,,,H,,3978,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.
12079,,,55,9615.0,,,BAO_0000019,F,178.0,CHEMBL619252,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,,3979,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood
12079,,,55,,,,BAO_0000019,F,178.0,CHEMBL619253,,,Autocuration,Blood,1,8,,,H,,3980,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood
11311,,,12166,,,,BAO_0000219,B,,CHEMBL619254,,,Autocuration,,1,8,,,H,,3981,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
12338,,,17140,,,,BAO_0000219,B,,CHEMBL619255,,,Expert,,1,8,,,H,,3982,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes
12143,,,17140,,,,BAO_0000219,B,,CHEMBL619256,,,Expert,,1,8,,,H,,3983,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).
12143,,,17140,,,,BAO_0000219,B,,CHEMBL875418,,,Autocuration,,1,8,,,H,,3984,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL)
12143,,,17140,,,,BAO_0000219,B,,CHEMBL619257,,,Expert,,1,8,,,H,,3985,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
12143,,,17140,,,,BAO_0000219,B,,CHEMBL619258,,,Autocuration,,1,8,,,H,,3986,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM
12365,,,17140,,,,BAO_0000357,B,,CHEMBL619259,,,Expert,,1,8,,,H,,3987,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.
13500,,,17140,,,,BAO_0000357,B,,CHEMBL619260,,,Expert,,1,8,,,H,,3988,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619261,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3989,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619263,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3990,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619264,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3991,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619265,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3992,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619266,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3993,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619902,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3994,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620058,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3995,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620059,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3996,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620060,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3997,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620061,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3998,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620062,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,3999,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620063,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4000,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620064,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4001,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620065,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4002,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620066,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4003,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620067,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4004,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620068,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4005,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620069,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4006,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620070,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4007,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620071,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4008,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620072,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4009,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620036,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4010,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL857702,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4011,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620037,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4012,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620038,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4013,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620039,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4014,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620040,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4015,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620041,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4016,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620042,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4017,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620043,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4018,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620044,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4019,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620045,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4020,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620046,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4021,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620047,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4022,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620048,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4023,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL857703,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4024,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620049,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4025,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620050,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4026,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL620051,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4027,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619213,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4028,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619214,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4029,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619804,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4030,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619805,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4031,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619806,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4032,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619807,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4033,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg"
12832,,,55,9615.0,,,BAO_0000218,F,178.0,CHEMBL619808,,,Autocuration,Blood,1,8,,Canis lupus familiaris,H,In vivo,4034,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg"
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL619809,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4035,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL619810,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4036,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL619811,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4037,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL620769,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4038,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL620770,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4039,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL620771,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4040,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL620772,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4041,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr
3595,,,55,9615.0,,,BAO_0000218,B,,CHEMBL620773,,,Autocuration,,1,8,,Canis lupus familiaris,H,,4042,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine
9203,,,55,10141.0,,,BAO_0000357,B,,CHEMBL620774,,,Autocuration,,1,8,,Cavia porcellus,H,,4043,Ability to inhibit 5-lipoxygenase in guinea pig
82,,,55,10141.0,,,BAO_0000357,B,,CHEMBL620775,,,Expert,,1,8,,Cavia porcellus,H,,4044,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN)
11090,,,55,10141.0,,,BAO_0000357,B,,CHEMBL620776,,,Autocuration,,1,8,,Cavia porcellus,H,,4045,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.
12832,,,55,10141.0,,,BAO_0000218,B,178.0,CHEMBL620777,,,Autocuration,Blood,1,8,,Cavia porcellus,H,,4046,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg"
1065,,,55,10141.0,,,BAO_0000357,B,,CHEMBL620778,,,Autocuration,,1,8,,Cavia porcellus,H,,4047,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production
1065,,,55,10141.0,,,BAO_0000357,B,,CHEMBL620779,,,Autocuration,,1,8,,Cavia porcellus,H,,4048,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production
12832,,,55,10141.0,,,BAO_0000019,B,,CHEMBL621500,,,Expert,,1,8,,Cavia porcellus,H,,4049,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes
12832,,,55,10141.0,,,BAO_0000019,B,,CHEMBL621501,,,Expert,,1,8,,Cavia porcellus,H,,4050,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
12832,,,55,10141.0,,,BAO_0000019,B,,CHEMBL618098,,,Autocuration,,1,8,,Cavia porcellus,H,,4051,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes
10504,,,55,10141.0,,,BAO_0000019,B,,CHEMBL618099,,,Autocuration,,1,8,,Cavia porcellus,H,,4052,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
7788,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618100,,,Autocuration,,1,8,,Cavia porcellus,H,,4053,Inhibitory activity against 5-lipoxygenase
10001,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618101,,,Autocuration,,1,8,,Cavia porcellus,H,,4054,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte
10193,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618102,,,Autocuration,,1,8,,Cavia porcellus,H,,4055,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant
13243,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618103,,,Autocuration,,1,8,,Cavia porcellus,H,,4056,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase
13243,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618104,,,Autocuration,,1,8,,Cavia porcellus,H,,4057,Inhibitory activity uM
969,,,55,10141.0,,,BAO_0000219,B,,CHEMBL883712,,,Autocuration,,1,8,,Cavia porcellus,H,,4058,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined
10001,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618105,,,Autocuration,,1,8,,Cavia porcellus,H,,4059,Inhibitory activity against 5-lipoxygenase at 10 uM
7788,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618106,,,Autocuration,,1,8,,Cavia porcellus,H,,4060,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
10001,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618107,,,Autocuration,,1,8,,Cavia porcellus,H,,4061,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM
10193,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618108,,,Autocuration,,1,8,,Cavia porcellus,H,,4062,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM
13243,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618109,,,Autocuration,,1,8,,Cavia porcellus,H,,4063,Inhibitory activity uM
13243,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618110,,,Autocuration,,1,8,,Cavia porcellus,H,,4064,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM
13243,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618111,,,Expert,,1,8,,Cavia porcellus,H,,4065,Inhibitory activity uM
13243,,,55,10141.0,,,BAO_0000019,F,,CHEMBL618112,,,Autocuration,,1,8,,Cavia porcellus,H,,4066,Inhibitory activity uM
10504,,,55,10141.0,,,BAO_0000019,B,,CHEMBL618113,,,Autocuration,,1,8,,Cavia porcellus,H,,4067,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes
7788,,,55,10141.0,,,BAO_0000357,B,,CHEMBL618114,,,Autocuration,,1,8,,Cavia porcellus,H,,4068,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM
10546,,,55,10141.0,,,BAO_0000221,F,2116.0,CHEMBL620871,,,Expert,Ileum,1,8,,Cavia porcellus,H,,4069,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum
13183,,,55,,,,BAO_0000357,B,,CHEMBL620872,,,Autocuration,,1,8,,,H,,4070,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
13183,,,55,,,,BAO_0000357,B,,CHEMBL620873,,,Autocuration,,1,8,,,H,,4071,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4)
2578,,,55,,,,BAO_0000357,B,,CHEMBL620874,,,Autocuration,,1,8,,,H,,4072,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO)
12780,,,55,,,,BAO_0000357,B,,CHEMBL620875,,,Expert,,1,8,,,H,,4073,In vitro inhibition of human 5-Lipoxygenase.
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620876,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4074,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620877,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4075,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL857854,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4076,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620878,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4077,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620879,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4078,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620880,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4079,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620881,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4080,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620882,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4081,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620883,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4082,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620884,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4083,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620885,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4084,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620886,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4085,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620887,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4086,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618039,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4087,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618040,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4088,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618041,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4089,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618216,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4090,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618217,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4091,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618218,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4092,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618219,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4093,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618220,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4094,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618221,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4095,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618222,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4096,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618223,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4097,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618224,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4098,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618225,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4099,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618226,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4100,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618227,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4101,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618228,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4102,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618229,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4103,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618230,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4104,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618231,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4105,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618232,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4106,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618233,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4107,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618234,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4108,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618235,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4109,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618115,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4110,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618116,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4111,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL618117,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4112,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619968,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4113,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619969,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4114,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619970,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4115,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619971,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4116,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619972,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4117,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619973,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4118,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619974,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4119,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619975,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4120,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,,CHEMBL619976,,Microsomes,Autocuration,,1,0,,Rattus norvegicus,U,,4121,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619977,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4122,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619978,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4123,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619979,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4124,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619980,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4125,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619981,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4126,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats"
10797,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619982,,,Intermediate,,1,1,,Homo sapiens,N,,4127,In vitro inhibition of 7226/S myeloma cancer cell line
6881,993.0,BEL-7404 tumor cell line,80698,9606.0,,,BAO_0000219,F,,CHEMBL619983,,,Intermediate,,1,1,,Homo sapiens,N,,4128,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells)
3838,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL620031,,,Intermediate,,1,1,,Homo sapiens,N,,4129,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
3838,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL620032,,,Intermediate,,1,1,,Homo sapiens,N,,4130,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer
12981,505.0,V79,81264,10029.0,,,BAO_0000219,F,,CHEMBL620033,,,Expert,,1,1,,Cricetulus griseus,N,,4131,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.
12981,505.0,V79,81264,10029.0,,,BAO_0000219,F,,CHEMBL620034,,,Expert,,1,1,,Cricetulus griseus,N,,4132,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.
7653,1119.0,7800C1 cell line,80635,10116.0,,,BAO_0000219,F,,CHEMBL620035,,,Intermediate,,1,1,,Rattus norvegicus,N,,4133,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose
7653,1119.0,7800C1 cell line,80635,10116.0,,,BAO_0000219,F,,CHEMBL618318,,,Intermediate,,1,1,,Rattus norvegicus,N,,4134,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose
7653,1119.0,7800C1 cell line,80635,10116.0,,,BAO_0000219,F,,CHEMBL618319,,,Intermediate,,1,1,,Rattus norvegicus,N,,4135,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose
7653,1119.0,7800C1 cell line,80635,10116.0,,,BAO_0000219,F,,CHEMBL618320,,,Intermediate,,1,1,,Rattus norvegicus,N,,4136,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose
7653,1119.0,7800C1 cell line,80635,10116.0,,,BAO_0000219,F,,CHEMBL618321,,,Intermediate,,1,1,,Rattus norvegicus,N,,4137,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose
7653,1119.0,7800C1 cell line,80635,10116.0,,,BAO_0000219,F,,CHEMBL883118,,,Intermediate,,1,1,,Rattus norvegicus,N,,4138,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose
17229,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL883795,,,Intermediate,,1,1,,Homo sapiens,N,,4139,In vitro antitumor activity against renal 786-0 tumor cell lines
12858,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL618322,,,Intermediate,,1,1,,Homo sapiens,N,,4140,Cytotoxic activity against 786-0 Renal cancer cell line
16325,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL618323,,,Intermediate,,1,1,,Homo sapiens,N,,4141,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer
16325,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL618324,,,Intermediate,,1,1,,Homo sapiens,N,,4142,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer
5858,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL618325,,,Intermediate,,1,1,,Homo sapiens,N,,4143,In vitro antitumor activity against human renal 786-0 cell line
16325,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL875416,,,Intermediate,,1,1,,Homo sapiens,N,,4144,Inhibition of Renal cancer in 786-0 cancer cell lines
14696,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL618326,,,Intermediate,,1,1,,Homo sapiens,N,,4145,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM
3786,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL618327,,,Intermediate,,1,1,,Homo sapiens,N,,4146,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0
14696,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619215,,,Intermediate,,1,1,,Homo sapiens,N,,4147,inhibition of the growth of renal cancer(786-0) cell line
14769,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619216,,,Intermediate,,1,1,,Homo sapiens,N,,4148,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
15354,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619217,,,Intermediate,,1,1,,Homo sapiens,N,,4149,Compound was tested for the growth inhibition of 786-0 renal tumor cell line
14255,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619218,,,Intermediate,,1,1,,Homo sapiens,N,,4150,The IC50 value was measured on 786-0 cell line in ovarian tumor
14255,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619219,,,Intermediate,,1,1,,Homo sapiens,N,,4151,The IC50 value was measured on 786-0 cell line in ovarian tumor t
14255,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619220,,,Intermediate,,1,1,,Homo sapiens,N,,4152,The IC50 value was measured on 786-0 cell line in renal tumor type.
14696,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619221,,,Intermediate,,1,1,,Homo sapiens,N,,4153,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM
12016,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619222,,,Intermediate,,1,1,,Homo sapiens,N,,4154,Tested for cytotoxic activity against renal cancer 786-0 cell line
2597,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL857454,,,Intermediate,,1,1,,Homo sapiens,N,,4155,Compound was tested for growth inhibitory activity against 786-0 cell line
12526,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619223,,,Autocuration,,1,8,,,H,,4156,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM
12526,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619224,,,Autocuration,,1,8,,,H,,4157,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive
14799,,,12166,,,,BAO_0000019,B,,CHEMBL619225,,,Autocuration,,1,8,,,H,,4158,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619226,,,Expert,,1,8,,,H,,4159,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1)
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619227,,,Expert,,1,8,,,H,,4160,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)
12767,,,12166,,,,BAO_0000357,B,,CHEMBL619228,,,Autocuration,,1,8,,,H,,4161,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase
10997,,,12166,,,,BAO_0000219,B,,CHEMBL619229,,,Autocuration,,1,8,,,H,,4162,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes
11388,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619230,,,Autocuration,,1,8,,,H,,4163,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line
167,,,12166,,,,BAO_0000357,B,,CHEMBL619231,,,Autocuration,,1,8,,,H,,4164,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated
167,,,12166,,,,BAO_0000357,B,,CHEMBL619232,,,Autocuration,,1,8,,,H,,4165,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated"
13744,,,12166,,,,BAO_0000357,B,,CHEMBL619233,,,Expert,,1,8,,,H,,4166,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.
1630,,,12166,,,,BAO_0000357,B,,CHEMBL619234,,,Autocuration,,1,8,,,H,,4167,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase
1630,,,12166,,,,BAO_0000357,B,,CHEMBL619235,,,Autocuration,,1,8,,,H,,4168,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO)
969,,,12166,10116.0,,,BAO_0000019,B,,CHEMBL619236,,,Expert,,1,9,,Rattus norvegicus,D,,4169,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production"
13621,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619237,,,Autocuration,,1,8,,,H,,4170,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells
10089,,,12166,,,,BAO_0000357,B,,CHEMBL619238,,,Autocuration,,1,8,,,H,,4171,Inhibitory concentration to inhibit 5-lipoxygenase in the rat
10193,,,12166,,,,BAO_0000357,B,,CHEMBL619239,,,Expert,,1,8,,,H,,4172,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase
11966,,,12166,,,,BAO_0000357,B,,CHEMBL619240,,,Autocuration,,1,8,,,H,,4173,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM
12251,,,12166,,,,BAO_0000019,B,,CHEMBL875417,,,Autocuration,,1,8,,,H,,4174,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
211,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619241,,,Autocuration,,1,8,,,H,,4175,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1)
12251,,,12166,,,,BAO_0000019,F,,CHEMBL619242,,,Expert,,1,8,,,H,,4176,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells
12495,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL883796,,,Autocuration,,1,8,,,H,,4177,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells
414,,,12166,,,,BAO_0000357,B,,CHEMBL619243,,,Autocuration,,1,8,,,H,,4178,Tested for its inhibitory activity against 5-lipoxygenase
414,,,12166,,,,BAO_0000357,B,,CHEMBL619244,,,Autocuration,,1,8,,,H,,4179,Tested for its inhibitory activity against 5-lipoxygenase; Not determined
10325,,,12166,,,,BAO_0000019,B,,CHEMBL619245,,,Expert,,1,8,,,H,,4180,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)"
11966,,,12166,,,,BAO_0000019,B,,CHEMBL619246,,,Expert,,1,8,,,H,,4181,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619984,,,Expert,,1,8,,,H,,4182,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619985,,,Autocuration,,1,8,,,H,,4183,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619986,,,Autocuration,,1,8,,,H,,4184,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619987,,,Expert,,1,8,,,H,,4185,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.
11311,,,12166,,,,BAO_0000218,B,,CHEMBL619988,,,Autocuration,,1,8,,,H,,4186,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse
11311,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619989,,,Autocuration,,1,8,,,H,,4187,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1
11311,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL619990,,,Autocuration,,1,8,,,H,,4188,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells
11311,,,12166,,,,BAO_0000219,B,,CHEMBL619991,,,Autocuration,,1,8,,,H,,4189,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS]
11311,,,12166,,,,BAO_0000219,B,,CHEMBL619992,,,Autocuration,,1,8,,,H,,4190,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro)
11311,,,12166,,,,BAO_0000218,B,,CHEMBL619993,,,Autocuration,,1,8,,,H,In vivo,4191,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo)
11311,663.0,RBL-2H3,12166,,,,BAO_0000219,F,,CHEMBL619994,,,Autocuration,,1,8,,,H,,4192,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells
11311,663.0,RBL-2H3,12166,,,,BAO_0000219,F,,CHEMBL619995,,,Autocuration,,1,8,,,H,,4193,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells
11311,,,12166,,,,BAO_0000019,B,,CHEMBL619996,,,Autocuration,,1,8,,,H,,4194,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS]
11732,,,12166,,,,BAO_0000019,B,,CHEMBL619997,,,Autocuration,,1,8,,,H,,4195,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase
11732,,,12166,,,,BAO_0000019,B,,CHEMBL619998,,,Expert,,1,8,,,H,,4196,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.
11087,,,12166,,,,BAO_0000019,B,,CHEMBL619999,,,Expert,,1,8,,,H,,4197,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells
11087,,,12166,,,,BAO_0000019,B,,CHEMBL620000,,,Autocuration,,1,8,,,H,,4198,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells
11087,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620001,,,Autocuration,,1,8,,,H,,4199,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells
11087,,,12166,10116.0,,,BAO_0000357,B,,CHEMBL620002,,,Expert,,1,9,,Rattus norvegicus,D,,4200,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL
496,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620003,,,Autocuration,,1,8,,,H,,4201,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620004,,,Expert,,1,8,,,H,,4202,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production
11520,,,12166,,,,BAO_0000357,B,,CHEMBL874063,,,Autocuration,,1,8,,,H,,4203,Compound was evaluated for the inhibition of 5-lipoxygenase
10293,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620005,,,Autocuration,,1,8,,,H,,4204,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM
303,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620006,,,Autocuration,,1,8,,,H,,4205,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay
303,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620007,,,Autocuration,,1,8,,,H,,4206,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620008,,,Autocuration,,1,8,,,H,,4207,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM
9247,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL620009,,,Expert,,1,9,,Rattus norvegicus,D,,4208,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620010,,,Autocuration,,1,8,,,H,,4209,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620011,,,Autocuration,,1,8,,,H,,4210,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620677,,,Autocuration,,1,8,,,H,,4211,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620678,,,Autocuration,,1,8,,,H,,4212,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620679,,,Autocuration,,1,8,,,H,,4213,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM
9247,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620680,,,Autocuration,,1,8,,,H,,4214,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM
11481,,,12166,10116.0,,,BAO_0000357,B,,CHEMBL620838,,,Expert,,1,9,,Rattus norvegicus,D,,4215,Inhibitory activity against 5-lipoxygenase at 10 uM
105,,,12166,,,,BAO_0000357,B,,CHEMBL620839,,,Autocuration,,1,8,,,H,,4216,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition
9029,,,12166,,,,BAO_0000357,B,,CHEMBL620840,,,Expert,,1,8,,,H,,4217,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM
1175,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620841,,,Expert,,1,8,,,H,,4218,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM
12118,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620842,,,Autocuration,,1,8,,,H,,4219,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM
12118,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620843,,,Autocuration,,1,8,,,H,,4220,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M
12118,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620844,,,Autocuration,,1,8,,,H,,4221,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM
9225,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620845,,,Autocuration,,1,8,,,H,,4222,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM
9401,,,12166,,,,BAO_0000019,B,,CHEMBL620846,,,Autocuration,,1,8,,,H,,4223,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration
137,,,12166,,,,BAO_0000357,B,,CHEMBL873951,,,Autocuration,,1,8,,,H,,4224,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
137,,,12166,,,,BAO_0000357,B,,CHEMBL620847,,,Autocuration,,1,8,,,H,,4225,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM
4717,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620848,,,Autocuration,,1,8,,,H,,4226,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620849,,,Autocuration,,1,8,,,H,,4227,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
10501,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620850,,,Autocuration,,1,8,,,H,,4228,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration
10501,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620851,,,Autocuration,,1,8,,,H,,4229,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM
10501,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620852,,,Autocuration,,1,8,,,H,,4230,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.
12526,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL875098,,,Autocuration,,1,8,,,H,,4231,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
14799,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL620853,,,Expert,,1,9,,Rattus norvegicus,D,,4232,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM
14799,,,12166,,,,BAO_0000019,B,,CHEMBL620854,,,Autocuration,,1,8,,,H,,4233,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620855,,,Autocuration,,1,8,,,H,,4234,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM
3595,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL839884,,,Expert,,1,8,,,H,,4235,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM
12526,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620856,,,Autocuration,,1,8,,,H,,4236,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
12526,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620857,,,Autocuration,,1,8,,,H,,4237,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187
10193,,,12166,,,,BAO_0000019,B,,CHEMBL620858,,,Autocuration,,1,8,,,H,,4238,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
10193,,,12166,,,,BAO_0000019,B,,CHEMBL620859,,,Autocuration,,1,8,,,H,,4239,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
10193,,,12166,,,,BAO_0000019,B,,CHEMBL620860,,,Autocuration,,1,8,,,H,,4240,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM
10193,,,12166,,,,BAO_0000019,B,,CHEMBL620861,,,Autocuration,,1,8,,,H,,4241,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM
9138,,,12166,,,,BAO_0000357,B,,CHEMBL620862,,,Expert,,1,8,,,H,,4242,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO)
9138,,,12166,,,,BAO_0000357,B,,CHEMBL620863,,,Autocuration,,1,8,,,H,,4243,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM
11966,,,12166,,,,BAO_0000019,B,,CHEMBL620864,,,Autocuration,,1,8,,,H,,4244,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620865,,,Autocuration,,1,8,,,H,,4245,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620866,,,Autocuration,,1,8,,,H,,4246,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM
11311,663.0,RBL-2H3,12166,,,,BAO_0000219,B,,CHEMBL620867,,,Autocuration,,1,8,,,H,,4247,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells
11311,663.0,RBL-2H3,12166,,,,BAO_0000219,B,,CHEMBL620868,,,Autocuration,,1,8,,,H,,4248,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
11311,663.0,RBL-2H3,12166,,,,BAO_0000219,F,,CHEMBL620869,,,Autocuration,,1,8,,,H,,4249,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells
11311,,,12166,,,,BAO_0000019,F,,CHEMBL873952,,,Autocuration,,1,8,,,H,,4250,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase
11311,,,12166,,,,BAO_0000357,B,,CHEMBL875099,,,Autocuration,,1,8,,,H,,4251,The compound was tested for inhibition of isolated 5-lipoxygenase
11311,663.0,RBL-2H3,12166,,,,BAO_0000219,F,,CHEMBL620870,,,Autocuration,,1,8,,,H,,4252,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells
11087,,,12166,,,,BAO_0000019,B,,CHEMBL618261,,,Autocuration,,1,8,,,H,,4253,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM
11087,,,12166,,,,BAO_0000019,B,,CHEMBL618262,,,Autocuration,,1,8,,,H,,4254,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM
11087,,,12166,,,,BAO_0000019,B,,CHEMBL619428,,,Autocuration,,1,8,,,H,,4255,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM
11087,,,12166,,,,BAO_0000019,B,,CHEMBL619429,,,Autocuration,,1,8,,,H,,4256,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
11087,,,12166,,,,BAO_0000019,B,,CHEMBL619430,,,Autocuration,,1,8,,,H,,4257,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration
496,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620017,,,Autocuration,,1,8,,,H,,4258,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM
496,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL620018,,,Autocuration,,1,8,,,H,,4259,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620019,,,Autocuration,,1,8,,,H,,4260,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620020,,,Autocuration,,1,8,,,H,,4261,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620021,,,Autocuration,,1,8,,,H,,4262,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620022,,,Autocuration,,1,8,,,H,,4263,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620023,,,Autocuration,,1,8,,,H,,4264,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620024,,,Autocuration,,1,8,,,H,,4265,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620025,,,Autocuration,,1,8,,,H,,4266,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620026,,,Autocuration,,1,8,,,H,,4267,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM
13986,702.0,RBL-1,12166,,,,BAO_0000219,F,,CHEMBL620027,,,Autocuration,,1,8,,,H,,4268,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM
13986,,,12166,10116.0,,,BAO_0000019,F,,CHEMBL620028,,,Expert,,1,9,,Rattus norvegicus,D,,4269,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM
10193,,,12166,,,,BAO_0000357,B,,CHEMBL620029,,,Autocuration,,1,8,,,H,,4270,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase
9295,,,12166,,,,BAO_0000357,B,,CHEMBL620030,,,Autocuration,,1,8,,,H,,4271,Compound was tested for the percent of inhibition against 5-LO at 10 uM
4717,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL875415,,,Autocuration,,1,8,,,H,,4272,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration
4717,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618256,,,Autocuration,,1,8,,,H,,4273,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration
11854,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618257,,,Autocuration,,1,8,,,H,,4274,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line
11854,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618258,,,Autocuration,,1,8,,,H,,4275,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM
11854,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618259,,,Autocuration,,1,8,,,H,,4276,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM
10193,,,12166,,,,BAO_0000019,B,,CHEMBL618260,,,Autocuration,,1,8,,,H,,4277,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618215,,,Autocuration,,1,8,,,H,,4278,Percent inhibition against RBL-1 5-LO in vitro at 10 uM
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618390,,,Autocuration,,1,8,,,H,,4279,Percent inhibition against RBL-1 5-LO in vitro at 100 uM
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618391,,,Autocuration,,1,8,,,H,,4280,Percent inhibition against RBL-1 5-LO in vitro at 30 uM
9295,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618392,,,Autocuration,,1,8,,,H,,4281,Percent inhibition against RBL-1 5-LO in vitro at 300 uM
165,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618393,,,Autocuration,,1,8,,,H,,4282,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM
11311,,,12166,,,,BAO_0000219,B,,CHEMBL618394,,,Autocuration,,1,8,,,H,,4283,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration
10489,702.0,RBL-1,12166,9606.0,,,BAO_0000219,B,,CHEMBL618395,,,Expert,,1,8,,Homo sapiens,H,,4284,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
10489,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL618396,,,Expert,,1,9,,Rattus norvegicus,D,,4285,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1)
10489,702.0,RBL-1,12166,10116.0,,,BAO_0000219,B,,CHEMBL858253,,,Expert,,1,9,,Rattus norvegicus,D,,4286,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1)
14799,,,12166,10116.0,,,BAO_0000019,B,,CHEMBL618397,,,Autocuration,,1,9,,Rattus norvegicus,D,,4287,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells
9295,,,12054,3847.0,,,BAO_0000357,B,,CHEMBL618398,,,Autocuration,,1,8,,Glycine max,H,,4288,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM)
16811,,,22226,,,,BAO_0000019,B,,CHEMBL618399,,,Autocuration,,1,0,,,U,,4289,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay"
168,,,55,,,,BAO_0000357,B,,CHEMBL618400,,,Expert,,1,8,,,H,,4290,In vitro inhibition of 5-Lipoxygenase; Inactive.
6309,,,55,,,,BAO_0000357,B,,CHEMBL618401,,,Autocuration,,1,8,,,H,,4291,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition
6309,,,55,,,,BAO_0000357,B,,CHEMBL618402,,,Autocuration,,1,8,,,H,,4292,Inhibitory concentration against 5-lipoxygenase; No inhibition
3092,702.0,RBL-1,55,,,,BAO_0000219,B,,CHEMBL876400,,,Autocuration,,1,8,,,H,,4293,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig
168,,,55,,,,BAO_0000357,B,,CHEMBL618403,,,Expert,,1,8,,,H,,4294,Inhibitory activity against 5-lipoxygenase.
168,,,55,,,,BAO_0000357,B,,CHEMBL618404,,,Autocuration,,1,8,,,H,,4295,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive
168,,,55,,,,BAO_0000357,B,,CHEMBL618405,,,Autocuration,,1,8,,,H,,4296,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM
168,,,55,,,,BAO_0000357,B,,CHEMBL618406,,,Autocuration,,1,8,,,H,,4297,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM
12338,,,55,,,,BAO_0000019,F,,CHEMBL618407,,,Expert,,1,8,,,H,,4298,Inhibitory concentration against arachidonic acid 5-lipoxygenation
4501,,,55,,,,BAO_0000357,B,,CHEMBL618408,,,Autocuration,,1,8,,,H,,4299,Tested for the inhibitory activity against 5-lipoxygenase
1132,,,55,,,,BAO_0000357,B,,CHEMBL618409,,,Autocuration,,1,8,,,H,,4300,Compound was tested for its inhibitory activity against 5-lipoxygenase
2117,,,55,,,,BAO_0000357,B,,CHEMBL618410,,,Autocuration,,1,8,,,H,,4301,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed
168,,,55,,,,BAO_0000357,B,,CHEMBL618411,,,Autocuration,,1,8,,,H,,4302,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active
168,,,55,,,,BAO_0000357,B,,CHEMBL618412,,,Autocuration,,1,8,,,H,,4303,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined
13575,702.0,RBL-1,12166,,,,BAO_0000219,B,,CHEMBL618413,,,Autocuration,,1,8,,,H,,4304,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase
11089,,,12166,,,,BAO_0000357,B,,CHEMBL618414,,,Autocuration,,1,8,,,H,,4305,
216,,,10102,,,,BAO_0000357,B,,CHEMBL618415,,,Autocuration,,1,8,,,H,,4306,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP)
13165,,,10102,,,,BAO_0000019,B,,CHEMBL618416,,,Autocuration,,1,8,,,H,,4307,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations
3278,,,10102,,,,BAO_0000357,B,,CHEMBL876401,,,Autocuration,,1,8,,,H,,4308,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.
3278,,,10102,,,,BAO_0000357,B,,CHEMBL618417,,,Expert,,1,8,,,H,,4309,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.
11966,,,10102,,,,BAO_0000357,B,,CHEMBL618418,,,Autocuration,,1,8,,,H,,4310,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein
175,,,10102,,,,BAO_0000357,B,,CHEMBL618419,,,Autocuration,,1,8,,,H,,4311,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein"
175,,,10102,,,,BAO_0000357,B,,CHEMBL618420,,,Autocuration,,1,8,,,H,,4312,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)"
13449,,,10102,,,,BAO_0000357,B,,CHEMBL618421,,,Autocuration,,1,8,,,H,,4313,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay
12014,,,11238,,,,BAO_0000019,B,,CHEMBL618422,,,Autocuration,,1,8,,,H,,4314,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane
12014,,,11238,,,,BAO_0000019,B,,CHEMBL618423,,,Autocuration,,1,8,,,H,,4315,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant)
12014,,,11238,,,,BAO_0000019,B,,CHEMBL618424,,,Autocuration,,1,8,,,H,,4316,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate)
99,,,100284,,,,BAO_0000220,B,,CHEMBL618425,,,Intermediate,,1,2,,,S,,4317,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit
4349,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL618426,,,Autocuration,,1,0,,Homo sapiens,U,,4318,The dark toxicity against 543 human galactophore carcinoma cells
4071,390.0,Panel (56 tumour cell lines),80623,9606.0,,,BAO_0000219,F,,CHEMBL618427,,,Expert,,1,1,,Homo sapiens,N,,4319,Tested in vitro for cytotoxicity against 56 human tumor cell lines
17589,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL618428,,,Expert,,1,1,,Homo sapiens,N,,4320,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value
15002,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL618429,,,Intermediate,,1,1,,Homo sapiens,N,,4321,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.
13958,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL618430,,,Intermediate,,1,1,,Homo sapiens,N,,4322,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line"
17589,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL618431,,,Expert,,1,1,,Homo sapiens,N,,4323,Growth inhibition against human 5637 cell lines
16748,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL883799,,,Expert,,1,1,,Homo sapiens,N,,4324,Antitumor activity against human bladder carcinoma 5637 cells.
16747,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL618432,,,Intermediate,,1,1,,Homo sapiens,N,,4325,Antitumor activity against human bladder carcinoma 5637 cells
16747,345.0,5637,80008,9606.0,,,BAO_0000219,F,,CHEMBL618433,,,Intermediate,,1,1,,Homo sapiens,N,,4326,Antitumor activity against human bladder carcinoma 5637 cells
15285,,,10443,9913.0,,,BAO_0000357,B,,CHEMBL618434,,,Expert,,1,9,,Bos taurus,D,,4327,In vitro inhibition of bovine trypsin(Trp).
3726,407.0,CV-1,240,9527.0,,,BAO_0000219,B,,CHEMBL618435,,,Expert,,1,8,,Cercopithecidae,H,,4328,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor
5033,,,10577,,,,BAO_0000357,B,,CHEMBL876402,,,Autocuration,,1,8,,,H,,4329,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor
11756,,,104698,,,,BAO_0000019,F,,CHEMBL618436,,,Autocuration,,1,6,,,H,,4330,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.
11953,,,22226,,,,BAO_0000218,F,,CHEMBL618437,,,Autocuration,,1,0,,,U,In vivo,4331,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat
5033,,,20033,10141.0,,,BAO_0000357,B,,CHEMBL618438,,,Intermediate,,1,9,,Cavia porcellus,D,,4332,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor
11347,,,17045,10116.0,,,BAO_0000251,A,,CHEMBL883800,,Microsomes,Expert,,1,8,,Rattus norvegicus,H,,4333,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
11347,,,17045,10116.0,,,BAO_0000251,A,,CHEMBL618439,,Microsomes,Expert,,1,8,,Rattus norvegicus,H,,4334,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes
1229,,,22226,,,,BAO_0000019,F,,CHEMBL618440,,,Intermediate,,1,0,,,U,,4335,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
1229,,,22226,,,,BAO_0000019,F,,CHEMBL618441,,,Intermediate,,1,0,,,U,,4336,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive
17588,,,11938,5691.0,,,BAO_0000019,B,,CHEMBL618442,,,Expert,,1,8,,Trypanosoma brucei,H,,4337,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli
17588,,,11938,5691.0,,,BAO_0000019,B,,CHEMBL618443,,,Autocuration,,1,8,,Trypanosoma brucei,H,,4338,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition
17588,,,11938,9940.0,,,BAO_0000019,B,,CHEMBL619158,,,Expert,,1,8,,Ovis aries,H,,4339,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver
17588,,,11938,9940.0,,,BAO_0000019,B,,CHEMBL620974,,,Autocuration,,1,8,,Ovis aries,H,,4340,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition
16485,,,11938,,,,BAO_0000357,B,,CHEMBL620975,,,Autocuration,,1,8,,,H,,4341,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase
4337,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL620976,,,Intermediate,,1,0,,Homo sapiens,U,,4342,Average inhibitory concentration against 60 human cell lines was reported
4112,,,22226,9606.0,,,BAO_0000019,F,,CHEMBL620977,,,Expert,,1,0,,Homo sapiens,U,,4343,Inhibition of proliferation in NCI panel of 60 human tumor cell lines
16160,542.0,Panel NCI-60 (60 carcinoma cell lines),80315,9606.0,,,BAO_0000219,F,,CHEMBL620978,,,Intermediate,,1,1,,Homo sapiens,N,,4344,Cancer specificity was measured from the +/- value under average log LC50 60-cell line
16160,542.0,Panel NCI-60 (60 carcinoma cell lines),80315,9606.0,,,BAO_0000219,F,,CHEMBL620979,,,Intermediate,,1,1,,Homo sapiens,N,,4345,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. 
17376,542.0,Panel NCI-60 (60 carcinoma cell lines),80315,,,,BAO_0000219,F,,CHEMBL620980,,,Expert,,1,1,,,N,,4346,In vitro mean growth inhibitory activity against 60-cell panel
17376,542.0,Panel NCI-60 (60 carcinoma cell lines),80315,,,,BAO_0000219,F,,CHEMBL620981,,,Expert,,1,1,,,N,,4347,In vitro mean growth lethal concentration against 60-cell panel
17376,542.0,Panel NCI-60 (60 carcinoma cell lines),80315,,,,BAO_0000219,F,,CHEMBL620982,,,Expert,,1,1,,,N,,4348,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel
17376,542.0,Panel NCI-60 (60 carcinoma cell lines),80315,,,,BAO_0000219,F,,CHEMBL620983,,,Expert,,1,1,,,N,,4349,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel
3241,,,104775,,,,BAO_0000019,F,,CHEMBL620984,,,Autocuration,,1,4,,,H,,4350,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
3241,,,104775,,,,BAO_0000019,F,,CHEMBL620985,,,Autocuration,,1,4,,,H,,4351,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM
3725,,,275,,,,BAO_0000357,B,,CHEMBL620986,,,Expert,,1,8,,,H,,4352,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha
10805,,,50425,5833.0,,,BAO_0000218,F,,CHEMBL620987,,,Expert,,1,1,,Plasmodium falciparum,N,,4353,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase
10805,,,50425,5833.0,,,BAO_0000218,F,,CHEMBL620988,,,Expert,,1,1,,Plasmodium falciparum,N,,4354,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells
10805,,,50425,5833.0,,,BAO_0000218,F,,CHEMBL620989,,,Expert,,1,1,,Plasmodium falciparum,N,,4355,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.
10805,,,50425,5833.0,,,BAO_0000218,F,,CHEMBL620990,,,Expert,,1,1,,Plasmodium falciparum,N,,4356,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.
10805,,,50425,5833.0,,,BAO_0000218,F,,CHEMBL620991,,,Intermediate,,1,1,,Plasmodium falciparum,N,,4357,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.
10144,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL620992,,,Intermediate,,1,1,,Mus musculus,N,,4358,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
10144,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL620993,,,Intermediate,,1,1,,Mus musculus,N,,4359,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
10144,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL620994,,,Intermediate,,1,1,,Mus musculus,N,,4360,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice
10144,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL620995,,,Intermediate,,1,1,,Mus musculus,N,,4361,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
10144,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL620996,,,Intermediate,,1,1,,Mus musculus,N,,4362,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
10144,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL875581,,,Intermediate,,1,1,,Mus musculus,N,,4363,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL620997,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4364,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL620998,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4365,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL620999,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4366,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days)
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621000,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4367,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621001,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4368,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621002,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4369,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621003,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4370,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621004,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4371,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg"
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621005,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4372,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days)
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621006,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4373,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days)
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621007,,,Autocuration,,1,0,,Mus musculus,U,In vivo,4374,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg
10144,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621008,,,Autocuration,,1,0,,Mus musculus,U,,4375,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice
10144,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL621009,,,Autocuration,,1,0,,Mus musculus,U,,4376,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice
10144,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL857705,,,Autocuration,,1,0,,Mus musculus,U,,4377,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice
10144,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL619828,,,Autocuration,,1,0,,Mus musculus,U,,4378,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL619829,,,Autocuration,,1,0,,Mus musculus,U,,4379,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL619830,,,Autocuration,,1,0,,Mus musculus,U,,4380,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL619831,,,Autocuration,,1,0,,Mus musculus,U,,4381,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally
10685,,,22224,10090.0,,,BAO_0000218,F,,CHEMBL619832,,,Autocuration,,1,0,,Mus musculus,U,,4382,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally
10685,,,22224,10090.0,,,BAO_0000218,A,,CHEMBL619833,,,Autocuration,,1,0,,Mus musculus,U,,4383,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10
10685,,,22224,10090.0,,,BAO_0000218,A,,CHEMBL619834,,,Autocuration,,1,0,,Mus musculus,U,,4384,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10
10685,,,22224,10090.0,,,BAO_0000218,A,,CHEMBL619835,,,Autocuration,,1,0,,Mus musculus,U,,4385,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10
10685,,,22224,10090.0,,,BAO_0000218,A,,CHEMBL619836,,,Autocuration,,1,0,,Mus musculus,U,,4386,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10
8831,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL619837,,,Intermediate,,1,1,,Mus musculus,N,,4387,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg"
11704,,,22224,,,,BAO_0000218,F,,CHEMBL619838,,,Autocuration,,1,0,,,U,In vivo,4388,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg
11704,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619839,,,Intermediate,,1,1,,Mus musculus,N,,4389,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10
10685,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL619840,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4390,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line
10685,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL619841,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4391,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition
11368,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL857704,,,Expert,,1,1,,Mus musculus,N,,4392,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8)
11368,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL619842,,,Intermediate,,1,1,,Mus musculus,N,,4393,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8)
11368,850.0,6C3HED,80628,10090.0,,,BAO_0000218,F,,CHEMBL619843,,,Expert,,1,1,,Mus musculus,N,,4394,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8)
17763,,,22226,1280.0,,,BAO_0000019,B,,CHEMBL619844,,,Autocuration,,1,0,,Staphylococcus aureus,U,,4395,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase"
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL857855,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4396,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619845,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4397,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619846,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4398,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619847,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4399,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL619848,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4400,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620893,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4401,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620894,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4402,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620895,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4403,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620896,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4404,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620897,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4405,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620898,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4406,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM
7411,,,22226,10116.0,,,BAO_0000251,B,2107.0,CHEMBL620899,,Microsomes,Autocuration,Liver,1,0,,Rattus norvegicus,U,,4407,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM
347,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL620900,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4408,The apparent total plasma clearance in monkey
3341,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620901,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4409,Compound was evaluated for Hepatic clearance in monkey
17853,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620902,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4410,Lower clearance in monkey (i.v.) at 0.5 mpk
4514,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620903,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4411,Plasma clearance in rhesus monkey
6062,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620904,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4412,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg
6821,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620905,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4413,Plasma clearance of compound was determined in monkey
6057,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620906,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4414,Plasma clearance was calculated in rhesus monkey
5145,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL875420,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4415,Plasma clearance in rhesus monkey
6641,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620907,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4416,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
5472,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620908,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4417,Plasma clearance was evaluated in rhesus
4257,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620909,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4418,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose
5546,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620910,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4419,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
5334,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620911,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4420,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
5334,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620912,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4421,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
17509,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620913,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4422,Cmax 24 hr after 2 mg/kg oral administration in monkeys
6535,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620914,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4423,Cmax in monkey after administration of 1 mg/kg iv
5668,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620915,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4424,Cmax was determine after peroral administration at 10 mpk in Rhesus
5922,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620916,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4425,Cmax in cynomolgus monkey by iv administration
5922,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620917,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4426,Cmax in cynomolgus monkey by po administration
6078,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620918,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4427,Cmax value evaluated in monkey
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620919,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4428,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey
3249,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL620920,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4429,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg
3249,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL620921,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4430,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg
5553,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL620922,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4431,Maximal plasma concentration in squirrel monkeys
1916,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620923,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4432,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
6227,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL620924,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4433,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620925,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4434,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620926,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4435,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620927,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4436,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620928,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4437,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620929,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4438,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys
6221,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL620930,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4439,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined
167,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620931,,,Autocuration,,1,0,,Cercopithecidae,U,,4440,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours
167,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620932,,,Autocuration,,1,0,,Cercopithecidae,U,,4441,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours
4257,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620933,,,Autocuration,,1,0,,monkey,U,In vivo,4442,Absolute bioavailability was evaluated in monkey
6221,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620934,,,Autocuration,,1,0,,monkey,U,In vivo,4443,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined
17667,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620935,,,Autocuration,,1,0,,monkey,U,In vivo,4444,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration
17267,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620936,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4445,Bioavailability of compound was determined in rhesus monkey
4256,,,22224,38020.0,,,BAO_0000218,A,,CHEMBL620937,,,Autocuration,,1,0,,marmosets,U,In vivo,4446,Bioavailability determined after oral administration in marmoset
4256,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL620938,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4447,Oral bioavailability in cynomolgus monkey
17853,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620939,,,Autocuration,,1,0,,monkey,U,In vivo,4448,Bioavailability in monkey (p.o.) at 2.0 mpk
16365,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620940,,,Autocuration,,1,0,,monkey,U,In vivo,4449,Bioavailability was evaluated after oral administration in monkey
1916,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL620941,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4450,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
5334,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620942,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4451,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
5334,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620943,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4452,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
17592,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620944,,,Autocuration,,1,0,,monkey,U,In vivo,4453,Bioavailability of the compound was determined in monkey
1399,,,22224,9521.0,,,BAO_0000218,A,,CHEMBL620945,,,Autocuration,,1,0,,Saimiri sciureus,U,In vivo,4454,Bioavailability in squirrel monkey (dose 5 mg/kg)
4809,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620946,,,Autocuration,,1,0,,monkey,U,In vivo,4455,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg)
3341,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620947,,,Autocuration,,1,0,,monkey,U,In vivo,4456,Oral bioavailability in monkey
64,,,22224,9521.0,,,BAO_0000218,A,,CHEMBL620948,,,Autocuration,,1,0,,Saimiri sciureus,U,In vivo,4457,Compound was tested for bioavailability in squirrel monkey
5005,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620949,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4458,Oral bioavailability in Rhesus monkey
5005,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620950,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4459,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.)
5237,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL620951,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4460,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable
5237,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL620952,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4461,Oral bioavailability in cynomolgus monkeys was determined; Acceptable
5302,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL875421,,,Autocuration,,1,0,,monkey,U,In vivo,4462,Oral bioavailability in monkey (dose 5 mg/kg)
17667,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620953,,,Autocuration,,1,0,,monkey,U,In vivo,4463,Oral bioavailability of compound at 5 mg/kg in monkey
6161,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873491,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4464,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog
6161,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620954,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4465,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog
3854,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL620955,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,4466,Plasma half life determined
993,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL618097,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,4467,Plasma half life in dog
4514,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL618268,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,4468,Plasma half-life in Beagle dogs
5334,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL618269,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,4469,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
5334,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL618270,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,4470,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male)
1466,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618271,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4471,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog
1466,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873493,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4472,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621031,,,Intermediate,,1,1,,Canis lupus familiaris,N,,4473,Tested for the half life period in dog
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621032,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4474,Tested for the half life period in dog at dosage of 10 mpk
3880,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621033,,,Intermediate,,1,1,,Canis lupus familiaris,N,,4475,The compound was tested for half life in dog
3639,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621034,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,4476,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma."
3880,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621035,,,Intermediate,,1,1,,Canis lupus familiaris,N,,4477,The half life was determined
3918,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621036,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,4478,The plasma half-life in dogs
16452,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621037,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,4479,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M
17796,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619812,,,Intermediate,,1,1,,Canis lupus familiaris,N,,4480,Half life in dog
5983,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619813,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4481,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.
1466,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873335,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4482,tmax upon peroral administration of 10.0 mg/Kg dose in dog
16456,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619814,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,4483,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg
6113,,,50506,9669.0,,,BAO_0000218,A,,CHEMBL619815,,,Expert,,1,1,,Mustela putorius furo,N,In vivo,4484,Cmax in ferrets after 30 mg/kg oral dose
6113,,,50506,9669.0,,,BAO_0000218,F,,CHEMBL619816,,,Expert,,1,1,,Mustela putorius furo,N,In vivo,4485,Emesis in ferrets at 30 mg/kg oral dose
17796,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL619817,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4486,Bioavailability in cynomolgus monkey
17796,,,100710,9541.0,,,BAO_0000218,A,,CHEMBL619818,,,Intermediate,,1,1,,Macaca fascicularis,N,In vivo,4487,Volume of distribution in cynomolgus
5308,,,22224,10141.0,,,BAO_0000218,A,1969.0,CHEMBL619819,,,Autocuration,Plasma,1,0,,Cavia porcellus,U,,4488,AUC tested in guinea pig when 3 mg/kg dose was given perorally
4877,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL619820,,,Autocuration,,1,0,,Cavia porcellus,U,,4489,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
4876,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL875419,,,Autocuration,,1,0,,Cavia porcellus,U,,4490,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg"
4878,,,22224,10141.0,,,BAO_0000218,A,1969.0,CHEMBL619821,,,Autocuration,Plasma,1,0,,Cavia porcellus,U,In vivo,4491,AUC in guinea pig after 3mg/kg oral dose
5308,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL619822,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4492,Bioavailability in guinea pig was tested
4877,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL619823,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4493,Tested for oral bioavailability in guinea pig at 5 mg/kg
4876,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL619824,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4494,Tested for the oral bioavailability of the compound
4876,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL619825,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4495,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported
5308,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL619826,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4496,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally
4877,,,22224,10141.0,,,BAO_0000218,A,2048.0,CHEMBL619827,,,Autocuration,Lung,1,0,,Cavia porcellus,U,In vivo,4497,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg
4878,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618167,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4498,Cmax in guinea pig after 3mg/kg oral dose
5689,,,22224,10141.0,,,BAO_0000019,A,178.0,CHEMBL618168,,,Autocuration,Blood,1,0,,Cavia porcellus,U,,4499,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,955.0,CHEMBL618169,,,Autocuration,Brain,1,0,,Cavia porcellus,U,,4500,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,,CHEMBL618170,,,Autocuration,,1,0,,Cavia porcellus,U,,4501,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,160.0,CHEMBL618171,,,Autocuration,Intestine,1,0,,Cavia porcellus,U,,4502,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,2113.0,CHEMBL618172,,,Autocuration,Kidney,1,0,,Cavia porcellus,U,,4503,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,2107.0,CHEMBL618173,,,Autocuration,Liver,1,0,,Cavia porcellus,U,,4504,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,,CHEMBL618174,,,Autocuration,,1,0,,Cavia porcellus,U,,4505,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram
5689,,,22224,10141.0,,,BAO_0000019,A,2106.0,CHEMBL875408,,,Autocuration,Spleen,1,0,,Cavia porcellus,U,,4506,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram
14465,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL839827,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4507,Elimination T1/2 in Guinea pig (PO dose)
5689,,,22224,10141.0,,,BAO_0000019,A,,CHEMBL618175,,,Autocuration,,1,0,,Cavia porcellus,U,,4508,Partition coefficient was measured as -log (counts per min )
611,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618176,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4509,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism
611,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618177,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4510,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism
14465,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618178,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4511,Elimination T1/2 in Guinea pig (PO dose)
4876,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618179,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4512,"Tested for the half life period of the compound, intravenously"
5689,,,22224,10141.0,,,BAO_0000019,A,,CHEMBL873489,,,Autocuration,,1,0,,Cavia porcellus,U,,4513,Half-life was measured
7515,,,22224,10141.0,,,BAO_0000019,A,,CHEMBL618180,,,Autocuration,,1,0,,Cavia porcellus,U,,4514,The time required for onset of inotropy after addition of a single dose of delta F75
17667,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618181,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4515,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration
17667,,,22224,10141.0,,,BAO_0000218,A,,CHEMBL618182,,,Autocuration,,1,0,,Cavia porcellus,U,In vivo,4516,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration
4727,,,22224,10029.0,,,BAO_0000218,A,,CHEMBL618183,,,Autocuration,,1,0,,Cricetulus griseus,U,In vivo,4517,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618184,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4518,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618185,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4519,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618186,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4520,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618187,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4521,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618188,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4522,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL875409,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4523,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618189,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4524,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
3655,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL618190,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4525,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL618191,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4526,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL618192,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4527,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL618193,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,4528,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL618194,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,4529,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL618195,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,4530,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL618196,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,4531,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL618197,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,4532,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL618198,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,4533,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL618199,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,4534,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL618200,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,4535,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL618201,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,4536,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL618202,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,4537,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL618203,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,4538,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL618204,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,4539,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL618205,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,4540,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL618206,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,4541,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL618207,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,4542,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL618208,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,4543,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL618932,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,4544,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL618933,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,4545,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL618934,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,4546,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL618935,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,4547,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL618936,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,4548,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL618937,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,4549,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL618938,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,4550,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL619104,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,4551,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL619105,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,4552,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL619106,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,4553,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL619107,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,4554,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL875410,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,4555,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL619108,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,4556,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours
3655,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL619109,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,4557,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619110,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4558,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
16597,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL619111,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4559,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619112,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4560,MRT value at a dose of 10 mg/kg intravenous administration in mice.
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619113,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4561,MRT value at a dose of 10 mg/kg peroral administration in mice.
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619114,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4562,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL619115,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4563,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg
3830,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619116,,,Intermediate,,1,1,,Homo sapiens,N,,4564,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr
3829,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619117,,,Intermediate,,1,1,,Homo sapiens,N,,4565,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr
2040,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619118,,,Intermediate,,1,1,,Homo sapiens,N,,4566,Compound was evaluated for cytotoxicity against A2780 cell lines.
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619119,,,Intermediate,,1,1,,Homo sapiens,N,,4567,Potentiation of growth inhibition of A2780 by compound alone in experiment 1
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619120,,,Intermediate,,1,1,,Homo sapiens,N,,4568,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619121,,,Intermediate,,1,1,,Homo sapiens,N,,4569,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619122,,,Intermediate,,1,1,,Homo sapiens,N,,4570,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619123,,,Intermediate,,1,1,,Homo sapiens,N,,4571,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619124,,,Intermediate,,1,1,,Homo sapiens,N,,4572,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
2859,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619125,,,Intermediate,,1,1,,Homo sapiens,N,,4573,Compound was evaluated for cytotoxicity against A2780 cell line
5618,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL875411,,,Intermediate,,1,1,,Homo sapiens,N,,4574,In vitro inhibitory activity against human tumor cell line A2780
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619126,,,Intermediate,,1,1,,Homo sapiens,N,,4575,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619127,,,Intermediate,,1,1,,Homo sapiens,N,,4576,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619128,,,Intermediate,,1,1,,Homo sapiens,N,,4577,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619129,,,Intermediate,,1,1,,Homo sapiens,N,,4578,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2
2113,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619130,,,Intermediate,,1,1,,Homo sapiens,N,,4579,The compound was tested for cytotoxic potency against A2780 human tumor cell lines
2113,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619131,,,Intermediate,,1,1,,Homo sapiens,N,,4580,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.
16745,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619132,,,Intermediate,,1,1,,Homo sapiens,N,,4581,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.
16597,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL619133,,,Expert,,1,1,,Homo sapiens,N,,4582,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619134,,,Intermediate,,1,1,,Homo sapiens,N,,4583,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1
15684,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619135,,,Intermediate,,1,1,,Homo sapiens,N,,4584,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2
2040,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619136,,,Intermediate,,1,1,,Homo sapiens,N,,4585,Compound was evaluated for cytotoxicity against A2780 cis cell lines.
2040,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619137,,,Intermediate,,1,1,,Homo sapiens,N,,4586,Relative resistance factor in A2780 cisplatin-resistant line
16165,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL883713,,,Intermediate,,1,1,,Homo sapiens,N,,4587,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells
16165,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL875412,,,Intermediate,,1,1,,Homo sapiens,N,,4588,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.
16597,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL619138,,,Expert,,1,1,,Homo sapiens,N,,4589,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
16597,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL619262,,,Expert,,1,1,,Homo sapiens,N,,4590,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7
3992,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619139,,,Intermediate,,1,1,,Homo sapiens,N,,4591,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test
10553,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619140,,,Intermediate,,1,1,,Homo sapiens,N,,4592,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619141,,,Intermediate,,1,1,,Homo sapiens,N,,4593,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619142,,,Intermediate,,1,1,,Homo sapiens,N,,4594,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619143,,,Intermediate,,1,1,,Homo sapiens,N,,4595,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619144,,,Intermediate,,1,1,,Homo sapiens,N,,4596,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619145,,,Intermediate,,1,1,,Homo sapiens,N,,4597,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619146,,,Intermediate,,1,1,,Homo sapiens,N,,4598,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8
15569,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619147,,,Intermediate,,1,1,,Homo sapiens,N,,4599,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure
17420,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619148,,,Intermediate,,1,1,,Homo sapiens,N,,4600,Antiproliferative effect of compound on A2780/DX cell line
17420,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619149,,,Intermediate,,1,1,,Homo sapiens,N,,4601,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined
15099,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619150,,,Intermediate,,1,1,,Homo sapiens,N,,4602,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI)
15099,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619151,,,Intermediate,,1,1,,Homo sapiens,N,,4603,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI)
17672,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL883794,,,Intermediate,,1,1,,Homo sapiens,N,,4604,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines
17672,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619152,,,Intermediate,,1,1,,Homo sapiens,N,,4605,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines
17270,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619153,,,Intermediate,,1,1,,Homo sapiens,N,,4606,In vitro cytotoxicity against A2780ADR cell line
17270,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619154,,,Intermediate,,1,1,,Homo sapiens,N,,4607,In vitro cytotoxicity against A2780CIS cell line
5574,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619155,,,Intermediate,,1,1,,Homo sapiens,N,,4608,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours
2113,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619156,,,Intermediate,,1,1,,Homo sapiens,N,,4609,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619157,,,Intermediate,,1,1,,Homo sapiens,N,,4610,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines"
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619797,,,Intermediate,,1,1,,Homo sapiens,N,,4611,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines"
17839,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL619798,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4612,Oral bioavailability of compound in rhesus macaques
6821,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL619799,,,Autocuration,,1,0,,monkey,U,In vivo,4613,Oral bioavailability in monkey
6078,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL619800,,,Autocuration,,1,0,,monkey,U,In vivo,4614,Oral bioavailability evaluated in monkey
6535,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL619801,,,Autocuration,,1,0,,monkey,U,In vivo,4615,Oral bioavailability in monkey (dose 1 mg/kg p.o.)
4449,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL619802,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4616,Oral bioavailability in Rhesus monkey
6057,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL619803,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4617,Oral bioavailability was calculated in rhesus monkey
5922,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL619965,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4618,Oral bioavailability in cynomolgus monkey
5940,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL619966,,,Autocuration,,1,0,,monkey,U,In vivo,4619,Oral bioavailability in monkey
6265,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL619967,,,Autocuration,,1,0,,monkey,U,In vivo,4620,Oral bioavailability in monkey
6265,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620073,,,Autocuration,,1,0,,monkey,U,In vivo,4621,Oral bioavailability in monkey (dose 1 mg/kg)
6265,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620074,,,Autocuration,,1,0,,monkey,U,In vivo,4622,Oral bioavailability in monkey (dose 5 mg/kg)
5940,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620075,,,Autocuration,,1,0,,monkey,U,In vivo,4623,Oral bioavailability in monkey
5940,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620076,,,Autocuration,,1,0,,monkey,U,In vivo,4624,Oral bioavailability in monkey
4514,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620077,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4625,Oral bioavailability in rhesus monkey
5546,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620078,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4626,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration
5553,,,22224,9521.0,,,BAO_0000218,A,,CHEMBL620079,,,Autocuration,,1,0,,Saimiri sciureus,U,In vivo,4627,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg
6641,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620080,,,Autocuration,,1,0,,monkey,U,In vivo,4628,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
5472,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620081,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4629,Oral bioavailability in Rhesus monkey
5668,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620082,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4630,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.)
5711,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL620083,,,Autocuration,,1,0,,monkey,U,In vivo,4631,Oral bioavailability in monkey at 10 mg/kg of the compound
5145,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL620084,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4632,Bioavailability in Rhesus monkey
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620085,,,Autocuration,,1,0,,Cercopithecidae,U,,4633,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL874595,,,Autocuration,,1,0,,Cercopithecidae,U,,4634,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3249,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL873352,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4635,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg
3249,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620086,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4636,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620087,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4637,Mean residence time was determined after intravenous administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620088,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4638,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620089,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4639,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620090,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4640,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620091,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4641,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg)
14294,,,22224,9527.0,,,BAO_0000251,A,,CHEMBL620092,,Microsomes,Autocuration,,1,0,,Cercopithecidae,U,,4642,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak)
14294,,,22224,9527.0,,,BAO_0000251,A,,CHEMBL620093,,Microsomes,Autocuration,,1,0,,Cercopithecidae,U,,4643,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak)
14294,,,22224,9527.0,,,BAO_0000251,A,,CHEMBL620094,,Microsomes,Autocuration,,1,0,,Cercopithecidae,U,,4644,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak)
14294,,,22224,9527.0,,,BAO_0000251,A,,CHEMBL620095,,Microsomes,Autocuration,,1,0,,Cercopithecidae,U,,4645,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak)
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620096,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4646,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620097,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4647,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL620098,,,Autocuration,,1,0,,Cercopithecidae,U,,4648,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620099,,,Autocuration,,1,0,,Cercopithecidae,U,,4649,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620100,,,Autocuration,,1,0,,Cercopithecidae,U,,4650,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
6821,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL620101,,,Autocuration,,1,0,,Cercopithecidae,U,,4651,Elimination Half-life of compound was determined in monkey
17267,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL620102,,,Autocuration,,1,0,,Cercopithecidae,U,,4652,Half life of compound was determined in rhesus monkey
5819,,,22224,9527.0,,,BAO_0000366,A,1969.0,CHEMBL620103,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,,4653,Half life in monkey plasma
5819,,,22224,9527.0,,,BAO_0000366,A,1969.0,CHEMBL620104,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,,4654,Half life in monkey plasma; Not detected
1916,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL874596,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4655,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
17509,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL873490,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4656,Half-life 24 hr after 2 mg/kg iv administration in monkeys
1399,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL620105,,,Autocuration,,1,0,,Cercopithecidae,U,,4657,Terminal half life of the compound.
1916,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620780,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4658,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620781,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4659,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg)
5546,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620956,,,Autocuration,,1,0,,Cercopithecidae,U,,4660,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
3443,,,22224,9527.0,,,BAO_0000218,A,1088.0,CHEMBL620957,,,Autocuration,Urine,1,0,,Cercopithecidae,U,,4661,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3443,,,22224,9527.0,,,BAO_0000218,A,1088.0,CHEMBL620958,,,Autocuration,Urine,1,0,,Cercopithecidae,U,,4662,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
4257,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620959,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4663,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose
6221,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620960,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4664,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined
5472,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL620961,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4665,Volume of distribution was evaluated in rhesus
4727,,,22224,10029.0,,,BAO_0000218,A,,CHEMBL620962,,,Autocuration,,1,0,,Cricetulus griseus,U,In vivo,4666,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration
4727,,,22224,10029.0,,,BAO_0000218,A,,CHEMBL620963,,,Autocuration,,1,0,,Cricetulus griseus,U,In vivo,4667,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration
4727,,,22224,10029.0,,,BAO_0000218,A,,CHEMBL620964,,,Autocuration,,1,0,,Cricetulus griseus,U,In vivo,4668,Bioavailability in hamster was determined
4727,,,22224,10029.0,,,BAO_0000218,A,,CHEMBL620965,,,Autocuration,,1,0,,Cricetulus griseus,U,In vivo,4669,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration
4727,,,22224,10029.0,,,BAO_0000218,A,,CHEMBL620966,,,Autocuration,,1,0,,Cricetulus griseus,U,In vivo,4670,Bioavailability in hamster at a dose of 3 mg/kg by oral administration
4727,,,22224,10029.0,,,BAO_0000221,A,178.0,CHEMBL620967,,,Autocuration,Blood,1,0,,Cricetulus griseus,U,,4671,Half life of compound was determined in hamster blood
1452,,,22224,9823.0,,,BAO_0000019,A,,CHEMBL620968,,,Autocuration,,1,0,,Sus scrofa,U,,4672,Michaelis-Menten constant of the compound.
1452,,,22224,9823.0,,,BAO_0000019,A,,CHEMBL874597,,,Autocuration,,1,0,,Sus scrofa,U,,4673,Vmax value was measured at 0 uM concentration of silyl ether.
1452,,,22224,9823.0,,,BAO_0000019,A,,CHEMBL620969,,,Autocuration,,1,0,,Sus scrofa,U,,4674,Vmax value was measured at 10 uM concentration of silyl ether.
1452,,,22224,9823.0,,,BAO_0000019,A,,CHEMBL620970,,,Autocuration,,1,0,,Sus scrofa,U,,4675,Vmax value was measured at 5 uM concentration of silyl ether.
11706,,,235,9606.0,,,BAO_0000357,B,,CHEMBL620971,,,Expert,,1,9,,Homo sapiens,D,,4676,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant
1916,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL620972,,,Autocuration,,1,0,,Homo sapiens,U,,4677,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration
17791,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620973,,,Autocuration,,1,0,,Homo sapiens,U,,4678,Compound was evaluated for area under the curve expressed as (h*ug/ml)
7766,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618243,,,Autocuration,,1,0,,Homo sapiens,U,,4679,Active metabolite of ifosfamide determined in humans; A-Active
6567,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618244,,,Autocuration,,1,0,,Homo sapiens,U,,4680,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis
6567,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618245,,,Autocuration,,1,0,,Homo sapiens,U,,4681,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1
6567,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618246,,,Autocuration,,1,0,,Homo sapiens,U,,4682,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2
6567,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618247,,,Autocuration,,1,0,,Homo sapiens,U,,4683,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace
17791,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL618248,,,Autocuration,,1,0,,Homo sapiens,U,,4684,Compound was evaluated for oral bioavailability in human
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618249,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4685,Metabolite of ifosfamide determined in urine; NF-Not found
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618250,,,Autocuration,,1,0,,Homo sapiens,U,,4686,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B)
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL874598,,,Autocuration,,1,0,,Homo sapiens,U,,4687,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618251,,,Autocuration,,1,0,,Homo sapiens,U,,4688,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618252,,,Autocuration,,1,0,,Homo sapiens,U,,4689,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618253,,,Autocuration,,1,0,,Homo sapiens,U,,4690,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618254,,,Autocuration,,1,0,,Homo sapiens,U,,4691,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C)
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618255,,,Autocuration,,1,0,,Homo sapiens,U,,4692,Percent of compound in healthy individuals (Group D)
4397,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618983,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,4693,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
17409,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618984,,,Autocuration,,1,0,,Homo sapiens,U,,4694,Binding towards human plasma protein at 10 uM
17409,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618985,,,Autocuration,,1,0,,Homo sapiens,U,,4695,Binding towards human plasma protein at 100 uM
17176,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618986,,,Autocuration,,1,0,,Homo sapiens,U,,4696,Human plasma protein binding activity was determined
15444,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618987,,,Autocuration,,1,0,,Homo sapiens,U,,4697,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.)
17267,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618988,,,Autocuration,,1,0,,Homo sapiens,U,,4698,Percent binding of compound towards human plasma protein was determined
5944,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618989,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4699,Plasma clearance in human liver microsomes
5668,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618990,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4700,In vitro intrinsic clearance in human liver microsome
5669,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618991,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4701,In vitro intrinsic clearance in human liver microsome
5041,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL876725,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,In vitro,4702,In vitro microsome metabolism clearance in human was determined
5041,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL618992,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,In vitro,4703,In vitro microsome metabolism clearance in human was determined; High
5041,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL618993,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,In vitro,4704,In vitro microsome metabolism clearance in human was determined; ND denotes no data
5676,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618994,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4705,Pharmacokinetic property (clearance) in human liver microsome
5944,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618995,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4706,Plasma clearance in human liver microsomes
17538,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618996,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4707,In vitro clearance in human liver microsomes
6331,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618997,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4708,Intrinsic clearance in human liver microsomes was determined
5948,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618998,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,4709,Intrinsic clearance in human liver microsomes was determined
5965,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL618999,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,4710,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human
1916,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL620223,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,4711,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration
5965,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL620224,,,Autocuration,,1,0,,Homo sapiens,U,,4712,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human
1299,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620225,,,Autocuration,,1,0,,Homo sapiens,U,,4713,Stability in human plasma 2 hr after incubation expressed as percent concentration
1299,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620226,,,Autocuration,,1,0,,Homo sapiens,U,,4714,Stability in human plasma 4 hr after incubation expressed as percent concentration
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL620227,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4715,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL876726,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4716,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL620228,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4717,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL620229,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4718,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620230,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4719,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620231,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4720,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620232,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4721,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620233,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4722,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg
14294,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620234,,,Intermediate,,1,1,,Mus musculus,N,,4723,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak)
14294,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620235,,,Intermediate,,1,1,,Mus musculus,N,,4724,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak)
14294,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620236,,,Intermediate,,1,1,,Mus musculus,N,,4725,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak)
6251,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL620237,,,Intermediate,Liver,1,1,,Mus musculus,N,,4726,In vitro metabolic potential in mouse liver microsomes
17582,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620238,,,Intermediate,,1,1,,Mus musculus,N,,4727,Ability of compound to bind to plasma protein was evaluated in HSA cells
17811,,,50594,10090.0,,,BAO_0000218,A,2369.0,CHEMBL620239,,,Intermediate,Adrenal gland,1,1,,Mus musculus,N,,4728,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled)
17811,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL620240,,,Intermediate,Brain,1,1,,Mus musculus,N,,4729,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g
17811,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL620241,,,Intermediate,Brain,1,1,,Mus musculus,N,,4730,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g
17811,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876727,,,Intermediate,,1,1,,Mus musculus,N,,4731,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled)
17811,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL620242,,,Intermediate,Kidney,1,1,,Mus musculus,N,,4732,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled)
17811,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620243,,,Intermediate,,1,1,,Mus musculus,N,,4733,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled)
5288,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620244,,,Intermediate,,1,1,,Mus musculus,N,,4734,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg
2717,,,50594,10090.0,,,BAO_0000218,A,1977.0,CHEMBL620245,,,Intermediate,Serum,1,1,,Mus musculus,N,,4735,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined
2717,,,50594,10090.0,,,BAO_0000218,A,1977.0,CHEMBL620246,,,Intermediate,Serum,1,1,,Mus musculus,N,,4736,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined
2717,,,50594,10090.0,,,BAO_0000218,A,1977.0,CHEMBL620247,,,Intermediate,Serum,1,1,,Mus musculus,N,,4737,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined
17753,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL620248,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,4738,Half life of compound was determined in plasma of mice at 24 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL873497,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,4739,Half life of compound was determined in plasma of mice at 40 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL620249,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,4740,Half life of compound was determined in plasma of mice at 5 mg/Kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620250,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4741,Half life after intraperitoneal administration in mice at 18 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620251,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4742,Half life after intraperitoneal administration in mice at 23 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620252,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4743,Half life after intraperitoneal administration in mice at 25 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620253,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4744,Half life after intraperitoneal administration in mice at 26 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL620254,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4745,Half life after intravenous administration in mice at 23 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620255,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4746,Half life after intravenous administration in mice at 24 uM/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620256,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4747,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876728,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4748,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620257,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4749,Maximum time required to reach Cp max was evaluated in mice after oral administration
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620258,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4750,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2)
4890,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620259,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4751,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period"
429,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620260,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4752,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg
17837,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL620261,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4753,Half life of compound in mouse blood following i.v. administration of 10 mg/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620262,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4754,Half life at a dose of 10 mg/kg intravenous administration in mice.
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620263,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4755,Half life at a dose of 10 mg/kg peroral administration in mice.
6619,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620264,,,Intermediate,,1,1,,Mus musculus,N,,4756,Half life in ob/ob mice
4066,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620265,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4757,Half-life at a single subcutaneous administration of 40 mg/kg in mice
4239,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620266,,,Intermediate,,1,1,,Mus musculus,N,,4758,Half-life was measured in mouse
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620267,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4759,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg
8999,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619364,,,Intermediate,,1,1,,Mus musculus,N,,4760,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation
8999,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619365,,,Intermediate,,1,1,,Mus musculus,N,,4761,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins
17641,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL619366,,,Intermediate,Brain,1,1,,Mus musculus,N,,4762,T2 in brain of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL619367,,,Intermediate,Kidney,1,1,,Mus musculus,N,,4763,T2 in kidney of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL619368,,,Intermediate,Liver,1,1,,Mus musculus,N,,4764,T2 in liver of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL619369,,,Intermediate,Lung,1,1,,Mus musculus,N,,4765,T2 in lungs of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL876729,,,Intermediate,Spleen,1,1,,Mus musculus,N,,4766,T2 in spleen of mice at the oral dose of 50 mg/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619370,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4767,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max
4890,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619371,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4768,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant"
429,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619372,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4769,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg
429,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620012,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4770,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620013,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4771,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL620014,,,Intermediate,,1,1,,Homo sapiens,N,,4772,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL620015,,,Intermediate,,1,1,,Homo sapiens,N,,4773,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines"
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621010,,,Intermediate,,1,1,,Homo sapiens,N,,4774,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines"
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621011,,,Intermediate,,1,1,,Homo sapiens,N,,4775,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines"
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621012,,,Intermediate,,1,1,,Homo sapiens,N,,4776,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
16913,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621013,,,Intermediate,,1,1,,Homo sapiens,N,,4777,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines"
17270,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621014,,,Intermediate,,1,1,,Homo sapiens,N,,4778,In vitro cytotoxicity against A2780TAX cell line
5618,481.0,A2780cisR,80017,9606.0,,,BAO_0000219,F,,CHEMBL618154,,,Intermediate,,1,1,,Homo sapiens,N,,4779,In vitro inhibitory activity against human tumor cell line A2780cis
17777,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618155,,,Expert,,1,1,,Homo sapiens,N,,4780,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines
16112,481.0,A2780cisR,80017,9606.0,,,BAO_0000219,F,,CHEMBL618156,,,Intermediate,,1,1,,Homo sapiens,N,,4781,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line
15748,481.0,A2780cisR,80017,9606.0,,,BAO_0000219,F,,CHEMBL618157,,,Intermediate,,1,1,,Homo sapiens,N,,4782,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
6633,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618328,,,Intermediate,,1,1,,Homo sapiens,N,,4783,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C
16930,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618329,,,Intermediate,,1,1,,Homo sapiens,N,,4784,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR
17496,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618330,,,Intermediate,,1,1,,Homo sapiens,N,,4785,Cytotoxicity against human ovarian carcinoma A2780cisR cell line
12989,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618331,,,Expert,,1,1,,Homo sapiens,N,,4786,In vitro antitumor activity against A2780cisR cell line.
4840,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618332,,,Intermediate,,1,1,,Homo sapiens,N,,4787,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin)
12989,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618333,,,Expert,,1,1,,Homo sapiens,N,,4788,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line
16745,481.0,A2780cisR,80017,9606.0,,,BAO_0000219,F,,CHEMBL618334,,,Intermediate,,1,1,,Homo sapiens,N,,4789,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay
16597,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618335,,,Expert,,1,1,,Homo sapiens,N,,4790,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation
16547,,,11736,10116.0,,,BAO_0000019,B,,CHEMBL618336,,,Expert,,1,9,,Rattus norvegicus,D,,4791,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes
16547,,,11736,,,,BAO_0000019,F,,CHEMBL618337,,,Expert,,1,8,,,H,,4792,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
16547,,,11736,10116.0,,,BAO_0000019,F,,CHEMBL618338,,,Expert,,1,9,,Rattus norvegicus,D,,4793,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity)
15856,722.0,HEK293,278,9606.0,,,BAO_0000219,F,,CHEMBL618339,,,Expert,,1,9,,Homo sapiens,D,,4794,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX
15856,722.0,HEK293,278,9606.0,,,BAO_0000219,F,,CHEMBL618340,,,Expert,,1,9,,Homo sapiens,D,,4795,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M
16547,,,11831,10090.0,,,BAO_0000019,B,,CHEMBL618341,,,Expert,,1,9,,Mus musculus,D,,4796,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes
16547,,,11831,,,,BAO_0000019,F,,CHEMBL618342,,,Expert,,1,8,,,H,,4797,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
16547,,,11831,10090.0,,,BAO_0000019,F,,CHEMBL618343,,,Expert,,1,9,,Mus musculus,D,,4798,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity)
17402,,,280,,,,BAO_0000357,B,,CHEMBL621038,,,Expert,,1,8,,,H,,4799,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM
11746,574.0,T-cells,22226,9606.0,,,BAO_0000219,F,,CHEMBL621039,,,Autocuration,,1,0,,Homo sapiens,U,,4800,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01)
11746,574.0,T-cells,22226,9606.0,,,BAO_0000219,F,,CHEMBL621040,,,Autocuration,,1,0,,Homo sapiens,U,,4801,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active
5455,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621041,,,Intermediate,,1,1,,Homo sapiens,N,,4802,Compound was evaluated for cytotoxic activity against human melanoma cell line A375
2068,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621042,,,Intermediate,,1,1,,Homo sapiens,N,,4803,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.
2683,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621043,,,Intermediate,,1,1,,Homo sapiens,N,,4804,In vitro antitumor activity against A375cell line extracted form melanoma
15313,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621044,,,Expert,,1,1,,Homo sapiens,N,,4805,Inhibition of cell growth in (A375) melan cell line
13739,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621045,,,Intermediate,,1,1,,Homo sapiens,N,,4806,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375
13739,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621046,,,Intermediate,,1,1,,Homo sapiens,N,,4807,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375
14750,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL621047,,,Intermediate,,1,1,,Homo sapiens,N,,4808,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.
14777,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621048,,,Intermediate,,1,1,,Homo sapiens,N,,4809,Antiproliferative activity measured against A427 human lung carcinoma
14777,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL883798,,,Intermediate,,1,1,,Homo sapiens,N,,4810,Antiproliferative activity measured against A427 human lung carcinoma
17672,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621049,,,Intermediate,,1,1,,Homo sapiens,N,,4811,Cytotoxicity against lung carcinoma A427 tumor cell lines
14368,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621050,,,Intermediate,,1,1,,Homo sapiens,N,,4812,Inhibition of large cell lung carcinoma (A427)
14368,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621051,,,Intermediate,,1,1,,Homo sapiens,N,,4813,Inhibition of large cell lung carcinoma (A427) after 48-h treatment
13866,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621052,,,Intermediate,,1,1,,Homo sapiens,N,,4814,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
2545,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621053,,,Intermediate,,1,1,,Homo sapiens,N,,4815,Inhibitory concentration in human lung carcinoma A427 cell line
2545,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL621054,,,Intermediate,,1,1,,Homo sapiens,N,,4816,Inhibitory concentration in human lung carcinoma A427/VCR cell line
6062,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621055,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4817,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg
4578,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL876398,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4818,Tested for volume of distribution upon iv administration to african green monkey
17592,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621056,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4819,Volume of distribution in monkey
5005,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL621057,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4820,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
5005,,,22224,9544.0,,,BAO_0000218,A,,CHEMBL621058,,,Autocuration,,1,0,,Macaca mulatta,U,In vivo,4821,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.
5922,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621059,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4822,Pharmacokinetic property(Vdss) in cynomolgus monkey
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621060,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4823,The distribution volume after intravenous administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621061,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4824,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621062,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4825,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable
6057,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621063,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4826,Volume displacement was calculated in rhesus monkey
5145,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621064,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4827,Volume of distribution in steady state was determined in rhesus monkey
6821,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621065,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4828,Volume of distribution of compound was determined in monkey
5334,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621066,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4829,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
5334,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621067,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4830,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
6641,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621068,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4831,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL876399,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4832,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey
6535,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621069,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4833,Volume distribution in monkey after administration of 1 mg/kg iv
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621070,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4834,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
6062,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621071,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4835,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621072,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4836,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
4578,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618209,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4837,Oral systemic bioavailability upon iv administration to african green monkey
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618210,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4838,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618211,,,Autocuration,,1,0,,Cercopithecidae,U,,4839,Baboon plasma free fraction. 
6057,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618212,,,Autocuration,,1,0,,Cercopithecidae,U,,4840,Area under the curve was calculated in rhesus monkey after iv administration
6057,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618213,,,Autocuration,,1,0,,Cercopithecidae,U,,4841,Area under the curve was calculated in rhesus monkey after peroral administration
17853,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618214,,,Autocuration,,1,0,,Cercopithecidae,U,,4842,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk
5302,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL873492,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4843,Half life period in monkey after 5 mg/kg dose
4257,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618272,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4844,Half-life was determined in monkey after 3 mg/kg of i.v. dose
4257,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618273,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4845,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined
13501,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL618274,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4846,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
5394,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618275,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4847,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618276,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4848,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey
3341,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618277,,,Autocuration,,1,0,,Cercopithecidae,U,,4849,Compound was evaluated for terminal half life in monkey
3045,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618278,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4850,Compound was evaluated for the half life period after iv administration in cynomolgus monkey
5005,,,22224,9544.0,,,BAO_0000218,A,1969.0,CHEMBL618279,,,Autocuration,Plasma,1,0,,Macaca mulatta,U,In vivo,4851,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
4847,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618280,,,Autocuration,,1,0,,Cercopithecidae,U,,4852,Half life of compound was determined in squirrel monkey
4256,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL618281,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,4853,Half life after iv administration in cynomolgus monkey
6535,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL618282,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,4854,Half life in monkey plasma after administration of 1 mg/kg iv
6057,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618283,,,Autocuration,,1,0,,Cercopithecidae,U,,4855,Half life was calculated in rhesus monkey
17592,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618284,,,Autocuration,,1,0,,Cercopithecidae,U,,4856,Half life in monkey
6641,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618285,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4857,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally)
5472,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618286,,,Autocuration,,1,0,,Cercopithecidae,U,,4858,Half life was evaluated in rhesus
6221,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618287,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4859,Half life period after oral administration (2.5 mg/kg) in monkey was determined
5668,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618288,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4860,Half life period was determine after peroral administration at 10 mpk in Rhesus
4809,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL876393,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4861,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg)
5546,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618289,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4862,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration
5553,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618290,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4863,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg
6078,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618291,,,Autocuration,,1,0,,Cercopithecidae,U,,4864,Half-life was calculated in monkey
5147,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618292,,,Autocuration,,1,0,,Cercopithecidae,U,,4865,Half-life in Squirrel monkey
5145,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618293,,,Autocuration,,1,0,,Cercopithecidae,U,,4866,Half-life in rhesus monkey
6062,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618294,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4867,Half-life was measured in monkey after an iv dose of 1 mg/kg
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618295,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4868,Half-life period after intravenous administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618296,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4869,Half-life period after oral administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618297,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,4870,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618298,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4871,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618299,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4872,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618300,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4873,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618301,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4874,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618302,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4875,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL876394,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4876,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618303,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4877,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618304,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4878,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined
1916,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL618305,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,4879,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined
16643,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL618306,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,4880,Oral bioavailability in human
17248,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618307,,,Autocuration,,1,0,,Homo sapiens,U,,4881,Compound was tested for human plasma protein binding
17248,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618308,,,Autocuration,,1,0,,Homo sapiens,U,,4882,Compound was tested for human plasma protein binding; Not determined
6241,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618309,,,Autocuration,,1,0,,Homo sapiens,U,,4883,Protein binding activity of compound in human plasma; % Free
17716,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618310,,,Autocuration,,1,0,,Homo sapiens,U,,4884,Unbound fraction (plasma)
17605,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL873353,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,4885,Half life for the hydrolysis of compound in human blood serum
17625,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618311,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,4886,Half life period in human plasma using phosphate buffer (0.08 M)
17625,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618312,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,4887,Half life period in human plasma using phosphate buffer (0.1 M)
17747,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618313,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,4888,Half-life in human plasma was determined
15613,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618314,,,Autocuration,,1,0,,Homo sapiens,U,,4889,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.
354,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618315,,,Autocuration,,1,0,,Homo sapiens,U,,4890,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT)
3741,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618316,,,Autocuration,,1,0,,Homo sapiens,U,,4891,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
3741,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618317,,,Autocuration,,1,0,,Homo sapiens,U,,4892,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
3741,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620138,,,Autocuration,,1,0,,Homo sapiens,U,,4893,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
17599,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL858280,,,Autocuration,,1,0,,Homo sapiens,U,,4894,Partition coefficient (logP)
5486,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620139,,,Autocuration,,1,0,,Homo sapiens,U,,4895,In vitro metabolic stability in human was measured as pmol/min/mg/protein
5600,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL620140,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,,4896,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes
14294,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620141,,,Autocuration,,1,0,,Homo sapiens,U,,4897,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak)
14294,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620142,,,Autocuration,,1,0,,Homo sapiens,U,,4898,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak)
14294,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL620143,,,Autocuration,,1,0,,Homo sapiens,U,,4899,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak)
14294,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL620144,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,,4900,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak)
14294,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL620145,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,,4901,Metabolism of compound in human microsomes ('++++' indicates largest observed peak)
14294,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL620146,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,,4902,Metabolism of compound in human microsomes; Trace
6260,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL620147,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,4903,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes
6187,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL620148,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,,4904,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min
6251,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL620149,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,4905,In vitro metabolic potential in human liver microsomes
3246,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL876412,,,Autocuration,,1,0,,Homo sapiens,U,,4906,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated
17313,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619352,,,Autocuration,,1,0,,Homo sapiens,U,,4907,Tested for human plasma protein binding of the compound; Not tested
6227,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619353,,,Autocuration,,1,0,,Homo sapiens,U,,4908,Compound was tested for percent protein binding (PB) in human
5530,,,22224,9606.0,,,BAO_0000019,A,1969.0,CHEMBL619354,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,4909,Protein binding in human plasma
6108,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619355,,,Autocuration,,1,0,,Homo sapiens,U,,4910,Permeability coefficient (B to A) in Caco-2 cell
6108,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619356,,,Autocuration,,1,0,,Homo sapiens,U,,4911,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell
2774,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619357,,,Autocuration,,1,0,,Homo sapiens,U,,4912,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3)
16643,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619358,,,Autocuration,,1,0,,Homo sapiens,U,,4913,In vitro rate of absorption observed as Caco-2 permeability in humans
17582,495.0,Caco-2,22224,9606.0,,,BAO_0000219,A,,CHEMBL619359,,,Autocuration,,1,0,,Homo sapiens,U,,4914,Cellular permeability of compound was determined in Caco-2 cells; High
6838,495.0,Caco-2,22224,9606.0,,,BAO_0000219,A,,CHEMBL619360,,,Autocuration,,1,0,,Homo sapiens,U,,4915,Permeability in Caco-2 cells of compound
6108,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619361,,,Autocuration,,1,0,,Homo sapiens,U,,4916,Permeability coefficient (A to B) in Caco-2 cell
6108,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619362,,,Autocuration,,1,0,,Homo sapiens,U,,4917,Permeability coefficient (B to A) in Caco-2 cell
6108,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619363,,,Autocuration,,1,0,,Homo sapiens,U,,4918,Permeability coefficient (Papp) (Caco-2 cell monolayer)
2146,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618942,,,Autocuration,,1,0,,Homo sapiens,U,,4919,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL
4514,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618943,,,Autocuration,,1,0,,Homo sapiens,U,,4920,Compound was tested for protein binding in human plasma
6108,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618944,,,Autocuration,,1,0,,Homo sapiens,U,,4921,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL618945,,,Autocuration,Urine,1,0,,Homo sapiens,U,,4922,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618946,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4923,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg
3277,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876413,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4924,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
3802,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618947,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4925,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse
2862,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL618948,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,4926,Time taken to reach maximum concentration in plasma upon oral administration in mouse
6348,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL618949,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,4927,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL618950,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4928,Tmax after intraperitoneal administration in mice at 23 uM/kg
5781,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618951,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4929,Tmax after oral administration at 30 mg/kg in ICR mouse
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618952,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4930,Tmax after peroral administration in mice at 2.4 uM/kg
4066,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618953,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4931,Tmax at a single subcutaneous administration of 40 mg/kg in mice
17641,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL618954,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,4932,Tmax in brain of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL618955,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,4933,Tmax in kidney of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL618956,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,4934,Tmax in liver of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL618957,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,4935,Tmax in lungs of mice at the oral dose of 50 mg/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL618958,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4936,Tmax in mice at 18 uM/kg i.p. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL618959,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4937,Tmax in mice at 23 uM/kg i.v. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL618960,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4938,Tmax in mice at 25 uM/kg i.p. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL876723,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4939,Tmax in mice at 26 uM/kg i.p. administration
17641,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618961,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,4940,Tmax in spleen of mice at the oral dose of 50 mg/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618962,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4941,Tmax value at a dose of 10 mg/kg intravenous administration in mice.
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618963,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4942,Tmax value at a dose of 10 mg/kg peroral administration in mice.
5951,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618964,,,Intermediate,,1,1,,Mus musculus,N,,4943,Tmax value in IRC mice
5506,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618965,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4944,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
5506,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618966,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4945,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
429,,,50594,10090.0,,,BAO_0000218,A,1088.0,CHEMBL618967,,,Intermediate,Urine,1,1,,Mus musculus,N,,4946,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr )
429,,,50594,10090.0,,,BAO_0000218,A,1088.0,CHEMBL618968,,,Intermediate,Urine,1,1,,Mus musculus,N,,4947,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr)
4066,,,50594,10090.0,,,BAO_0000218,A,1088.0,CHEMBL618969,,,Intermediate,Urine,1,1,,Mus musculus,N,,4948,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h)
17734,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618970,,,Intermediate,,1,1,,Mus musculus,N,,4949,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
17734,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618971,,,Intermediate,,1,1,,Mus musculus,N,,4950,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice
6062,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618972,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4951,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618973,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4952,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618974,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4953,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618975,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4954,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
5980,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618976,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4955,Vd in mice
17592,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618977,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4956,Volume of distribution in mouse
6348,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876724,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4957,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618978,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4958,Volume of distribution of compound in plasma was determined at 24 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618979,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4959,Volume of distribution of compound in plasma was determined at 40 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618980,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4960,Volume of distribution of compound in plasma was determined at 5 mg/Kg
4239,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618981,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4961,Pharmacokinetic property (vdss) was measured in mouse
2862,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL618982,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4962,Value distribution upon iv administration in mouse
17734,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620150,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4963,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620151,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4964,Volume of distribution was evaluated in mice after intravenous administration
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620152,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4965,Volume of distribution was evaluated in mice after oral administration
17837,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620153,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4966,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg
5727,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876395,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4967,Steady state volume of distribution was determined in mice
17852,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620154,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4968,Volume distribution (steady state) of compound was determined in mouse
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620155,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4969,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620156,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4970,Vss value at a dose of 10 mg/kg intravenous administration in mice.
6062,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620157,,,Intermediate,,1,1,,Mus musculus,N,In vivo,4971,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL620158,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,4972,Biodistribution of compound (oxidized form) in in kidney tissue
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL620159,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4973,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL620160,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4974,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL620161,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,4975,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
10708,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL620162,,,Intermediate,,1,1,,Homo sapiens,N,,4976,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay
16597,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL620163,,,Expert,,1,1,,Homo sapiens,N,,4977,Inhibition of A431 human squamous cell carcinoma cell proliferation
16062,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL620833,,,Expert,,1,1,,Homo sapiens,N,,4978,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay
16062,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL876396,,,Expert,,1,1,,Homo sapiens,N,,4979,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth
16958,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL620834,,,Expert,,1,1,,Homo sapiens,N,,4980,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line
6700,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL620835,,,Expert,,1,1,,Homo sapiens,N,,4981,Inhibition of A431 human carcinoma cell proliferation
17226,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL620836,,,Expert,,1,1,,Homo sapiens,N,,4982,In vitro inhibition of A431 (human carcinoma) cell basal growth.
6828,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL620837,,,Intermediate,,1,1,,Homo sapiens,N,,4983,Inhibitory concentration of compound against growth of human A431 cell line; Resistant
12314,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621017,,,Intermediate,,1,1,,Homo sapiens,N,,4984,In vitro cytotoxicity against epidermoid carcinoma cell line
13412,500.0,A-431,9,9606.0,,,BAO_0000218,F,,CHEMBL621018,,,Expert,,1,9,,Homo sapiens,D,,4985,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R"
13299,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621019,,,Intermediate,,1,1,,Homo sapiens,N,,4986,Antiproliferative activity of compound was measured on human tumor cell line A431.
17420,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621020,,,Intermediate,,1,1,,Homo sapiens,N,,4987,Antiproliferative effect of compound on A431 cell line expressing mutant p53
13678,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621021,,,Intermediate,,1,1,,Homo sapiens,N,,4988,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound
14171,500.0,A-431,9,,,,BAO_0000219,F,,CHEMBL621022,,,Expert,,1,8,,,H,,4989,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.
6333,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621023,,,Expert,,1,1,,Homo sapiens,N,,4990,Tested for antiproliferative activity against human A431 cells
2356,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621024,,,Expert,,1,9,,Homo sapiens,D,,4991,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells
15578,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621025,,,Expert,,1,1,,Homo sapiens,N,,4992,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines
5126,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621026,,,Expert,,1,1,,Homo sapiens,N,,4993,Inhibition of A431 cell proliferation
6844,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621027,,,Expert,,1,1,,Homo sapiens,N,,4994,Cytotoxic effect on A431 human epidermoid carcinoma cells
6844,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL876397,,,Expert,,1,1,,Homo sapiens,N,,4995,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM)
4925,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL883797,,,Intermediate,,1,1,,Homo sapiens,N,,4996,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line
4925,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621028,,,Intermediate,,1,1,,Homo sapiens,N,,4997,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested
13978,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621029,,,Intermediate,,1,1,,Homo sapiens,N,,4998,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line
16786,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621030,,,Intermediate,,1,1,,Homo sapiens,N,,4999,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure
13412,500.0,A-431,9,,,,BAO_0000219,F,,CHEMBL621147,,,Expert,,1,8,,,H,,5000,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R
17824,500.0,A-431,80852,9606.0,,,BAO_0000218,F,,CHEMBL621148,,,Intermediate,,1,1,,Homo sapiens,N,,5001,In vivo antiproliferative activity against A431 cell line
12751,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621149,,,Expert,,1,9,,Homo sapiens,D,,5002,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells
12380,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621150,,,Expert,,1,1,,Homo sapiens,N,,5003,Inhibition of A431 human epidermoid carcinoma cell proliferation
4959,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621151,,,Expert,,1,9,,Homo sapiens,D,,5004,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells
6333,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621152,,,Intermediate,,1,1,,Homo sapiens,N,,5005,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178)
6333,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621153,,,Intermediate,,1,1,,Homo sapiens,N,,5006,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38)
6333,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL884000,,,Intermediate,,1,1,,Homo sapiens,N,,5007,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21)
5296,,,9,9606.0,,,BAO_0000019,F,,CHEMBL621154,,,Expert,,1,9,,Homo sapiens,D,,5008,Inhibition of EGFR overexpressing A431 cell proliferation
12624,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621155,,,Expert,,1,1,,Homo sapiens,N,,5009,Inhibition of A431 cell proliferation
14926,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621156,,,Expert,,1,9,,Homo sapiens,D,,5010,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor
14926,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621157,,,Expert,,1,9,,Homo sapiens,D,,5011,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor"
14926,500.0,A-431,9,,,,BAO_0000219,F,,CHEMBL621158,,,Expert,,1,8,,,H,,5012,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor)
15144,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621159,,,Intermediate,,1,1,,Homo sapiens,N,,5013,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
15144,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621160,,,Intermediate,,1,1,,Homo sapiens,N,,5014,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621161,,,Intermediate,,1,1,,Homo sapiens,N,,5015,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621162,,,Intermediate,,1,1,,Homo sapiens,N,,5016,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621163,,,Intermediate,,1,1,,Homo sapiens,N,,5017,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621164,,,Intermediate,,1,1,,Homo sapiens,N,,5018,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621165,,,Intermediate,,1,1,,Homo sapiens,N,,5019,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death
5922,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619159,,,Autocuration,,1,0,,Cercopithecidae,U,,5020,Half-life period in cynomolgus monkey
1116,,,22224,9527.0,,,BAO_0000366,A,1969.0,CHEMBL619160,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vitro,5021,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma"
17853,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL619161,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5022,Longer half-life in monkey (i.v.) at 0.5 mpk
993,,,22224,9527.0,,,BAO_0000366,A,1969.0,CHEMBL619162,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,,5023,Plasma half life in monkey
4514,,,22224,9527.0,,,BAO_0000366,A,1969.0,CHEMBL619163,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,,5024,Plasma half-life in rhesus monkey
5334,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL619164,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,5025,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male)
5334,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL619320,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,5026,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male)
4578,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL619321,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5027,Tested for half life upon iv administration to african green monkey
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL873336,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5028,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL619322,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5029,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL619323,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5030,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL619324,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5031,The time for peak concentration value after oral administration in cynomolgus monkeys
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619325,,,Autocuration,,1,0,,Cercopithecidae,U,,5032,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL876411,,,Autocuration,,1,0,,Cercopithecidae,U,,5033,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619326,,,Autocuration,,1,0,,Cercopithecidae,U,,5034,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619327,,,Autocuration,,1,0,,Cercopithecidae,U,,5035,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619328,,,Autocuration,,1,0,,Cercopithecidae,U,,5036,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619329,,,Autocuration,,1,0,,Cercopithecidae,U,,5037,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619330,,,Autocuration,,1,0,,Cercopithecidae,U,,5038,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619331,,,Autocuration,,1,0,,Cercopithecidae,U,,5039,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619332,,,Autocuration,,1,0,,Cercopithecidae,U,,5040,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619333,,,Autocuration,,1,0,,Cercopithecidae,U,,5041,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619334,,,Autocuration,,1,0,,Cercopithecidae,U,,5042,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619335,,,Autocuration,,1,0,,Cercopithecidae,U,,5043,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619336,,,Autocuration,,1,0,,Cercopithecidae,U,,5044,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619337,,,Autocuration,,1,0,,Cercopithecidae,U,,5045,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619338,,,Autocuration,,1,0,,Cercopithecidae,U,,5046,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound
11271,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL619339,,,Autocuration,,1,0,,Cercopithecidae,U,,5047,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound
5809,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL619340,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,5048,Bioavailability in rat (cannulated) (dose 2 mg/kg)
17720,,,50597,10116.0,,,BAO_0000218,A,1969.0,CHEMBL873496,,,Intermediate,Plasma,1,1,,Rattus norvegicus,N,In vivo,5049,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration
3546,,,50597,10116.0,,,BAO_0000218,A,1969.0,CHEMBL619341,,,Intermediate,Plasma,1,1,,Rattus norvegicus,N,,5050,AUC value in rat after IV administration at a dose of 10 mg/kg
3546,,,50597,10116.0,,,BAO_0000218,A,1969.0,CHEMBL619342,,,Intermediate,Plasma,1,1,,Rattus norvegicus,N,,5051,AUC value in rat after oral administration at a dose of 10 mg/kg
3546,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL619343,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,5052,Cmax value in rat after oral administration at a dose of 10 mg/kg
3546,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL619344,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,5053,Bioavailability in rat after oral administration at a dose of 10 mg/kg
3546,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL619345,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,5054,Tmax value in rat after oral administration at a dose of 10 mg/kg
3546,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL619346,,,Intermediate,,1,1,,Rattus norvegicus,N,,5055,Vc value in rat after IV administration at a dose of 10 mg/kg
3546,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL619347,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,5056,Half life period in rat after IV administration at a dose of 10 mg/kg
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL619348,,,Autocuration,,1,0,,Papio hamadryas,U,,5057,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL619349,,,Autocuration,,1,0,,Papio hamadryas,U,,5058,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11)
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL619350,,,Autocuration,,1,0,,Papio hamadryas,U,,5059,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11)
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL619351,,,Autocuration,,1,0,,Papio hamadryas,U,,5060,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL875953,,,Autocuration,,1,0,,Papio hamadryas,U,,5061,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL621716,,,Autocuration,,1,0,,Papio hamadryas,U,,5062,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL621717,,,Autocuration,,1,0,,Papio hamadryas,U,,5063,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound
10625,,,22224,9557.0,,,BAO_0000019,A,,CHEMBL621718,,,Autocuration,,1,0,,Papio hamadryas,U,,5064,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon
3510,,,22224,9615.0,,,BAO_0000019,A,,CHEMBL621719,,,Autocuration,,1,0,,beagle,U,,5065,Area under curve after 1 mpk peroral administration to beagles
3510,,,22224,9615.0,,,BAO_0000019,A,,CHEMBL621720,,,Autocuration,,1,0,,beagle,U,,5066,Area under curve after 2 mpk peroral administration to beagles
3510,,,22224,9615.0,,,BAO_0000218,A,,CHEMBL621721,,,Autocuration,,1,0,,beagle,U,In vivo,5067,Cmax value after 1 mpk peroral administration to beagles
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL621722,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5068,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL621723,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5069,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL621724,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5070,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL623443,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5071,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL623444,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5072,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL623445,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5073,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5
7766,,,22224,9606.0,,,BAO_0000019,A,1088.0,CHEMBL623446,,,Autocuration,Urine,1,0,,Homo sapiens,U,,5074,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4
16643,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL623447,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5075,Metabolic stability observed at 30 min after administration in human liver microsomes
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL623448,,,Autocuration,,1,0,,Homo sapiens,U,,5076,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL623449,,,Autocuration,,1,0,,Homo sapiens,U,,5077,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients
6852,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL623450,,,Autocuration,,1,0,,Homo sapiens,U,,5078,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients
6567,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL623451,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5079,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer"
6570,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL623452,,,Autocuration,,1,0,,Homo sapiens,U,,5080,Metabolic stability (% remaining at 30 mins) in human S9.
6570,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL623453,,,Autocuration,,1,0,,Homo sapiens,U,,5081,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined
5237,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL623454,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5082,Percent parent compound remaining after 20 min incubation with human liver microsomes
5237,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL623455,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5083,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data
5237,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624371,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5084,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data
5202,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL624372,,,Autocuration,,1,0,,Homo sapiens,U,,5085,First pass metabolism and metabolic bioavailability using human hepatic microsomes
5481,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624373,,,Autocuration,,1,0,,Homo sapiens,U,,5086,Percent compound remaining in human plasma after incubation for 60 min at 37 C.
5481,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624374,,,Autocuration,,1,0,,Homo sapiens,U,,5087,Percent remaining in human plasma after incubation for 60 min at 37 C.
3956,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624556,,,Autocuration,,1,0,,Homo sapiens,U,,5088,The percent remaining in human plasma after 30 min was determined
5074,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL624557,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5089,Conversion rate of the prodrug in human plasma
5074,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL624558,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5090,Conversion rate of the prodrug in human plasma; ND means no data
4727,,,22224,9606.0,,,BAO_0000221,A,178.0,CHEMBL624559,,,Autocuration,Blood,1,0,,Homo sapiens,U,,5091,Half life of compound was determined in human blood
5965,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624560,,,Autocuration,,1,0,,Homo sapiens,U,,5092,Half life of compound was determined in man with once daily dosing
5732,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL624561,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,In vitro,5093,Half life in human microsomes
5819,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL624562,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5094,Half life in human plasma
5819,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL624563,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5095,Half life in human plasma; Not detected
1916,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL624564,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,5096,Half life period was evaluated against man at a dose of 10 mg/kg after po administration
6597,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624565,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,5097,Half-life for oxidative metabolic stability was determined using rat liver microsomes
5229,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL875152,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5098,Half-life in human plasma
5229,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL624566,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5099,Half-life of the parent prodrug in plasma
2192,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL873805,,,Autocuration,Plasma,1,0,,Homo sapiens,U,In vitro,5100,In vitro half life in human plasma was determined
3032,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624567,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,5101,The compound was tested In Vitro for half life in human liver microsomes.
1916,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL624568,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,5102,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration
17716,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL624569,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,5103,Observed volume of distribution
15778,,,22224,9606.0,,,BAO_0000218,A,,CHEMBL624570,,,Autocuration,,1,0,,Homo sapiens,U,In vivo,5104,Oral bioavailability in human
17313,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624571,,,Autocuration,,1,0,,Homo sapiens,U,,5105,Tested for human plasma protein binding of the compound
4231,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624572,,,Autocuration,,1,0,,Homo sapiens,U,,5106,"First order rate constant, k was determined in human plasma"
4755,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624573,,,Autocuration,,1,0,,Homo sapiens,U,,5107,Observed rate constant in 80% human plasma at 37 degree Centigrade
4755,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL875153,,,Autocuration,,1,0,,Homo sapiens,U,,5108,Observed rate constant in 80% human plasma at 37 degree Centigrade
16907,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624574,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5109,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
10839,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624575,,,Autocuration,,1,0,,Homo sapiens,U,,5110,The compound was tested for the plasma binding in human
10839,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL624576,,,Autocuration,,1,0,,Homo sapiens,U,,5111,Plasma protein binding (human)
3199,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624577,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,5112,Compound was evaluated for half-life in human liver microsomes
1345,,,22224,9606.0,,,BAO_0000221,A,178.0,CHEMBL624578,,,Autocuration,Blood,1,0,,Homo sapiens,U,In vitro,5113,Half life measured in vitro for its stability in human blood
4297,,,22224,9606.0,,,BAO_0000019,A,1977.0,CHEMBL622796,,,Autocuration,Serum,1,0,,Homo sapiens,U,,5114,Half life in human serum
4297,,,22224,9606.0,,,BAO_0000019,A,1977.0,CHEMBL622797,,,Autocuration,Serum,1,0,,Homo sapiens,U,,5115,Half life in human serum; ND=not determined
4297,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL622798,,,Autocuration,,1,0,,Homo sapiens,U,,5116,Half life were determined in CEM-SS cell extract in decomposition step 1
4297,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL622799,,,Autocuration,,1,0,,Homo sapiens,U,,5117,Half life were determined in CEM-SS cell extract in decomposition step 2
4231,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL622800,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5118,Half life of the in human plasma
5633,,,22224,9606.0,,,BAO_0000220,A,,CHEMBL622801,,S9,Autocuration,,1,0,,Homo sapiens,U,In vitro,5119,Half life period in human hepatic S9 fraction was determined
5633,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL622802,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,5120,Half life period in human liver microsome was determined
17791,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL622803,,,Autocuration,,1,0,,Homo sapiens,U,,5121,Half life period was determined; 6-7
17791,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL875154,,,Autocuration,,1,0,,Homo sapiens,U,,5122,Half life period was evaluated in human
3160,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL622804,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5123,Half life time in human plasma
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622805,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5124,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622611,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5125,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622612,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5126,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL875160,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5127,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL622613,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5128,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL622614,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5129,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL622615,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5130,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL622616,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5131,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution
16438,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL622617,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5132,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL622618,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,5133,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution
16438,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL622619,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,5134,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL622620,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,5135,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622621,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5136,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622622,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5137,Biodistribution of compound (oxidized form) in blood tissue
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622623,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5138,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622624,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5139,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622625,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5140,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622626,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5141,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622627,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5142,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622628,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5143,Biodistribution of compound (oxidized form) in brain tissue of mice
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622629,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5144,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622630,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5145,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622631,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5146,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622632,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5147,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622633,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,5148,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622634,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5149,Biodistribution of compound (oxidized form) in heart tissue of mice
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622635,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5150,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL875161,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5151,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622636,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5152,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL623335,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5153,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL623336,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5154,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623337,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5155,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623338,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5156,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623339,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5157,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO"
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623524,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5158,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623525,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5159,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution"
16438,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623526,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5160,Biodistribution of compound (oxidized form) in liver tissue
16438,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623527,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5161,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol."
16438,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623528,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5162,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO"
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL624615,,,Intermediate,,1,1,,Homo sapiens,N,,5163,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death
5245,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621672,,,Intermediate,,1,1,,Homo sapiens,N,,5164,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL621673,,,Expert,,1,1,,,N,,5165,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL621674,,,Expert,,1,1,,,N,,5166,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)"
16093,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL884002,,,Expert,,1,9,,Homo sapiens,D,,5167,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
16825,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621850,,,Intermediate,,1,1,,Homo sapiens,N,,5168,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. "
4848,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL621851,,,Intermediate,,1,1,,Homo sapiens,N,,5169,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells
14827,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621852,,,Expert,,1,9,,Homo sapiens,D,,5170,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells
14827,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL621853,,,Expert,,1,9,,Homo sapiens,D,,5171,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL621854,,,Expert,,1,1,,,N,,5172,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL621855,,,Expert,,1,1,,,N,,5173,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL623724,,,Expert,,1,1,,,N,,5174,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL623725,,,Expert,,1,1,,,N,,5175,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL623726,,,Expert,,1,1,,,N,,5176,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26"
16289,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL623727,,,Expert,,1,9,,Homo sapiens,D,,5177,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound"
16289,500.0,A-431,9,,,,BAO_0000219,F,,CHEMBL623728,,,Expert,,1,8,,,H,,5178,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL623729,,,Expert,,1,1,,,N,,5179,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL623730,,,Expert,,1,1,,,N,,5180,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
16289,500.0,A-431,80852,,,,BAO_0000218,F,,CHEMBL623731,,,Expert,,1,1,,,N,,5181,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26"
14555,500.0,A-431,80852,10090.0,,,BAO_0000218,F,,CHEMBL623732,,,Expert,,1,1,,Mus musculus,N,,5182,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration"
14555,500.0,A-431,80852,10090.0,,,BAO_0000218,F,,CHEMBL623733,,,Expert,,1,1,,Mus musculus,N,,5183,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration"
14555,500.0,A-431,80852,10090.0,,,BAO_0000218,F,,CHEMBL623734,,,Expert,,1,1,,Mus musculus,N,,5184,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
14555,500.0,A-431,80852,10090.0,,,BAO_0000218,F,,CHEMBL623735,,,Expert,,1,1,,Mus musculus,N,,5185,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration"
1937,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL623736,,,Expert,,1,1,,Homo sapiens,N,,5186,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells
13739,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL623737,,,Intermediate,,1,1,,Homo sapiens,N,,5187,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines
3558,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL623738,,,Intermediate,,1,1,,Homo sapiens,N,,5188,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye
3558,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL875168,,,Intermediate,,1,1,,Homo sapiens,N,,5189,Dose giving a 50% decrease in the living cell number (A437 cells)
17686,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623739,,,Expert,,1,1,,Homo sapiens,N,,5190,In vitro inhibitory concentration against proliferation of A459 cell line.
5305,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623740,,,Intermediate,,1,1,,Homo sapiens,N,,5191,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined
3614,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624424,,,Intermediate,,1,1,,Homo sapiens,N,,5192,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure
17229,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624425,,,Intermediate,,1,1,,Homo sapiens,N,,5193,In vitro antitumor activity against renal A498 tumor cell lines
15935,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624426,,,Intermediate,,1,1,,Homo sapiens,N,,5194,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors"
15935,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624427,,,Intermediate,,1,1,,Homo sapiens,N,,5195,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium"
15560,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624428,,,Intermediate,,1,1,,Homo sapiens,N,,5196,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test
13891,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624429,,,Intermediate,,1,1,,Homo sapiens,N,,5197,Cytotoxicity concentration against human kidney carcinoma A-498 cell line
13891,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624620,,,Intermediate,,1,1,,Homo sapiens,N,,5198,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested
13788,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624621,,,Intermediate,,1,1,,Homo sapiens,N,,5199,Cytotoxicity on kidney carcinoma (A-498) cell line
15403,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624622,,,Intermediate,,1,1,,Homo sapiens,N,,5200,Compound was evaluated against Human cell line renal A498
1009,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624623,,,Intermediate,,1,1,,Homo sapiens,N,,5201,Compound was tested for inhibition of A498 human renal cancer cell line
1043,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL874365,,,Intermediate,,1,1,,Homo sapiens,N,,5202,Growth inhibitory activity against A498 human cancer cell line
5858,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624624,,,Intermediate,,1,1,,Homo sapiens,N,,5203,In vitro antitumor activity against human renal A498 cell line
5958,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624625,,,Intermediate,,1,1,,Homo sapiens,N,,5204,In vitro cytotoxic activity against renal (A498) cell line
5506,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624626,,,Intermediate,,1,1,,Homo sapiens,N,,5205,In vitro cytotoxic activity against human renal cancer (A498) cell line
12781,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624627,,,Intermediate,,1,1,,Homo sapiens,N,,5206,Tested for cytostatic activity against renal A498 cell line
14399,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL883157,,,Intermediate,,1,1,,Homo sapiens,N,,5207,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.
5958,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624628,,,Expert,,1,1,,Homo sapiens,N,,5208,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M
3510,,,22224,9615.0,,,BAO_0000218,A,,CHEMBL624629,,,Autocuration,,1,0,,beagle,U,In vivo,5209,Cmax value after 2 mpk peroral administration to beagles
3510,,,22224,9615.0,,,BAO_0000218,A,,CHEMBL623551,,,Autocuration,,1,0,beagle,Canis lupus familiaris,U,In vivo,5210,Bioavailability
3510,,,22224,9615.0,,,BAO_0000218,A,,CHEMBL623552,,,Autocuration,,1,0,beagle,Canis lupus familiaris,U,In vivo,5211,Bioavailability after 1 mpk peroral administration to beagles
3510,,,22224,9615.0,,,BAO_0000218,A,,CHEMBL623553,,,Autocuration,,1,0,beagle,Canis lupus familiaris,U,In vivo,5212,Bioavailability after 2 mpk peroral administration to beagles
3085,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623554,,,Autocuration,,1,0,,Bos taurus,U,,5213,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9
3085,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623555,,,Autocuration,,1,0,,Bos taurus,U,,5214,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat
3085,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623556,,,Autocuration,,1,0,,Bos taurus,U,,5215,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound
9372,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623557,,,Autocuration,,1,0,,Bos taurus,U,,5216,Solubility against bovine alpha-chymotrypsin
3085,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623558,,,Autocuration,,1,0,,Bos taurus,U,,5217,Rate constant of the bovine serum albumin catalyzed reaction of the compound
3085,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623559,,,Autocuration,,1,0,,Bos taurus,U,,5218,Rate constant of the bovine serum albumin catalyzed reaction of the compound
1469,,,22224,9913.0,,,BAO_0000221,A,2106.0,CHEMBL623560,,,Autocuration,Spleen,1,0,,Bos taurus,U,,5219,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg
4297,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623561,,,Autocuration,,1,0,,Bos taurus,U,,5220,Half life in culture medium containing 10% of heat inactivated foetal calf serum
4297,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623562,,,Autocuration,,1,0,,Bos taurus,U,,5221,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined
17585,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623563,,,Autocuration,,1,0,,Bos taurus,U,,5222,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2
1336,,,22224,9913.0,,,BAO_0000221,A,2106.0,CHEMBL623564,,,Autocuration,Spleen,1,0,,Bos taurus,U,,5223,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase
3085,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL873806,,,Autocuration,,1,0,,Bos taurus,U,,5224,Half life in presence of 2 mg/mL BSA at pH 8.8
2857,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623565,,,Autocuration,,1,0,,Bos taurus,U,,5225,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1
2857,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623566,,,Autocuration,,1,0,,Bos taurus,U,,5226,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2
2857,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623567,,,Autocuration,,1,0,,Bos taurus,U,,5227,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined
1540,,,22224,9913.0,,,BAO_0000019,A,,CHEMBL623568,,,Autocuration,,1,0,,Bos taurus,U,,5228,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS)
6316,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623569,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5229,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg
17594,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623570,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5230,AUC after administration at 100 mg/kg/day in dogs
4953,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624254,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5231,AUC in dog at 0-24 hr by peroral administration at 3 mpk
16907,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624255,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5232,AUC value after 15 mg/kg iv dose in Dogs
16907,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624256,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5233,AUC value after 30 mg/kg po dose in Dogs
2959,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624257,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5234,AUC value after administration of 4 mg/Kg oral dose in dog
17594,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624258,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5235,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs
5356,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875277,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5236,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL
16807,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622667,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5237,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622668,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5238,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622669,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5239,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622670,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5240,Area under curve determined in dogs after intravenous administration of 3 mg/kg
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622671,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5241,Area under curve determined in dogs after oral administration of 10 mg/kg
5802,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622672,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5242,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
3598,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622673,,,Expert,,1,1,,Canis lupus familiaris,N,,5243,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg
3598,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622674,,,Expert,,1,1,,Canis lupus familiaris,N,,5244,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622675,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5245,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622676,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5246,Area under curve determined in dog at a dose of 10 mg/kg by oral administration
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622677,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5247,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622678,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5248,Area under curve determined in dog at a dose of 5 mg/kg by oral administration
4186,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622679,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5249,Area under curve in dog after administration of 20 mg/kg dose through peroral route
5007,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622680,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5250,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622681,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5251,Area under curve was determine after peroral administration at 10 mpk in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875278,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5252,Area under curve was determine after peroral administration at 5 mpk in dog
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622682,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5253,Area under curve was determined
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622683,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5254,Area under curve in dogs
3771,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622684,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5255,Area under curve in dogs at 10 mg/kg dose fo oral administration
3771,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622685,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5256,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia)
3771,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622686,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5257,Area under curve in dogs at 3 mg/kg dose fo intravenous administration
1916,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618344,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5258,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
5302,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875582,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5259,Area under curve value in dog at a dose of 5 mg/kg
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618345,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5260,Area under curve was determined after 0.1 mg/kg iv administration in dog
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618346,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5261,Area under curve was determined after 0.3 mg/kg po administration in dog
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618347,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5262,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg
4368,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618348,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5263,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog
5318,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618349,,,Autocuration,,1,0,,Homo sapiens,U,,5264,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase
5318,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618350,,,Autocuration,,1,0,,Homo sapiens,U,,5265,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
5318,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618351,,,Autocuration,,1,0,,Homo sapiens,U,,5266,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase
5318,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618352,,,Autocuration,,1,0,,Homo sapiens,U,,5267,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase
14518,,,22224,9606.0,,,BAO_0000221,A,178.0,CHEMBL873494,,,Autocuration,Blood,1,0,,Homo sapiens,U,,5268,Time taken to reduce 50% of the concentration of compound in blood plasma
2209,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618353,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5269,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
6787,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618354,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5270,Half life in human plasma
4898,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL875583,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5271,Half life in human plasma was reported
6072,,,22224,9606.0,,,BAO_0000019,A,1977.0,CHEMBL618355,,,Autocuration,Serum,1,0,,Homo sapiens,U,,5272,Half life in human serum
16907,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618356,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5273,Half life upon exposure to human plasma
5656,,,22224,9606.0,,,BAO_0000251,A,,CHEMBL618357,,Microsomes,Autocuration,,1,0,,Homo sapiens,U,In vitro,5274,t1/2 in human microsomes
4755,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618358,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5275,Half life period in 80% human plasma at 37 degree Centigrade
17503,,,22224,9606.0,,,BAO_0000221,A,14.0,CHEMBL618359,,,Autocuration,Zone of skin,1,0,,Homo sapiens,U,,5276,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4)
12357,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618360,,,Autocuration,Plasma,1,0,,Homo sapiens,U,In vitro,5277,Half-life measured in in vitro Cathepsin B assay in human plasma
3076,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618361,,,Autocuration,,1,0,,Homo sapiens,U,,5278,Half-life at initial concentration of 5*10e-5 M in CEM cell extract
6410,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618362,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,5279,Half-life determined by human liver microsome stability assay at a concentration of 5 uM
3741,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618363,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5280,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma"
3741,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618364,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5281,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)"
3741,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL875584,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5282,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)"
1540,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618365,,,Autocuration,,1,0,,Homo sapiens,U,,5283,Half-life in the CEM cell extracts
2905,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL873495,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5284,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade
2905,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618366,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5285,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed
5523,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618367,,,Autocuration,,1,0,,Homo sapiens,U,,5286,Half-life was determined
1499,,,22224,9606.0,,,BAO_0000221,A,178.0,CHEMBL618368,,,Autocuration,Blood,1,0,,Homo sapiens,U,,5287,Half-life (human blood stability)
1499,,,22224,9606.0,,,BAO_0000221,A,178.0,CHEMBL618369,,,Autocuration,Blood,1,0,,Homo sapiens,U,,5288,Half-life (human blood stability); no data
17065,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618370,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5289,Half-life in human plasma
6861,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618371,,,Autocuration,,1,0,,Homo sapiens,U,,5290,CYP3A4 metabolism half-life (t1/2)
1499,,,22224,9606.0,,,BAO_0000221,A,178.0,CHEMBL618372,,,Autocuration,Blood,1,0,,Homo sapiens,U,,5291,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability)
530,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618373,,,Autocuration,Plasma,1,0,,Homo sapiens,U,In vitro,5292,In vitro half life in human plasma
1116,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618374,,,Autocuration,Plasma,1,0,,Homo sapiens,U,In vitro,5293,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma"
6695,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618375,,,Autocuration,Plasma,1,0,,Homo sapiens,U,In vitro,5294,In vitro hydrolysis in human plasma
6695,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618376,,,Autocuration,Plasma,1,0,,Homo sapiens,U,In vitro,5295,In vitro hydrolysis in human plasma; no data
10,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL618377,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,In vitro,5296,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C
993,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618378,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5297,Plasma half life in human
15429,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618379,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5298,Stability after incubation with human plasma (at 37 degree C)
1675,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618380,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5299,T1/2 was evaluated in human plasma
2209,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618381,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5300,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I)."
2209,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL618382,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5301,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined"
5318,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618383,,,Autocuration,,1,0,,Homo sapiens,U,,5302,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase
2412,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618384,,,Autocuration,,1,0,,Homo sapiens,U,In vitro,5303,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase
2412,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL618385,,,Autocuration,,1,0,,Homo sapiens,U,In vitro,5304,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined
2906,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL619099,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5305,The release rate of the free drug from the substrate in human plasma by human plasma stability assay
2906,,,22224,9606.0,,,BAO_0000366,A,1969.0,CHEMBL619100,,,Autocuration,Plasma,1,0,,Homo sapiens,U,,5306,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed
5495,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619101,,,Autocuration,,1,0,,Homo sapiens,U,,5307,Time taken for 50% to be consumed by serum PON1 was determined
5495,,,22224,9606.0,,,BAO_0000019,A,,CHEMBL619102,,,Autocuration,,1,0,,Homo sapiens,U,,5308,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed
4397,,,22224,9606.0,,,BAO_0000251,A,2107.0,CHEMBL619103,,Microsomes,Autocuration,Liver,1,0,,Homo sapiens,U,,5309,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL619268,,,Autocuration,,1,0,,Mus sp.,U,,5310,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL619269,,,Autocuration,,1,0,,Mus sp.,U,,5311,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL619270,,,Autocuration,,1,0,,Mus sp.,U,,5312,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL619271,,,Autocuration,,1,0,,Mus sp.,U,,5313,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL875585,,,Autocuration,,1,0,,Mus sp.,U,,5314,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL619272,,,Autocuration,,1,0,,Mus sp.,U,,5315,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour
6058,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619273,,,Intermediate,,1,1,,Homo sapiens,N,,5316,Compound tested for growth inhibition of renal cancer cell line 786-0
17708,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619274,,,Intermediate,,1,1,,Homo sapiens,N,,5317,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line
14017,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619275,,,Expert,,1,1,,Homo sapiens,N,,5318,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line
16818,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619276,,,Intermediate,,1,1,,Homo sapiens,N,,5319,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration"
16818,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619277,,,Intermediate,,1,1,,Homo sapiens,N,,5320,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration"
16818,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619278,,,Intermediate,,1,1,,Homo sapiens,N,,5321,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration"
11970,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619279,,,Intermediate,,1,1,,Homo sapiens,N,,5322,Tested for cytotoxicity against 786-0 cell lines in renal cancer
12400,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL858458,,,Intermediate,,1,1,,Homo sapiens,N,,5323,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer
12888,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619280,,,Expert,,1,1,,Homo sapiens,N,,5324,Cytotoxic effect on renal cancer line 786-0
15300,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619281,,,Intermediate,,1,1,,Homo sapiens,N,,5325,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay
14769,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619282,,,Intermediate,,1,1,,Homo sapiens,N,,5326,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells )
15895,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619283,,,Intermediate,,1,1,,Homo sapiens,N,,5327,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line"
17376,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619284,,,Intermediate,,1,1,,Homo sapiens,N,,5328,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line
14882,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619285,,,Intermediate,,1,1,,Homo sapiens,N,,5329,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).
14882,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619286,,,Intermediate,,1,1,,Homo sapiens,N,,5330,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death)
15176,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619287,,,Intermediate,,1,1,,Homo sapiens,N,,5331,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.
12696,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL857455,,,Intermediate,,1,1,,Homo sapiens,N,,5332,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
2496,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL883801,,,Intermediate,,1,1,,Homo sapiens,N,,5333,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619288,,,Intermediate,,1,1,,Homo sapiens,N,,5334,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619289,,,Intermediate,,1,1,,Homo sapiens,N,,5335,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619290,,,Intermediate,,1,1,,Homo sapiens,N,,5336,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619291,,,Intermediate,,1,1,,Homo sapiens,N,,5337,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619292,,,Intermediate,,1,1,,Homo sapiens,N,,5338,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619293,,,Intermediate,,1,1,,Homo sapiens,N,,5339,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619294,,,Intermediate,,1,1,,Homo sapiens,N,,5340,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619295,,,Intermediate,,1,1,,Homo sapiens,N,,5341,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619296,,,Intermediate,,1,1,,Homo sapiens,N,,5342,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved)
11831,972.0,791T cell line,80641,9606.0,,,BAO_0000219,F,,CHEMBL619297,,,Intermediate,,1,1,,Homo sapiens,N,,5343,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved
12782,391.0,786-0,80640,9606.0,,,BAO_0000219,F,,CHEMBL619298,,,Intermediate,,1,1,,Homo sapiens,N,,5344,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line
1229,,,22226,,,,BAO_0000019,F,,CHEMBL619299,,,Intermediate,,1,0,,,U,,5345,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive
15313,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619300,,,Expert,,1,1,,Homo sapiens,N,,5346,Inhibition of cell growth in drug resistant 8226 myeloma cell line
15313,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619301,,,Expert,,1,1,,Homo sapiens,N,,5347,Inhibition of cell growth in drug sensitive 8226 myeloma cell line
11544,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619302,,,Intermediate,,1,1,,Homo sapiens,N,,5348,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619303,,,Intermediate,,1,1,,Homo sapiens,N,,5349,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619304,,,Intermediate,,1,1,,Homo sapiens,N,,5350,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL857706,,,Intermediate,,1,1,,Homo sapiens,N,,5351,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619305,,,Intermediate,,1,1,,Homo sapiens,N,,5352,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619306,,,Intermediate,,1,1,,Homo sapiens,N,,5353,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619307,,,Intermediate,,1,1,,Homo sapiens,N,,5354,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619308,,,Intermediate,,1,1,,Homo sapiens,N,,5355,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619309,,,Intermediate,,1,1,,Homo sapiens,N,,5356,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL619310,,,Intermediate,,1,1,,Homo sapiens,N,,5357,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
14769,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619311,,,Intermediate,,1,1,,Homo sapiens,N,,5358,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
15354,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619312,,,Intermediate,,1,1,,Homo sapiens,N,,5359,Compound was tested for the growth inhibition of A498 renal tumor cell line
17445,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619313,,,Intermediate,,1,1,,Homo sapiens,N,,5360,In vitro cytotoxicity against human tumor A498 cell line (renal cancer)
4337,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619314,,,Intermediate,,1,1,,Homo sapiens,N,,5361,In vitro inhibitory concentration against renal cancer cell line A498
15277,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619959,,,Intermediate,,1,1,,Homo sapiens,N,,5362,Cytotoxicity against A 498 tumor cell line
4812,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619960,,,Intermediate,,1,1,,Homo sapiens,N,,5363,In vitro antitumor activity against A498 human cancer cell line
4812,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619961,,,Intermediate,,1,1,,Homo sapiens,N,,5364,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening)
4995,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619962,,,Intermediate,,1,1,,Homo sapiens,N,,5365,Inhibitory dose required against A498 human tumor cell lines
5847,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL875586,,,Intermediate,,1,1,,Homo sapiens,N,,5366,Anticancer activity against one renal cancer (A498 cell line)
6557,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619963,,,Intermediate,,1,1,,Homo sapiens,N,,5367,In vitro cytotoxicity against melanoma A498 cell line
2597,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619964,,,Intermediate,,1,1,,Homo sapiens,N,,5368,Compound was tested for growth inhibitory activity against A498 cell line
6058,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620108,,,Intermediate,,1,1,,Homo sapiens,N,,5369,Compound tested for growth inhibition of renal cancer cell line A498
17708,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620109,,,Intermediate,,1,1,,Homo sapiens,N,,5370,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line
15176,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620110,,,Intermediate,,1,1,,Homo sapiens,N,,5371,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.
15300,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620111,,,Intermediate,,1,1,,Homo sapiens,N,,5372,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay
11970,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620112,,,Intermediate,,1,1,,Homo sapiens,N,,5373,Tested for cytotoxicity against A498 cell lines in renal cancer
12400,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620113,,,Intermediate,,1,1,,Homo sapiens,N,,5374,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer
12888,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620114,,,Expert,,1,1,,Homo sapiens,N,,5375,Cytotoxic effect on renal cancer lines A498
3030,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620115,,,Intermediate,,1,1,,Homo sapiens,N,,5376,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM
14769,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620116,,,Intermediate,,1,1,,Homo sapiens,N,,5377,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells )
17376,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620117,,,Intermediate,,1,1,,Homo sapiens,N,,5378,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line
16558,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620118,,,Intermediate,,1,1,,Homo sapiens,N,,5379,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay
5194,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620119,,,Intermediate,,1,1,,Homo sapiens,N,,5380,Cytotoxicity against human kidney carcinoma cell lines A4982LM
10708,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620120,,,Intermediate,,1,1,,Homo sapiens,N,,5381,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay
16880,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620121,,,Expert,,1,1,,Homo sapiens,N,,5382,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.
10196,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620122,,,Intermediate,,1,1,,Homo sapiens,N,,5383,Antitumor activity against A549 human lung carcinoma cell line
10196,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620123,,,Intermediate,,1,1,,Homo sapiens,N,,5384,Antitumor activity against A549 human lung carcinoma cell line in experiment 1
10196,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620124,,,Intermediate,,1,1,,Homo sapiens,N,,5385,Antitumor activity against A549 human lung carcinoma cell line in experiment 2
12083,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620125,,,Intermediate,,1,1,,Homo sapiens,N,,5386,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line"
16464,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620126,,,Expert,,1,1,,Homo sapiens,N,,5387,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay
16464,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL883027,,,Intermediate,,1,1,,Homo sapiens,N,,5388,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
16470,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620127,,,Expert,,1,1,,Homo sapiens,N,,5389,In vitro cytotoxic activity against human lung A549 cell line
16470,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620128,,,Intermediate,,1,1,,Homo sapiens,N,,5390,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis)
16470,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620129,,,Intermediate,,1,1,,Homo sapiens,N,,5391,In vitro cytotoxic activity against human lung A549 cell line)
16470,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620130,,,Intermediate,,1,1,,Homo sapiens,N,,5392,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested
16582,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620131,,,Expert,,1,1,,Homo sapiens,N,,5393,In vitro cytotoxicity against human non small-cell-lung cell line A549.
15935,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620132,,,Intermediate,,1,1,,Homo sapiens,N,,5394,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors"
15935,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620133,,,Intermediate,,1,1,,Homo sapiens,N,,5395,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium"
16597,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620134,,,Expert,,1,1,,Homo sapiens,N,,5396,Inhibition of A549 human lung carcinoma cell proliferation
17376,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620135,,,Intermediate,,1,1,,Homo sapiens,N,,5397,Inhibitory activity against A549 lung adenocarcinoma cell line
16496,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620136,,,Intermediate,,1,1,,Homo sapiens,N,,5398,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay
16152,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620137,,,Intermediate,,1,1,,Homo sapiens,N,,5399,in vitro anticancer activity against cultured A549 human tumor(lung) cell line
16152,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620268,,,Intermediate,,1,1,,Homo sapiens,N,,5400,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line
16464,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620269,,,Intermediate,,1,1,,Homo sapiens,N,,5401,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
2288,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620270,,,Intermediate,,1,1,,Homo sapiens,N,,5402,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line
17350,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620271,,,Intermediate,,1,1,,Homo sapiens,N,,5403,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
4090,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620272,,,Expert,,1,1,,Homo sapiens,N,,5404,Inhibition of A549 cancer cell proliferation
4090,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620273,,,Expert,,1,1,,Homo sapiens,N,,5405,Inhibition of A549 cancer cell proliferation (Not tested)
17350,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620274,,,Intermediate,,1,1,,Homo sapiens,N,,5406,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay
4197,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620275,,,Intermediate,,1,1,,Homo sapiens,N,,5407,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation
17072,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620276,,,Intermediate,,1,1,,Homo sapiens,N,,5408,Antiproliferative potency determined as inhibitory concentration against A549 cells
17072,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620277,,,Intermediate,,1,1,,Homo sapiens,N,,5409,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel
5194,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620278,,,Intermediate,,1,1,,Homo sapiens,N,,5410,Cytotoxicity against Renal cell lines A549 was determined
4257,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620279,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5411,Area under curve was determined in dog after a 3 mg/kg of oral dose
6123,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620280,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5412,Area under curve was determined in dog after oral administration at 1 mg/kg
1337,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620281,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5413,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
1337,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620282,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5414,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
8833,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621134,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5415,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins)
8833,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621135,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5416,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins)
8833,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621136,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5417,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins)
8833,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621137,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5418,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins)
17657,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621138,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5419,Area under plasma concentration time curve in dog upon oral administration
17650,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL875587,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5420,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg
1977,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621139,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5421,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.
1977,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621140,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5422,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.
3132,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621141,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5423,Area under the curve for the compound was obtained when tested in dog
5473,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621142,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5424,Area under the curve at a dose of 1 mg/kg
5474,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621143,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5425,Area under the curve at a dose of 1 mg/kg (oral)
5474,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621144,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5426,Area under the curve at i.v. dose of 0.2 mg/kg
6062,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621145,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5427,Area under the curve was measured in dog after an iv dose of 1 mg/kg
4709,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621146,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5428,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622567,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5429,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622568,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5430,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally
2877,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622569,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5431,Compound was evaluated for area under the curve in dog blood.
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622570,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5432,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog
5130,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622571,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5433,AUC in dog after oral dose (1 mg/kg)
6265,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622572,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5434,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg
4657,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622573,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5435,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported."
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622574,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5436,Pharmacokinetic parameter AUC after intravenous administration to dogs
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622575,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5437,Pharmacokinetic parameter AUC after oral administration to dogs
9579,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622576,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5438,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b
9579,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622577,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5439,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b
5983,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622578,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5440,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.
6241,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622579,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5441,Pharmacokinetic property in dogs after oral administration at 1 mg/kg
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622580,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5442,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog"
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622581,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5443,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk"
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622582,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5444,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622583,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5445,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
6641,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622584,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5446,Oral AUCN in dog (dosed at 0.5 mpk iv )
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622585,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5447,Oral AUCN in dog (dosed at 0.5 mpk iv )
17791,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622586,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5448,Compound was evaluated for oral bioavailability in dog; 90-100
17655,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623281,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5449,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay
17655,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623282,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5450,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined
6596,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623283,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5451,PAPP (membrane permeability) in dog kidney cell monolayer assay
3880,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623284,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5452,Oral bioavailability in dog
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623285,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5453,Bioavailability administered orally at a dose of 10 mg/kg to dogs
17409,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623463,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5454,Plasma protein binding towards dog plasma at 10 uM
17409,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL875952,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5455,Plasma protein binding towards dog plasma at 100 uM
2959,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621705,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5456,Bioavailability in dog (dose 4 mg/kg p.o.)
13501,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621706,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5457,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621707,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5458,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined
15145,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621708,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5459,Bioavailability in dogs
4219,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621709,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5460,Bioavailability
17538,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621710,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5461,Oral bioavailability in dog (dose 10 mg/kg)
17538,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621711,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5462,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined
1466,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621712,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5463,Bioavailability in dog (dose 10.0 mg/kg p.o.)
17650,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621713,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5464,Bioavailability was measured in dogs after an oral dose of 10 uM/kg
3132,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621714,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5465,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL621715,,,Autocuration,,1,0,,Mus sp.,U,,5466,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2107.0,CHEMBL623717,,,Autocuration,Liver,1,0,,Mus sp.,U,,5467,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2107.0,CHEMBL623718,,,Autocuration,Liver,1,0,,Mus sp.,U,,5468,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2107.0,CHEMBL623719,,,Autocuration,Liver,1,0,,Mus sp.,U,,5469,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL623720,,,Autocuration,,1,0,,Mus sp.,U,,5470,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL623721,,,Autocuration,,1,0,,Mus sp.,U,,5471,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2385.0,CHEMBL623722,,,Autocuration,Muscle tissue,1,0,,Mus sp.,U,,5472,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2385.0,CHEMBL623723,,,Autocuration,Muscle tissue,1,0,,Mus sp.,U,,5473,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2385.0,CHEMBL618543,,,Autocuration,Muscle tissue,1,0,,Mus sp.,U,,5474,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2106.0,CHEMBL618544,,,Autocuration,Spleen,1,0,,Mus sp.,U,,5475,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,2106.0,CHEMBL875155,,,Autocuration,Spleen,1,0,,Mus sp.,U,,5476,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL618545,,,Autocuration,,1,0,,Mus sp.,U,,5477,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL618546,,,Autocuration,,1,0,,Mus sp.,U,,5478,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL623529,,,Autocuration,,1,0,,Mus sp.,U,,5479,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL623530,,,Autocuration,,1,0,,Mus sp.,U,,5480,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour
2413,,,22224,10095.0,,,BAO_0000218,A,,CHEMBL621764,,,Autocuration,,1,0,,Mus sp.,U,,5481,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour
17827,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621765,,,Autocuration,,1,0,,Cercopithecidae,U,,5482,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,2037.0,CHEMBL621766,,,Autocuration,Cerebellum,1,0,,Cercopithecidae,U,,5483,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,1870.0,CHEMBL621767,,,Autocuration,Frontal cortex,1,0,,Cercopithecidae,U,,5484,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621768,,,Autocuration,,1,0,,Cercopithecidae,U,,5485,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,2435.0,CHEMBL621769,,,Autocuration,Striatum,1,0,,Cercopithecidae,U,,5486,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621770,,,Autocuration,,1,0,,Cercopithecidae,U,,5487,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,2037.0,CHEMBL621771,,,Autocuration,Cerebellum,1,0,,Cercopithecidae,U,,5488,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,1870.0,CHEMBL621772,,,Autocuration,Frontal cortex,1,0,,Cercopithecidae,U,,5489,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621773,,,Autocuration,,1,0,,Cercopithecidae,U,,5490,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound)
17827,,,22224,9527.0,,,BAO_0000019,A,2435.0,CHEMBL621774,,,Autocuration,Striatum,1,0,,Cercopithecidae,U,,5491,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound)
17791,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621775,,,Autocuration,,1,0,,Cercopithecidae,U,,5492,Compound was evaluated for oral bioavailability in rats
17667,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL621776,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,In vivo,5493,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration
17791,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621777,,,Autocuration,,1,0,,Cercopithecidae,U,,5494,Half life period was evaluated in monkey
110,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL875162,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,5495,Half-life in rhesus monkeys by intravenous administration of dose
5781,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL621778,,,Intermediate,Plasma,1,1,,Mus musculus,N,,5496,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse
17734,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL621779,,,Intermediate,Plasma,1,1,,Mus musculus,N,,5497,AUC after intraperitoneal administration of 100 mg/kg in mice
17718,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622479,,,Intermediate,Plasma,1,1,,Mus musculus,N,,5498,AUC value was determined after oral administration
4573,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622480,,,Intermediate,,1,1,,Mus musculus,N,,5499,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice
3277,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622481,,,Intermediate,,1,1,,Mus musculus,N,,5500,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
2862,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622482,,,Intermediate,,1,1,,Mus musculus,N,,5501,Area under curve by ioral administration in mouse
2862,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622483,,,Intermediate,,1,1,,Mus musculus,N,,5502,Area under curve by iv administration in mouse
5951,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622484,,,Intermediate,,1,1,,Mus musculus,N,,5503,Area under curve at 0-8 hr in IRC mice after peroral administration
17729,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622641,,,Intermediate,,1,1,,Mus musculus,N,,5504,Area under curve when injected i.p. in mice at a dose of 50 mg/kg
17728,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622642,,,Intermediate,,1,1,,Mus musculus,N,,5505,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg
17728,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622643,,,Intermediate,,1,1,,Mus musculus,N,,5506,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg
17729,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622644,,,Intermediate,,1,1,,Mus musculus,N,,5507,Area under curve when injected intravenously in mice at a dose of 20 mg/kg
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL622645,,,Intermediate,,1,1,,Homo sapiens,N,,5508,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL622646,,,Intermediate,,1,1,,Homo sapiens,N,,5509,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL621238,,,Intermediate,,1,1,,Homo sapiens,N,,5510,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL621239,,,Intermediate,,1,1,,Homo sapiens,N,,5511,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL621240,,,Intermediate,,1,1,,Homo sapiens,N,,5512,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL621241,,,Intermediate,,1,1,,Homo sapiens,N,,5513,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL621242,,,Intermediate,,1,1,,Homo sapiens,N,,5514,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620350,,,Intermediate,,1,1,,Homo sapiens,N,,5515,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620351,,,Intermediate,,1,1,,Homo sapiens,N,,5516,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620352,,,Intermediate,,1,1,,Homo sapiens,N,,5517,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620353,,,Intermediate,,1,1,,Homo sapiens,N,,5518,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620354,,,Intermediate,,1,1,,Homo sapiens,N,,5519,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620355,,,Intermediate,,1,1,,Homo sapiens,N,,5520,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620356,,,Intermediate,,1,1,,Homo sapiens,N,,5521,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620357,,,Intermediate,,1,1,,Homo sapiens,N,,5522,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620358,,,Intermediate,,1,1,,Homo sapiens,N,,5523,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill)
9424,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620359,,,Expert,,1,1,,Homo sapiens,N,,5524,In vitro inhibition of human 8226 myeloma tumor cell line growth.
11544,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620360,,,Intermediate,,1,1,,Homo sapiens,N,,5525,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.
17378,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620361,,,Intermediate,,1,1,,Homo sapiens,N,,5526,Cytotoxicity of compound against 8226/DOX1V cells
17378,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620362,,,Intermediate,,1,1,,Homo sapiens,N,,5527,Cytotoxicity of compound against 8226/S cells
17079,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620363,,,Intermediate,,1,1,,Homo sapiens,N,,5528,Inhibitory concentration against 8226 myeloma cancer cell line
17079,741.0,RPMI-8226,80433,9606.0,,,BAO_0000219,F,,CHEMBL620364,,,Intermediate,,1,1,,Homo sapiens,N,,5529,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line
13466,854.0,833K,80647,9606.0,,,BAO_0000219,F,,CHEMBL620365,,,Intermediate,,1,1,,Homo sapiens,N,,5530,Inhibition of cell growth was studied in human teratocarcinoma (833K).
13466,854.0,833K,80647,9606.0,,,BAO_0000219,F,,CHEMBL620366,,,Intermediate,,1,1,,Homo sapiens,N,,5531,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined'
2392,854.0,833K,80647,9606.0,,,BAO_0000219,F,,CHEMBL620367,,,Expert,,1,1,,Homo sapiens,N,,5532,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells
2392,854.0,833K,80647,9606.0,,,BAO_0000219,F,,CHEMBL620368,,,Intermediate,,1,1,,Homo sapiens,N,,5533,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data
6608,,,22226,,,,BAO_0000019,B,,CHEMBL620369,,,Autocuration,,1,0,,,U,,5534,Inhibitory activity against caspase-1
10199,,,45,1351.0,,,BAO_0000357,B,,CHEMBL620370,,,Autocuration,,1,8,,Enterococcus faecalis,H,,5535,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound
17749,705.0,8701-BC,80648,9606.0,,,BAO_0000219,F,,CHEMBL620371,,,Intermediate,,1,1,,Homo sapiens,N,,5536,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay
17749,705.0,8701-BC,80648,9606.0,,,BAO_0000219,F,,CHEMBL620372,,,Intermediate,,1,1,,Homo sapiens,N,,5537,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM
1229,,,22226,,,,BAO_0000019,F,,CHEMBL876492,,,Intermediate,,1,0,,,U,,5538,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive
1229,,,22226,,,,BAO_0000019,F,,CHEMBL620373,,,Intermediate,,1,0,,,U,,5539,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive
1229,,,22226,,,,BAO_0000019,F,,CHEMBL620374,,,Intermediate,,1,0,,,U,,5540,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive
6390,,,22226,,,,BAO_0000019,B,,CHEMBL620375,,,Autocuration,,1,0,,,U,,5541,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin
16219,,,22226,1314.0,,,BAO_0000019,F,,CHEMBL857902,,,Autocuration,,1,0,,Streptococcus pyogenes,U,,5542,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
16219,,,22226,1314.0,,,BAO_0000019,F,,CHEMBL620376,,,Autocuration,,1,0,,Streptococcus pyogenes,U,,5543,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB
17043,,,11922,,,,BAO_0000357,B,,CHEMBL620377,,,Autocuration,,1,8,,,H,,5544,Percent inhibition against Cdc25C phosphatase at 50 uM of compound
6929,324.0,KB ,81115,9606.0,,,BAO_0000219,F,,CHEMBL620378,,,Intermediate,,1,1,,Homo sapiens,N,,5545,Tested for in vitro cytotoxic potency of compound in 9KB assay
6929,324.0,KB ,81115,9606.0,,,BAO_0000219,A,,CHEMBL620379,,,Intermediate,,1,1,,Homo sapiens,N,,5546,Tested for in vitro cytotoxic potency of compound in 9KB assay
7083,,,22226,9606.0,,,BAO_0000219,F,,CHEMBL620380,,,Autocuration,,1,0,,Homo sapiens,U,,5547,In vitro cytotoxicity of compound was tested against 9KB cells.
12446,392.0,9L,80653,10116.0,,,BAO_0000219,F,,CHEMBL884006,,,Intermediate,,1,1,,Rattus norvegicus,N,,5548,Cytotoxic concentration against 9L cells was determined on day 3
15345,392.0,9L,80653,10116.0,,,BAO_0000219,F,,CHEMBL620381,,,Expert,,1,1,,Rattus norvegicus,N,,5549,Tested in vitro for anticancer activity against 9L cells
15345,392.0,9L,80653,10116.0,,,BAO_0000219,F,,CHEMBL620382,,,Expert,,1,1,,Rattus norvegicus,N,,5550,Tested in vitro for anticancer activity against 9L cells; Not determined
6301,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620383,,,Intermediate,,1,1,,Homo sapiens,N,,5551,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active
4833,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876493,,,Intermediate,,1,1,,Homo sapiens,N,,5552,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition
4833,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620384,,,Intermediate,,1,1,,Homo sapiens,N,,5553,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition
4833,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620385,,,Intermediate,,1,1,,Homo sapiens,N,,5554,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition
13330,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620386,,,Expert,,1,1,,Homo sapiens,N,,5555,Cytotoxicity against human lung carcinoma A549 cell line
17517,646.0,A549,25,9606.0,,,BAO_0000219,F,,CHEMBL620387,,,Expert,,1,9,,Homo sapiens,D,,5556,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.
17517,646.0,A549,25,9606.0,,,BAO_0000219,F,,CHEMBL621404,,,Expert,,1,9,,Homo sapiens,D,,5557,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%."
14425,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621405,,,Intermediate,,1,1,,Homo sapiens,N,,5558,"In vitro growth inhibition of A549, lung carcinoma"
14425,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621406,,,Intermediate,,1,1,,Homo sapiens,N,,5559,"In vitro growth inhibition of A549, lung carcinoma."
5228,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621407,,,Expert,,1,1,,Homo sapiens,N,,5560,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
5351,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621408,,,Intermediate,,1,1,,Homo sapiens,N,,5561,Cytotoxic activity against human lung cancer A549 cell line was determined
12198,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL885345,,,Expert,,1,1,,Homo sapiens,N,,5562,Cytotoxicity against human solid tumor lung carcinoma A549 cell line
13891,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621409,,,Intermediate,,1,1,,Homo sapiens,N,,5563,Cytotoxicity concentration against human lung carcinoma A-549 cell line
5677,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876034,,,Expert,,1,1,,Homo sapiens,N,,5564,Cytotoxicity in A549 (human carcinoma) cell line.
13788,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621410,,,Intermediate,,1,1,,Homo sapiens,N,,5565,Cytotoxicity on lung carcinoma (A-549) cell line
13384,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621411,,,Expert,,1,1,,Homo sapiens,N,,5566,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.
6726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621412,,,Intermediate,,1,1,,Homo sapiens,N,,5567,Effective dose of compound against replication of A549 cell line was evaluated
3455,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621413,,,Expert,,1,1,,Homo sapiens,N,,5568,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line
5726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621414,,,Intermediate,,1,1,,Homo sapiens,N,,5569,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line)
5726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621415,,,Intermediate,,1,1,,Homo sapiens,N,,5570,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active
3936,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621416,,,Intermediate,,1,1,,Homo sapiens,N,,5571,The compound was evaluated for antiproliferative activity against A549 cell line
14991,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621417,,,Intermediate,,1,1,,Homo sapiens,N,,5572,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.
5243,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621418,,,Intermediate,,1,1,,Homo sapiens,N,,5573,Concentration required for growth inhibition of human lung carcinoma cell line A549
12858,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621419,,,Intermediate,,1,1,,Homo sapiens,N,,5574,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line
6776,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621420,,,Intermediate,,1,1,,Homo sapiens,N,,5575,Growth inhibition against A549 cell line was evaluated
16558,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL875823,,,Intermediate,,1,1,,Homo sapiens,N,,5576,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay
4583,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621421,,,Expert,,1,1,,Homo sapiens,N,,5577,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar
13514,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621422,,,Intermediate,,1,1,,Homo sapiens,N,,5578,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs
15166,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884014,,,Expert,,1,1,,Homo sapiens,N,,5579,Chemosensitivity against DT-diaphorase rich A549 cell lines
13873,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621423,,,Intermediate,,1,1,,Homo sapiens,N,,5580,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.
6447,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621424,,,Expert,,1,1,,Homo sapiens,N,,5581,In vitro cytotoxicity against human A549 (lung cancer) cell line.
2068,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621425,,,Intermediate,,1,1,,Homo sapiens,N,,5582,In vitro antitumor activity against A549 (lung) human tumor cell lines.
1863,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621426,,,Expert,,1,1,,Homo sapiens,N,,5583,In vitro cytotoxic activity against human lung carcinoma A549 cell line
13873,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621427,,,Intermediate,,1,1,,Homo sapiens,N,,5584,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.
13873,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621428,,,Intermediate,,1,1,,Homo sapiens,N,,5585,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
13873,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621429,,,Expert,,1,1,,Homo sapiens,N,,5586,Tested against A549 lung carcinoma in the sulforhodamine B assay.
579,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621430,,,Intermediate,,1,1,,Homo sapiens,N,,5587,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction)
579,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621431,,,Intermediate,,1,1,,Homo sapiens,N,,5588,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).
4584,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621432,,,Intermediate,,1,1,,Homo sapiens,N,,5589,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621433,,,Expert,,1,1,,Homo sapiens,N,,5590,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL875824,,,Intermediate,,1,1,,Homo sapiens,N,,5591,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621434,,,Intermediate,,1,1,,Homo sapiens,N,,5592,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621435,,,Intermediate,,1,1,,Homo sapiens,N,,5593,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed
14188,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621436,,,Intermediate,,1,1,,Homo sapiens,N,,5594,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.
14188,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621437,,,Intermediate,,1,1,,Homo sapiens,N,,5595,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.
15354,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621438,,,Intermediate,,1,1,,Homo sapiens,N,,5596,Compound was tested for the growth inhibition of A549 lung tumor cell line
14253,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621439,,,Expert,,1,1,,Homo sapiens,N,,5597,Growth inhibition of human non-small-lung carcinoma (A549) cell line
13873,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621440,,,Intermediate,,1,1,,Homo sapiens,N,,5598,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.
3043,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621441,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5599,Oral bioavailability in dog (conscious)
3045,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621442,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5600,Compound was evaluated for the oral bioavailability after oral administration in dog.
3022,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621443,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5601,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs
4453,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621444,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5602,Oral bioavailability in dog
1696,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625133,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5603,Oral bioavailability in dog
5045,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625134,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5604,Oral bioavailability in dog
5356,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625135,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5605,Oral bioavailability in dog (fasted)
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625136,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5606,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg
6448,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625137,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5607,Oral bioavailability in dog
1475,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625138,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5608,Oral bioavailability in dog
3788,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625139,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5609,Percent bioavailability in dog
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL872264,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5610,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog
13397,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625140,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5611,Oral bioavailability in dog
2137,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624436,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5612,The compound was evaluated for bioavailability in dogs; 34-44
2959,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624437,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5613,Bioavailability in dog (dose 4 mg/kg p.o.)
6448,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL872261,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5614,Oral bioavailability in dog
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624438,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5615,8 hour trough Blood level in dog was measured after administration of compound
3639,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624439,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5616,The compound was tested for maximum concentration ( Cmax ) in dog plasma.
6316,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624440,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5617,C24 after oral administration at 5 mg/kg
5238,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624441,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5618,Clearance after oral and iv dosing in dogs
17796,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624442,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,5619,Clearance of the drug was measured in the plasma of dog
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624443,,,Intermediate,,1,1,,Canis lupus familiaris,N,,5620,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously
5654,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624444,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5621,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
6621,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624445,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5622,Clearance of compound was determined in dogs
6505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624446,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5623,Clearance on i.v. administration of 2 mg/kg was measured in dog
5802,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624447,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5624,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
17267,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624448,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5625,Plasma clearance in dog was determined
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624449,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5626,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624450,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5627,Plasma clearance in dog after administration of 0.25 mg/kg iv
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875942,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5628,Plasma clearance in dog after administration of 1 mg/kg iv
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624451,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5629,Plasma clearance in dogs
5542,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624452,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5630,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg
5199,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624453,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5631,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624454,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5632,Plasma clearance after 15 mg/kg iv dose in Dogs
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624455,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5633,Plasma clearance after 30 mg/kg po dose in Dogs
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624456,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5634,Plasma administration to dogs
5505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624457,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5635,Plasma clearance was determined
6215,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624458,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5636,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog
1466,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624459,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5637,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog
5007,,,102164,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624460,,Microsomes,Intermediate,Liver,1,2,,Homo sapiens,S,In vitro,5638,Intrinsic clearance in human liver microsomes
5007,,,102164,9606.0,,,BAO_0000251,A,2107.0,CHEMBL624461,,Microsomes,Intermediate,Liver,1,2,,Homo sapiens,S,In vitro,5639,Intrinsic clearance in human liver microsomes
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875943,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5640,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624462,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5641,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624463,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5642,Clearance in dog (dose 1 mg/kg i.v.)
6221,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624464,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5643,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined
5007,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624465,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5644,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624466,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5645,Plasma clearance after peroral administration at 10 mpk in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624467,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5646,Plasma clearance after peroral administration at 5 mpk in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624468,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5647,Plasma clearance after peroral administration at 5 mg/kg in dog
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624469,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5648,Plasma clearance was measured in dog
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624470,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5649,Plasma clearance was measured in dog
5983,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624471,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5650,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624472,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5651,Total clearance was determined after 0.1 mg/kg iv administration in dog
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622775,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5652,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg
6039,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622776,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5653,Clearance after intravenous administration of 0.5 mg/kg in dog was determined
6039,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622777,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5654,Clearance after intravenous administration of 1.0 mg/kg in dog was determined
6039,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622778,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5655,Clearance after peroral administration of 0.2 mg/kg in dog was determined
4368,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622779,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5656,Clearance by intravenous administration of 1.2 mg/kg in dog
4305,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622780,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5657,Clearance by iv administration in dogs at a dose of 1 mg/kg
1918,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622781,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5658,Clearance value was evaluated in dog plasma
6005,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622782,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5659,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg
4839,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622783,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5660,Compound was tested for plasma clearance in dog
4239,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622784,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5661,Pharmacokinetic property (Plasma clearance) was measured in dog
17729,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622785,,,Intermediate,,1,1,,Mus musculus,N,,5662,Area under curve when injected perorally in mice at a dose of 50 mg/kg
17728,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622786,,,Intermediate,,1,1,,Mus musculus,N,,5663,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg
5302,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622787,,,Intermediate,,1,1,,Mus musculus,N,,5664,Area under curve value in mouse at a dose of 10 mg/kg
5506,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL875949,,,Intermediate,,1,1,,Mus musculus,N,,5665,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice
5506,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622788,,,Intermediate,,1,1,,Mus musculus,N,,5666,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622789,,,Intermediate,,1,1,,Mus musculus,N,,5667,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622790,,,Intermediate,,1,1,,Mus musculus,N,,5668,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622791,,,Intermediate,,1,1,,Mus musculus,N,,5669,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622792,,,Intermediate,,1,1,,Mus musculus,N,,5670,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622793,,,Intermediate,,1,1,,Mus musculus,N,,5671,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622794,,,Intermediate,,1,1,,Mus musculus,N,,5672,Area under curve was determined for the compound at 24 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622795,,,Intermediate,,1,1,,Mus musculus,N,,5673,Area under curve was determined for the compound at 40 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621803,,,Intermediate,,1,1,,Mus musculus,N,,5674,Area under curve was determined for the compound at 5 mg/Kg
3132,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621804,,,Intermediate,,1,1,,Mus musculus,N,,5675,Area under the curve for the compound is obtained at dose 25 mg/kg
3132,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621805,,,Intermediate,,1,1,,Mus musculus,N,,5676,Area under the curve for the compound was obtained when tested in mouse
17837,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621806,,,Intermediate,,1,1,,Mus musculus,N,,5677,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg
17837,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621807,,,Intermediate,,1,1,,Mus musculus,N,,5678,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg
6062,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621808,,,Intermediate,,1,1,,Mus musculus,N,,5679,Area under the curve was measured in mouse after an iv dose of 1 mg/kg
4066,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621809,,,Intermediate,,1,1,,Mus musculus,N,,5680,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621810,,,Intermediate,,1,1,,Mus musculus,N,,5681,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
14239,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL875164,,,Intermediate,,1,1,,Mus musculus,N,,5682,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice
14239,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621811,,,Intermediate,,1,1,,Mus musculus,N,,5683,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice
4890,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621812,,,Intermediate,,1,1,,Mus musculus,N,,5684,"Compound was evaluated for the pharmacokinetic parameter, area under curve"
429,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621813,,,Intermediate,,1,1,,Mus musculus,N,,5685,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr )
429,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621814,,,Intermediate,,1,1,,Mus musculus,N,,5686,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr)
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621815,,,Intermediate,,1,1,,Mus musculus,N,,5687,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621816,,,Intermediate,,1,1,,Mus musculus,N,,5688,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621817,,,Intermediate,,1,1,,Mus musculus,N,,5689,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
6091,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621818,,,Intermediate,,1,1,,Mus musculus,N,,5690,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse
6091,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621819,,,Intermediate,,1,1,,Mus musculus,N,,5691,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined
6091,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621820,,,Intermediate,,1,1,,Mus musculus,N,,5692,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice
6091,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621821,,,Intermediate,,1,1,,Mus musculus,N,,5693,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined
6178,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621822,,,Intermediate,,1,1,,Mus musculus,N,,5694,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice
6178,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619474,,,Intermediate,,1,1,,Mus musculus,N,,5695,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice
6619,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619475,,,Intermediate,,1,1,,Mus musculus,N,,5696,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
6619,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619476,,,Intermediate,,1,1,,Mus musculus,N,,5697,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)"
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619477,,,Intermediate,,1,1,,Mus musculus,N,,5698,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice"
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619478,,,Intermediate,,1,1,,Mus musculus,N,,5699,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice"
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619479,,,Intermediate,,1,1,,Mus musculus,N,,5700,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice"
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619480,,,Intermediate,,1,1,,Mus musculus,N,,5701,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice"
3192,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619481,,,Intermediate,,1,1,,Mus musculus,N,,5702,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1
3192,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619482,,,Intermediate,,1,1,,Mus musculus,N,,5703,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619483,,,Intermediate,,1,1,,Mus musculus,N,,5704,Area under the curve was evaluated in mice after intravenous administration
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619484,,,Intermediate,,1,1,,Mus musculus,N,,5705,Area under the curve was evaluated in mice after oral administration
16597,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL619485,,,Intermediate,Plasma,1,1,,Mus musculus,N,,5706,AUC total value at a dose of 10 mg/kg intravenous administration in mice.
16597,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL619486,,,Intermediate,Plasma,1,1,,Mus musculus,N,,5707,AUC total value at a dose of 10 mg/kg peroral administration in mice.
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619487,,,Intermediate,,1,1,,Mus musculus,N,,5708,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot)
17734,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL619488,,,Intermediate,,1,1,,Mus musculus,N,,5709,AUMC after intraperitoneal administration of 100 mg/kg in mice
7767,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL620106,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5710,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram
15345,392.0,9L,80653,,,,BAO_0000219,F,,CHEMBL620107,,,Intermediate,,1,1,,,N,,5711,The compound was tested in vitro for anticancer activity against 9L cells
2181,,,22226,10116.0,,,BAO_0000019,F,,CHEMBL620283,,,Autocuration,,1,0,,Rattus norvegicus,U,,5712,Anti proliferation activity determined; Weak effect
2181,,,22226,10116.0,,,BAO_0000219,F,,CHEMBL875176,,,Autocuration,,1,0,,Rattus norvegicus,U,,5713,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process
2181,,,22226,10116.0,,,BAO_0000219,F,,CHEMBL620284,,,Autocuration,,1,0,,Rattus norvegicus,U,,5714,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells
2181,,,22226,10116.0,,,BAO_0000219,F,,CHEMBL623515,,,Autocuration,,1,0,,Rattus norvegicus,U,,5715,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process
10486,,,22226,10090.0,,,BAO_0000019,F,,CHEMBL623516,,,Autocuration,,1,0,,Mus musculus,U,,5716,The cytotoxic activity was in vitro tested by 9PS assay method
10486,,,22226,10090.0,,,BAO_0000019,F,,CHEMBL623517,,,Autocuration,,1,0,,Mus musculus,U,,5717,The cytotoxic activity was in vitro tested by 9PS assay method.
15508,,,22224,,,,BAO_0000019,A,,CHEMBL857878,,,Autocuration,,1,0,,,U,,5718,Partition coefficient (logD6.5)
5242,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623518,,,Expert,,1,1,,Homo sapiens,N,,5719,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells
16167,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL624195,,,Intermediate,,1,1,,Homo sapiens,N,,5720,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM)
4782,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL624196,,,Expert,,1,1,,Homo sapiens,N,,5721,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line
16093,500.0,A-431,9,9606.0,,,BAO_0000219,F,,CHEMBL624197,,,Expert,,1,9,,Homo sapiens,D,,5722,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R
2596,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL624198,,,Intermediate,,1,1,,Homo sapiens,N,,5723,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line
2596,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL621287,,,Intermediate,,1,1,,Homo sapiens,N,,5724,in vitro cytotoxicity against A 498 cancer cell line
3239,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL621288,,,Intermediate,,1,1,,Homo sapiens,N,,5725,In vitro cytotoxic activity against renal (A 498) cancer cell line.
1847,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL876496,,,Intermediate,,1,1,,Homo sapiens,N,,5726,Cytotoxic activity against A 498 renal cancer cell lines.
10553,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL621289,,,Intermediate,,1,1,,Homo sapiens,N,,5727,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen
16219,,,22226,1280.0,,,BAO_0000019,F,,CHEMBL621290,,,Autocuration,,1,0,,Staphylococcus aureus,U,,5728,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
16219,,,22226,1280.0,,,BAO_0000019,F,,CHEMBL621291,,,Autocuration,,1,0,,Staphylococcus aureus,U,,5729,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i
16219,,,22226,1280.0,,,BAO_0000019,F,,CHEMBL621292,,,Autocuration,,1,0,,Staphylococcus aureus,U,,5730,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
16219,,,22226,1280.0,,,BAO_0000019,F,,CHEMBL621293,,,Autocuration,,1,0,,Staphylococcus aureus,U,,5731,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c
4782,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621294,,,Intermediate,,1,1,,Homo sapiens,N,,5732,Inhibitory concentration required against A 549 lung cancer cell line
11805,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621295,,,Intermediate,,1,1,,Homo sapiens,N,,5733,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time
11805,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884007,,,Intermediate,,1,1,,Homo sapiens,N,,5734,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time
2007,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621296,,,Intermediate,,1,1,,Homo sapiens,N,,5735,In vitro cytotoxicity against lung cancer A 549 cell lines
4594,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621297,,,Intermediate,,1,1,,Homo sapiens,N,,5736,Compound was tested for its cytotoxicity against A 549 cell line
6018,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL839828,,,Expert,,1,1,,Homo sapiens,N,,5737,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay."
6018,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620397,,,Intermediate,,1,1,,Homo sapiens,N,,5738,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data"
3599,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620398,,,Expert,,1,1,,Homo sapiens,N,,5739,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay
2551,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620399,,,Intermediate,,1,1,,Homo sapiens,N,,5740,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
16132,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620400,,,Expert,,1,1,,Homo sapiens,N,,5741,In vitro inhibition of A549 (human lung cancer) cell growth.
16132,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620401,,,Intermediate,,1,1,,Homo sapiens,N,,5742,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available
2551,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620402,,,Expert,,1,1,,Homo sapiens,N,,5743,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay
2551,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620403,,,Expert,,1,1,,Homo sapiens,N,,5744,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM)
11913,,,22226,,,,BAO_0000218,F,,CHEMBL620404,,,Autocuration,,1,0,,,U,,5745,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h
12621,,,104694,,,,BAO_0000218,F,,CHEMBL620405,,,Autocuration,,1,4,,,H,In vivo,5746,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.
12621,,,104694,,,,BAO_0000218,F,,CHEMBL620406,,,Autocuration,,1,4,,,H,In vivo,5747,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.
12621,,,104694,,,,BAO_0000218,F,,CHEMBL620407,,,Autocuration,,1,4,,,H,In vivo,5748,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.
12621,,,104694,,,,BAO_0000218,F,,CHEMBL620408,,,Autocuration,,1,4,,,H,In vivo,5749,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.
12621,,,104694,,,,BAO_0000218,F,,CHEMBL620409,,,Autocuration,,1,4,,,H,In vivo,5750,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.
3600,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL620410,,,Expert,,1,1,,Homo sapiens,N,,5751,Inhibition of A-498 human Renal cell proliferation
1796,,,22226,10116.0,,,BAO_0000019,F,,CHEMBL620411,,,Autocuration,,1,0,,Rattus norvegicus,U,,5752,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM"
1796,,,22226,10116.0,,,BAO_0000019,F,,CHEMBL620412,,,Autocuration,,1,0,,Rattus norvegicus,U,,5753,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM"
1796,,,22226,10116.0,,,BAO_0000019,F,,CHEMBL876596,,,Autocuration,,1,0,,Rattus norvegicus,U,,5754,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM"
16464,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL620413,,,Expert,,1,1,,Homo sapiens,N,,5755,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay
16464,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL620414,,,Intermediate,,1,1,,Homo sapiens,N,,5756,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
16464,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL620415,,,Intermediate,,1,1,,Homo sapiens,N,,5757,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5
13617,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620416,,,Expert,,1,1,,Homo sapiens,N,,5758,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.
4584,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620417,,,Intermediate,,1,1,,Homo sapiens,N,,5759,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549
13799,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620418,,,Expert,,1,1,,Homo sapiens,N,,5760,Cytotoxic activity evaluated against A549 tumor cells
16726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620419,,,Intermediate,,1,1,,Homo sapiens,N,,5761,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line
16109,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620420,,,Intermediate,,1,1,,Homo sapiens,N,,5762,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr
16109,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620421,,,Intermediate,,1,1,,Homo sapiens,N,,5763,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs
15474,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620422,,,Intermediate,,1,1,,Homo sapiens,N,,5764,Cytotoxicity against A549 tumor cell line determined by WST-1 assay
6851,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620423,,,Intermediate,,1,1,,Homo sapiens,N,,5765,Cytotoxicity of compound against A549 cell line
17534,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620424,,,Expert,,1,1,,Homo sapiens,N,,5766,Cytotoxicity against human lung cell carcinoma A549 cell line
2621,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620425,,,Intermediate,,1,1,,Homo sapiens,N,,5767,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay
830,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620426,,,Intermediate,,1,1,,Homo sapiens,N,,5768,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines
14255,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620427,,,Intermediate,,1,1,,Homo sapiens,N,,5769,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum
14255,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620428,,,Intermediate,,1,1,,Homo sapiens,N,,5770,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined
1590,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620429,,,Intermediate,,1,1,,Homo sapiens,N,,5771,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells
6146,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620430,,,Expert,,1,1,,Homo sapiens,N,,5772,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line
17427,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL839887,,,Expert,,1,1,,Homo sapiens,N,,5773,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
5280,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620431,,,Intermediate,,1,1,,Homo sapiens,N,,5774,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549
16786,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884010,,,Intermediate,,1,1,,Homo sapiens,N,,5775,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure
5895,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620538,,,Intermediate,,1,1,,Homo sapiens,N,,5776,In vitro cytotoxicity against A549 (human lung cancer)
14297,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620539,,,Expert,,1,1,,Homo sapiens,N,,5777,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
17824,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL623373,,,Intermediate,,1,1,,Homo sapiens,N,,5778,In vivo antiproliferative activity against A549 cell line
14368,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623374,,,Intermediate,,1,1,,Homo sapiens,N,,5779,Inhibition of non-small-cell lung adenocarcinoma (A549)
14368,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623375,,,Intermediate,,1,1,,Homo sapiens,N,,5780,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment
14254,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623376,,,Intermediate,,1,1,,Homo sapiens,N,,5781,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure
15897,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623377,,,Intermediate,,1,1,,Homo sapiens,N,,5782,Inhibitory activity against A549 cell line using MTT assay(Wild type p53)
13866,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623378,,,Intermediate,,1,1,,Homo sapiens,N,,5783,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr
13370,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623379,,,Intermediate,,1,1,,Homo sapiens,N,,5784,Inhibitory activity of compound against human A549 lung carcinoma cell line.
4862,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623380,,,Intermediate,,1,1,,Homo sapiens,N,,5785,Inhibitory activity against A549 lung cancer cell line
4862,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623381,,,Intermediate,,1,1,,Homo sapiens,N,,5786,Inhibitory activity against Taxol-resistant A549 lung cancer cell line
4862,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623382,,,Intermediate,,1,1,,Homo sapiens,N,,5787,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined
15970,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623383,,,Intermediate,,1,1,,Homo sapiens,N,,5788,Inhibitory concentration against A549 (lung cancer) cell line
17713,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623384,,,Expert,,1,1,,Homo sapiens,N,,5789,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.
4833,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623385,,,Intermediate,,1,1,,Homo sapiens,N,,5790,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line
13736,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623386,,,Expert,,1,1,,Homo sapiens,N,,5791,Activity against A549 cancer cell line.
4312,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884105,,,Intermediate,,1,1,,Homo sapiens,N,,5792,The compound was evaluated for cytotoxicity against A549 cell line
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623387,,,Intermediate,,1,1,,Homo sapiens,N,,5793,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621568,,,Intermediate,,1,1,,Homo sapiens,N,,5794,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line
14717,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621569,,,Intermediate,,1,1,,Homo sapiens,N,,5795,Growth inhibitory activity was measured for human A549 tumor cell line.
4634,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621570,,,Intermediate,,1,1,,Homo sapiens,N,,5796,Inhibitory activity against A549 lung cancer cell line
1149,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621571,,,Intermediate,,1,1,,Homo sapiens,N,,5797,Inhibitory activity against A549 cell line; inactive
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621572,,,Expert,,1,1,,Homo sapiens,N,,5798,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621573,,,Expert,,1,1,,Homo sapiens,N,,5799,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM
5421,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621574,,,Intermediate,,1,1,,Homo sapiens,N,,5800,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration
3320,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621575,,,Intermediate,,1,1,,Homo sapiens,N,,5801,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L)
3320,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621576,,,Intermediate,,1,1,,Homo sapiens,N,,5802,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L)
3320,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621577,,,Intermediate,,1,1,,Homo sapiens,N,,5803,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L)
3320,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621578,,,Intermediate,,1,1,,Homo sapiens,N,,5804,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L)
3320,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621579,,,Intermediate,,1,1,,Homo sapiens,N,,5805,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L)
5726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621580,,,Intermediate,,1,1,,Homo sapiens,N,,5806,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL
17800,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621581,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5807,Plasma clearance (in vivo) in mongrel dogs was determined
5985,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621582,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5808,Plasma clearance was measured in dog
5530,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621583,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5809,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
5530,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621584,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5810,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg
4839,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621585,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5811,Tested for plasma clearance in dog
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621586,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5812,The compound was tested for clearance in dog plasma.
4838,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875835,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5813,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration"
4137,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621587,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5814,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog
5017,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621588,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5815,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
17538,,,50588,9615.0,,,BAO_0000218,A,2107.0,CHEMBL621589,,Microsomes,Intermediate,Liver,1,1,,Canis lupus familiaris,N,In vitro,5816,In vitro clearance in dog liver microsomes
6161,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621590,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5817,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog
6161,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621591,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5818,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog
1696,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621592,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5819,Plasma clearance in dog
6762,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621593,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5820,Clearance rate in dog
5932,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621594,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5821,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose
6305,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621595,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5822,Clearance in dogs
4942,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621596,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5823,Plasma clearance in dogs
4219,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621597,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5824,Plasma clearance was determined
17853,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621598,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5825,Lower clearance in dog (i.v.) at 0.5 mpk
4514,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621599,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5826,Plasma clearance in Beagle dogs
6448,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875836,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5827,Plasma clearance (Clp) in dog
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621600,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5828,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621601,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5829,Plasma clearance (pharmacokinetic parameter) in dog was determined
6062,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618474,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5830,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg
6821,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618475,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5831,Plasma clearance of compound was determined in dog
4709,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624524,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5832,Plasma clearance after intravenous administration of 1 mg/kg in dog
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624525,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5833,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
5374,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624526,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5834,Plasma clearance in dog was determined
6057,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624527,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5835,Plasma clearance was calculated in dog
4727,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624528,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5836,Plasma clearance at the dose of 2 mg/kg in dog
5145,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624529,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5837,Plasma clearance in dog
17657,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624530,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5838,Plasma clearance in dog
17657,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624531,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5839,Plasma clearance in dog; Unable to calculate
5145,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624532,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5840,Plasma clearance in rhesus monkey
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624533,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5841,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
6641,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624534,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5842,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624535,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5843,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624536,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5844,Plasma clearance was evaluated in dog
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624537,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5845,Plasma clearance was evaluated in dog; Not tested
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624538,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5846,Plasma clearance was evaluated in rhesus
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624539,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5847,Plasma clearance was evaluated in rhesus; Not tested
4257,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624540,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5848,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose
6679,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624541,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5849,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
5546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624542,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5850,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration
6348,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624543,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5851,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
5474,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624544,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5852,Clearance value at a dose of 0.2 mg/kg i.v.
6316,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624545,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5853,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg
17594,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624546,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5854,Cmax after oral dose of compound at 3 mg/kg in dogs
17594,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875957,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5855,Cmax after single intravenous bolus of 1 mg/kg in dogs
5802,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624547,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5856,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624548,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5857,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624549,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5858,Cmax in dog after administration of 1 mg/kg iv
1466,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624550,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,5859,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog
6505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621613,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5860,Cmax on p.o. administration of 10 mg/kg was measured in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621614,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5861,Cmax was determine after peroral administration at 10 mpk in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623431,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5862,Cmax was determine after peroral administration at 5 mpk in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623432,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5863,Cmax was determine after peroral administration at 5 mg/kg in dog
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623433,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5864,Cmax after 0.3 mg/kg po administration in dog
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623434,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5865,Cmax after peroral administration in dogs at 2.4 uM/kg
6123,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623435,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5866,Cmax in dog after oral administration at 1 mg/kg
6123,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623436,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5867,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation
6757,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875958,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5868,Cmax upon oral administration in male Beagle dog at 10 mg/kg
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623437,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5869,Cmax value after 15 mg/kg iv dose in Dogs
7767,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL623438,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5870,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL623439,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,5871,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL623440,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,5872,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL623441,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,5873,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL623442,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,5874,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623469,,,Intermediate,,1,1,,Mus musculus,N,In vivo,5875,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623470,,,Intermediate,,1,1,,Mus musculus,N,In vivo,5876,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623471,,,Intermediate,,1,1,,Mus musculus,N,In vivo,5877,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL623472,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5878,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL623473,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5879,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL623474,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,5880,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623475,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5881,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623476,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5882,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623477,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,5883,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL621896,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,5884,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL621897,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,5885,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL621898,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,5886,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621899,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5887,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621900,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5888,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621901,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,5889,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL621902,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,5890,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL621903,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,5891,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL622587,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,5892,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL620285,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,5893,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL875285,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,5894,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL620286,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,5895,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620287,,,Intermediate,,1,1,,Mus musculus,N,In vivo,5896,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620288,,,Intermediate,,1,1,,Mus musculus,N,In vivo,5897,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL620289,,,Intermediate,,1,1,,Mus musculus,N,In vivo,5898,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL620290,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,5899,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL620291,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,5900,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,160.0,CHEMBL620292,,,Intermediate,Intestine,1,1,,Mus musculus,N,In vivo,5901,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL620293,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,5902,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL620294,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,5903,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618614,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,5904,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL618615,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,5905,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL618616,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,5906,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram
2036,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL618617,,,Expert,,1,1,,Homo sapiens,N,,5907,Cytotoxicity against A-172 human tumor cell lines
2357,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL618618,,,Intermediate,,1,1,,Homo sapiens,N,,5908,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line
1457,623.0,A204,80014,9606.0,,,BAO_0000219,F,,CHEMBL618619,,,Intermediate,,1,1,,Homo sapiens,N,,5909,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells
4379,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618620,,,Intermediate,,1,1,,Homo sapiens,N,,5910,Tested for antiproliferative activity against A-2780 tumoral cell line
1093,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL618621,,,Intermediate,,1,1,,Homo sapiens,N,,5911,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined
12152,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL618622,,,Intermediate,,1,1,,Homo sapiens,N,,5912,Tested in vitro against A-375 cell line human melanoma
16464,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618623,,,Expert,,1,1,,Homo sapiens,N,,5913,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay
16464,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618624,,,Intermediate,,1,1,,Homo sapiens,N,,5914,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
16582,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618625,,,Expert,,1,1,,Homo sapiens,N,,5915,In vitro cytotoxicity against human non small-cell-lung cell line A-427.
16464,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618626,,,Intermediate,,1,1,,Homo sapiens,N,,5916,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5
10413,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618627,,,Intermediate,,1,1,,Homo sapiens,N,,5917,Antitumor activity on A-427 lung carcinoma cell lines
6418,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618628,,,Intermediate,,1,1,,Homo sapiens,N,,5918,Cytotoxic activity against human A-427 lung tumor cell line
17134,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618629,,,Expert,,1,1,,Homo sapiens,N,,5919,In vitro antitumor effects against human A-427 cell lines.
16132,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618630,,,Expert,,1,1,,Homo sapiens,N,,5920,In vitro inhibition of A-427 (human lung cancer) cell growth.
16132,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618631,,,Intermediate,,1,1,,Homo sapiens,N,,5921,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available
16780,797.0,A-427,80019,9606.0,,,BAO_0000219,F,,CHEMBL618632,,,Intermediate,,1,1,,Homo sapiens,N,,5922,Cytotoxic activity of compound against A-427 lung human tumor cell line
4085,500.0,A-431,80852,9606.0,,,BAO_0000219,F,,CHEMBL618633,,,Expert,,1,1,,Homo sapiens,N,,5923,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line
1276,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619315,,,Intermediate,,1,1,,Homo sapiens,N,,5924,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line
3498,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619316,,,Expert,,1,1,,Homo sapiens,N,,5925,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined
1169,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619317,,,Intermediate,,1,1,,Homo sapiens,N,,5926,Cytotoxicity against human kidney carcinoma A-498cell lines
4450,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619318,,,Intermediate,,1,1,,Homo sapiens,N,,5927,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line
3311,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619319,,,Intermediate,,1,1,,Homo sapiens,N,,5928,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.
4461,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619739,,,Intermediate,,1,1,,Homo sapiens,N,,5929,Antitumor cytotoxic activity against A-498 cell line was determined
3311,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619740,,,Intermediate,,1,1,,Homo sapiens,N,,5930,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.
3311,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL883158,,,Intermediate,,1,1,,Homo sapiens,N,,5931,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data
1457,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL884012,,,Intermediate,,1,1,,Homo sapiens,N,,5932,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells
3664,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619741,,,Intermediate,,1,1,,Homo sapiens,N,,5933,In vitro inhibitory activity against A-498 ovarian cancer cell lines
15895,624.0,A498,80021,9606.0,,,BAO_0000219,F,,CHEMBL619742,,,Intermediate,,1,1,,Homo sapiens,N,,5934,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line"
11843,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876610,,,Intermediate,,1,1,,Homo sapiens,N,,5935,Inhibition of growth lung non-small cell carcinoma A-549 cell line
11843,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619743,,,Intermediate,,1,1,,Homo sapiens,N,,5936,Inhibition of growth of lung non-small cell carcinoma A-549 cell line
17705,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619744,,,Intermediate,,1,1,,Homo sapiens,N,,5937,In vitro antiproliferative activity against human A-549 NSCL cell line
17705,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619745,,,Intermediate,,1,1,,Homo sapiens,N,,5938,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619746,,,Intermediate,,1,1,,Homo sapiens,N,,5939,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619747,,,Intermediate,,1,1,,Homo sapiens,N,,5940,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619748,,,Intermediate,,1,1,,Homo sapiens,N,,5941,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619749,,,Intermediate,,1,1,,Homo sapiens,N,,5942,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619750,,,Intermediate,,1,1,,Homo sapiens,N,,5943,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624014,,,Intermediate,,1,1,,Homo sapiens,N,,5944,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay
4369,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624015,,,Intermediate,,1,1,,Homo sapiens,N,,5945,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data
4787,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL885344,,,Expert,,1,1,,Homo sapiens,N,,5946,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation
4787,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623224,,,Intermediate,,1,1,,Homo sapiens,N,,5947,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation
6513,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL623225,,,Intermediate,,1,1,,Homo sapiens,N,,5948,Cytotoxic activity against A-549 cell line
6690,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622698,,,Intermediate,,1,1,,Homo sapiens,N,,5949,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03
6690,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622699,,,Intermediate,,1,1,,Homo sapiens,N,,5950,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1
12263,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622700,,,Expert,,1,1,,Homo sapiens,N,,5951,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line"
1054,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622701,,,Intermediate,,1,1,,Homo sapiens,N,,5952,Compound was tested for cytotoxic activity against human lung carcinoma (A-549)
1359,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622702,,,Intermediate,,1,1,,Homo sapiens,N,,5953,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma)
3547,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622703,,,Intermediate,,1,1,,Homo sapiens,N,,5954,Cytotoxic activity against human lung carcinoma (A-549) cell line
5771,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622704,,,Expert,,1,1,,Homo sapiens,N,,5955,Cytotoxic activity towards A-549 cells
14425,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622705,,,Intermediate,,1,1,,Homo sapiens,N,,5956,"In vitro percent inhibition of A549, lung carcinoma."
14425,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622706,,,Intermediate,,1,1,,Homo sapiens,N,,5957,"In vitro percent inhibition of A549, lung carcinoma"
14425,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622707,,,Intermediate,,1,1,,Homo sapiens,N,,5958,"In vitro percent inhibition of A549, lung carcinoma."
14425,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622708,,,Intermediate,,1,1,,Homo sapiens,N,,5959,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23"
5280,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622709,,,Intermediate,,1,1,,Homo sapiens,N,,5960,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM
15176,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622710,,,Intermediate,,1,1,,Homo sapiens,N,,5961,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.
15300,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622711,,,Intermediate,,1,1,,Homo sapiens,N,,5962,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay
17824,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL622712,,,Intermediate,,1,1,,Homo sapiens,N,,5963,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
17824,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL622713,,,Intermediate,,1,1,,Homo sapiens,N,,5964,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
17824,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL622714,,,Intermediate,,1,1,,Homo sapiens,N,,5965,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
17824,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL622715,,,Intermediate,,1,1,,Homo sapiens,N,,5966,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
17824,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL622716,,,Intermediate,,1,1,,Homo sapiens,N,,5967,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose"
17824,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622717,,,Intermediate,,1,1,,Homo sapiens,N,,5968,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested"
17528,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL622718,,,Intermediate,,1,1,,Homo sapiens,N,,5969,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3)
6870,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622719,,,Expert,,1,1,,Homo sapiens,N,,5970,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration
6870,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622720,,,Intermediate,,1,1,,Homo sapiens,N,,5971,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
6870,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622721,,,Intermediate,,1,1,,Homo sapiens,N,,5972,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration
6870,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622722,,,Intermediate,,1,1,,Homo sapiens,N,,5973,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined
16726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876030,,,Intermediate,,1,1,,Homo sapiens,N,,5974,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
6170,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620206,,,Intermediate,,1,1,,Homo sapiens,N,,5975,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation"
6583,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620207,,,Expert,,1,1,,Homo sapiens,N,,5976,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L
6583,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620208,,,Expert,,1,1,,Homo sapiens,N,,5977,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L
6583,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620209,,,Expert,,1,1,,Homo sapiens,N,,5978,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L
6583,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620210,,,Expert,,1,1,,Homo sapiens,N,,5979,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L
6583,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621639,,,Expert,,1,1,,Homo sapiens,N,,5980,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L
17321,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621640,,,Intermediate,,1,1,,Homo sapiens,N,,5981,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line
17528,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621641,,,Expert,,1,1,,Homo sapiens,N,,5982,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
12888,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621642,,,Expert,,1,1,,Homo sapiens,N,,5983,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC
4312,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621643,,,Intermediate,,1,1,,Homo sapiens,N,,5984,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line
4312,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621644,,,Intermediate,,1,1,,Homo sapiens,N,,5985,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line
4312,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL621645,,,Intermediate,,1,1,,Homo sapiens,N,,5986,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data
17737,646.0,A549,80682,10090.0,,,BAO_0000219,F,,CHEMBL621646,,,Intermediate,,1,1,,Mus musculus,N,,5987,In vitro antiproliferative activity against A549 cell line
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621647,,,Intermediate,,1,1,,,N,,5988,Synergism with indomethacin in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621648,,,Intermediate,,1,1,,,N,,5989,Synergism with tolmetin in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621649,,,Intermediate,,1,1,,,N,,5990,Synergism with sulindac in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621650,,,Intermediate,,1,1,,,N,,5991,Antagonism of indomethacin in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621651,,,Intermediate,,1,1,,,N,,5992,Antagonism of sulindac in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621652,,,Intermediate,,1,1,,,N,,5993,Antagonism of tolmetin in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621653,,,Intermediate,,1,1,,,N,,5994,Synergism with indomethacin in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621654,,,Intermediate,,1,1,,,N,,5995,Synergism with sulindac in A549 cells
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL621655,,,Intermediate,,1,1,,,N,,5996,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621656,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5997,Cmax value after 30 mg/kg po dose in Dogs
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621657,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5998,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg)
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621658,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,5999,Cmax value determined in dog at a dose of 10 mg/kg by oral administration
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621659,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6000,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg)
5944,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621660,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6001,Cmax value determined in dog at a dose of 5 mg/kg by oral administration
2959,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621661,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6002,Cmax value after administration of 4 mg/Kg oral dose in dog
6241,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621662,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6003,Cmax value in dog
6241,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621663,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6004,Cmax value in dogs after oral administration at 1 mg/kg
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621664,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6005,Bioavailability as Cmax in dogs at 5 mg/kg oral dose
1806,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621665,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6006,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs
1806,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621666,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6007,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs
1021,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621667,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6008,Concentration maxima after oral dosing in dogs
1021,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876738,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6009,Concentration maxima after oral dosing in dogs; not available
1021,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621668,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6010,Concentration maxima after oral dosing in dogs; not available
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621669,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6011,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621670,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6012,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621671,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6013,In vivo maximal concentration was calculated at 1 mg/kg in dog
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622360,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6014,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622361,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6015,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption
5130,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622362,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6016,Cmax in dog plasma after oral dose (1 mg/kg)
3249,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622363,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6017,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg
5473,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622364,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6018,Maximal plasma concentration at a dose of 1 mg/kg
5474,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622365,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6019,Maximal plasma concentration at a dose of 1 mg/kg (oral)
4657,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622533,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6020,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally
3031,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622534,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6021,Maximum concentration of compound in dog was evaluated.
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622535,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6022,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined
4186,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876739,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6023,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route
5007,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622536,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6024,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
3132,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL622537,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6025,Maximum concentration obtained in dog plasma was determined
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622538,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6026,Maximum concentration was determined
4727,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL627867,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6027,Maximum concentration at the dose of 2 mg/kg in dog
1916,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL627868,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6028,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
1918,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627869,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6029,Maximum concentration was evaluated in dog plasma
3045,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL627870,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6030,Maximum concentration was evaluated after 75 min after administration in dog
9579,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627871,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6031,Maximum plasma concentration determined in dog after oral administration of 17b
9579,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627872,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6032,Maximum plasma concentration determined in dog after oral administration of 2b
933,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627873,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6033,Maximum plasma concentration in dog
17839,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627874,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6034,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627875,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6035,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627876,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6036,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627877,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6037,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg
6348,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627878,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6038,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
16367,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627879,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6039,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg
1337,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL875355,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6040,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
1337,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627880,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6041,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
5199,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627881,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6042,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
17650,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627882,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6043,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
6679,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL627883,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6044,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration
5356,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL628526,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6045,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL
5356,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL628527,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6046,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL
6227,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL628528,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6047,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg
6227,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL628529,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6048,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg
6227,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL628530,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6049,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg
6227,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL625243,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6050,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg
3598,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL625244,,,Expert,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6051,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg
4368,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625245,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6052,Maximum concentration by intravenous administration of 1.2 mg/kg in dog
6265,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625246,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6053,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg
7767,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL625247,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,6054,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,1088.0,CHEMBL625248,,,Intermediate,Urine,1,1,,Mus musculus,N,In vivo,6055,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram
7767,,,50594,10090.0,,,BAO_0000218,A,1088.0,CHEMBL625249,,,Intermediate,Urine,1,1,,Mus musculus,N,In vivo,6056,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data
7767,,,50594,10090.0,,,BAO_0000218,A,1088.0,CHEMBL625250,,,Intermediate,Urine,1,1,,Mus musculus,N,In vivo,6057,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data
17811,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625251,,,Intermediate,,1,1,,Mus musculus,N,,6058,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase
17811,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL875356,,,Intermediate,,1,1,,Mus musculus,N,,6059,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625252,,,Intermediate,,1,1,,Mus musculus,N,,6060,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL625253,,,Intermediate,Blood,1,1,,Mus musculus,N,,6061,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625254,,,Intermediate,,1,1,,Mus musculus,N,,6062,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625255,,,Intermediate,,1,1,,Mus musculus,N,,6063,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625256,,,Intermediate,,1,1,,Mus musculus,N,,6064,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL625257,,,Intermediate,Blood,1,1,,Mus musculus,N,,6065,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL625258,,,Intermediate,Blood,1,1,,Mus musculus,N,,6066,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625259,,,Intermediate,,1,1,,Mus musculus,N,,6067,Compound was evaluated for washout rate in mice (Radiolabeled compound)
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625260,,,Intermediate,,1,1,,Mus musculus,N,,6068,Compound was evaluated for washout rate in mice after radiolabeled ligand injected
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625261,,,Intermediate,,1,1,,Mus musculus,N,,6069,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625262,,,Intermediate,,1,1,,Mus musculus,N,,6070,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622639,,,Intermediate,,1,1,,Mus musculus,N,,6071,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)"
17257,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622640,,,Intermediate,,1,1,,Mus musculus,N,,6072,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice
17257,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622812,,,Intermediate,,1,1,,Mus musculus,N,,6073,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.
17257,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622813,,,Intermediate,,1,1,,Mus musculus,N,,6074,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice
17257,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622814,,,Intermediate,,1,1,,Mus musculus,N,,6075,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined
17827,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622815,,,Intermediate,,1,1,,Mus musculus,N,,6076,Time at maximum activity in mice (Radiolabeled compound)
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625342,,,Intermediate,,1,1,,Mus musculus,N,,6077,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625343,,,Intermediate,,1,1,,Mus musculus,N,,6078,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice
17409,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL877591,,,Intermediate,,1,1,,Mus musculus,N,,6079,Binding towards mouse plasma protein at 10 uM
17409,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625344,,,Intermediate,,1,1,,Mus musculus,N,,6080,Binding towards mouse plasma protein at 100 uM
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625345,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6081,Bioavailability was evaluated in mice after intravenous administration
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625346,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6082,Bioavailability was evaluated in mice after oral administration
3132,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625347,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6083,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse
3132,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625348,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6084,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625349,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6085,Bioavailability at a dose of 10 mg/kg peroral administration in mice.
2862,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL625350,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6086,Oral bioavailability in mouse
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL882952,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6087,Oral bioavailability after intravenous administration in mice at 24 uM/kg
846,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL625351,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6088,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL625352,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6089,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL877592,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6090,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL625353,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6091,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL625354,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6092,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL626019,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6093,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL626020,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,6094,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL626021,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,6095,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL626022,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,6096,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL626192,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,6097,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
1276,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626193,,,Intermediate,,1,1,,Homo sapiens,N,,6098,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma)
3498,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626194,,,Expert,,1,1,,Homo sapiens,N,,6099,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined
1169,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626195,,,Intermediate,,1,1,,Homo sapiens,N,,6100,Cytotoxicity against human lung carcinoma A-549 cell lines
4450,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626196,,,Intermediate,,1,1,,Homo sapiens,N,,6101,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626197,,,Intermediate,,1,1,,Homo sapiens,N,,6102,In vitro cytotoxicity against human lung carcinoma cell line A-549
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626198,,,Intermediate,,1,1,,Homo sapiens,N,,6103,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626199,,,Intermediate,,1,1,,Homo sapiens,N,,6104,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626200,,,Intermediate,,1,1,,Homo sapiens,N,,6105,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626201,,,Intermediate,,1,1,,Homo sapiens,N,,6106,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626202,,,Intermediate,,1,1,,Homo sapiens,N,,6107,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M
358,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626203,,,Intermediate,,1,1,,Homo sapiens,N,,6108,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M
15167,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL626204,,,Intermediate,,1,1,,Homo sapiens,N,,6109,In vitro cytotoxicity against A-549 human lung cancer cells
4139,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624701,,,Intermediate,,1,1,,Homo sapiens,N,,6110,In vitro cytotoxicity against human lung carcinoma (A-549) cell line
833,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624702,,,Intermediate,,1,1,,Homo sapiens,N,,6111,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines
15718,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624703,,,Expert,,1,1,,Homo sapiens,N,,6112,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
12373,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624704,,,Intermediate,,1,1,,Homo sapiens,N,,6113,Tested in vitro for cytotoxicity against A-549 lung cancer cells
637,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624705,,,Intermediate,,1,1,,Homo sapiens,N,,6114,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma
14867,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624706,,,Expert,,1,1,,Homo sapiens,N,,6115,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.
4461,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624707,,,Intermediate,,1,1,,Homo sapiens,N,,6116,Antitumor cytotoxic activity against A-549 cell line was determined
5406,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624708,,,Intermediate,,1,1,,Homo sapiens,N,,6117,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported"
4457,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624709,,,Intermediate,,1,1,,Homo sapiens,N,,6118,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
1386,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884107,,,Expert,,1,1,,Homo sapiens,N,,6119,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
3265,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624710,,,Intermediate,,1,1,,Homo sapiens,N,,6120,Antitumoral activity was assayed against A-549 cell line
2359,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624711,,,Intermediate,,1,1,,Homo sapiens,N,,6121,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation
4457,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624712,,,Intermediate,,1,1,,Homo sapiens,N,,6122,Compound was tested for cytotoxicity against A-549 human solid tumor cell line
12454,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624713,,,Expert,,1,1,,Homo sapiens,N,,6123,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.
1481,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624714,,,Intermediate,,1,1,,Homo sapiens,N,,6124,Compound was tested for inhibition of cell growth of A-549 cells
1750,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624715,,,Intermediate,,1,1,,Homo sapiens,N,,6125,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.
5065,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624716,,,Intermediate,,1,1,,Homo sapiens,N,,6126,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined
808,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619505,,,Expert,,1,1,,Homo sapiens,N,,6127,In vitro cytotoxicity against A549-human lung carcinoma cells.
16364,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619506,,,Expert,,1,1,,Homo sapiens,N,,6128,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.
1847,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619507,,,Intermediate,,1,1,,Homo sapiens,N,,6129,Cytotoxic activity against A-549 cell lines.
1747,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619508,,,Expert,,1,1,,Homo sapiens,N,,6130,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.
1003,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619509,,,Intermediate,,1,1,,Homo sapiens,N,,6131,Cytotoxicity against human A549 non small cell lung cell lines
15313,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619510,,,Expert,,1,1,,Homo sapiens,N,,6132,Inhibition of cell growth in (A-549) lung cell line
3122,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619511,,,Intermediate,,1,1,,Homo sapiens,N,,6133,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line
16049,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619512,,,Intermediate,,1,1,,Homo sapiens,N,,6134,In vitro antitumor activity against A-549 tumor cells.
17134,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619513,,,Expert,,1,1,,Homo sapiens,N,,6135,In vitro antitumor effects against human A-549 cell lines.
6406,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619514,,,Intermediate,,1,1,,Homo sapiens,N,,6136,In vitro cytotoxic activity of compound against A-549 cell line
627,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619515,,,Intermediate,,1,1,,Homo sapiens,N,,6137,In vitro cytotoxicity against human lung carcinoma A-549 cell line
12307,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619516,,,Intermediate,,1,1,,Homo sapiens,N,,6138,In vitro cytotoxicity against human non-small cell lung carcinoma A549
17861,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884005,,,Intermediate,,1,1,,Homo sapiens,N,,6139,In vitro cytotoxicity against human A-549 cancer cell line was evaluated
6682,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619517,,,Expert,,1,1,,Homo sapiens,N,,6140,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619518,,,Intermediate,,1,1,,Homo sapiens,N,,6141,Inhibitory concentration of compound against A-549 cell line
2454,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619519,,,Intermediate,,1,1,,Homo sapiens,N,,6142,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells
14709,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876489,,,Intermediate,,1,1,,Homo sapiens,N,,6143,cytotoxic activity against leukemia (A-549) cancer cell line
15718,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619520,,,Expert,,1,1,,Homo sapiens,N,,6144,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line
15718,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619521,,,Intermediate,,1,1,,Homo sapiens,N,,6145,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619522,,,Intermediate,,1,1,,Homo sapiens,N,,6146,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml)
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619523,,,Intermediate,,1,1,,Homo sapiens,N,,6147,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml)
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619524,,,Intermediate,,1,1,,Homo sapiens,N,,6148,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml)
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619525,,,Intermediate,,1,1,,Homo sapiens,N,,6149,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)
6630,646.0,A549,80682,,,,BAO_0000219,F,,CHEMBL619526,,,Intermediate,,1,1,,,N,,6150,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available
16726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619527,,,Intermediate,,1,1,,Homo sapiens,N,,6151,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound
17846,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619528,,,Intermediate,,1,1,,Homo sapiens,N,,6152,Cytotoxicity against A549 cells; No cytotoxicity
3415,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619529,,,Expert,,1,1,,Homo sapiens,N,,6153,Cytotoxicity against human lung carcinoma (A549) cell lines
3415,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619530,,,Expert,,1,1,,Homo sapiens,N,,6154,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active
5609,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876490,,,Intermediate,,1,1,,Homo sapiens,N,,6155,In vitro anticancer activity against human lung (A549) cell line
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619531,,,Intermediate,,1,1,,Homo sapiens,N,,6156,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619532,,,Intermediate,,1,1,,Homo sapiens,N,,6157,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619533,,,Intermediate,,1,1,,Homo sapiens,N,,6158,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619534,,,Intermediate,,1,1,,Homo sapiens,N,,6159,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620164,,,Intermediate,,1,1,,Homo sapiens,N,,6160,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620165,,,Intermediate,,1,1,,Homo sapiens,N,,6161,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
16295,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620166,,,Expert,,1,1,,Homo sapiens,N,,6162,Inhibition of A549 human lung tumor cell proliferation
16825,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620167,,,Intermediate,,1,1,,Homo sapiens,N,,6163,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. "
3439,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620168,,,Expert,,1,1,,Homo sapiens,N,,6164,In vitro cytotoxicity against human tumor cell line A549
10870,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620338,,,Intermediate,,1,1,,Homo sapiens,N,,6165,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. 
4845,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620339,,,Intermediate,,1,1,,Homo sapiens,N,,6166,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line
5822,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620340,,,Intermediate,,1,1,,Homo sapiens,N,,6167,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells
5822,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620341,,,Intermediate,,1,1,,Homo sapiens,N,,6168,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells
5822,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876491,,,Intermediate,,1,1,,Homo sapiens,N,,6169,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620342,,,Intermediate,,1,1,,Homo sapiens,N,,6170,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620343,,,Intermediate,,1,1,,Homo sapiens,N,,6171,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620344,,,Intermediate,,1,1,,Homo sapiens,N,,6172,% inhibition against A549 cells (lung cancer) at 4 ug/mL
5609,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620345,,,Intermediate,,1,1,,Homo sapiens,N,,6173,In vitro anticancer activity against human lung (A549) cell line
4644,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620346,,,Intermediate,,1,1,,Homo sapiens,N,,6174,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined
4644,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620347,,,Intermediate,,1,1,,Homo sapiens,N,,6175,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined
4644,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620348,,,Intermediate,,1,1,,Homo sapiens,N,,6176,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined
4644,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620349,,,Intermediate,,1,1,,Homo sapiens,N,,6177,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined
5822,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL618667,,,Intermediate,,1,1,,Homo sapiens,N,,6178,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM
3415,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL618668,,,Expert,,1,1,,Homo sapiens,N,,6179,Percentage inhibition of human lung carcinoma (A549) cell lines
16726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876031,,,Intermediate,,1,1,,Homo sapiens,N,,6180,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL618759,,,Intermediate,,1,1,,Homo sapiens,N,,6181,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined"
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL618760,,,Intermediate,,1,1,,Homo sapiens,N,,6182,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619000,,,Intermediate,,1,1,,Homo sapiens,N,,6183,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619001,,,Intermediate,,1,1,,Homo sapiens,N,,6184,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)"
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619002,,,Intermediate,,1,1,,Homo sapiens,N,,6185,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM"
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619003,,,Intermediate,,1,1,,Homo sapiens,N,,6186,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM"
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619597,,,Intermediate,,1,1,,Homo sapiens,N,,6187,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM"
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619598,,,Intermediate,,1,1,,Homo sapiens,N,,6188,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM"
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619599,,,Intermediate,,1,1,,Homo sapiens,N,,6189,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619600,,,Intermediate,,1,1,,Homo sapiens,N,,6190,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells
16726,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619601,,,Intermediate,,1,1,,Homo sapiens,N,,6191,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619602,,,Intermediate,,1,1,,Homo sapiens,N,,6192,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619603,,,Intermediate,,1,1,,Homo sapiens,N,,6193,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619604,,,Intermediate,,1,1,,Homo sapiens,N,,6194,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619605,,,Intermediate,,1,1,,Homo sapiens,N,,6195,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619606,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6196,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876032,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6197,Pharmacokinetic activity (Cmax) in dog
4809,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619607,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6198,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
5983,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619608,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6199,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg
6251,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619609,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6200,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg
5932,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL619610,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6201,Cmax in dog plasma after 30mg/kg oral dose
4273,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL619611,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,In vivo,6202,Tested for the peak blood level in dog
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619612,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6203,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog"
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619613,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6204,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk"
6221,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL619614,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,In vivo,6205,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined
4709,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619615,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6206,Concentration in the plasma after intravenous administration of 1 mg/kg in dog
167,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619616,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6207,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours
6241,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL619617,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,6208,Final plasma concentration in dogs after oral administration at 1 mg/kg
344,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619618,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6209,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min
344,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876033,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6210,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min
344,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619619,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6211,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min
2189,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619620,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6212,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs
2189,,,50588,9615.0,,,BAO_0000218,A,1088.0,CHEMBL619621,,,Intermediate,Urine,1,1,,Canis lupus familiaris,N,,6213,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs
2189,,,50588,9615.0,,,BAO_0000218,A,1088.0,CHEMBL619622,,,Intermediate,Urine,1,1,,Canis lupus familiaris,N,,6214,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data
2189,,,50588,9615.0,,,BAO_0000218,A,1088.0,CHEMBL618874,,,Intermediate,Urine,1,1,,Canis lupus familiaris,N,,6215,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data
4257,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618875,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6216,Absolute bioavailability was evaluated in dog
6221,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618876,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6217,Bioavailability after oral administration (2.5 mg/kg) in dog was determined
6215,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618877,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6218,Bioavailability after peroral administration (1 mg/kg) was determined in dog
17267,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618878,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6219,Bioavailability in dog
6621,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618879,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6220,Bioavailability in dog
3854,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618880,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6221,Bioavailability after intravenous administration in dogs
3854,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618881,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6222,Bioavailability after peroral administration in dogs
5007,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618882,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6223,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
4333,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624226,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6224,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr
4333,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624227,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6225,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624228,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6226,Bioavailability
5199,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624229,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6227,Bioavailability
4368,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624230,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6228,Bioavailability by intravenous administration of 1.2 mg/kg in dog
3771,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624231,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6229,Bioavailability in dog
4953,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624232,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6230,Bioavailability in dog
5064,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625127,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6231,Bioavailability in dog
17657,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625128,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6232,Bioavailability in dog
17796,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621675,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6233,Bioavailability in dog
17853,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621676,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6234,Bioavailability in dog (p.o.) at 2.0 mpk
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621677,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6235,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.)
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621678,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6236,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621679,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6237,Bioavailability in dog
16365,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621680,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6238,Bioavailability was evaluated after oral administration in dog
1916,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621681,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6239,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
1918,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876740,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6240,Bioavailability was evaluated in dog
4239,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621682,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6241,Bioavailability in dog
6505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621683,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6242,Bioavailability in dog
5334,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621684,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6243,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
5334,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621685,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6244,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
4809,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621686,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6245,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
6348,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621687,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6246,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
6005,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621688,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6247,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg
17804,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621689,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6248,Bioavailability of compound in dog was determined after peroral administration
3184,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621690,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6249,Oral bioavailability in dog
1806,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621691,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6250,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs
1806,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875941,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6251,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs
1806,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621692,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6252,Compound was evaluated for oral bioavailability in dogs; 37-38 %
4839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621693,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6253,Bioavailability in dog
5017,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621694,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6254,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.)
846,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621695,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,6255,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621696,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,6256,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621697,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6257,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621698,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6258,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623420,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6259,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623421,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6260,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623422,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6261,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623423,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6262,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623424,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6263,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623425,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6264,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623426,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6265,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623427,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6266,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623428,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6267,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL875947,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6268,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623429,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6269,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623430,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6270,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL622588,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6271,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL622589,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6272,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL622751,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6273,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ
846,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL622752,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6274,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL622753,,,Intermediate,,1,1,,Mus musculus,N,,6275,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL622647,,,Intermediate,,1,1,,Mus musculus,N,,6276,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL875163,,,Intermediate,,1,1,,Mus musculus,N,,6277,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL622648,,,Intermediate,,1,1,,Mus musculus,N,,6278,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL622649,,,Intermediate,,1,1,,Mus musculus,N,,6279,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622650,,,Intermediate,Brain,1,1,,Mus musculus,N,,6280,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622651,,,Intermediate,Brain,1,1,,Mus musculus,N,,6281,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622652,,,Intermediate,Brain,1,1,,Mus musculus,N,,6282,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622653,,,Intermediate,Brain,1,1,,Mus musculus,N,,6283,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL622654,,,Intermediate,Brain,1,1,,Mus musculus,N,,6284,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622655,,,Intermediate,Heart,1,1,,Mus musculus,N,,6285,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622656,,,Intermediate,Heart,1,1,,Mus musculus,N,,6286,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622657,,,Intermediate,Heart,1,1,,Mus musculus,N,,6287,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622658,,,Intermediate,Heart,1,1,,Mus musculus,N,,6288,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL622659,,,Intermediate,Heart,1,1,,Mus musculus,N,,6289,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL624630,,,Intermediate,Kidney,1,1,,Mus musculus,N,,6290,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL624631,,,Intermediate,Kidney,1,1,,Mus musculus,N,,6291,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL624632,,,Intermediate,Kidney,1,1,,Mus musculus,N,,6292,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624633,,,Intermediate,,1,1,,Homo sapiens,N,,6293,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624634,,,Intermediate,,1,1,,Homo sapiens,N,,6294,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624635,,,Intermediate,,1,1,,Homo sapiens,N,,6295,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)
17130,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624636,,,Intermediate,,1,1,,Homo sapiens,N,,6296,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml))
3263,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL857055,,,Expert,,1,1,,Homo sapiens,N,,6297,Antineoplastic activity against A-549 (human lung carcinoma) cell line.
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624637,,,Expert,,1,1,,Homo sapiens,N,,6298,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624638,,,Expert,,1,1,,Homo sapiens,N,,6299,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL874366,,,Expert,,1,1,,Homo sapiens,N,,6300,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624639,,,Expert,,1,1,,Homo sapiens,N,,6301,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624640,,,Expert,,1,1,,Homo sapiens,N,,6302,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624641,,,Intermediate,,1,1,,Homo sapiens,N,,6303,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624642,,,Intermediate,,1,1,,Homo sapiens,N,,6304,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624643,,,Intermediate,,1,1,,Homo sapiens,N,,6305,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624644,,,Intermediate,,1,1,,Homo sapiens,N,,6306,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM
6663,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL624645,,,Intermediate,,1,1,,Homo sapiens,N,,6307,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM
3983,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619445,,,Intermediate,,1,1,,Homo sapiens,N,,6308,The compound was evaluated for its cytotoxic potency against A-549 cell line
11141,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL839886,,,Expert,,1,1,,Homo sapiens,N,,6309,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines
5076,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619446,,,Intermediate,,1,1,,Homo sapiens,N,,6310,Cytotoxic activity of compound against A-549 tumor cell line.
3311,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619447,,,Intermediate,,1,1,,Homo sapiens,N,,6311,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.
3311,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619448,,,Intermediate,,1,1,,Homo sapiens,N,,6312,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.
3311,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619449,,,Intermediate,,1,1,,Homo sapiens,N,,6313,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data
5076,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619450,,,Intermediate,,1,1,,Homo sapiens,N,,6314,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL
4150,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619451,,,Intermediate,,1,1,,Homo sapiens,N,,6315,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185)
2150,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619452,,,Expert,,1,1,,Homo sapiens,N,,6316,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma
4644,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619453,,,Intermediate,,1,1,,Homo sapiens,N,,6317,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells
263,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL874367,,,Intermediate,,1,1,,Homo sapiens,N,,6318,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity
11333,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619454,,,Intermediate,,1,1,,Homo sapiens,N,,6319,Cytotoxic concentration against A-549 tumor cells.
11333,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619455,,,Intermediate,,1,1,,Homo sapiens,N,,6320,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.
15895,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619456,,,Intermediate,,1,1,,Homo sapiens,N,,6321,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line"
16677,,,50191,470.0,,,BAO_0000218,F,,CHEMBL619457,,,Expert,,1,1,,Acinetobacter baumannii,N,,6322,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A
10624,,,50192,471.0,,,BAO_0000218,F,,CHEMBL619458,,,Intermediate,,1,1,,Acinetobacter calcoaceticus,N,,6323,Activity against Acinetobacter calcoaceticus (AC54)
16717,,,50274,5059.0,,,BAO_0000218,F,,CHEMBL619459,,,Expert,,1,1,,Aspergillus flavus,N,,6324,In vitro antifungal activity against Aspergillus flavus CM74
16717,,,50274,5059.0,,,BAO_0000218,F,,CHEMBL619460,,,Expert,,1,1,,Aspergillus flavus,N,,6325,In vitro antifungal activity against Aspergillus flavus CM74
5513,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL619461,,,Intermediate,,1,1,,Aspergillus fumigatus,N,,6326,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration
15962,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL619462,,,Intermediate,,1,1,,Aspergillus fumigatus,N,,6327,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC)
15962,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL620388,,,Intermediate,,1,1,,Aspergillus fumigatus,N,,6328,Antimicrobial activity against Aspergillus fumigatus (MIC)
15962,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL620389,,,Intermediate,,1,1,,Aspergillus fumigatus,N,,6329,Antimicrobial activity against Aspergillus fumigatus (MIC)
15962,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL620390,,,Intermediate,,1,1,,Aspergillus fumigatus,N,,6330,In vitro antimicrobial activity against Aspergillus fumigatus (MIC)
16717,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL620391,,,Expert,,1,1,,Aspergillus fumigatus,N,,6331,In vitro antifungal activity against Aspergillus fumigatus 48238E
16717,,,50416,746128.0,,,BAO_0000218,F,,CHEMBL621073,,,Expert,,1,1,,Aspergillus fumigatus,N,,6332,In vitro antifungal activity against Aspergillus fumigatus 48238E
8117,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL621074,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6333,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631
8117,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL621075,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6334,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100
15472,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL619554,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6335,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
15472,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL619555,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6336,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally)
16443,,,50169,714.0,,,BAO_0000218,F,,CHEMBL619556,,,Intermediate,,1,1,,Aggregatibacter actinomycetemcomitans,N,,6337,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527
16443,,,50169,714.0,,,BAO_0000218,F,,CHEMBL619557,,,Intermediate,,1,1,,Aggregatibacter actinomycetemcomitans,N,,6338,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2
16443,,,50169,714.0,,,BAO_0000218,F,,CHEMBL619558,,,Intermediate,,1,1,,Aggregatibacter actinomycetemcomitans,N,,6339,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619559,,,Intermediate,,1,1,,Homo sapiens,N,,6340,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619560,,,Intermediate,,1,1,,Homo sapiens,N,,6341,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619561,,,Intermediate,,1,1,,Homo sapiens,N,,6342,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619562,,,Intermediate,,1,1,,Homo sapiens,N,,6343,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619563,,,Intermediate,,1,1,,Homo sapiens,N,,6344,% inhibition against A549 cells (lung cancer) at 4 ug/mL
16381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL857457,,,Intermediate,,1,1,,Homo sapiens,N,,6345,GI values against A549 cells (lung cancer)
17206,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619564,,,Intermediate,,1,1,,Homo sapiens,N,,6346,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells
16325,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619565,,,Intermediate,,1,1,,Homo sapiens,N,,6347,Inhibitory activity against A549 human adenocarcinoma
10708,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL619566,,,Intermediate,,1,1,,Homo sapiens,N,,6348,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg
10708,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL619567,,,Intermediate,,1,1,,Homo sapiens,N,,6349,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg
17376,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619568,,,Intermediate,,1,1,,Homo sapiens,N,,6350,Inhibitory activity against A549 lung adenocarcinoma cell line
17376,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619569,,,Intermediate,,1,1,,Homo sapiens,N,,6351,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined
17488,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619570,,,Intermediate,,1,1,,Homo sapiens,N,,6352,Cytotoxicity against human A549 lung cells
17404,646.0,A549,80682,9606.0,,,BAO_0000218,F,,CHEMBL619571,,,Intermediate,,1,1,,Homo sapiens,N,,6353,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor
10958,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619572,,,Expert,,1,1,,Homo sapiens,N,,6354,Growth inhibition of A549 (human lung carcinoma) cell line.
17099,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619573,,,Expert,,1,1,,Homo sapiens,N,,6355,Effective dose required for inhibitory activity against A549 human tumor cell line.
17099,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619574,,,Intermediate,,1,1,,Homo sapiens,N,,6356,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active
4096,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619575,,,Intermediate,,1,1,,Homo sapiens,N,,6357,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive
4096,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619576,,,Expert,,1,1,,Homo sapiens,N,,6358,Cytotoxicity evaluated against A549 tumor cell lines; significant activity
4096,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619577,,,Intermediate,,1,1,,Homo sapiens,N,,6359,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active
2525,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619578,,,Intermediate,,1,1,,Homo sapiens,N,,6360,In vitro inhibitory activity against A549 tumor cell culture
2525,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884009,,,Intermediate,,1,1,,Homo sapiens,N,,6361,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive
5302,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619579,,,Intermediate,,1,1,,Homo sapiens,N,,6362,Activity against human lung cancer with mutated beta-tubulin (A549-T2415)
16325,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619580,,,Intermediate,,1,1,,Homo sapiens,N,,6363,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer
16939,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619581,,,Intermediate,,1,1,,Homo sapiens,N,,6364,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line
17229,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619582,,,Intermediate,,1,1,,Homo sapiens,N,,6365,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines
17380,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619583,,,Intermediate,,1,1,,Homo sapiens,N,,6366,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells
17380,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL876502,,,Intermediate,,1,1,,Homo sapiens,N,,6367,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data
1903,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619584,,,Intermediate,,1,1,,Homo sapiens,N,,6368,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.
3838,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619585,,,Intermediate,,1,1,,Homo sapiens,N,,6369,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
14696,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619586,,,Intermediate,,1,1,,Homo sapiens,N,,6370,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
3838,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619587,,,Intermediate,,1,1,,Homo sapiens,N,,6371,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer
1522,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619588,,,Intermediate,,1,1,,Homo sapiens,N,,6372,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC
12400,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619589,,,Intermediate,,1,1,,Homo sapiens,N,,6373,Tested in vitro for cytotoxicity in A549/ATCC cell lines
14696,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619590,,,Intermediate,,1,1,,Homo sapiens,N,,6374,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line
14769,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619591,,,Intermediate,,1,1,,Homo sapiens,N,,6375,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells )
14696,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619592,,,Intermediate,,1,1,,Homo sapiens,N,,6376,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM
1888,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL619593,,,Intermediate,,1,1,,Homo sapiens,N,,6377,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.
12016,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620217,,,Intermediate,,1,1,,Homo sapiens,N,,6378,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line
6058,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620218,,,Intermediate,,1,1,,Homo sapiens,N,,6379,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC
17708,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620219,,,Intermediate,,1,1,,Homo sapiens,N,,6380,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line
12301,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL620220,,,Intermediate,,1,1,,Homo sapiens,N,,6381,Antitumor activity against A549/ATCC cell line
11970,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL625141,,,Intermediate,,1,1,,Homo sapiens,N,,6382,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer
11818,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL625142,,,Expert,,1,1,,Homo sapiens,N,,6383,In vitro cytotoxicity against A549/ATCC cell line.
12400,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL625143,,,Intermediate,,1,1,,Homo sapiens,N,,6384,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer
3381,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL625144,,,Intermediate,,1,1,,Homo sapiens,N,,6385,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines
17376,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL622474,,,Intermediate,,1,1,,Homo sapiens,N,,6386,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line
10708,646.0,A549,80682,9606.0,,,BAO_0000219,F,,CHEMBL884104,,,Intermediate,,1,1,,Homo sapiens,N,,6387,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay
2964,,,22226,9606.0,,,BAO_0000219,F,,CHEMBL622475,,,Autocuration,,1,0,,Homo sapiens,U,,6388,Cytotoxicity was evaluated against A649 human mammary carcinoma cells
5005,,,22224,9615.0,,,BAO_0000218,A,,CHEMBL622476,,,Intermediate,,1,0,,Canis lupus familiaris,U,In vivo,6389,Compound was tested for oral bioavailability in dogs
6229,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875831,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6390,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr
6229,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622477,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6391,Compound was tested for orally bioavailable in dogs with a half life of 1.2h
5374,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622478,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6392,Oral bioavailability in dog
5374,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623172,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6393,Compound was tested for the oral bioavailability in dog; No availability
6265,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623173,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6394,Oral bioavailability in dog (dose 5 mg/kg)
5654,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623174,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6395,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
5654,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623175,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6396,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined
16456,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623340,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6397,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg)
5302,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623341,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6398,Oral bioavailability in dog (dose 5 mg/kg)
3624,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623342,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6399,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution)
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623343,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6400,Oral bioavailability of active FTIs in dogs
5802,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623344,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6401,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.)
3598,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623345,,,Expert,,1,1,,Canis lupus familiaris,N,In vivo,6402,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875832,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6403,Oral bioavailability in dog
6762,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623346,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6404,Oral bioavailability in dog
6821,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623347,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6405,Oral bioavailability in dog
6821,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623348,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6406,Oral bioavailability of compound was determined in dog; Not tested
5210,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623349,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6407,Oral bioavailability in dog
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623350,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6408,Oral bioavailability (10 mg/kg) was determined in dog
761,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623351,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6409,Oral bioavailability
761,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623352,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6410,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule)
761,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623353,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6411,Oral bioavailability administered in solution in rats
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875833,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6412,Oral bioavailability after 30 mg/kg po dose in Dogs
5474,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623354,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6413,Oral bioavailability at a dose of 1 mg/kg in dogs
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623355,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6414,Oral bioavailability in dog (dose 1 mg/kg p.o.)
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623356,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6415,Oral bioavailability in Dog; ND = not determined
3352,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623357,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6416,Oral bioavailability in dog
6168,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623358,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6417,Oral bioavailability in dog
5988,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623359,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6418,Oral bioavailability in dog
4942,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623360,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6419,Oral bioavailability in dog
4942,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623361,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6420,Oral bioavailability in dogs; No data
14541,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623362,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6421,Oral bioavailability measured in dogs
4449,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623363,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6422,Oral bioavailability in dog
6057,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623364,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6423,Oral bioavailability was calculated in dog
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875834,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6424,Oral bioavailability after 0.3 mg/kg po administration in dog
5542,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623365,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6425,Oral bioavailability in dog (i.v. dosing)
5542,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623366,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6426,Oral bioavailability in dog
5546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623367,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6427,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration
4514,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623368,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6428,Oral bioavailability in Beagle dogs
3624,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623369,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6429,Oral bioavailability in dog
3854,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623370,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6430,Oral bioavailability in dog
5836,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623371,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6431,Oral bioavailability in dog
5940,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623372,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6432,Oral bioavailability in dog
6168,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621351,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6433,Oral bioavailability in dog
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621352,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6434,Oral bioavailability in dog
6251,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621353,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6435,Oral bioavailability in dog
6448,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621354,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6436,Oral bioavailability in dog
6647,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621355,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6437,Oral bioavailability in dog
5940,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621356,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6438,Oral bioavailability in dog
933,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621357,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6439,Oral bioavailability in dog
5210,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621358,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6440,Oral bioavailability in dog
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621359,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6441,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only)
6641,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621360,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6442,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621361,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6443,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.)
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621362,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6444,Oral bioavailability in dog
5985,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621363,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6445,Oral bioavailability in dog
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621364,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6446,Oral bioavailability in dog
5530,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621166,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6447,Oral bioavailability in dog (dose 0.2 mg/kg i.v.)
5530,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621167,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6448,Oral bioavailability in dog (dose 1 mg/kg i.v.)
6305,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621168,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6449,Oral bioavailability (F) in dogs
5210,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621169,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6450,Oral bioavailability in dog
5238,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875950,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6451,Bioavailability in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621170,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6452,Oral bioavailability in dog (dose 10 mg/kg)
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621171,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6453,Oral bioavailability after peroral administration at 5 mpk in Dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621172,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6454,Oral bioavailability in dog (dose 5 mg/kg)
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621173,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6455,Oral bioavailability in dog (dose 10 mg/kg)
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621174,,,Intermediate,Kidney,1,1,,Mus musculus,N,,6456,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621175,,,Intermediate,Kidney,1,1,,Mus musculus,N,,6457,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621176,,,Intermediate,Liver,1,1,,Mus musculus,N,,6458,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621177,,,Intermediate,Liver,1,1,,Mus musculus,N,,6459,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621178,,,Intermediate,Liver,1,1,,Mus musculus,N,,6460,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621179,,,Intermediate,Liver,1,1,,Mus musculus,N,,6461,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621180,,,Intermediate,Liver,1,1,,Mus musculus,N,,6462,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL875951,,,Intermediate,Lung,1,1,,Mus musculus,N,,6463,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL621181,,,Intermediate,Lung,1,1,,Mus musculus,N,,6464,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL621182,,,Intermediate,Lung,1,1,,Mus musculus,N,,6465,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL621183,,,Intermediate,Lung,1,1,,Mus musculus,N,,6466,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL621184,,,Intermediate,Lung,1,1,,Mus musculus,N,,6467,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621185,,,Intermediate,,1,1,,Mus musculus,N,,6468,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621186,,,Intermediate,,1,1,,Mus musculus,N,,6469,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621187,,,Intermediate,,1,1,,Mus musculus,N,,6470,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621188,,,Intermediate,,1,1,,Mus musculus,N,,6471,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621189,,,Intermediate,,1,1,,Mus musculus,N,,6472,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL621190,,,Intermediate,Spleen,1,1,,Mus musculus,N,,6473,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618520,,,Intermediate,Spleen,1,1,,Mus musculus,N,,6474,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL621739,,,Intermediate,Spleen,1,1,,Mus musculus,N,,6475,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL621740,,,Intermediate,Spleen,1,1,,Mus musculus,N,,6476,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL621741,,,Intermediate,Spleen,1,1,,Mus musculus,N,,6477,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621742,,,Intermediate,,1,1,,Mus musculus,N,,6478,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621743,,,Intermediate,,1,1,,Mus musculus,N,,6479,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621744,,,Intermediate,,1,1,,Mus musculus,N,,6480,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621745,,,Intermediate,,1,1,,Mus musculus,N,,6481,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621746,,,Intermediate,,1,1,,Mus musculus,N,,6482,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621747,,,Intermediate,,1,1,,Mus musculus,N,,6483,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621748,,,Intermediate,,1,1,,Mus musculus,N,,6484,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621749,,,Intermediate,,1,1,,Mus musculus,N,,6485,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621750,,,Intermediate,,1,1,,Mus musculus,N,,6486,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL621751,,,Intermediate,,1,1,,Mus musculus,N,,6487,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621752,,,Intermediate,Heart,1,1,,Mus musculus,N,,6488,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621753,,,Intermediate,Heart,1,1,,Mus musculus,N,,6489,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL875955,,,Intermediate,Heart,1,1,,Mus musculus,N,,6490,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621754,,,Intermediate,Heart,1,1,,Mus musculus,N,,6491,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621755,,,Intermediate,Heart,1,1,,Mus musculus,N,,6492,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621756,,,Intermediate,Liver,1,1,,Mus musculus,N,,6493,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624199,,,Intermediate,Liver,1,1,,Mus musculus,N,,6494,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624200,,,Intermediate,Liver,1,1,,Mus musculus,N,,6495,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624375,,,Intermediate,Liver,1,1,,Mus musculus,N,,6496,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624376,,,Intermediate,Liver,1,1,,Mus musculus,N,,6497,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL624377,,,Intermediate,Lung,1,1,,Mus musculus,N,,6498,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL624378,,,Intermediate,Lung,1,1,,Mus musculus,N,,6499,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours
12269,,,50067,107673.0,,,BAO_0000218,F,,CHEMBL857901,,,Intermediate,,1,1,,aeinetobacter anitrotap,N,,6500,Compound tested for the antimicrobial activity against Acinetobacter anitratus
12269,,,50067,107673.0,,,BAO_0000218,F,,CHEMBL875274,,,Intermediate,,1,1,,Acinetobacter calcoaceticus subsp. anitratus,N,,6501,Compound tested for the antimicrobial activity against Acinetobacter anitratus
12269,,,50067,107673.0,,,BAO_0000218,F,,CHEMBL624379,,,Intermediate,,1,1,,Acinetobacter calcoaceticus subsp. anitratus,N,,6502,Compound tested for the antimicrobial activity against Acinetobacter anitratus
12269,,,50067,107673.0,,,BAO_0000218,F,,CHEMBL624380,,,Intermediate,,1,1,,aeinetobacter anitrotap,N,,6503,Compound tested for the antimicrobial activity against Acinetobacter anitratus
10624,,,50192,471.0,,,BAO_0000218,F,,CHEMBL624381,,,Intermediate,,1,1,,Acinetobacter calcoaceticus,N,,6504,Activity against Acinetobacter calcoaceticus (AC54)
17216,,,50714,28377.0,,,BAO_0000218,F,,CHEMBL624382,,,Intermediate,,1,1,,Anolis carolinensis,N,,6505,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity
17216,,,50714,28377.0,,,BAO_0000218,F,,CHEMBL624383,,,Intermediate,,1,1,,Anolis carolinensis,N,,6506,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624384,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6507,Chlorohexidine coefficient for Actinomyces naeslundii 631
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624385,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6508,Chlorohexidine coefficient for Actinomyces naeslundii B74
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624386,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6509,Chlorohexidine coefficient for Actinomyces naeslundii N/3
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624387,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6510,Chlorohexidine coefficient for Actinomyces naeslundii N/9
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624388,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6511,Plaque bactericidal index against Actinomyces naeslundii 631
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624389,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6512,Plaque bactericidal index against Actinomyces naeslundii N/9
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL624390,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6513,Plaque bactericidal index against Actinomyces naeslundii B74
9560,,,50296,1655.0,,,BAO_0000218,F,,CHEMBL875275,,,Intermediate,,1,1,,Actinomyces naeslundii,N,,6514,Plaque bactericidal index against Actinomyces naeslundii N/3
114,,,50056,85549.0,,,BAO_0000218,F,,CHEMBL624391,,,Intermediate,,1,1,,Artemia salina,N,,6515,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay
114,,,50056,85549.0,,,BAO_0000218,F,,CHEMBL623636,,,Intermediate,,1,1,,Artemia salina,N,,6516,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity"
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623637,,,Intermediate,,1,1,,Ascaris suum,N,,6517,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623638,,,Intermediate,,1,1,,Ascaris suum,N,,6518,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623639,,,Intermediate,,1,1,,Ascaris suum,N,,6519,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623640,,,Intermediate,,1,1,,Ascaris suum,N,,6520,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623641,,,Intermediate,,1,1,,Ascaris suum,N,,6521,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623642,,,Intermediate,,1,1,,Ascaris suum,N,,6522,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623643,,,Intermediate,,1,1,,Ascaris suum,N,,6523,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623644,,,Intermediate,,1,1,,Ascaris suum,N,,6524,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623645,,,Intermediate,,1,1,,Ascaris suum,N,,6525,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623646,,,Intermediate,,1,1,,Ascaris suum,N,,6526,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623647,,,Intermediate,,1,1,,Ascaris suum,N,,6527,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM
10841,,,50532,6253.0,,,BAO_0000218,F,,CHEMBL623648,,,Intermediate,,1,1,,Ascaris suum,N,,6528,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM
8117,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623649,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6529,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
8117,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623650,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6530,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623651,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6531,Chlorohexidine coefficient for Actinomyces viscosus 8A06
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623652,,,Expert,,1,1,,Actinomyces viscosus,N,,6532,Chlorohexidine coefficient for Actinomyces viscosus M-100
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623653,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6533,Chlorohexidine coefficient for Actinomyces viscosus M-626
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623654,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6534,Chlorohexidine coefficient for Actinomyces viscosus T14V
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623655,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6535,Plaque bactericidal index against Actinomyces viscosus 8A06
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623656,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6536,Plaque bactericidal index against Actinomyces viscosus M-100
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623657,,,Expert,,1,1,,Actinomyces viscosus,N,,6537,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623658,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6538,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623659,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6539,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)"
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623660,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6540,Plaque bactericidal index against Actinomyces viscosus 626
9560,,,50366,1656.0,,,BAO_0000218,F,,CHEMBL623661,,,Intermediate,,1,1,,Actinomyces viscosus,N,,6541,Plaque bactericidal index against Actinomyces viscosus T14V
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL875281,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6542,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL623662,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6543,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL623663,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6544,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL623664,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6545,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL623665,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6546,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose
10708,165.0,A673,80023,9606.0,,,BAO_0000219,F,,CHEMBL621856,,,Intermediate,,1,1,,Homo sapiens,N,,6547,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay
10708,645.0,A704,80661,9606.0,,,BAO_0000219,F,,CHEMBL620432,,,Intermediate,,1,1,,Homo sapiens,N,,6548,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay
416,,,22226,10116.0,,,BAO_0000219,F,,CHEMBL620433,,,Autocuration,,1,0,,Rattus norvegicus,U,,6549,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells
14354,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL620434,,,Intermediate,,1,1,,Mus musculus,N,,6550,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
14354,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL620435,,,Intermediate,,1,1,,Mus musculus,N,,6551,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors
5116,625.0,A9,80024,9606.0,,,BAO_0000219,F,,CHEMBL620436,,,Intermediate,,1,1,,Homo sapiens,N,,6552,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested
5116,625.0,A9,80024,9606.0,,,BAO_0000219,F,,CHEMBL876597,,,Intermediate,,1,1,,Homo sapiens,N,,6553,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line
15694,874.0,Human ovarian carcinoma cell line,81037,9606.0,,,BAO_0000219,F,,CHEMBL620437,,,Expert,,1,1,,Homo sapiens,N,,6554,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation
13038,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL620438,,,Expert,,1,1,,Mus musculus,N,,6555,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM."
13038,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL620439,,,Expert,,1,1,,Mus musculus,N,,6556,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.
10923,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL619657,,,Expert,,1,1,,Mus musculus,N,,6557,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.
10923,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL619658,,,Intermediate,,1,1,,Mus musculus,N,,6558,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined
10923,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL619659,,,Intermediate,,1,1,,Mus musculus,N,,6559,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive
10923,,,10649,,,,BAO_0000019,F,,CHEMBL619660,,,Expert,,1,8,,,H,,6560,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar"
10923,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL619661,,,Intermediate,,1,1,,Mus musculus,N,,6561,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined
10923,625.0,A9,80024,10090.0,,,BAO_0000219,F,,CHEMBL619662,,,Intermediate,,1,1,,Mus musculus,N,,6562,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive
8158,975.0,AA6,80663,10029.0,,,BAO_0000219,F,,CHEMBL619663,,,Intermediate,,1,1,,Cricetulus griseus,N,,6563,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined
15494,,,22226,9606.0,,,BAO_0000219,F,,CHEMBL619664,,,Autocuration,,1,0,,Homo sapiens,U,,6564,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.
15494,,,22226,9606.0,,,BAO_0000219,F,,CHEMBL619665,,,Autocuration,,1,0,,Homo sapiens,U,,6565,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation."
12348,974.0,AA5,80662,9606.0,,,BAO_0000219,F,,CHEMBL883244,,,Intermediate,,1,1,,Homo sapiens,N,,6566,Anti -HIV activity was measured against AA5/HIV-1(IIIB)
12348,974.0,AA5,80662,9606.0,,,BAO_0000219,F,,CHEMBL884011,,,Intermediate,,1,1,,Homo sapiens,N,,6567,Cytotoxicity was measured against AA5/HIV-1(IIIB)
2726,974.0,AA5,80662,9606.0,,,BAO_0000219,F,,CHEMBL619666,,,Intermediate,,1,1,,Homo sapiens,N,,6568,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell
2726,379.0,U-937,80566,9606.0,,,BAO_0000219,F,,CHEMBL619667,,,Intermediate,,1,1,,Homo sapiens,N,,6569,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell
10747,274.0,UV4,80578,10029.0,,,BAO_0000219,F,,CHEMBL619668,,,Intermediate,,1,1,,Cricetulus griseus,N,,6570,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines
11005,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619669,,,Expert,,1,1,,Cricetulus griseus,N,,6571,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL876608,,,Intermediate,,1,1,,Cricetulus griseus,N,,6572,Average intracellular compound concentration when the hypoxic SER=1.6
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619670,,,Intermediate,,1,1,,Cricetulus griseus,N,,6573,Average intracellular compound concentration when the hypoxic SER=1.6.
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619671,,,Intermediate,,1,1,,Cricetulus griseus,N,,6574,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619672,,,Intermediate,,1,1,,Cricetulus griseus,N,,6575,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619673,,,Intermediate,,1,1,,Cricetulus griseus,N,,6576,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.
13436,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619674,,,Intermediate,,1,1,,Cricetulus griseus,N,,6577,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay."
13435,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619675,,,Intermediate,,1,1,,Cricetulus griseus,N,,6578,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml"
13302,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619676,,,Intermediate,,1,1,,Cricetulus griseus,N,,6579,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL619677,,,Intermediate,,1,1,,Cricetulus griseus,N,,6580,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL619678,,,Intermediate,,1,1,,Cricetulus griseus,N,,6581,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL619679,,,Intermediate,,1,1,,Cricetulus griseus,N,,6582,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.
12878,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL619680,,,Expert,,1,1,,Cricetulus griseus,N,,6583,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay
12878,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL621457,,,Intermediate,,1,1,,Cricetulus griseus,N,,6584,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit
14367,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL876609,,,Expert,,1,1,,Cricetulus griseus,N,,6585,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay
14367,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL621458,,,Intermediate,,1,1,,Cricetulus griseus,N,,6586,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay
12398,185.0,CHO-AA8,80089,36483.0,,,BAO_0000219,F,,CHEMBL621459,,,Expert,,1,1,,hampster,N,,6587,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8
12878,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL621460,,,Expert,,1,1,,Cricetulus griseus,N,,6588,Aerobic growth inhibition in Chinese hamster cell line AA8
13820,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL621461,,,Expert,,1,1,,Cricetulus griseus,N,,6589,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.
13436,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL621462,,,Expert,,1,1,,Cricetulus griseus,N,,6590,Inhibition of growth under aerobic conditions in AA8 cells
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621463,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6591,Oral bioavailability in dog (dose 10 mg/kg)
5711,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621464,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6592,Oral bioavailability in dog at 10 mg/kg of the compound
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621465,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6593,Oral bioavailability in dog (dose 5 uM/kg)
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621466,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6594,Oral bioavailability in dog (dose 5 uM/kg)
17800,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621467,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6595,Oral bioavailability in dog (mongrel)
3994,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621468,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6596,Oral bioavailability in dog (dose 10 mg/kg)
3994,,,50588,9615.0,,,BAO_0000218,F,,CHEMBL876734,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6597,Oral bioavailability in dog (dose 10 mg/kg)
5145,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618476,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6598,Bioavailability in dog
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618477,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6599,Bioavailability in dog (dose 1 mg/kg i.v.)
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618478,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6600,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses)
5983,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618479,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6601,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg
4273,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618480,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6602,Bioavailability in dog
12500,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618481,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6603,Bioavailability in dog (dose 3-10 mg/kg)
12500,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL618482,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6604,The compound was tested for bioavailability of compound in plasma of dog; Complete
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618483,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6605,Oral bioavailability in dog
3880,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618484,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6606,Oral bioavailability in dog
4838,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618485,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6607,Bioavailability in dog
15600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618486,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6608,oral bioavailability was measured in dogs
17248,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618487,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6609,Compound was tested for plasma protein binding in dog; Not determined
17248,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618488,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6610,Compound was tested for plasma protein binding of dog
17248,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876735,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6611,Compound was tested for plasma protein binding of dog; Not determined
17443,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618489,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6612,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.
4186,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618490,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6613,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route
3749,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618491,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6614,Half life was determined
3249,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618492,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6615,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg
3022,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873354,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6616,Half life was evaluated in dog
3749,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618493,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6617,Half life was determined
2517,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618494,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6618,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT)
2517,,,50588,9615.0,,,BAO_0000218,A,948.0,CHEMBL618495,,,Intermediate,Heart,1,1,,Canis lupus familiaris,N,In vivo,6619,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT)
2517,,,50588,9615.0,,,BAO_0000218,A,2113.0,CHEMBL618496,,,Intermediate,Kidney,1,1,,Canis lupus familiaris,N,In vivo,6620,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT)
2517,,,50588,9615.0,,,BAO_0000218,A,2107.0,CHEMBL618497,,,Intermediate,Liver,1,1,,Canis lupus familiaris,N,In vivo,6621,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT)
2517,,,50588,9615.0,,,BAO_0000218,A,2048.0,CHEMBL618498,,,Intermediate,Lung,1,1,,Canis lupus familiaris,N,In vivo,6622,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT)
2517,,,50588,9615.0,,,BAO_0000218,A,2106.0,CHEMBL618499,,,Intermediate,Spleen,1,1,,Canis lupus familiaris,N,In vivo,6623,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT)
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876736,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6624,LogP in dog
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618500,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6625,Partition coefficient (logP)
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL857831,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6626,Partition coefficient in dog
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618501,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6627,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg
4809,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618502,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6628,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg)
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618503,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6629,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes
14294,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618504,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6630,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak)
14294,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618505,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6631,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak)
14294,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618506,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6632,Metabolism of compound in dog S9 microsomes; Trace
6251,,,50588,9615.0,,,BAO_0000218,A,2107.0,CHEMBL618507,,,Intermediate,Liver,1,1,,Canis lupus familiaris,N,,6633,In vitro metabolic potential in dog liver microsomes
3748,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876737,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6634,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs
2713,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618508,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6635,Oral bioavailability in dog
6512,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618509,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6636,Oral bioavailability in dog
6679,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618510,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6637,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
3749,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618511,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6638,The compound was tested for bioavailability in dogs
3749,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618512,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6639,The compound was tested for oral bioavailability in dogs
6742,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618513,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6640,Oral bioavailability in dog
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618514,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6641,Compound was tested for percent protein binding (PB) in dog
6874,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620052,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6642,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells
2877,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL620053,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6643,Compound was evaluated for plasma clearance.
12500,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL620054,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6644,The compound was tested for plasma clearance in dog
12500,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL620055,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6645,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg
4709,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620056,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6646,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog
5542,,,50588,9615.0,,,BAO_0000218,A,2107.0,CHEMBL620057,,,Intermediate,Liver,1,1,,Canis lupus familiaris,N,,6647,In vitro relative rate of metabolism was determined in dog liver microsomes
17594,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618939,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6648,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618940,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6649,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618941,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6650,Half life after intravenous administration in dogs at 1.2 uM/kg
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL624473,,,Intermediate,Lung,1,1,,Mus musculus,N,,6651,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL624474,,,Intermediate,Lung,1,1,,Mus musculus,N,,6652,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL624475,,,Intermediate,Lung,1,1,,Mus musculus,N,,6653,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL624476,,,Intermediate,,1,1,,Mus musculus,N,,6654,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL623478,,,Intermediate,,1,1,,Mus musculus,N,,6655,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL623479,,,Intermediate,,1,1,,Mus musculus,N,,6656,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL623480,,,Intermediate,,1,1,,Mus musculus,N,,6657,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours
6599,42.0,CCRF S-180,50594,10090.0,,,BAO_0000218,A,,CHEMBL623481,,,Intermediate,,1,1,,Mus musculus,N,,6658,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours
17641,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL623482,,,Intermediate,Brain,1,1,,Mus musculus,N,,6659,C2 in brain of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623483,,,Intermediate,Kidney,1,1,,Mus musculus,N,,6660,C2 in kidney of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623484,,,Intermediate,Liver,1,1,,Mus musculus,N,,6661,C2 in liver of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623485,,,Intermediate,Lung,1,1,,Mus musculus,N,,6662,C2 in lungs of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL623486,,,Intermediate,Spleen,1,1,,Mus musculus,N,,6663,C2 in spleen of mice at the oral dose of 50 mg/kg
17852,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623487,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6664,Plasma clearance in mouse
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623488,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6665,Clearance of compound after intravenous administration in mice at 24 uM/kg
17837,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623489,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6666,Clearance from mouse blood following i.v. administration of 10 mg/kg
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL875157,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6667,Clearance was evaluated in mice after intravenous administration
2675,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623490,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6668,Clearance was evaluated in mice after oral administration
4239,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623491,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6669,Pharmacokinetic property (Plasma clearance) was measured in mouse
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623492,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6670,Plasma clearance of compound was determined at 40 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623493,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6671,Plasma clearance of at 24 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623494,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6672,Plasma clearance at 24 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623495,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6673,Plasma clearance at 5 mg/Kg
5727,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623496,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6674,Plasma clearance in mice
2862,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623497,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6675,Plasma clearance value upon iv administration in mouse
5980,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623498,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6676,Total plasma clearance in mice
17592,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623499,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6677,Clearance in mouse
17718,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623500,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6678,Clearance value was determined
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623501,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6679,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.
17384,,,22229,,,,BAO_0000100,P,,CHEMBL875158,,,Intermediate,,1,0,,,U,,6680,Calculated partition coefficient (clogP)
6062,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623502,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6681,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg
17734,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623503,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6682,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice
6348,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623504,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6683,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623505,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6684,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623506,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6685,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623507,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6686,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623508,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6687,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax
5781,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623509,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6688,Cmax after oral administration at 30 mg/kg in ICR mouse
17764,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL875159,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6689,Cmax after peroral administration in mice at 2.4 uM/kg
17641,,,50594,10090.0,,,BAO_0000218,A,955.0,CHEMBL623510,,,Intermediate,Brain,1,1,,Mus musculus,N,In vivo,6690,Cmax in brain of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL623511,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,6691,Cmax in kidney of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL623512,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,6692,Cmax in liver of mice at the oral dose of 50 mg/kg
17641,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623513,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,6693,Cmax in lungs of mice at the oral dose of 50 mg/kg
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL623514,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6694,Cmax in mice at 18 uM/kg i.p. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622609,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6695,Cmax in mice at 23 uM/kg i.v. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622610,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6696,Cmax in mice at 24 uM/kg i.p. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL621823,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6697,Cmax in mice at 25 uM/kg i.p. administration
17764,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL621824,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6698,Cmax in mice at 26 uM/kg i.p. administration
17641,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL621825,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,6699,Cmax in spleen of mice at the oral dose of 50 mg/kg
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621826,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6700,Cmax value at a dose of 10 mg/kg intravenous administration in mice.
16597,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621827,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6701,Cmax value at a dose of 10 mg/kg peroral administration in mice.
5727,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621828,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6702,Cmax value was determined
5951,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621829,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6703,Cmax value in IRC mice
5506,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621830,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6704,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice
5506,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL621831,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6705,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice
14239,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL621832,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6706,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice
4890,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL624579,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6707,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration"
429,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624580,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6708,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL624581,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6709,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL624582,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6710,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose
10986,,,50535,6277.0,,,BAO_0000218,F,,CHEMBL624583,,,Intermediate,,1,1,,Acanthocheilonema viteae,N,,6711,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose
13227,455.0,A-375,80018,9606.0,,,BAO_0000219,F,,CHEMBL624584,,,Intermediate,,1,1,,Homo sapiens,N,,6712,Inhibitory activity against human tumor cell line A0375 melanoma.
4481,,,12512,10116.0,,,BAO_0000249,B,,CHEMBL624585,,Brain membranes,Expert,,1,9,,Rattus norvegicus,D,,6713,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes
16931,,,114,9606.0,,,BAO_0000019,F,,CHEMBL875165,,,Expert,,1,9,,Homo sapiens,D,,6714,Forskolin-induced cAMP production at human A1 adenosine receptor
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619490,,,Autocuration,,1,8,,,H,,6715,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619491,,,Autocuration,,1,8,,,H,,6716,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619492,,,Expert,,1,8,,,H,,6717,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619493,,,Expert,,1,8,,,H,,6718,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619494,,,Autocuration,,1,8,,,H,,6719,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619495,,,Autocuration,,1,8,,,H,,6720,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619496,,,Autocuration,,1,8,,,H,,6721,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.
3850,449.0,CHO,114,9606.0,,,BAO_0000219,F,,CHEMBL619497,,,Expert,,1,9,,Homo sapiens,D,,6722,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619498,,,Autocuration,,1,8,,,H,,6723,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619499,,,Autocuration,,1,8,,,H,,6724,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619500,,,Expert,,1,8,,,H,,6725,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619501,,,Autocuration,,1,8,,,H,,6726,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619502,,,Expert,,1,8,,,H,,6727,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619503,,,Autocuration,,1,8,,,H,,6728,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL619504,,,Autocuration,,1,8,,,H,,6729,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL621298,,,Autocuration,,1,8,,,H,,6730,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL621299,,,Expert,,1,8,,,H,,6731,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL621300,,,Autocuration,,1,8,,,H,,6732,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL621301,,,Autocuration,,1,8,,,H,,6733,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.
3850,449.0,CHO,114,,,,BAO_0000219,F,,CHEMBL621302,,,Expert,,1,8,,,H,,6734,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells
12680,164.0,A10,80013,9986.0,,,BAO_0000219,F,,CHEMBL621303,,,Intermediate,,1,1,,Oryctolagus cuniculus,N,,6735,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells
1313,164.0,A10,22226,10116.0,,,BAO_0000219,F,,CHEMBL621304,,,Autocuration,,1,0,,Rattus norvegicus,U,,6736,In vitro potassium channel opening activity in A10 (smooth muscle) cells
1313,164.0,A10,22226,10116.0,,,BAO_0000219,F,,CHEMBL621305,,,Autocuration,,1,0,,Rattus norvegicus,U,,6737,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive
17567,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL621306,,,Intermediate,,1,1,,Rattus norvegicus,N,,6738,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats
17567,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL618444,,,Intermediate,,1,1,,Rattus norvegicus,N,,6739,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats
11819,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL618445,,,Intermediate,,1,1,,Rattus norvegicus,N,,6740,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM
13436,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618446,,,Intermediate,,1,1,,Cricetulus griseus,N,,6741,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618447,,,Intermediate,,1,1,,Cricetulus griseus,N,,6742,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay
12651,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618448,,,Intermediate,,1,1,,Cricetulus griseus,N,,6743,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture
13300,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618449,,,Intermediate,,1,1,,Cricetulus griseus,N,,6744,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined
15296,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618637,,,Intermediate,,1,1,,Cricetulus griseus,N,,6745,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
15328,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618638,,,Intermediate,,1,1,,Cricetulus griseus,N,,6746,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay."
13302,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618639,,,Intermediate,,1,1,,Cricetulus griseus,N,,6747,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure)
14367,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618640,,,Expert,,1,1,,Cricetulus griseus,N,,6748,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure"
17002,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618641,,,Expert,,1,1,,Cricetulus griseus,N,,6749,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure
13436,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618642,,,Intermediate,,1,1,,Cricetulus griseus,N,,6750,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure
13435,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618643,,,Intermediate,,1,1,,Cricetulus griseus,N,,6751,Inhibitory activity against aerobic growth of AA8 cells.
10503,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL884013,,,Intermediate,,1,1,,Cricetulus griseus,N,,6752,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
10503,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622723,,,Expert,,1,1,,Cricetulus griseus,N,,6753,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
10503,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622724,,,Intermediate,,1,1,,Cricetulus griseus,N,,6754,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8
15090,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622725,,,Expert,,1,1,,Cricetulus griseus,N,,6755,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).
10368,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622726,,,Expert,,1,1,,Cricetulus griseus,N,,6756,Cytotoxicity against AA8 cell line
12651,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622727,,,Intermediate,,1,1,,Cricetulus griseus,N,,6757,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4)
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL622728,,,Intermediate,,1,1,,Cricetulus griseus,N,,6758,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622729,,,Intermediate,,1,1,,Cricetulus griseus,N,,6759,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
12687,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,A,,CHEMBL622730,,,Intermediate,,1,1,,Cricetulus griseus,N,,6760,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6)
1890,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622731,,,Intermediate,,1,1,,Cricetulus griseus,N,,6761,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4
10747,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622732,,,Intermediate,,1,1,,Cricetulus griseus,N,,6762,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
10747,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622733,,,Intermediate,,1,1,,Cricetulus griseus,N,,6763,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.
11616,,,22224,10029.0,,,BAO_0000218,F,,CHEMBL622734,,,Autocuration,,1,0,,Cricetulus griseus,U,,6764,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose)
11616,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL622735,,,Expert,,1,1,,Cricetulus griseus,N,,6765,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618746,,,Autocuration,,1,0,,Cricetulus griseus,U,,6766,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618747,,,Autocuration,,1,0,,Cricetulus griseus,U,,6767,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL620540,,,Autocuration,,1,0,,Cricetulus griseus,U,,6768,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL620541,,,Autocuration,,1,0,,Cricetulus griseus,U,,6769,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL620542,,,Autocuration,,1,0,,Cricetulus griseus,U,,6770,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL620543,,,Autocuration,,1,0,,Cricetulus griseus,U,,6771,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions
3471,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618832,,,Autocuration,,1,0,,Cricetulus griseus,U,,6772,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition
11616,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL618833,,,Expert,,1,1,,Cricetulus griseus,N,,6773,Concentration required to reduce AA8 cell survival by 10%
2656,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618834,,,Autocuration,,1,0,,Cricetulus griseus,U,,6774,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells"
10518,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618835,,,Autocuration,,1,0,,Cricetulus griseus,U,,6775,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
10518,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618836,,,Autocuration,,1,0,,Cricetulus griseus,U,,6776,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay
10518,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618837,,,Autocuration,,1,0,,Cricetulus griseus,U,,6777,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5
10518,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618838,,,Autocuration,,1,0,,Cricetulus griseus,U,,6778,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2
16156,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618839,,,Autocuration,,1,0,,Cricetulus griseus,U,,6779,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air
2656,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618840,,,Autocuration,,1,0,,Cricetulus griseus,U,,6780,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells
11005,,,22224,10029.0,,,BAO_0000019,F,,CHEMBL618841,,,Autocuration,,1,0,,Cricetulus griseus,U,,6781,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8"
11942,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618842,,,Autocuration,,1,0,,Cricetulus griseus,U,,6782,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure
2128,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL618843,,,Autocuration,,1,0,,Cricetulus griseus,U,,6783,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618844,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6784,Half life period after 15 mg/kg iv dose in Dogs
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618845,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6785,Half life period after 30 mg/kg po dose in Dogs
9579,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618846,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6786,Half life was measured after oral 2b administration (tested in 6 dogs)
9579,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618847,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6787,Half life was measured in dog after oral 17b administration
9579,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618848,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6788,Pharmacokinetic parameter T max determined in dog after oral administration of 17b
9579,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618849,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6789,Pharmacokinetic parameter T max determined in dog after oral administration of 2b
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618850,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6790,Tmax value after 15 mg/kg iv dose in Dogs
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618851,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6791,Tmax value after 30 mg/kg po dose in Dogs
3184,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873815,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6792,Compound was evaluated for its half life when administered intravenously in dog
5017,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL618852,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6793,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg)
6821,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618853,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6794,Elimination Half-life of compound was determined in dog
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618854,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6795,Half life of compound in dog following oral administration
17267,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618855,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6796,Half life of compound was determined in dog
4727,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL618856,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,,6797,Half life of compound was determined in dog blood
5238,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875827,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6798,Half life after oral and iv dosing in dogs
4942,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618857,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6799,Half life in dogs in hours
6505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618858,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6800,Half life on i.v. administration of 2 mg/kg was measured in dog
5130,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618859,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6801,t1/2 in dog after oral dose (1 mg/kg)
1475,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618860,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6802,Half life was evaluated in dog
17804,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618861,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6803,Half life period of compound was determined after intravenous administration at 2 mg/kg
17804,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622539,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6804,Half life period of compound was determined after peroral administration at 2 mg/kg
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622540,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6805,Half life period (10 mg/kg) was determined in dog
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873803,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6806,Half life period (10 mg/kg) was determined in dog
5542,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873804,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6807,Half life period by iv administration in dog at a dose of 0.3 mg/kg
5542,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624311,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6808,Half life period by po administration in dog at a dose of 0.3 mg/kg
6084,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624312,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6809,Half life period in dog
6241,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624313,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6810,Half life period in dogs after oral administration at 1 mg/kg
1916,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624314,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6811,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
6621,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624315,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6812,Half-life of compound was determined in dogs
1696,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624316,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,6813,Half-life in dog plasma
17800,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624317,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6814,Half-life in mongrel dogs was determined
17657,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624318,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6815,Half-life in dog upon oral administration
17657,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624319,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6816,Half-life in dog upon oral administration; Unable to calculate
4239,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624496,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6817,Half-life was measured in dog
5985,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624497,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6818,Half-life was measured in dog
9932,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624498,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6819,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs
5199,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624499,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6820,Oral half life was determined
5199,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624500,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6821,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).
1475,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL624501,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,6822,Plasma half life was evaluated
1475,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623666,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,6823,Plasma half life was evaluated in Dog
1475,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623667,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,6824,Plasma half life was evaluated in dog
6316,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623668,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6825,T1/2 (Half-life) was after oral administration at 5 mg/kg
4883,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623669,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6826,Tested for the half life value in dog
4727,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623670,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6827,Maximum time at the dose of 2 mg/kg in dog
1916,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623671,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6828,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration
1337,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL875945,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,In vivo,6829,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
1337,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL623672,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,In vivo,6830,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
6265,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623673,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6831,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg
4809,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623674,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6832,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg)
5983,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623675,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6833,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL872526,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6834,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog"
5313,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623676,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6835,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk"
17650,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623677,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6836,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg
5199,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623678,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6837,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.
933,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623679,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,6838,Time taken for maximum plasma concentration in dog
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623680,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6839,Time to reach Cmax after oral administration to dogs
6348,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623681,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,6840,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
6316,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623682,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6841,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg
6215,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623683,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6842,Tmax after peroral administration (1 mg/kg) was determined in dog
3598,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623684,,,Expert,,1,1,,Canis lupus familiaris,N,In vivo,6843,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622745,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6844,Tmax by oral administration at a dose of 10 uM/kg in dog was determined
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622746,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6845,Tmax after peroral administration in dogs at 2.4 uM/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622747,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6846,In vivo Cmax in mice at dose of 100 mg/kg
5969,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622748,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6847,In vivo Cmax in mice at dose of 50 mg/kg
4573,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622749,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6848,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice
3277,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622750,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6849,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4)
17734,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623411,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6850,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice
3132,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL875946,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6851,Maximum concentration obtained in mouse plasma was determined
3132,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623412,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6852,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg
6348,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623413,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6853,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
17729,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623414,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6854,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg
17729,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623415,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6855,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg
17729,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623416,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6856,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg
17728,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623417,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6857,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose
17728,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623418,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6858,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose
17728,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623419,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6859,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose
4066,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622816,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6860,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice
6178,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623313,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6861,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice
6178,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623314,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6862,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876788,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6863,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623315,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6864,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623316,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6865,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice
3760,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623317,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6866,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice
5961,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623319,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6868,Cmax in male mice after 2 mg/kg oral dose
6137,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623320,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6869,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine
3802,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623321,,,Intermediate,,1,1,,Mus musculus,N,In vivo,6870,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse
3535,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623322,,,Intermediate,,1,1,,Mus musculus,N,,6871,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr
3535,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623323,,,Intermediate,,1,1,,Mus musculus,N,,6872,Concentration in plasma (systemic) following oral dose in mouse at 1 hr
3535,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623324,,,Intermediate,,1,1,,Mus musculus,N,,6873,Concentration in plasma (systemic) following oral dose in mouse at 24 hr
3535,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623325,,,Intermediate,,1,1,,Mus musculus,N,,6874,Concentration in plasma (systemic) following oral dose in mouse at 2 hr
3535,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623326,,,Intermediate,,1,1,,Mus musculus,N,,6875,Concentration in plasma (systemic) following oral dose in mouse at 4 hr
3535,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL623327,,,Intermediate,,1,1,,Mus musculus,N,,6876,Concentration in plasma (systemic) following oral dose in mouse at 6 hr
2862,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623328,,,Intermediate,Plasma,1,1,,Mus musculus,N,,6877,Maximum concentration in plasma upon oral administration in mouse
2675,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623329,,,Intermediate,Plasma,1,1,,Mus musculus,N,,6878,Maximum plasma concentration was evaluated in mice after oral administration
2675,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL623330,,,Intermediate,Plasma,1,1,,Mus musculus,N,In vivo,6879,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined
5399,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL876789,,,Intermediate,,1,1,,Mus musculus,N,,6880,Dose at which the compound induced fecal excretion in mice
11819,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL623333,,,Expert,,1,1,,Rattus norvegicus,N,,6893,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM
11819,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL623334,,,Expert,,1,1,,Rattus norvegicus,N,,6894,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM
11819,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL627536,,,Expert,,1,1,,Rattus norvegicus,N,,6895,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM
11819,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL627537,,,Expert,,1,1,,Rattus norvegicus,N,,6896,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM
16361,164.0,A10,80013,10116.0,,,BAO_0000219,F,,CHEMBL627538,,,Intermediate,,1,1,,Rattus norvegicus,N,,6897,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM)
2288,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL884106,,,Intermediate,,1,1,,Homo sapiens,N,,6898,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line
10404,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625294,,,Intermediate,,1,1,,Homo sapiens,N,,6899,Anticancer activity against human ovarian carcinoma A121 cells
14790,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625295,,,Intermediate,,1,1,,Homo sapiens,N,,6900,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM
14790,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625296,,,Intermediate,,1,1,,Homo sapiens,N,,6901,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM
14253,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625297,,,Expert,,1,1,,Homo sapiens,N,,6902,Growth inhibition of human ovarian carcinoma (A121) cell line
13617,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625298,,,Expert,,1,1,,Homo sapiens,N,,6903,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.
1003,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625960,,,Intermediate,,1,1,,Homo sapiens,N,,6904,Cytotoxicity against human A121 ovarian cells
830,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625961,,,Intermediate,,1,1,,Homo sapiens,N,,6905,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines
12307,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL625962,,,Intermediate,,1,1,,Homo sapiens,N,,6906,In vitro cytotoxicity against human ovarian carcinoma A21
14254,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL624717,,,Intermediate,,1,1,,Homo sapiens,N,,6907,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure
13370,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL624718,,,Intermediate,,1,1,,Homo sapiens,N,,6908,Inhibitory activity of compound against human A121 ovarian cell line.
14790,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL624719,,,Intermediate,,1,1,,Homo sapiens,N,,6909,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.
3614,393.0,A121,80655,9606.0,,,BAO_0000219,F,,CHEMBL624720,,,Intermediate,,1,1,,Homo sapiens,N,,6910,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure
2664,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL624721,,,Intermediate,,1,1,,Homo sapiens,N,,6911,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line
2037,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL624722,,,Expert,,1,1,,Homo sapiens,N,,6912,In vitro cytotoxicity against A172 human tumor cell lines.
14539,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL877597,,,Intermediate,,1,1,,Homo sapiens,N,,6913,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM
2836,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL624723,,,Intermediate,,1,1,,Homo sapiens,N,,6914,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line
10708,622.0,A 172,80012,9606.0,,,BAO_0000219,F,,CHEMBL624724,,,Intermediate,,1,1,,Homo sapiens,N,,6915,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay
8975,,,104729,9615.0,,,BAO_0000224,B,,CHEMBL624725,,,Autocuration,,1,4,,Canis lupus familiaris,H,,6916,Association constant against A2 adenosine receptor
7645,1085.0,A2,80656,,,,BAO_0000219,F,,CHEMBL624726,,,Intermediate,,1,1,,fish,N,,6917,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma
11377,,,104713,10116.0,,,BAO_0000224,B,,CHEMBL857535,,,Autocuration,,1,5,,Rattus norvegicus,D,,6918,Ratio of Ki for adenosine A2 and A1 receptor binding
13528,623.0,A204,80014,9606.0,,,BAO_0000219,F,,CHEMBL624727,,,Expert,,1,1,,Homo sapiens,N,,6919,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line
10160,623.0,A204,80014,9606.0,,,BAO_0000219,F,,CHEMBL624728,,,Expert,,1,1,,Homo sapiens,N,,6920,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined
15144,404.0,A2058,80015,9606.0,,,BAO_0000219,F,,CHEMBL624729,,,Intermediate,,1,1,,Homo sapiens,N,,6921,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines
13160,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL624730,,,Intermediate,,1,1,,Homo sapiens,N,,6922,Growth inhibition against Human squamous cell line(A 253)
12898,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL624731,,,Intermediate,,1,1,,Homo sapiens,N,,6923,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line
13069,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL624732,,,Intermediate,,1,1,,Homo sapiens,N,,6924,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells
15984,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL883245,,,Intermediate,,1,1,,Homo sapiens,N,,6925,Growth inhibition of A253 cell lines.
15564,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL624733,,,Intermediate,,1,1,,Homo sapiens,N,,6926,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h)
15564,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL624734,,,Intermediate,,1,1,,Homo sapiens,N,,6927,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
15564,973.0,A253 cell line,80657,9606.0,,,BAO_0000219,F,,CHEMBL624735,,,Intermediate,,1,1,,Homo sapiens,N,,6928,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined
4720,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621780,,,Intermediate,,1,1,,Homo sapiens,N,,6929,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line
16112,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL877598,,,Intermediate,,1,1,,Homo sapiens,N,,6930,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line
16597,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621781,,,Expert,,1,1,,Homo sapiens,N,,6931,Cytotoxic activity against A2780 human ovarian carcinoma cell line
16378,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621782,,,Intermediate,,1,1,,Homo sapiens,N,,6932,Cytotoxicity against human cancer cell lines A2780 (ovarian)
16085,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621783,,,Expert,,1,1,,Homo sapiens,N,,6933,Growth and colony formation inhibition of A2780 ovarian cancer cell lines
16317,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621784,,,Intermediate,,1,1,,Homo sapiens,N,,6934,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay
15748,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621785,,,Intermediate,,1,1,,Homo sapiens,N,,6935,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
16597,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621968,,,Expert,,1,1,,Homo sapiens,N,,6936,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation
16597,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621969,,,Expert,,1,1,,Homo sapiens,N,,6937,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation
16597,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621970,,,Expert,,1,1,,Homo sapiens,N,,6938,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621971,,,Intermediate,,1,1,,Homo sapiens,N,,6939,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621972,,,Intermediate,,1,1,,Homo sapiens,N,,6940,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL884108,,,Intermediate,,1,1,,Homo sapiens,N,,6941,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5
15296,,,22224,10029.0,,,BAO_0000019,F,,CHEMBL623826,,,Autocuration,,1,0,,Cricetulus griseus,U,,6942,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).
10251,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,A,,CHEMBL623827,,,Autocuration,,1,0,,Cricetulus griseus,U,,6943,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay
10251,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623828,,,Autocuration,,1,0,,Cricetulus griseus,U,,6944,Evaluated for growth inhibition of AA8 cells under aerobic conditions
10251,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623829,,,Autocuration,,1,0,,Cricetulus griseus,U,,6945,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions
10251,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623830,,,Autocuration,,1,0,,Cricetulus griseus,U,,6946,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2)
11858,,,22224,10029.0,,,BAO_0000019,F,,CHEMBL623831,,,Autocuration,,1,0,,Cricetulus griseus,U,,6947,Growth inhibition against CHO-derived cell line AA8
11858,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623832,,,Autocuration,,1,0,,Cricetulus griseus,U,,6948,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control]
11616,185.0,CHO-AA8,80089,36483.0,,,BAO_0000219,F,,CHEMBL623833,,,Expert,,1,1,,hampster,N,,6949,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions
11616,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL623834,,,Expert,,1,1,,Cricetulus griseus,N,,6950,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions
10518,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623835,,,Autocuration,,1,0,,Cricetulus griseus,U,,6951,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay
11396,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623836,,,Autocuration,,1,0,,Cricetulus griseus,U,,6952,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours
10518,185.0,CHO-AA8,22224,10029.0,,,BAO_0000219,F,,CHEMBL623837,,,Autocuration,,1,0,,Cricetulus griseus,U,,6953,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay
11616,185.0,CHO-AA8,80089,10029.0,,,BAO_0000219,F,,CHEMBL623838,,,Expert,,1,1,,Cricetulus griseus,N,,6954,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.
14837,,,12675,,,,BAO_0000019,F,,CHEMBL623839,,,Autocuration,,1,8,,,H,,6955,compound was evaluated for association constant (Ka) of isolated serum protein AAG
14837,,,12675,,,,BAO_0000019,F,,CHEMBL623840,,,Autocuration,,1,8,,,H,,6956,Number of binding sites (n) of isolated serum protein AAG
16037,,,22222,,,,BAO_0000225,B,,CHEMBL623841,,,Intermediate,,1,3,,,M,,6957,Association constant for binding to AATT duplex
16597,416.0,ABAE,100090,9606.0,,,BAO_0000219,F,,CHEMBL623842,,,Expert,,1,1,,Homo sapiens,N,,6958,Inhibition of ABAE human fibroblast cell proliferation
8831,1064.0,AC755,80668,10090.0,,,BAO_0000218,F,,CHEMBL623843,,,Intermediate,,1,1,,Mus musculus,N,,6959,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg"
13419,,,102444,9986.0,,,BAO_0000218,F,,CHEMBL618669,,,Expert,,1,9,,Oryctolagus cuniculus,D,,6960,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model
13419,,,102444,9986.0,,,BAO_0000218,F,,CHEMBL618670,,,Expert,,1,9,,Oryctolagus cuniculus,D,In vivo,6961,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay
15778,,,69,,,,BAO_0000357,B,,CHEMBL618671,,,Autocuration,,1,8,,,H,,6962,Inhibitory activity against angiotensin-converting enzyme (ACE).
15778,,,69,,,,BAO_0000357,B,,CHEMBL618672,,,Autocuration,,1,8,,,H,,6963,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.
12988,978.0,ACH-2 cell line,80669,9606.0,,,BAO_0000219,F,,CHEMBL618673,,,Intermediate,,1,1,,Homo sapiens,N,,6964,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells
12988,978.0,ACH-2 cell line,80669,9606.0,,,BAO_0000219,F,,CHEMBL618674,,,Intermediate,,1,1,,Homo sapiens,N,,6965,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate)
12988,998.0,T cell line,22224,11676.0,,,BAO_0000219,F,,CHEMBL618675,,,Autocuration,,1,0,,Human immunodeficiency virus 1,U,,6966,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2
12988,998.0,T cell line,22224,11676.0,,,BAO_0000219,F,,CHEMBL618676,,,Autocuration,,1,0,,Human immunodeficiency virus 1,U,,6967,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate)
12988,998.0,T cell line,22224,11676.0,,,BAO_0000219,F,,CHEMBL618677,,,Autocuration,,1,0,,Human immunodeficiency virus 1,U,,6968,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate)
11843,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618678,,,Intermediate,,1,1,,Homo sapiens,N,,6969,Inhibition of growth of renal cancer ACHN cell line
16939,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618679,,,Intermediate,,1,1,,Homo sapiens,N,,6970,Inhibition of growth of ACHN renal cancer cell line
4782,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618680,,,Intermediate,,1,1,,Homo sapiens,N,,6971,Inhibitory concentration required against ACHN renal cancer cell line
6310,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618681,,,Expert,,1,1,,Homo sapiens,N,,6972,Concentration required to inhibit growth of human renal (ACHN) cell line
6310,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618682,,,Intermediate,,1,1,,Homo sapiens,N,,6973,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested
12858,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618683,,,Intermediate,,1,1,,Homo sapiens,N,,6974,Cytotoxic activity against ACHN Renal cancer cell line
17380,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618684,,,Intermediate,,1,1,,Homo sapiens,N,,6975,Cytotoxicity evaluation against ACHN renal cancer cells
5858,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618685,,,Intermediate,,1,1,,Homo sapiens,N,,6976,In vitro antitumor activity against human renal ACHN cell line
3838,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL876499,,,Intermediate,,1,1,,Homo sapiens,N,,6977,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
3838,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618686,,,Intermediate,,1,1,,Homo sapiens,N,,6978,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer
5406,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618687,,,Intermediate,,1,1,,Homo sapiens,N,,6979,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported"
4071,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618688,,,Intermediate,,1,1,,Homo sapiens,N,,6980,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
4071,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618689,,,Expert,,1,1,,Homo sapiens,N,,6981,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).
4071,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618690,,,Intermediate,,1,1,,Homo sapiens,N,,6982,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined
15002,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL618691,,,Intermediate,,1,1,,Homo sapiens,N,,6983,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.
14769,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL619373,,,Intermediate,,1,1,,Homo sapiens,N,,6984,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
13958,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL884008,,,Intermediate,,1,1,,Homo sapiens,N,,6985,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma"
1665,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL619374,,,Intermediate,,1,1,,Homo sapiens,N,,6986,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma
15354,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL619375,,,Intermediate,,1,1,,Homo sapiens,N,,6987,Compound was tested for the growth inhibition of ACHN renal tumor cell line
15354,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL619376,,,Intermediate,,1,1,,Homo sapiens,N,,6988,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined
13978,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL619377,,,Intermediate,,1,1,,Homo sapiens,N,,6989,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line
6798,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL619378,,,Intermediate,,1,1,,Homo sapiens,N,,6990,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line
2959,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL872527,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6991,Tmax value after administration of 4 mg/Kg oral dose in dog
9932,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876500,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6992,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously"
5546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619379,,,Intermediate,,1,1,,Canis lupus familiaris,N,,6993,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619538,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6994,Volume distribution after 15 mg/kg iv dose in Dogs
16907,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619539,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6995,Volume distribution after 30 mg/kg po dose in Dogs
4257,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619540,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6996,Volume of distribution was determined in dog after a 3 mg/kg of iv dose
4305,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619541,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6997,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619542,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6998,Volume of distribution was evaluated in dog
6062,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619543,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,6999,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg
3598,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619544,,,Expert,,1,1,,Canis lupus familiaris,N,,7000,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg
12500,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619545,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7001,The compound was tested for volume of distribution in dog
12500,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619546,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7002,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619547,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7003,Vd (1 mg/kg) was determined in dog (in vivo)
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619548,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7004,Vd in dog
4219,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619549,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7005,Volume distribution was determined
1696,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619550,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7006,Volume of distribution in dog
5542,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876501,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7007,Volume of distribution by as 4 fold increase by iv administration in dogs
5199,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619551,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7008,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).
6348,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619552,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7009,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
4727,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619553,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7010,Volume distribution at the dose of 2 mg/kg in dog
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618722,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7011,Steady state volume of distribution was determined
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618723,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7012,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618724,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7013,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618725,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7014,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618726,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7015,Bioavailability in dog (dose 1 mg/kg i.v.)
5334,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618727,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7016,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male)
4239,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624233,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7017,Pharmacokinetic property (vdss) was measured in dog
4709,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624234,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7018,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624235,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7019,Vdss was determined after iv 0.1 mg/kg administration in dog
6057,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624236,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7020,Volume displacement was calculated in dog
5654,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624237,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7021,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
5505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624238,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7022,Volume distribution constant was determined
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624239,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7023,Volume distribution at a dose of 1 uM/kg in dog was determined
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875829,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7024,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624240,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7025,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624241,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7026,Volume distribution (Vdss) was measured in dog
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624242,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7027,Volume distribution (Vdss) was measured in dog
6679,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624243,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7028,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
5145,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624244,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7029,Volume of distribution in steady state was determined in dog
6821,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624245,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7030,Volume of distribution of compound was determined in dog
4137,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624246,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7031,Volume of distribution after intravenous administration of 1 mg/kg/h in dog
5334,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624247,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7032,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male)
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624248,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7033,Volume of distribution (Vdss) was measured in dog
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624249,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7034,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
6641,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624250,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7035,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624251,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7036,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
11659,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624252,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7037,Maximum rate of depolarization of the upstroke of the action potential
6448,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624253,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7038,Steady state volume distribution in dog
5474,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624950,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7039,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.
1466,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624951,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7040,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875830,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7041,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined
6535,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624952,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7042,Volume distribution in dog after administration of 1 mg/kg iv
17764,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624953,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7043,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg
6215,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624954,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7044,Vss after intravenous administration (0.5 mg/kg) was determined in dog
6505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624955,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7045,Vss on i.v. administration of 2 mg/kg was measured in dog
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624956,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7046,Vss was determined
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625129,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7047,Vss in dog
6062,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625130,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7048,Volume of distribution was measured in dog after an iv dose of 1 mg/kg
4942,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625131,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7049,Volume distribution in dogs
17796,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625132,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7050,Volume of distribution in dog
4883,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL872263,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7051,Tested for the oral bioavailability in dog
17837,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624336,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7060,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg
17729,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624337,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7061,Bioavailability after i.p. administration of 50 mg/kg of dose in mice
17729,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624338,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7062,Bioavailability after peroral administration of 50 mg/kg of dose in mice
4239,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624339,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7063,Bioavailability was measured in mouse
17592,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624340,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7064,Bioavailability in mouse
6348,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624341,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7065,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration
2801,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624342,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7066,Bioavailability in mouse
2801,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624343,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7067,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg
17718,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624344,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7068,Oral bioavailability in mouse
5727,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624345,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7069,Oral availability at 50 mg/kg po in male mice
5302,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624346,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7070,Oral bioavailability in mouse (dose 10 mg/kg)
3598,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624347,,,Expert,,1,1,,Mus musculus,N,In vivo,7071,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg
5961,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL624348,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7072,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose"
6091,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622754,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7074,Oral bioavailability in mouse
6091,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622755,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7075,Oral bioavailability in vivo in mice;ND=Not determined
5711,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622756,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7076,Oral bioavailability in mouse at 10 mg/kg of the compound
17728,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622757,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7077,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.)
17728,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622758,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7078,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.)
3802,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622759,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7079,Tested for bioavailability of the compound
3802,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622760,,,Intermediate,,1,1,,Mus musculus,N,In vivo,7080,Tested for half life at the dose of 10 mg/kg when administered intravenously
14029,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622761,,,Intermediate,Plasma,1,1,,Mus musculus,N,,7081,The plasma half life of compound was determined on EDTA prepared by mouse plasma. 
14029,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622762,,,Intermediate,Plasma,1,1,,Mus musculus,N,,7082,The plasma half life of compound was determined on heparin prepared by human plasma. 
14029,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622763,,,Intermediate,Plasma,1,1,,Mus musculus,N,,7083,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded
14029,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622764,,,Intermediate,Plasma,1,1,,Mus musculus,N,,7084,The plasma half life of compound was determined on heparin prepared by mouse plasma. 
14029,,,50594,10090.0,,,BAO_0000218,A,1969.0,CHEMBL622765,,,Intermediate,Plasma,1,1,,Mus musculus,N,,7085,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded
17753,,,50594,10090.0,,,BAO_0000218,F,,CHEMBL622766,,,Intermediate,,1,1,,Mus musculus,N,,7086,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622767,,,Intermediate,,1,1,,Mus musculus,N,,7087,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg
17753,,,50594,10090.0,,,BAO_0000218,A,,CHEMBL622768,,,Intermediate,,1,1,,Mus musculus,N,,7088,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL875948,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7089,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622769,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7090,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622770,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7091,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622771,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7092,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622772,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7093,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622773,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7094,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,178.0,CHEMBL622774,,,Intermediate,Blood,1,1,,Mus musculus,N,In vivo,7095,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL621725,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7096,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL621726,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7097,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
15608,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621727,,,Intermediate,,1,1,,Homo sapiens,N,,7098,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8
3290,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622413,,,Expert,,1,1,,Homo sapiens,N,,7099,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay
2859,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622414,,,Intermediate,,1,1,,Homo sapiens,N,,7100,Compound was evaluated for cytotoxicity against A2780 cell line
15688,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622415,,,Expert,,1,1,,Homo sapiens,N,,7101,Inhibition of A2780 cell clonogenic assay
5642,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL884001,,,Expert,,1,1,,Homo sapiens,N,,7102,Cytotoxic effect on ovarian cancer cell line (A2780)
6633,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622416,,,Intermediate,,1,1,,Homo sapiens,N,,7103,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C
3906,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622417,,,Intermediate,,1,1,,Homo sapiens,N,,7104,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL"
6788,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622590,,,Expert,,1,1,,Homo sapiens,N,,7105,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells
17582,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622591,,,Expert,,1,1,,Homo sapiens,N,,7106,Antiproliferative activity against human A2780 cells
17764,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622592,,,Expert,,1,1,,Homo sapiens,N,,7107,Inhibition of human A2780 cell proliferation
17764,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622593,,,Expert,,1,1,,Homo sapiens,N,,7108,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay
17764,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622594,,,Expert,,1,1,,Homo sapiens,N,,7109,Inhibition of human A2780 cell proliferation (No data)
2815,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622595,,,Intermediate,,1,1,,Homo sapiens,N,,7110,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line
16930,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622596,,,Intermediate,,1,1,,Homo sapiens,N,,7111,Compound was evaluated against human Ovarian carcinoma cell line A2780
17777,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622597,,,Expert,,1,1,,Homo sapiens,N,,7112,Growth inhibition against A2780 wild-type ovarian cell lines
17777,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622598,,,Intermediate,,1,1,,Homo sapiens,N,,7113,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data
16936,,,104766,9606.0,,,BAO_0000019,F,,CHEMBL622599,,,Autocuration,,1,5,,Homo sapiens,D,,7114,Inhibition of tubulin polymerization in human ovarian cancer cell lines
13759,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622600,,,Intermediate,,1,1,,Homo sapiens,N,,7115,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
13759,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622601,,,Intermediate,,1,1,,Homo sapiens,N,,7116,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
13759,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622602,,,Intermediate,,1,1,,Homo sapiens,N,,7117,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780
13759,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622603,,,Intermediate,,1,1,,Homo sapiens,N,,7118,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R
15292,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622604,,,Intermediate,,1,1,,Homo sapiens,N,,7119,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values
15292,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622605,,,Intermediate,,1,1,,Homo sapiens,N,,7120,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values
15069,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622606,,,Expert,,1,1,,Homo sapiens,N,,7121,In vitro inhibition of human ovarian cell line A2780
15069,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619463,,,Expert,,1,1,,Homo sapiens,N,,7122,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR)."
14073,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619464,,,Intermediate,,1,1,,Homo sapiens,N,,7123,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro)
14553,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619465,,,Expert,,1,1,,Homo sapiens,N,,7124,Concentration required to inhibit A2780-cell growth by 50%
13040,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619466,,,Expert,,1,1,,Homo sapiens,N,,7125,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.
6891,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619467,,,Expert,,1,1,,Homo sapiens,N,,7126,Cytotoxic effect on human ovarian (A2780) cancer cell line
15569,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619468,,,Intermediate,,1,1,,Homo sapiens,N,,7127,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure
14190,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619469,,,Expert,,1,1,,Homo sapiens,N,,7128,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs
15014,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619470,,,Expert,,1,1,,Homo sapiens,N,,7129,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
15014,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619471,,,Intermediate,,1,1,,Homo sapiens,N,,7130,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay
17496,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619472,,,Intermediate,,1,1,,Homo sapiens,N,,7131,Cytotoxicity against human ovarian carcinoma A2780 cell line
13617,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL619473,,,Intermediate,,1,1,,Homo sapiens,N,,7132,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line"
13617,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL874368,,,Intermediate,,1,1,,Homo sapiens,N,,7133,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line"
13617,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL884003,,,Intermediate,,1,1,,Homo sapiens,N,,7134,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line"
13617,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622690,,,Intermediate,,1,1,,Homo sapiens,N,,7135,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line"
17672,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622691,,,Intermediate,,1,1,,Homo sapiens,N,,7136,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines
4544,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL622692,,,Intermediate,,1,1,,Homo sapiens,N,,7137,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
4544,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623406,,,Intermediate,,1,1,,Homo sapiens,N,,7138,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay
16317,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL884004,,,Intermediate,,1,1,,Homo sapiens,N,,7139,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay"
15099,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623407,,,Intermediate,,1,1,,Homo sapiens,N,,7140,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780
13978,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623408,,,Intermediate,,1,1,,Homo sapiens,N,,7141,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line
12989,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623409,,,Expert,,1,1,,Homo sapiens,N,,7142,In vitro antitumor activity against A2780 cell line.
5574,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623410,,,Intermediate,,1,1,,Homo sapiens,N,,7143,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours
13528,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL623576,,,Expert,,1,1,,Homo sapiens,N,,7144,In vitro cytotoxicity against A2780 human ovarian cancer cell line
12782,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623577,,,Intermediate,,1,1,,Homo sapiens,N,,7145,Inhibitory activity against kidney A-CHN tumor cell growth in culture
14255,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623578,,,Intermediate,,1,1,,Homo sapiens,N,,7146,The IC50 value was measured on ACHN cell line in renal tumor type.
16364,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623579,,,Intermediate,,1,1,,Homo sapiens,N,,7147,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro
17376,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623580,,,Expert,,1,1,,Homo sapiens,N,,7148,In vitro lethal concentration against most sensitive ACHN cell line
12016,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623581,,,Intermediate,,1,1,,Homo sapiens,N,,7149,Tested for cytotoxic activity against renal cancer ACHN cell line
6058,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL857456,,,Intermediate,,1,1,,Homo sapiens,N,,7150,Compound tested for growth inhibition of renal cancer cell line ACHN
17708,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623582,,,Intermediate,,1,1,,Homo sapiens,N,,7151,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line
15176,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623583,,,Intermediate,,1,1,,Homo sapiens,N,,7152,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.
2806,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623584,,,Intermediate,,1,1,,Homo sapiens,N,,7153,In vitro anticancer activity against ACHN renal cancer cell line
15300,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623585,,,Intermediate,,1,1,,Homo sapiens,N,,7154,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay
16364,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623586,,,Intermediate,,1,1,,Homo sapiens,N,,7155,Percent selectivity was evaluated in renal ACHN cell lines
13859,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623587,,,Intermediate,,1,1,,Homo sapiens,N,,7156,In vitro inhibitory activity against renal ACHN cancer cell line
11970,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL875279,,,Intermediate,,1,1,,Homo sapiens,N,,7157,Tested for cytotoxicity against ACHN cell lines in renal cancer
2450,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623588,,,Intermediate,,1,1,,Homo sapiens,N,,7158,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line
12696,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623589,,,Intermediate,,1,1,,Homo sapiens,N,,7159,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined
12400,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623590,,,Intermediate,,1,1,,Homo sapiens,N,,7160,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer
12888,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623591,,,Expert,,1,1,,Homo sapiens,N,,7161,Cytotoxic effect on renal cancer line ACHN
3156,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623592,,,Intermediate,,1,1,,Homo sapiens,N,,7162,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line
3381,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623593,,,Intermediate,,1,1,,Homo sapiens,N,,7163,In vitro inhibition of Renal Cancer ACHN cell lines
16747,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL623594,,,Intermediate,,1,1,,Homo sapiens,N,,7164,Antitumor activity against human renal adenocarcinoma ACHN cells
16748,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621833,,,Expert,,1,1,,Homo sapiens,N,,7165,Antitumor activity against human renal adenocarcinoma ACHN cells.
12062,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621834,,,Intermediate,,1,1,,Homo sapiens,N,,7166,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN
14769,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621835,,,Intermediate,,1,1,,Homo sapiens,N,,7167,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells )
15895,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621836,,,Intermediate,,1,1,,Homo sapiens,N,,7168,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line"
17376,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621837,,,Intermediate,,1,1,,Homo sapiens,N,,7169,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line
14882,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL875280,,,Intermediate,,1,1,,Homo sapiens,N,,7170,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).
14882,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621838,,,Intermediate,,1,1,,Homo sapiens,N,,7171,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).
15661,626.0,ACHN,80025,9606.0,,,BAO_0000219,F,,CHEMBL621839,,,Intermediate,,1,1,,Homo sapiens,N,,7172,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.
9680,,,22224,,,,BAO_0000019,A,,CHEMBL621840,,,Autocuration,,1,0,,,U,,7173,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade
14579,,,10647,,,,BAO_0000019,F,,CHEMBL621841,,,Autocuration,,1,8,,,H,,7174,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.
17290,468.0,HEL,50529,10358.0,,,BAO_0000218,F,,CHEMBL622979,,,Expert,,1,1,,Cytomegalovirus,N,,7175,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.
17290,,,50529,10358.0,,,BAO_0000218,F,,CHEMBL876595,,,Intermediate,,1,1,,Cytomegalovirus,N,,7176,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data
15891,,,12159,,,,BAO_0000357,B,,CHEMBL620221,,,Autocuration,,1,8,,,H,,7177,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA)
15890,,,12159,,,,BAO_0000357,B,,CHEMBL620222,,,Autocuration,,1,8,,,H,,7178,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA)
3801,979.0,ADDP cell line,80670,9913.0,,,BAO_0000219,F,,CHEMBL620506,,,Intermediate,,1,1,,Bos taurus,N,,7179,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound
9222,980.0,ADJ/PC6,80671,10090.0,,,BAO_0000219,F,,CHEMBL620507,,,Intermediate,,1,1,,Mus musculus,N,,7180,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells
9222,980.0,ADJ/PC6,80671,10090.0,,,BAO_0000219,F,,CHEMBL620508,,,Intermediate,,1,1,,Mus musculus,N,,7181,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells
7257,980.0,ADJ/PC6,80671,10090.0,,,BAO_0000219,F,,CHEMBL620509,,,Intermediate,,1,1,,Mus musculus,N,,7182,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor"
7257,980.0,ADJ/PC6,80671,10090.0,,,BAO_0000219,F,,CHEMBL620510,,,Intermediate,,1,1,,Mus musculus,N,,7183,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg
7257,980.0,ADJ/PC6,80671,10090.0,,,BAO_0000219,A,,CHEMBL620511,,,Intermediate,,1,1,,Mus musculus,N,,7184,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group
8084,980.0,ADJ/PC6,80671,10090.0,,,BAO_0000219,F,,CHEMBL620512,,,Intermediate,,1,1,,Mus musculus,N,,7185,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells
14943,,,22224,10090.0,,,BAO_0000019,F,,CHEMBL620513,,,Autocuration,,1,0,,Mus musculus,U,,7186,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma
14943,,,22224,10090.0,,,BAO_0000019,F,,CHEMBL620514,,,Autocuration,,1,0,,Mus musculus,U,,7187,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined
14943,,,22224,10090.0,,,BAO_0000019,F,,CHEMBL620515,,,Autocuration,,1,0,,Mus musculus,U,,7188,Tested for cytotoxicity against ADJ/PC6 plasmacytoma
10524,,,22224,1423.0,,,BAO_0000218,A,,CHEMBL620516,,,Autocuration,,1,0,,Bacillus subtilis,U,In vivo,7189,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg)
3546,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL620517,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7190,AUC value in dog after IV administration at a dose of 5 mg/kg
3546,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL620518,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7191,AUC value in dog after oral administration at a dose of 5 mg/kg
3546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL620519,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7192,Cmax value in dog after oral administration at a dose of 5 mg/kg
3546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621386,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7193,Bioavailability in dog after oral administration at a dose of 5 mg/kg
3546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621387,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7194,Tmax value in dog after oral administration at a dose of 5 mg/kg
3184,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621388,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7195,Compound was evaluated for its clearance when administered intravenously in dog
16456,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621389,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7196,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg
4809,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621390,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7197,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
4219,,,22229,,,,BAO_0000100,P,,CHEMBL621391,,,Intermediate,,1,0,,,U,,7198,Calculated partition coefficient (clogP)
3748,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621392,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7199,Half life in dog
3132,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621393,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7200,Time taken for EC90 was determined when tested in dog
4219,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621394,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7201,Half life (iv) was determined
16907,,,50588,9615.0,,,BAO_0000218,A,2107.0,CHEMBL621395,,,Intermediate,Liver,1,1,,Canis lupus familiaris,N,,7202,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes
6057,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621396,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7203,Area under the curve was calculated in dog after iv administration
6057,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621397,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7204,Area under the curve was calculated in dog after peroral administration
17853,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621398,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7205,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk
3639,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618818,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7206,pKa was evaluated in dog
14541,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618819,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7207,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound
16456,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618820,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7208,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
16456,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873810,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7209,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg
2652,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876606,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7210,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally
3624,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618821,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7211,Compound was evaluated for the half-life (t 1/2) in hours
1337,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL618822,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,In vivo,7212,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.
1337,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL618823,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,In vivo,7213,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.
4709,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618824,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7214,Half life after intravenous administration of 1 mg/kg in dog
15660,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618825,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7215,Half life was measured in dog
5302,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618826,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7216,Half life period in dog after 5 mg/kg dose
17791,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618827,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7217,Half life period was evaluated in dog; 4-4.8
6348,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618828,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7218,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration
4257,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618829,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7219,Half-life was determined in dog after a3 mg/kg of iv dose
3771,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618830,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7220,Half-life was determined
6305,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL618831,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7221,Half life in dogs
13501,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL619489,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,7222,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog
17594,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619649,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7223,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs
3045,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876607,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7224,Compound was evaluated for the half life period after iv administration in Beagle dog.
3043,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619650,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7225,Compound was evaluated for the half life period after oral administration in conscious dog.
4839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619651,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7226,Compound was tested for half life in dog
4839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619652,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7227,Compound was tested for its half life in dog
5802,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619653,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7228,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619654,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7229,Half life of compound in dog was determined
4219,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619655,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7230,Half life (iv) was determined
13966,,,50588,9615.0,,,BAO_0000218,A,178.0,CHEMBL619656,,,Intermediate,Blood,1,1,,Canis lupus familiaris,N,,7231,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity)
3994,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL873812,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,7232,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
3994,,,50588,9615.0,,,BAO_0000218,F,1969.0,CHEMBL621365,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,7233,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration
4453,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621366,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7234,Half life in dog
6535,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621367,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7235,Half life in dog plasma
6535,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621368,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,7236,Half life in dog plasma after administration of 0.25 mg/kg iv
6535,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621369,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,7237,Half life in dog plasma after administration of 1 mg/kg iv
3132,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621370,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vivo,7238,Half life in dog plasma was determined at dose 10 mg/kg
5374,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621371,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7239,Half life in dog was determined
5007,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621372,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7240,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg)
16907,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621373,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7241,Half life upon exposure to human plasma
6057,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621374,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7242,Half life was calculated in dog
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621375,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7243,Half life was determined
5473,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621376,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7244,Half life was determined
4368,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619624,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7245,Half life by intravenous administration of 1.2 mg/kg in dog
6448,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL875840,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7246,Half life in dog
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619625,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7247,Half life in dog after intra venous administration of the compound
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619626,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7248,Half life in dog after intra venous administration of the compound; ND means Not determined
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619627,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7249,Half life in dog after po administration of the compound
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873817,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7250,Half life in dog after po administration of the compound; ND means Not determined
6265,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619628,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7251,Half life in dog at the single oral dose of 1 mg/kg
5006,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619629,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7252,Half life in dogs
5356,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619630,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7253,Half life in dogs at 1 mg/kg oral dosing; 35-100 min
405,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619631,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7254,Half life in rat
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL619632,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7255,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only)
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL619633,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7256,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL875841,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7257,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL619634,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7258,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL619635,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7259,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000001.0,CHEMBL619636,,,Intermediate,Bone,1,1,,Mus musculus,N,In vivo,7260,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619637,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7261,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619638,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7262,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619639,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7263,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619640,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7264,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619641,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7265,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619642,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7266,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,10000004.0,CHEMBL619643,,,Intermediate,Gut,1,1,,Mus musculus,N,In vivo,7267,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL619644,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7268,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621112,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7269,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621113,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7270,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621114,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7271,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621115,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7272,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621116,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7273,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,948.0,CHEMBL621117,,,Intermediate,Heart,1,1,,Mus musculus,N,In vivo,7274,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621118,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7275,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621119,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7276,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621120,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7277,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621757,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7278,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621758,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7279,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621759,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7280,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2113.0,CHEMBL621760,,,Intermediate,Kidney,1,1,,Mus musculus,N,In vivo,7281,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621761,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7282,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621762,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7283,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL621763,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7284,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624502,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7285,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624503,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7286,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624504,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7287,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2107.0,CHEMBL624505,,,Intermediate,Liver,1,1,,Mus musculus,N,In vivo,7288,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL624506,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7289,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
5895,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624507,,,Intermediate,,1,1,,Homo sapiens,N,,7290,In vitro cytotoxicity against A2780 (human ovarian cancer)
6338,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624508,,,Intermediate,,1,1,,Homo sapiens,N,,7291,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780
15163,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624509,,,Intermediate,,1,1,,Homo sapiens,N,,7292,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.
15163,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624510,,,Intermediate,,1,1,,Homo sapiens,N,,7293,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).
15000,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL875956,,,Expert,,1,1,,Homo sapiens,N,,7294,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line
15000,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL839885,,,Expert,,1,1,,Homo sapiens,N,,7295,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line
14729,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624511,,,Expert,,1,1,,Homo sapiens,N,,7296,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.
17270,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624512,,,Intermediate,,1,1,,Homo sapiens,N,,7297,In vitro cytotoxicity against A2780 cell line
5685,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624513,,,Intermediate,,1,1,,Homo sapiens,N,,7298,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined
3563,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL624514,,,Intermediate,,1,1,,Homo sapiens,N,,7299,In vitro inhibitory activity against human ovarian cancer A2780 cell line
17753,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL618547,,,Intermediate,,1,1,,Homo sapiens,N,,7300,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure
16317,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618548,,,Intermediate,,1,1,,Homo sapiens,N,,7301,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay"
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618549,,,Intermediate,,1,1,,Homo sapiens,N,,7302,Inhibition of tubulin polymerization in analogy of ca.
3801,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618550,,,Intermediate,,1,1,,Homo sapiens,N,,7303,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound
6181,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618551,,,Expert,,1,1,,Homo sapiens,N,,7304,Cytotoxic effect in ovarian cancer cell line (A2780)
5318,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618552,,,Intermediate,,1,1,,Homo sapiens,N,,7305,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene
4840,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618553,,,Intermediate,,1,1,,Homo sapiens,N,,7306,Tested for the cytotoxicity in A2780 ovarian cell line
15748,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618554,,,Intermediate,,1,1,,Homo sapiens,N,,7307,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma )
15748,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618555,,,Intermediate,,1,1,,Homo sapiens,N,,7308,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma
15748,481.0,A2780cisR,80017,,,,BAO_0000219,F,,CHEMBL618556,,,Intermediate,,1,1,,,N,,7309,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma
15748,481.0,A2780cisR,80017,,,,BAO_0000219,F,,CHEMBL618557,,,Intermediate,,1,1,,,N,,7310,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma )
15748,481.0,A2780cisR,80017,,,,BAO_0000219,F,,CHEMBL618558,,,Intermediate,,1,1,,,N,,7311,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data
15748,481.0,A2780cisR,80017,,,,BAO_0000219,F,,CHEMBL618559,,,Intermediate,,1,1,,,N,,7312,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma)
17753,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL618560,,,Intermediate,,1,1,,Homo sapiens,N,,7313,In vivo log of cells killed after administration of compound in A2780 cell line
17753,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL618561,,,Intermediate,,1,1,,Homo sapiens,N,In vivo,7314,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618562,,,Intermediate,,1,1,,Homo sapiens,N,,7315,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618563,,,Intermediate,,1,1,,Homo sapiens,N,,7316,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618564,,,Intermediate,,1,1,,Homo sapiens,N,,7317,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618565,,,Intermediate,,1,1,,Homo sapiens,N,,7318,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data
17528,478.0,A2780,81034,9606.0,,,BAO_0000218,F,,CHEMBL618566,,,Intermediate,,1,1,,Homo sapiens,N,,7319,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2)
6633,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618567,,,Intermediate,,1,1,,Homo sapiens,N,,7320,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line
15000,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618568,,,Expert,,1,1,,Homo sapiens,N,,7321,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line
17528,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL618569,,,Expert,,1,1,,Homo sapiens,N,,7322,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621857,,,Intermediate,,1,1,,Homo sapiens,N,,7323,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621858,,,Intermediate,,1,1,,Homo sapiens,N,,7324,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621859,,,Intermediate,,1,1,,Homo sapiens,N,,7325,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621860,,,Intermediate,,1,1,,Homo sapiens,N,,7326,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)"
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621861,,,Intermediate,,1,1,,Homo sapiens,N,,7327,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM )
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621862,,,Expert,,1,1,,Homo sapiens,N,,7328,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )"
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621863,,,Intermediate,,1,1,,Homo sapiens,N,,7329,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621864,,,Intermediate,,1,1,,Homo sapiens,N,,7330,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM )
16936,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621865,,,Intermediate,,1,1,,Homo sapiens,N,,7331,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM )
17737,478.0,A2780,81034,10090.0,,,BAO_0000219,F,,CHEMBL621866,,,Intermediate,,1,1,,Mus musculus,N,,7332,In vitro antiproliferative activity against A2780 cell line
17764,478.0,A2780,81034,10090.0,,,BAO_0000219,F,,CHEMBL621867,,,Expert,,1,1,,Mus musculus,N,,7333,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days
3830,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL621868,,,Intermediate,,1,1,,Homo sapiens,N,,7334,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr
3829,478.0,A2780,81034,9606.0,,,BAO_0000219,F,,CHEMBL875282,,,Intermediate,,1,1,,Homo sapiens,N,,7335,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr
3546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621869,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7336,Vc value in dog after IV administration at a dose of 5 mg/kg
3546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621870,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7337,Half life period in dog after IV administration at a dose of 5 mg/kg
5668,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621871,,,Autocuration,,1,0,,Cercopithecidae,U,,7338,Area under curve was determine after peroral administration at 10 mpk in Rhesus
3443,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL621243,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,,7339,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3443,,,22224,9527.0,,,BAO_0000218,A,1969.0,CHEMBL621244,,,Autocuration,Plasma,1,0,,Cercopithecidae,U,,7340,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
4256,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL621245,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,7341,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey
4256,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL621246,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,7342,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey
4256,,,22224,9541.0,,,BAO_0000218,A,,CHEMBL621247,,,Autocuration,,1,0,,Macaca fascicularis,U,In vivo,7343,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey
4256,,,22224,10116.0,,,BAO_0000218,A,,CHEMBL618386,,,Autocuration,,1,0,,Rattus norvegicus,U,In vivo,7344,Oral Bioavailability in rat
1916,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618387,,,Autocuration,,1,0,,Cercopithecidae,U,,7345,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration
5302,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618388,,,Autocuration,,1,0,,Cercopithecidae,U,,7346,Area under curve value in monkey at a dose of 5 mg/kg
4257,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618389,,,Autocuration,,1,0,,Cercopithecidae,U,,7347,Area under curve was determined in monkey after a 3 mg/kg of oral dose
5355,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618574,,,Autocuration,,1,0,,Cercopithecidae,U,,7348,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618575,,,Autocuration,,1,0,,Cercopithecidae,U,,7349,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618576,,,Autocuration,,1,0,,Cercopithecidae,U,,7350,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined
6078,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618577,,,Autocuration,,1,0,,Cercopithecidae,U,,7351,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey
6078,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL876487,,,Autocuration,,1,0,,Cercopithecidae,U,,7352,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey
6062,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618578,,,Autocuration,,1,0,,Cercopithecidae,U,,7353,Area under the curve was measured in monkey after an iv dose of 1 mg/kg
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618579,,,Autocuration,,1,0,,Cercopithecidae,U,,7354,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey
2661,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618580,,,Autocuration,,1,0,,Cercopithecidae,U,,7355,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey
5394,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618581,,,Autocuration,,1,0,,Cercopithecidae,U,,7356,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg
4397,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618582,,,Autocuration,,1,0,,Cercopithecidae,U,,7357,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.
17509,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618583,,,Autocuration,,1,0,,Cercopithecidae,U,,7358,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys
17509,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618584,,,Autocuration,,1,0,,Cercopithecidae,U,,7359,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys
6641,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618585,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7360,Oral AUCN in monkey (dosed at 0.5 mpk iv )
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618586,,,Autocuration,,1,0,,Cercopithecidae,U,,7361,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration)
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618587,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7362,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
3443,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618588,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7363,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection
17409,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618589,,,Autocuration,,1,0,,Cercopithecidae,U,,7364,Binding towards monkey plasma protein at 10 uM
17409,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL618590,,,Autocuration,,1,0,,Cercopithecidae,U,,7365,Binding towards monkey plasma protein at 100 uM
1052,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL872262,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7366,Apparent bioavailability in squirrel monkey was determined
13501,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618591,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7367,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey
17509,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL618592,,,Autocuration,,1,0,,monkey,U,In vivo,7368,Bioavailability in monkey (dose 2 mg/kg)
5394,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL876488,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7369,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618593,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7370,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey
11219,,,22224,9443.0,,,BAO_0000218,A,,CHEMBL618594,,,Autocuration,,1,0,,monkey,U,In vivo,7371,Bioavailability in monkey (i.d. dosing)
3045,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL618595,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7372,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined
17796,,,22224,9527.0,,,BAO_0000019,A,,CHEMBL621469,,,Autocuration,,1,0,,Cercopithecidae,U,,7373,Clearance of the drug was measured in cynomolgus
1399,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621470,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7374,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg
2661,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621471,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7375,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey
5005,,,22224,9544.0,,,BAO_0000218,A,1969.0,CHEMBL621472,,,Autocuration,Plasma,1,0,,Macaca mulatta,U,In vivo,7376,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po
17267,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621473,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7377,Plasma clearance in rhesus monkey was determined
6535,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621474,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7378,Plasma clearance in monkey after administration of 1 mg/kg iv
5922,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621475,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7379,Plasma clearance in cynomolgus monkey
6221,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL621476,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7380,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined
5668,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL624290,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7381,Plasma clearance after peroral administration at 10 mpk in Rhesus
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL624291,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7382,The total clearance was determined after intravenous administration in cynomolgus monkeys
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL624292,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7383,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable
5355,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL624293,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7384,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable
4578,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL624294,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7385,Tested for Clearance upon iv administration to african green monkey
17592,,,22224,9527.0,,,BAO_0000218,A,,CHEMBL624295,,,Autocuration,,1,0,,Cercopithecidae,U,In vivo,7386,Clearance in monkey
6641,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624296,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7387,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
6642,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624297,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7388,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally)
16367,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624298,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7389,Half life was evaluated after intravenous administration to dogs
5472,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624299,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7390,Half life was evaluated in dog
5474,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624300,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7391,Half life was evaluated in dog
5654,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624301,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7392,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624302,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7393,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo)
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876026,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7394,Half life period after intravenous administration in dog
6221,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624303,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7395,Half life period after oral administration (2.5 mg/kg) in dog was determined
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624304,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7396,Half life period at a dose of 1 uM/kg in dog was determined
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624305,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7397,Half life period was determine after peroral administration at 10 mpk in dog
5668,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624306,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7398,Half life period was determine after peroral administration at 5 mpk in dog
3854,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624307,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7399,Half life period was determined
5505,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624308,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7400,Half life period was determined
6251,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624309,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7401,Half life period by iv administration in dog at a dose of 6 mg/kg
1918,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624310,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7402,Half life period was evaluated in dog
5546,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625003,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7403,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration
4809,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625004,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7404,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg)
6215,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625005,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7405,Half life time after intravenous administration (0.5 mg/kg) was determined in dog
4527,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873813,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7406,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined
17594,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625006,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7407,Half-life after oral dose of compound at 3 mg/kg in dogs
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625007,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7408,Half-life of compound in dog following p.o. administration of 0.5 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876027,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7409,Half-life of compound in dog following p.o. administration of 0.9 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625008,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7410,Half-life of compound in dog following p.o. administration of 0.95 mg/kg
17839,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625009,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7411,Half-life of compound in dog following p.o. administration of 1 mg/kg
5210,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL625010,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7412,Half-life of compound in plasma of dog was determined
5210,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL625011,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7413,Half-life of compound was determined in dogs
2959,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621553,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7414,Half-life after administration of 4 mg/Kg oral dose in dog
4137,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621554,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7415,Half-life after intravenous administration of 1 mg/kg/h in dog
5064,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621555,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7416,Half-life in Dog
5147,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621556,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7417,Half-life in Dog
5145,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621557,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7418,Half-life in dog
6123,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621558,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7419,Half-life in dog after oral administration at 1 mg/kg
6123,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621559,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7420,Half-life in dog after oral administration at 1 mg/kg; nd is not determined
4333,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621560,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7421,Half-life in dogs
4333,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL876028,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7422,Half-life in dogs; ND indicates not determined
12500,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621561,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7423,Half-life in plasma of dog
12500,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL621562,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,,7424,Half-life in plasma of dog at dose of 3-10 mgkg
6005,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621563,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7425,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg
6062,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621564,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7426,Half-life was measured in dog after an iv dose of 1 mg/kg
17650,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621565,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7427,Half-life was measured in dogs after an oral dose of 10 uM/kg
5530,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621566,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7428,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg
5530,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL621567,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7429,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg
5600,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL622978,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7430,Half-life of the compound after 0.3 mg/kg po administration in dog
6039,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL873814,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7431,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined
6039,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623219,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7432,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined
6039,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624477,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7433,Half-life period after peroral administration of 0.2 mg/kg in dog was determined
6227,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624478,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7434,t1/2 in dog
14541,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624479,,,Intermediate,,1,1,,Canis lupus familiaris,N,,7435,Half-life period measured in dogs
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL624480,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7436,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration
4521,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623595,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7437,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined
6679,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623596,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7438,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration
1116,,,50588,9615.0,,,BAO_0000218,A,1969.0,CHEMBL623597,,,Intermediate,Plasma,1,1,,Canis lupus familiaris,N,In vitro,7439,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma"
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623598,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7440,In vivo half life period was calculated at 1 mg/kg in dog
5444,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623599,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7441,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined
17853,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623600,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7442,Longer half-life in dog (i.v.) at 0.5 mpk
4353,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623601,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7443,Oral bioavailability in dog (dose 5 uM/kg)
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623602,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7444,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623603,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7445,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously
16452,,,50588,9615.0,,,BAO_0000218,A,,CHEMBL623604,,,Intermediate,,1,1,,Canis lupus familiaris,N,In vivo,7446,Bioavailability in dog (dose 1 mg/kg i.v.)
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623605,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7447,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623606,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7448,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623607,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7449,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623608,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7450,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623609,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7451,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2048.0,CHEMBL623610,,,Intermediate,Lung,1,1,,Mus musculus,N,In vivo,7452,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623611,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7453,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623612,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7454,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623613,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7455,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623614,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7456,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623615,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7457,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623616,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7458,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2385.0,CHEMBL623617,,,Intermediate,Muscle tissue,1,1,,Mus musculus,N,In vivo,7459,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL875944,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7460,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL623618,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7461,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL623619,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7462,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL623620,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7463,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL623621,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7464,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL623622,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7465,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,14.0,CHEMBL623623,,,Intermediate,Zone of skin,1,1,,Mus musculus,N,In vivo,7466,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL623624,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7467,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618521,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7468,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618522,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7469,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618523,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7470,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618524,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7471,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL618525,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7472,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,2106.0,CHEMBL624586,,,Intermediate,Spleen,1,1,,Mus musculus,N,In vivo,7473,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624587,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7474,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624588,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7475,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624589,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7476,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624590,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7477,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624591,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7478,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624592,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7479,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours
10107,,,50594,10090.0,,,BAO_0000218,A,945.0,CHEMBL624593,,,Intermediate,Stomach,1,1,,Mus musculus,N,In vivo,7480,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours
4689,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624594,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7481,Oral bioavailability in rat
4950,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624595,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7482,Tested for the bioavailability in rat
5328,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624596,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7483,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.)
406,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624597,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7484,Bioavailability in rat
12500,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624598,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7485,Bioavailability in rat
12500,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624599,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7486,Bioavailability in rat (dose 3-10 mg/kg)
5247,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL875166,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7487,Bioavailability in rat
4186,,,50597,10116.0,,,BAO_0000218,A,1969.0,CHEMBL624600,,,Intermediate,Plasma,1,1,,Rattus norvegicus,N,In vivo,7488,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route
4186,,,50597,10116.0,,,BAO_0000218,A,1969.0,CHEMBL624601,,,Intermediate,Plasma,1,1,,Rattus norvegicus,N,In vivo,7489,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route
6647,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624602,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7490,Half life after oral administration was determined in rats at 6 mg/kg
6484,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624603,,,Intermediate,,1,1,,Rattus norvegicus,N,,7491,Half life was determined
3249,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624604,,,Intermediate,,1,1,,Rattus norvegicus,N,In vivo,7492,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg
6281,,,50597,10116.0,,,BAO_0000218,A,1969.0,CHEMBL624605,,,Intermediate,Plasma,1,1,,Rattus norvegicus,N,In vivo,7493,Plasma half life in rat at oral dose 2.8 mg/mk body weight
3307,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624606,,,Intermediate,,1,1,,Rattus norvegicus,N,,7494,Half life in rats
12058,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624607,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,In vivo,7495,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration
8833,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624608,,,Intermediate,,1,1,,Rattus norvegicus,N,,7496,Hill coefficient of the compound
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624609,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7497,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624610,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7498,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624611,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7499,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624612,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7500,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL875167,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7501,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624613,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7502,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min
3193,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624614,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,,7503,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min"
5960,,,50597,10116.0,,,BAO_0000218,A,,CHEMBL624392,,,Intermediate,,1,1,,Rattus norvegicus,N,,7504,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS
13950,,,50597,10116.0,,,BAO_0000218,A,955.0,CHEMBL624393,,,Intermediate,Brain,1,1,,Rattus norvegicus,N,In vivo,7505,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,955.0,CHEMBL624394,,,Intermediate,Brain,1,1,,Rattus norvegicus,N,In vivo,7506,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,955.0,CHEMBL624395,,,Intermediate,Brain,1,1,,Rattus norvegicus,N,In vivo,7507,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,955.0,CHEMBL624396,,,Intermediate,Brain,1,1,,Rattus norvegicus,N,In vivo,7508,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,955.0,CHEMBL624397,,,Intermediate,Brain,1,1,,Rattus norvegicus,N,In vivo,7509,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,2046.0,CHEMBL624398,,,Intermediate,Thyroid gland,1,1,,Rattus norvegicus,N,In vivo,7510,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,2046.0,CHEMBL624399,,,Intermediate,Thyroid gland,1,1,,Rattus norvegicus,N,In vivo,7511,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,2046.0,CHEMBL624400,,,Intermediate,Thyroid gland,1,1,,Rattus norvegicus,N,In vivo,7512,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,2046.0,CHEMBL624401,,,Intermediate,Thyroid gland,1,1,,Rattus norvegicus,N,In vivo,7513,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ
13950,,,50597,10116.0,,,BAO_0000218,A,2046.0,CHEMBL624402,,,Intermediate,Thyroid gland,1,1,,Rattus norvegicus,N,In vivo,7514,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ
9866,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624403,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,In vivo,7515,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr
9866,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624404,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,In vivo,7516,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig
9866,,,50597,10116.0,,,BAO_0000218,A,178.0,CHEMBL624405,,,Intermediate,Blood,1,1,,Rattus norvegicus,N,In vivo,7517,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr
9866,,,50597,10116.0,,,BAO_0000218,A,10000001.0,CHEMBL624406,,,Intermediate,Bone,1,1,,Rattus norvegicus,N,In vivo,7518,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr
9866,,,50597,10116.0,,,BAO_0000218,A,10000001.0,CHEMBL624407,,,Intermediate,Bone,1,1,,Rattus norvegicus,N,In vivo,7519,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig
9866,,,50597,10116.0,,,BAO_0000218,A,10000001.0,CHEMBL624408,,,Intermediate,Bone,1,1,,Rattus norvegicus,N,In vivo,7520,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr
9866,,,50597,10116.0,,,BAO_0000218,A,948.0,CHEMBL618644,,,Intermediate,Heart,1,1,,Rattus norvegicus,N,In vivo,7521,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr
9866,,,50597,10116.0,,,BAO_0000218,A,948.0,CHEMBL618645,,,Intermediate,Heart,1,1,,Rattus norvegicus,N,In vivo,7522,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig
9866,,,50597,10116.0,,,BAO_0000218,A,948.0,CHEMBL618646,,,Intermediate,Heart,1,1,,Rattus norvegicus,N,In vivo,7523,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr
